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Chapter 1: General introduction 
 
Cancer or malignant neoplasm is a group of diseases resulting from dysregulation of cell 
proliferation, differentiation or cell death and involving alteration of genomic structures and 
gene expression. The properties most likely to result in mortality among patients are 
invasiveness (destroying adjacent tissues or organs), aggressiveness (immortal cell division 
and infinite growth), metastasis (spreading to remote organs via blood circulation, 
cerebrospinal fluid (CSF) or the lymphatic system). At present, many types of neoplasm are 
unable to be cured effectively without short or long term adverse reactions in response to 
aggressive treatments such as surgery, chemotherapy and radiotherapy. Many cancers often 
relapse even long periods after completion of treatment due to tumour regrowth after 
treatment failure. This can be due to a number of different factors including incomplete 
resection of the tumour, metastasis being present at diagnosis and development of resistance 
to chemotherapy or radiotherapy. This project is focused on the development of resistance to 
chemotherapy specifically when this resistance encompasses a number of different types of 
drugs i.e. multidrug resistance.  
 
Cancer stem cells (CSCs), which comprise a small proportion of the tumours/cancers 
[Ignatova, T. N. et al (2002) and Singh, S. K. et al (2004)], are proposed to associate with 
multidrug resistance [Dean, M. et al (2001) and Schinkel, A. et al (2003)].  Consequently, 
enormous efforts have been made to improve our understanding of multidrug resistance in 
CSCs. One of the key drug resistance mechanisms in CSCs is active drug efflux. The ATP-
binding cassette (ABC) transporter family is the most important drug efflux transporter 
believed to play a role in drug resistance in many cancers. This chapter introduces 5 relevant 
topics, which form the background of this study, before leading to the results and discussions. 
These are paediatric brain tumours (PBTs), chemotherapeutic treatment in PBTs, ABC 
transporters, CSCs and drug resistance in paediatric brain tumours.   
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1.1 Paediatric brain tumours 
 
The most common solid neoplasms in children are tumours of the central nervous system 
(CNS), which are the second most common type of paediatric cancer behind leukaemia, and 
account for one third of childhood cancers [Pollack, Ian F. (1994), and Stewart, E.S. and 
Cohen, D.G. (1998)]. The most common PBTs are low grade astrocytomas with all types of 
astrocytoma accounting for 52% of PBTs. Embryonal tumours or primitive neuroectodermal 
tumours (PNETs) (the majority of which are medulloblastomas) represent approximately 21% 
of PBTs, hence, medulloblastoma is the second most common malignant brain tumour in 
children. Ependymomas and other gliomas account for 9% and 15% respectively [Baldwin, 
R.T. and Martin, S.P. (2004) and Jay, V. et al (2003)].  
 
In western countries, children under 15 years of age diagnosed with cancer account for 2% of 
all cancer cases. Moreover, the incidence of PBTs in Europe and the United States is 
estimated at approximately 130 new cases per year per million children [Scotting, P.J. et al 
(2005)]. There are several pieces of evidence supporting the fact that childhood solid 
tumours are different from adult solid tumours in terms of biology, genetics and 
environmental influences [Scotting, P.J. et al (2005)]. Some tumours develop mainly in 
FKLOGUHQDQGDUHXQFRPPRQLQDGXOWVVXFKDVQHXUREODVWRPD:LOP¶VWXPRXURVWHRVDUFRPD
and retinoblastoma [Kline, N.E. and Sevier, N. (2003)]. Several differences between 
childhood and adult brain tumours are shown in Table 1.1. The majority of children with brain 
tumours have a much better prognosis than adults with respect to median survival rate. Brain 
tumours developing in children are generally primary brain tumours, whilst adults often 
develop tumours that are more aggressive, such as the highly malignant tumour glioblastoma 
multiforme [Albright, A.L. (1993)]. However, when one compares the prognosis of brain 
tumours among children, it is revealed that infants and young children with brain tumours 
fare less well than older children since tumours in young children appear to become 
biologically aggressive. Surveillance, Epidemiology, and End Results (SEER) data collected 
from 1985 to 1994 revealed that 5 year survival rates for all CNS cancers was 45% for  
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Table 1.1 The comparison of brain tumours in adults and children [Stewart, E.S. and 
Cohen, D.G. (1998)]. 
 
children younger than 1 year, 59% for 1 to 4 years, 64% for 5-9 years, 70% for 10-14 years 
and 77% for 15-19 years [Gupta, N. et al. (2004)]. It has been shown that the older the age 
of the child developing a brain tumours, the better the prognosis. There are several reasons 
why this may be the case. Young children are capable of cranial enlargement to compensate 
for the increase in intracranial pressure from growing brain tumours, resulting in delayed 
diagnosis. Young children also have less tolerance than older children to complications from 
surgery and the toxic effects of radiation and chemotherapy. Radiotherapy is commonly 
avoided or reduced in young children with brain tumours due to the fact that their developing 
cells are easily affected by radiation. Also the types of tumours are seen varies with age with 
germ cell tumours seen mainly in teenagers. 
 
Histology type of brain tumours is the most reliable method used to predict the biological 
behaviour of a neoplasm. It is therefore routinely used to determine treatment options such 
as manipulation of adjuvant radiation and specific chemotherapy [Kleihues, P. et al. (2007)]. 
Classification of brain tumours is predominantly based on the histological features from light 
microscopy. In 1979, neuropathologists working under the control of the World Health 
Organization (WHO) developed a new classification and grading system for brain tumours that 
was more valuable for treatment evaluation. Since then the classification and grading system 
for brain tumours had been continuously developed to give more appropriate categories and 
cover all brain tumours. Presently, the revised WHO classification still classifies brain tumours 
Comparison of Brain Tumours in Adults and Children 
 Adults Children (<15yr) 
Incidence of primary brain tumours 28,500/yr 2,200/yr 
Incidence rate 10.9 per 100,000 3.7-4.1 per 100,000 
Survival 20%-30% survival  60% survival 
Most common Metastatic brain tumours Primary brain tumours 
Standard of care Palliative treatment Surgery±radiation+chemotherapy 
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predominantly from the evidence of histological findings, which provides a major advantage 
for diagnosis of brain tumours. PBTs classified according to 4th edition of the WHO 
classification are shown in Table 1.2 [Kleihues, P. et al. (2007)].  
 
The grading system in paediatric brain tumours is very important due to the fact that the 
histological grading of tumours is one of the significant factors indicating the biological 
behaviour of tumours. Additionally, grading of tumours is an essential factor for treatment 
consideration in using adjuvant radiation and specific chemotherapy protocols [Pollack, I. F. 
(1994)]. WHO grades of central nervous system tumours are classified into 4 grades. Grade I 
describes tumours containing cells with a low proliferative potential and only complete 
surgical resection is required to cure grade I tumours. Tumours classified as grade II are 
generally infiltrative and have a low level of proliferative activity. Some grade II tumours are 
able to develop to a higher grade tumour e.g. low grade diffuse astrocytomas can develop to 
anaplastic astrocytoma or glioblastoma. Grade III identifies tumours with histological features 
of malignancy with regard to nuclear atypia and high mitotic activity. These tumours types 
normally require adjuvant radiation and/or chemotherapy. Grade IV describes tumours that 
are the most aggressive and hence have the poorest prognosis. Grade IV tumours comprise 
cytological malignancy characteristics including high mitotic activity, necrosis, rapid pre and 
postoperative progression and consequently have poor treatment outcome [Rorke, L. B. et al 
(1985) and Louis, D. N. et al (2007)]. 
 
Only the 5 types of paediatric brain tumour that were used in this study are covered in more 
depth (ependymoma, medulloblastoma, oligodendroglioma, glioblastoma multiforme and CNS 
PNET). Each tumour type will be described in terms of histopathological features, incidence, 
localisation, growth and invasion, genetic abnormalities, and prognosis. There will particular 
emphasis given to the tumour sub-type from which the cell lines used in this study were 
derived. 
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Table 1.2 WHO grades of CNS tumours [Kleihues, P. et al. (2007)] 
Tumours 
Grades 
 
Tumours 
Grades 
I II III IV I II III IV 
Astrocytic tumours Central neurocytoma  ł   
Subependymal giant cell 
astrocytoma 
ł    Extraventricular neurocytoma  ł   
Pilocytic astrocytoma ł    Cerebellar liponeurocytoma  ł   
Pilomyxoid astrocytoma  ł   Paraganglioma of the spinal cord ł    
Diffuse astrocytoma  ł   Papillary glioneuronal tumour ł    
Pleomorphic xanthoastrocytoma  ł   Rosette-forming glioneuronal 
tumour of the fourth ventricle 
ł    
Anaplastic astrocytoma   ł  Pineal tumours 
Glioblastoma    ł Pineocytoma ł    
Giant cell glioblastoma    ł Pineal parenchymal tumour of 
intermediate differentiation 
 ł ł  
Gliosarcoma    ł Pineoblastoma    ł 
Oligodendroglial tumours Papillary tumour of the pineal 
region 
 ł ł  
Oligodendroglioma  ł   Enbryonal tumours 
Anaplastic oligodendroglioma   ł  Medulloblastoma    ł 
 
Oligoastrocytic tumours 
CNS primitive neuroectodermal 
tumour (PNET) 
   ł 
Oligoastrocytoma  ł   Atypical teratoid/rhabdoid tumour    ł 
Anaplastic oligoastrocytoma   ł  Tumours of the cranial and paraspinal nerves 
Ependymal tumours Schwannoma ł    
Subependymoma ł    Neurofibroma ł    
Myxopapillary ependymoma ł    Perneurioma ł ł ł  
Ependymoma  ł   Malignant peripheral nerve sheath 
tumour (MPNST) 
 ł ł ł 
Anaplastic ependymoma   ł  
Meningeal tumours 
Choroid plexus tumours 
Choroid plexus papilloma ł    Meningioma ł    
Atypical choroid plexus papilloma  ł   Atypical meningioma  ł   
Choroid plexus carcinoma   ł  Anaplastic/malignant meningioma   ł  
Other neuroepithelial tumours Haemangiopericytoma  ł   
Angiocentric glioma ł    Anaplastic haemangiopericytoma   ł  
Chordoid glioma of the third 
ventricle 
 ł   Haemangioblastoma ł    
Neuronal and mixed neuronal-glial tumours 
Tumours of the sellar region 
Gangliocytoma ł    
Ganglioglioma ł    Craniopharyngioma ł    
Desmoplastic infantile astrocytoma 
and ganglioglioma 
ł    Granular cell tumour of the 
neurohypophysis 
ł    
Anaplastic ganglioglioma   ł  Pituicytoma ł    
Dysembryoplastic neuroepithelial 
tumour 
ł    Spindle cell oncocytoma of the 
adenohypophysis 
ł    
b 
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1.1.1 Ependymoma 
Ependymomas are ependymal tumours, which are classified into 4 subtypes; 
subependymoma (WHO grade I), myxopapillary ependymoma (WHO grade I), ependymoma 
(WHO grade II) and anaplastic ependymoma (WHO grade III) (Table 1.3). Ependymomas 
commonly develop in young children between 3-8 years of age at diagnosis. The majority of 
Ependymoma cases (90%) are intracranial, whilst the remainder are located in the spinal 
cord. The most common area in which ependymoma is located is the 4th ventricle followed by 
the spinal cord, the lateral ventricle and the 3rd ventricle [Prayson, R. A. (1999)]. Two thirds 
of paediatric intracranial ependymomas are found in the infratentorial region, hence this is 
the predominant subtype found in children [Horn, B.N. and Smyth, M. (2004)].  
 
The most frequent genetic abnormality found in 30% of ependymoma is the aberration of 
chromosome 22 [Hamilton, R. L. and Pollack, I. F. (1997)]. Whilst the most frequent genetic 
abnormality in spinal ependymoma is monosomy 22, deletions and translocations in 
chromosome 22q also occur [Huang, B. et al (2003)]. Genetic abnormalities, which were 
commonly found in ependymoma although less frequently, include losses of 6q, 9q, 3p14, 
10q23 and 11q [Huang, B. et al (2003)]. A description of histology and histological images of 
all ependymal tumour subtypes are shown in Table 1.3 and Figure 1.1.  
 
In Europe from 1990-1994, 1-year survival and 5-year of children diagnosed with 
ependymoma were 80% and 55%, respectively. The survival rate in infant is very low (24%). 
Interestingly, the survival rate then increases in older ages; 44% in 1-4 year age, 68% in 5-9 
year age and 75% in 10-14 year age [Reni, M. et al (2007)]. Factors indicating prognostic 
value in ependymoma have been studied in many aspects, however, it is still controversial. 
Ependymoma, which is diagnosed during the first 2 years of life in children, leads to poor 
prognosis [Horn, B. et al (1999)]. Supratentorial tumours provide a better prognosis than 
infratentorial tumours whilst spinal tumours also have a better prognosis than intracranial 
tumours [Emestus, R. I. et al (1996)]. The histological grading of tumour also plays a role in 
prognosis. The histological factors indicating poor prognosis in ependymoma include mitotic  
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Table 1.3 Ependymal tumours [Derived from McLendon, R.E. et al, chapter 3, (2007)]
 
Subtypes of 
ependymoma 
 
WHO 
grade 
 
Frequency 
 
Location 
 
Histopathology 
 
Genetics  Prognostic and predictive factors 
Subependymoma I - rare and accounts for 
approximately 8% of 
ependymal tumours 
- more frequent in middle-
aged and elderly patients 
- fourth 
ventricle (50-
60%) and 
lateral 
ventricles (30-
40%) 
- clusters of isomorphic 
nuclei in a dense fibrillary 
matrix of glial processes 
(Figure 3.1, a and b) 
- no consistent 
cytogenetic 
information 
- good prognosis 
- surgical removal is usually curative 
-recurrence reported following incomplete 
resection 
Myxopapillary 
ependymoma 
I - accounts for 9-13% of 
ependymal tumours 
- age ranges between 4 
and 82 years 
- median age of 36 years 
- conus 
medullaris-
cauda equina- 
filum terminale 
region 
- GFAP expressing, cuboidal 
to elongated tumour cells 
radially arranged in a 
papillary manner around 
vascularised stromal cores 
(Figure 3.1, c and d) 
- no consistent 
cytogenetic 
information 
- favourable prognosis 
- more than 10-year survival after total or 
partial resection 
- late recurrence and distant metastasis may 
occur in incomplete resections 
Ependymoma II - accounts for 6-12% of all 
intracranial tumours and 
up to 30% in children 
younger than 3 years 
- the most common spinal 
cord tumour (50-60%) in 
adults, but rare in children 
- most 
common in the 
fourth 
ventricle and 
spinal cord  
- well-delineated, 
moderately cellular glioma 
with a monomorphic 
nuclear morphology 
- perivascular 
pseudorosettes and 
ependymal rosettes (Figure 
3.1, e and f) 
- 30% have losses 
at 6q and 9q and 
aberrations of 
chromosome 22 
eg.  monosomy 22, 
deletions or 
translocations 
involving 22q 
- children tend to fare worse than adults 
SUREDEO\GXHWRWKHWXPRXU¶VORFDWLRQEHLQJ
commonly posterior fossa in children but spinal 
cord in adults)  
- supratentorial ependymomas have better 
survival rates than infratentorial lesions 
- spinal ependymomas have a better outcome 
than cerebral lesions, although late 
recurrences are common 
Anaplastic 
ependymoma 
III - variable incidence data 
due to uncertainty of 
histological criteria of 
malignancy 
- more frequent in 
childhood intracranial 
ependymomas than spinal 
cord 
- intracranial 
and posterior 
fossa 
- increased cellularity and 
brisk mitotic activity 
- perivascular 
pseudorosettes and 
pseudopalisading necrosis 
(Figure 3.1, g and h) 
- largely unknown - poor prognostic indicators include; age below 
3 years, anaplasia, incomplete tumour 
resection and cerebrospinal fluid (CSF) 
metastasis 
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Figure 1.1 Histological features of fourth ventricle subependymoma, myxopapillary 
ependymoma of cauda equine, ependymoma and anaplastic ependymoma. 
Subependymomas (a and b) typically arise in the ventricular lumen and present as firm 
nodules which bulge into the lumen. This tumour is characterised by lobular architecture and 
clusters of isomorphic nuclei embedded in a dense fibrillary matrix of glial cell processes (a). 
Clustered nuclei and fibrillary stroma (b) with small cysts (*) are frequently present. 
Myxopapillary ependymoma (c and d) commonly arises in the conus medullaris-cuada equine-
filum terminale region. Tumour cells are frequently found around vessels with mucoid 
degeneration (c). Furthermore, this tumour is characterised by GFAP expression of 
perivascular cells described as cuboidal to elongated tumour cells radially arranged in a 
papillary manner around vascularised stromal cores (d). Ependymomas (e and f) are able to 
develop at any site along the ventricular system and spinal cord. The hallmark features of this 
tumour are perivascular pseudorosettes (e) described as vessels surrounded by ependymal 
tumour cells with a nuclear-free zone which has thin ependymal processes directed toward 
the walls of vessels and ependymal rosettes (f) defined as ependymal tumour cells arranged 
around an empty lumen. Anaplastic ependymomas (g and h) commonly occur in children, 
particularly in the posterior fossa. Poorly differentiated tumour cells with brisk mitotic activity 
(g) are frequently described.  In addition, foci of necrosis (     ), an area of dead cells without 
nuclei, are commonly displayed (h) [McLendon, R.E. et al, chapter 3, (2007)].   
a c d 
e f g h 
* 
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activity, degree of proliferation, foci of hypercellular cells and less differentiated cells 
[Korshunov, A. et al (2004), Kurt, E. et al (2006), Schiffer, D. and Giordana, M. T. (1998)].     
 
In this study, the two cell lines, which were derived from patients who were diagnosed with 
ependymoma, were EPN-1 and EPN-2. The EPN-1 cell line was derived from a patient who 
had had a 2nd relapse and had been treated with chemotherapy and radiation. The tumour 
tissues were obtained from the 3rd surgery. Whilst, the EPN-2 cell line was derived from a 
primary tumour.   
 
1.1.2 Embryonal tumours 
Embryonal tumours were classified by WHO as highly malignant tumours and these tumours 
are the most common brain tumours in children, accounting for 25% of all children brain 
tumours [Kleihues, P. et al (2000)]. Embryonal tumours are categorised into 3 groups; 
medulloblastoma, CNS PNET and atypical teratoid/rhabdoid tumour (AT/RT) (Table 1.4). 
Medulloblastoma and CNS PNET, which were studied in this project, are described in the next 
section.   
 
1.1.2.1 Medulloblastoma 
Medulloblastomas are the most frequent malignant brain tumour in children. 
Medulloblastomas originate from granular-cell progenitors located in the external granular 
layers and also cells situated in the neuroepithelium of the cerebellum [Dahmane, N. and 
Altaba, A. R. (1999)]. Medulloblastomas are classified as highly malignant (grade IV) tumours 
by the WHO classification. Approximately 80% of cases arise in the vermis and the median 
part of cerebellum whilst the remainder arise in the cerebellar hemispheres. Due to the highly 
malignant capacity of medulloblastoma, remote dissemination may occur in the meninges and 
cerebrospinal fluid (CSF).  
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Table 1.4 Embryonal tumours [Derived from McLendon, R.E. et al, chapter 3, (2007)] 
Subtypes of 
ependymoma 
Grade 
(WHO) 
Frequency Location Histopathology Genetics 
Prognostic and 
predictive factors 
Medulloblastoma IV - the most 
common PBT 
accounting for 
20% 
- 70% occurs in 
individuals younger 
than 16 year 
- the peak 
incidence occurs at 
7 years of age 
- 75% arise in the 
vermis and project 
into the 4th ventricle 
- described as small, round-to-oval 
cells, tightly packed and poorly 
differentiated with scanty cytoplasm 
and dense basophilic nuclei.  
- Pseudorosettes or Homer-Wright 
rosettes (<40%) and rhythmic 
palisading tumours (Figure 3.2) are 
observed  
- isochromosome 17q 
(i(17)q) present in 30-
40% of cases.  
- both loss of 17p and 
gain of 17q resulting in 
i(17)q may also occur 
independently 
- 50-60% of cases are 
expected to survive and be 
progression free following 
treatment.  
- Children with localised 
disease and who have 
received three-drug 
adjuvant chemotherapy 
regimen have a better 
five-year progression-free 
survival of up to 80% or 
more 
CNS PNET IV - rare in children 
accounting for 2-
3% of all PBTs 
- commonly arises in 
cerebral hemispheres 
and also in pineal 
region 
- also found in spinal 
cord or supracellar 
region 
- described as very poorly 
differentiated and round regular 
nuclei with a high nucleus:cytoplasm 
ratio.  
- better differentiated CNS PNETs 
may show more clear neuronal 
features, with oval to elongated 
nuclei having vesicular chromatin 
and nucleioli. 
- still unclear 
- RASSF1A promoter 
methylation, expression 
of the Neuro D family of 
basic helix-loop-helix 
transcription factors and 
achaete scute 
(neurogenic transcription 
factor with homology to 
Neuro D genes) are 
proposed to have a 
correlation with CNS PNET 
- far worse prognosis 
compared with 
medulloblastoma 
- overall 5-year survival 
rate is 18% but it can 
increase up to 50-60% 
after aggressive treatment 
Atypical 
teratoid/rhabdoid 
tumour (AT/RT) 
IV - rare in children 
accounting for only 
1-2% of all PBTs 
- located in both 
supratentorial 
(cerebral 
hemispheres, 
ventricular system, 
supracellar region 
and pineal gland) and 
infratentorial regions 
(cerebellar 
hemispheres, 
cerebellopontine 
angle and brain 
stem) 
- the most striking feature: classic 
rhabdoid features described as 
eccentrically placed nuclei containing 
vesicular chromatin, prominent 
eosinophilic nucleoli, abundant 
cytoplasm with an obvious 
eosinophilic globular cytoplasmic 
inclusion and well-defined cell 
borders.  
- the genetic hallmark is 
mutation or loss of the 
INI1 (hSNF5/SMARCB1) 
locus at 22q11.2 
- the overall prognosis of 
AT/RT is poor 
- one study showed mean 
survival after surgery of 
only 11 months 
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The most common genetic abnormality in medulloblastoma is isochromosome 17q (i(17)q) 
present in 30-40% of cases. Both loss of 17p and gain of 17q resulting in i(17)q may also 
occur independently [Griffin, C. A. et al (1988)]. The Sonic-Hedgehog-patched (Shh-Ptch) 
signalling pathway was also proposed as a significant genetic mutation found in 25% of 
sporadic human medulloblastomas. Shh-Ptch is the major signalling pathway which regulates 
the cell-fate determination and proliferation of the external granular layer (EGL) progenitor 
cells [Zurawel, R. H. et al (2000)]. Additionally, Wnt signalling pathway, which regulates the 
proliferation of EGL progenitor cells, was another important gene abnormality found in 15% 
of medulloblastoma with nucleaUDFFXPXODWLRQRIǃ-FDWHQLQDQG*6.ǃDVWKHPDLQLQKLELWRU\
component [Zurawel, R. H. et al (1998) and Jia, J. et al (2002)]. Medulloblastoma was also 
discovered to present in rare autosomal dominant familial syndromes including Gorlin 
syndrome (Naevoid basal cell carcinoma syndrome: NBCCS) found in 4% of patients under 3 
years of age, Turcot type 2 found in the setting of familial adenomatous polyposis (FAP) and 
a germ line APC mutations and in 14% of cases of Li-Fraumeni syndrome with a germline 
TP53 mutation [Reviewed in Ellison, D. (2002)].  
 
Histologically, medulloblastoma and the other variant medulloblastoma are described in 
Figure 1.2. Since they are highly malignant, medulloblastomas cannot be reliably be cured by 
surgery alone. However, it is a chemosensitive and radiosensitive tumour. Therefore, 50-60% 
of cases are expected to survive and be progression free following treatment. Several studies 
have proposed a number of prognostic indicators that influence treatment outcomes and 
median survival rate of patients. None of these indicators have, however, been proved to 
affect prognosis of medulloblastoma patients in the context of therapeutic trials [Jakacki, R. I. 
(2005)]. The clinical criteria categorises medulloblastoma into 2 groups of high-risk and 
standard-risk patients. This might be useful and probably can indicate prognosis of disease. 
The high-risk patients were identified as diagnosis of disease at age less than 3 years, 
incomplete surgical resection leaving more than 1.5 cm2 of residual tumours and presentation 
of metastasis [Reviewed in Packer, R. J. (1999)]. However, this criteria is not generally 
accepted. 
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Figure 1.2 Histological features of different types of medulloblastoma. 
Medulloblastomas are typically located in cerebellar hemispheres. Hallmark histological 
features of this tumour are areas of Homer-Wright rosettes (neuroblastic, a), and 
arrangement of tumour cells in parallel rows described as a rhythmic palisading tumour cells 
(b). Desmoplastic medulloblastoma have pale nodular areas surrounded by densely packed 
hyperchromatic cells and reticulin (c) or reticular fibers, a histological term used to describe 
structural fibers composed of type III collagen staining (     ) shows reticulin-free zones 
described as pale islands (d). Variant medulloblastoma with extensive nodularity (e and f) 
was primarily classified as cerebellar neuroblastoma. The histological features were described 
as expanded lobular architecture with large elongated reticulin-free zones (e) due to the fact 
that such zones become unusually enlarged and rich in neurophil-like tissue. These zones 
contain small round neurocytic cells, which are similar to central neurocytoma and exhibit a 
streaming pattern, in the fibrillary background (f). Anaplastic medulloblastomas are 
characterised by increased nuclear size and pleomorphism (g). Large cell medulloblastomas 
show enlarged vesicular nuclei, prominent nucleoli, and moderate cytoplasm (h). Large cell 
and anaplastic medulloblastomas have substantial cytological overlap, therefore, many 
studies classify both into a large cell/anaplastic category. Any variant of medulloblastoma 
which comprises focal rhabdomyoblastic elements is described as medullomyoblastoma (i). 
This variant occasionally contains striated muscle fibers (    ) with brisk mitotic activity. 
Melanocytic medulloblastoma shows melanotic cells commonly appearing as tubular epithelial 
structures (j). Melanotic tumour cells may also appear in different variants of 
medulloblastoma [Giangaspero, F. et al, chapter 8, (2007)].   
a b c d 
e f g h 
i j 
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The cell lines which derived from medulloblastoma tumours, were MED-1 and MED-2. The 
MED-1 cell line was established from a primary medulloblastoma, which had not previously 
been treated. MED-2 was derived from a recurrent medulloblastoma, which had been treated 
with both chemotherapy and radiation. 
 
1.1.2.2 CNS primitive neuroectodermal tumours (CNS PNET) 
CNS/supratentorial primitive neuroectodermal tumours (CNS PNET/SPNET) are described as 
PNETs developing in the CNS and spinal cord. CNS PNETs, a group of highly malignant 
lesions, comprise undifferentiated or poorly differentiated neuroepithelial cells, which may 
differentiate along neuronal, astrocytic, ependymal, muscular or melanocytic lines. CNS 
PNETs are rare in children accounting for approximately 2-3% of all PBTs. CNS PNET currently 
has a far worse prognosis than medulloblastoma (pineoblastoma). [Kuhl, J. et al. (2004)].  
 
Several studies have revealed a variety of non-random cytogenetic gains and losses 
associated with CNS PNETs but not i(17)q. These include RASSF1A promoter methylation 
[Chang, Q. et al (2005)], expression of the Neuro D family of basic helix-loop-helix 
transcription factors and achaete scute (neurogenic transcription factor with homology to 
Neuro D genes [Rostomily, R. C. et al (1997)]. However, there is no evidence, which 
convincingly confirms genetic abnormalities specifically found in CNS PNETs. 
 
The typical histological features of CNS PNET are described and shown in Figure 1.3. They are 
difficult to histologically distinguish from medulloblastomas. Therefore, the diagnosis of this 
tumour is still primarily based on a supratentorial location and the histological features of a 
predominantly undifferentiated neuroepithelial tumour with focal areas of divergent 
differentiation. CNS PNET patients have a much worse 5-year survival rate compared to 
children diagnosed with medulloblastoma especially in children aged under 2 years [Geyer, J. 
R. et al (2005)]. One study demonstrated that the 5-year survival rates of children with CNS 
PNET or medulloblastoma treated with pre- irradiation chemotherapy were 30% and 57%, 
respectively [Kühl, J. et al (1998)]. Due to the fact that CNS PNETs are commonly located in 
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Figure 1.3 Histological features of CNS PNETs, cerebral neuroblastomas and 
ganglioneuroblastomas. Typical histology of PNETs are described as poorly differentiated 
cells with round regular nuclei and high nucleus:cytoplasm ratios. Tumours with only 
advanced neuronal differentiation exhibiting a nodular architecture (*) with typical streaming 
of tumour cells (   ) are defined as cerebral neuroblastoma (a). Neurofilament (an 
intermediate filament which is a major element of the cytoskeleton of axon cytoplasm) 
staining (    ) predominantly expresses in tumour cell processes (b). PNETs having better 
differentiation may show different stages of neuronal differentiation (c). Cerebral 
neuroblastomas might express cluster of mature ganglion cells (arrows) with poorly 
differentiated area (d). Tumours having ganglion cells are defined as ganglioblastomas which 
may show regions of low cellularity with a neuronal phenotype (e) [McLendon, R.E. et al, 
chapter 8, (2007)]. 
 
 
 
 
* 
 
 
a b 
c d e 
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paraventricular, thalamic and hypothalamic regions, they are difficult to resect surgically. 
In phase II trials, up-front multidrug chemotherapy was used to treat high-risk patients. 
Complete response plus partial response accounted for 57% in CNS PNET and 67% in 
medulloblastoma. Children diagnosed with CNS PNETs should be treated with postoperative 
craniospinal radiotherapy (CSRT) and chemotherapy; due to the fact that, occult microscopic 
dissemination frequently occurs in patients. Reduction of CSRT or total tumour dose or 
excluding CSRT may frequently result in fatal outcome [Kühl, J. et al. (2004)]. 
 
The cell line, which was established from CNS PNET tumour, is SPNET-1. This CNS PNET 
tumour was a primary tumour which had only been partially resected, then despite adjuvant 
chemotherapy and radiation the tumour recurred several times. 
 
1.1.3 Oligodendroglioma 
Oligodendroglioma belongs to a family of oligodendroglial tumours which includes anaplastic 
oligodendroglioma, oligoastrocytoma and anaplastic oligoastrocytoma (Table 1.5). 
Additionally, oligodendroglial tumours range from well-differentiated neoplasms to malignant 
tumours defined as WHO grade II and III, respectively. Oligodendroglioma rarely occurs in 
children and represents only 1% of all PBTs diagnosed in children younger than 2 years 
[Razak, N. et la (1998)]. Oligodendroglioma is commonly situated in the cortex and the white 
matter of the cerebral hemispheres [Kros, J. M. et al (1994)]. Bilateral cerebral spreading of 
oligodendroglioma commonly occurs in patients [Packer, R. J. et al (1985)].  
 
The most frequent genetic mutations found in oligodendrogliomas is unbalanced translocation 
between chromosomes 1 and 19 [t(1;19)(q10;p10)] which appears to be co-deletion of 1p 
and 19q. 1p and 19q deletion is the hallmark alteration in oligodendrogliomas and is found up 
to 80% of these cases. Entire loss of one copy of 1p and 19q commonly occurs in patients 
whilst partial deletions of these regions are infrequent. This genetic abnormality is used to 
distinguish between glioblastoma, occasionally have similar histology with oligodendroglioma, 
and oligodendroglioma since it is rare in glioblastoma [Aldape, K et al (2007)]. 
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Table 1.5 Oligodendroglial tumours [Derived from Reifenberger, G. et al, chapter 2, (2007)]. 
Subtypes of 
ependymoma 
Grade 
(WHO) 
Frequency Location Histopathology Genetics Prognostic and 
predictive factors 
Oligodendroglioma II - 2.5% of all primary brain 
tumours and 5-6% of all 
gliomas 
- majority of cases arise in 
adults (peak incidence 40-
45 years of age) 
- rare in children ( 2% of all 
brain tumours in patients < 
14 years of age)  
- in the cortex and 
white matter of the 
cerebral hemispheres  
- 50-60% in the  frontal 
lobe 
- commonly involves 
more than one cerebral 
lobe or bilateral tumour 
spread 
- composed of monomorphic cells 
with uniform round nuclei and 
SHULQXFOHDUKDORV³KRQH\FRPE
DSSHDUDQFH´PLFURFDOFLILFDWLRQV
mucoid/cystic degeneration and a 
dense network of branching 
capillaries 
- 80% of cases show 
co-deletion of 
chromosomal arms 
1p and 19q  
- other genetic 
alterations include 
gain on chromosome 
7 and losses on 
chromosomes 4,6, 
11p, 14 and 22q 
- typically slowly 
growing tumours with 
relatively long 
survival times 
Anaplastic 
oligodendroglioma 
III - 1.2% of all primary brain 
tumours and 20-35% of all 
oligodendroglial tumours 
- predominant in adults 
(peak incidence 45-50 years 
of age) 
- in the cerebral 
hemispheres with a 
preference at the 
frontal lobe, followed by 
the temporal lobe 
- rounded hyperchromatic nuclei, 
perinuclear halos, few cellular 
process and focal 
microcalcifications, mitotic activity 
prominent, gliofibrillary 
oligodendrocytes and 
minigemistocytes are frequent 
- approximately two 
thirds of cases have 
total losses of 1p and 
19q 
- additional 
chromosomal 
abnormalities include 
gains on 7 and 15q, 
and losses on 4q, 6, 
9p, 10q, 11, 13q, 18 
and 22q 
- combined therapy 
(chemo-radiotherapy) 
significantly prolongs 
progression-free 
survival 
(approximately 2-2.5 
years) and overall 
survival times of 
about 4-5 years 
Oligoastrocytoma II -reported incidence has 
been increasing over the 
last 10 years due to varying 
pathological criteria and 
increased recognition 
- studies report incidence of 
1.8% and 19% 
- usually develop in middle-
age between 35-45 years of 
age 
- in cerebral 
hemispheres  
- order of site 
frequency; frontal, 
temporal, parietal then 
occipital 
- cerebellar localization 
very uncommon 
- moderately cellular neoplasms 
with no or low mitotic activity   
- microcalcifications and 
microcystic degeneration may be 
present 
- necrosis and microvascular 
proliferation are absent 
- neoplastic glial cells with 
astrocytic or oligodendroglial 
phenotypes 
- divided into biphasic (compact) 
and intermingled (diffuse) variants 
- 30-50% 
characterised by 
combined loss on 
chromosome 1p and 
19q 
- 30% have 
mutations of the 
TP53 gene 
- factors associated 
with longer survival; 
younger age at 
operation (< 37 
years), gross total 
tumour resection, 
postoperative 
radiotherapy and low 
Ki-67 levels (index of 
mitotic activity) 
Anaplastic 
oligoastrocytoma 
III - precise epidemiological 
data is not available 
- peaks in the fifth decade 
(mean at 44 years) 
- predominantly in 
cerebral hemispheres 
- mostly occur in the 
frontal lobe followed by 
the temporal lobe  
- oligoastrocytomas with 
histological features of anaplasia, 
including nuclear atypia, cellular 
pleomorphism, high cellularity, and 
high mitotic activity 
- microvascular proliferation may 
be present 
- loss of 1p/19q or 
TP53 mutations 
- important 
prognostic markers; 
necrosis is associated 
with worse prognosis 
and 1p loss 
associated which is 
improved 
progression-free and 
overall survival 
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Histological features of oligodendroglioma are described in Figure 1.4. Presently, there are 
no specific immunohistochemistry markers that are able to identify human oligodendroglial 
tumours because oligodendrogliomas express many markers similar to other brain tumours 
such as S-100 protein, the HNK1 (anti-Leu7, CD57) carbohydrate epitope [Nakagawa, Y. 
(1986)], microtubule-associated protein 2 (MAP2) [Blumcke, I. et al (2001)], oligodendrocyte 
lineage-specific transcription factors (OLIG-1 and OLIG-2) [Riemenschneider, M. J. et al 
(2004)] and SOX10 [Bannykh, S. I. et al (2006)]. Therefore, these markers might not help in 
diagnosis of oligodendroglioma.  
 
A retrospective review of 106 patients diagnosed between 1979-1997 (77 oligodendroglioma 
and 29 mixed glioma) found that 5- and 10-year survival rates were 71% and 54%, 
respectively [Olson, J.D. et al (2000)]. Factors involved in worse prognosis are necrosis, high 
mitotic activity, increased cellularity, nuclear atypia, cellular pleomorphism and microvascular 
proliferation. Low or high expression of Ki-67 indicates low or high grade histology of 
neoplasms, respectively. Several studies have reported as Ki-67 index over 3-5% as a 
significant factor involved in worse prognosis [Dehghani, F. et al (1998), Heegaard, S. et al 
(1995)].    
 
Olig-1 is the cell line that was derived from an oligodendroglioma tumour. This 
oligodendroglioma tumour was a primary tumour. This cell line was included in some 
experiments to compare the results with cell lines (EPN-2, MED-2, SPNET-1 and PFSK-1) and 
it was mainly studied by Dr. Deema Hussein, Postdoctoral researcher. 
 
1.1.4 Glioblastoma multiforme (GBM) 
Glioblastoma multiforme (glioblastoma, GBM) is rare in children and it preferentially affects 
adults between 45 and 75 years of age [Ohgaki, H. et al (2004)]. The variants of 
glioblastoma are explained in Table 1.6. GBM may be biologically and clinically subdivided 
into primary (> 90%) and secondary (< 10%) GBM. Primary GBM develop very rapidly 
(usually < 3 months) without clinical histopathological evidence of a pre-existing precursor 
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Figure 1.4 Histological features of oligodendrogliomas. Tumour cells degenerated by 
acute swelling result in an enlarged round cell with clear cytoplasm and well defined plasma 
membrane are described as typical honeycomb pattern (a). Oligodendroglioma normally 
shows a dense network of branching capillaries which is similar to the pattern of chicken-wire 
and occasionally causes intratumoural haemorrhage (b). Rare growth of oligodendroglioma as 
tumour cells form parallel rows with elongated nuclei forming a striking pattern of nuclear 
palisading (c). Some oligodendrogliomas contains tumour cells with the appearance of small 
gemistocytes with eccentric cytoplasm which is positive for glial fibrillary acidic protein (GFAP) 
(d). These cells were identified as minigemistocytes or microgemistocytes [Reifenberger, G. 
et al, chapter 2, (2007)]. 
 
 
 
 
a b 
c d 
 20 
lesion. Conversely, secondary GBM gradually develop through progression of diffuse 
astrocytoma grade II or anaplastic astrocytoma grade III. The prognosis of GBM is extremely 
poor and survival rates of more than one year and more than 3 years are found in less than 
20% and 3%, respectively, of all GBM cases. Secondary GBM has significantly longer survival 
rate (7.8 months) than that of the primary GBM (4.7 months) [Ohgaki, H. et al (2004), 
Ohgaki, H. and Kleihues, P. (2005)]. Histological features demonstrating necrosis [Burger, P. 
C. et al (1987), Pierallini, A. et al (1998)] and genetic alteration of LOH 10q [Ohgaki, H. et al 
(2004)] also correlate with a shorter survival.  
 
There are several genetic abnormalities in GBM including TP53 mutation, loss of 
heterozygosity (LOH) on chromosome 10q and 17p, epidermal growth factor receptor (EGFR) 
amplification, P16INK4a deletion, and PTEN mutation. Secondary GBM predominantly have 
TP53 mutations (65%), whereas, LOH 10q typically occurs in primary GBM. Patients 
diagnosed with GBM normally carry a poor prognosis. [von Deimling, A. et al (1993)]. GBMs 
display variable histological features and morphological heterogeneity [Figure 1.5]. 
 
BT-4 was the cell line used in this study. It was derived from a primary tumour originally 
described as a giant cell GBM but rediagnosed as malignant glioneuronal tumour (MGNT) 
during the course of this study (Hussein et al unpublished).  
  
Low grade brain tumours (grade II: Ependymoma and Oligodendroglioma) and high grade 
brain tumours (grade IV: Medulloblastoma, CNS PNET and Glioblastoma multiforme) were 
included in this study. These brain tumours include those with low survival rates 
(medulloblastoma, CNS PNET and GBM) and these that commonly recur after treatment 
(ependymoma). Chemotherapy is still the standard treatment in many cancers. This is 
described in the next topic. Presently, the failure of chemotherapeutic treatment due to 
multidrug resistance in cancers is an unresolved problem.  
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Table 1.6 Glioblastoma tumour variants [Derived from Kleihues, P. et a, chapter 1, (2007)]. 
Variant types 
of 
Glioblastoma 
Grade 
(WHO) 
Frequency Location Histopathology Genetics Prognostic and 
predictive factors 
Glioblastoma IV - the most frequent 
brain tumour (12-15% 
of all intracranial 
tumours) 
- 60-75% of astrocytic 
tumours 
- preferentially affects 
adults between 45-75 
years of age  
- the subcortical 
white matter of the 
cerebral hemispheres 
(temporal lobe: 31%, 
parietal lobe: 24%, 
frontal lobe: 23%, 
and occipital lobe: 
16%) 
- histopathology is extremely variable, 
with a high degree of cellular ranging 
from nuclear polymorphism with 
numerous multinucleated giant cells to 
monotonous cells 
- predominant features: poorly 
differentiated cells, pleomorphic 
astrocytic tumour cells with marked 
nuclear atypia and brisk mitotic 
activity, prominent microvascular 
proliferation and/or necrosis  
- significant genetic 
alterations combining 
TP53 mutations, loss of 
heterozygosity (LOH) 
on chromosomes 10 
and 17p and EGFR 
amplification 
- overall survival is 
extremely poor, less than 
20% of patients survive 
more than one year 
- predictive factors that 
associate with poor 
prognosis such as age > 
50 years at diagnosis, 
presence and extent of 
necrosis, presence of LOH 
10 
Giant cell 
glioblastoma 
(GC-GBM) 
IV - accounts for up to 
5% of glioblastomas 
and less than 1% of all 
brain tumours 
- mean age at clinical 
manifestation is 41 
years 
- often located 
subcortically  in the 
temporal and parietal 
lobes  
- comprised of numerous 
multinucleated giant cells, smaller 
fusiform cells and, to a varying extent, 
a reticulin network 
- may be heavily lipidized 
- frequent atypical mitosis and necrosis 
 
- characterised by 
frequent TP53 
mutations (75-90% of 
cases) and PTEN 
mutations (33%), but 
typically lacks EGFR 
amplification/ 
overexpression and 
homozygous p16 
deletion 
- carry a poor prognosis 
but some reports indicate 
the clinical outcome is 
better than ordinary 
glioblastoma (possibly 
because it is less 
frequent) 
Gliosarcoma 
(GS) 
IV - accounts for 
approximately 2% of 
all glioblastomas 
- preferentially 
manifests between 
ages 40 and 60 
- rarely occurs in 
children 
- located in the 
cerebral henispheres, 
involving temporal, 
frontal, parietal and 
occipital lobes in 
decreasing order of 
frequency 
- rarely occurs in the 
posterior fossa and 
spinal cord 
- mixed gliomatous and sarcomatous 
tissue confers a biphasic tissue pattern 
- epithelial differentiation manifest as 
carcinomatous features with gland-like 
or adenoid formations and squamous 
metaplasia 
- sarcomatous features of malignant 
transformation component shows 
nuclear atypia, mitotic activity and 
necrosis  
 
- contains PTEN 
mutations (38-45%), 
p16INK4A deletions 
(38%) and TP53 
mutations (23-24%) 
- has a more favourable 
prognosis than ordinary 
glioblastoma 
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Figure 1.5 Histological features of GBM and variant GBM. *OLREODVWRPD³PXOWLIRUPH´VXJJHVWV
the histopathology of this tumour is variable. GBM shows essential histological characteristics 
for diagnosis which are a large ischemic necrosis (    , a) and several large thrombosed 
tumour vessels (*, a). Microvascular proliferation with formation of a multilayered 
µJORPHUXORLG WXIW¶      E DQG D KLJK GHJUHH RI DQDSODVLD F DUH DOVR VLJQLILFDQW
characteristics for diagnosis. GC-GBM comprise cells of variable size and shape (d) (may 
measure more than 500µm in diameter), a giant cell with an atypical mitotic figure (    , e) 
and a very large multinucleated giant cell (*, f). GBM are characterised by a biphasic tissue 
pattern with alternating areas displaying glial and mesenchymal differentiation. GBM typically 
express strong GFAP expression of gliomatous components geographically separated from 
sarcomatous tumour cells (     , g) or GFAP staining cells blended with sarcomatous tumour 
cells (h). A biphasic tissue pattern may also be displayed as reticulin-rich sarcomatous and 
reticulin-free gliomatous elements (i) [Kleihues, P. et al, chapter 1, (2007)]. 
 
* 
* 
* 
a b c 
d e f 
g h i 
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1.2 Chemotherapeutic treatment of paediatric brain tumours 
 
The general principles of treatment in paediatric brain tumours consist of surgical treatment, 
radiotherapy and chemotherapy. Surgery is the initial treatment, which provides a tissue 
biopsy for histologic diagnosis and decreases tumour burden. However, some brain tumours 
such as diffuse glioma of brain stem or deep-seated tumours are less surgically accessible 
due to the high risk of destroying vital brain areas. Radiotherapy is essential for some 
tumours such as medulloblastomas, which frequently disseminate throughout the neuraxis, 
and glioblastoma multiformes, which are highly aggressive and locally invasive tumours. 
However, for children ages less than 2 or 3 years radiotherapy is avoided due to the fact that 
radiation affects the developing nervous system resulting in impaired cognition and memory. 
Therefore, postoperative chemotherapy is necessary in patient at these ages. Chemotherapy 
is mandatory treatment in many cancers and commonly used as postoperative treatment 
[Reviewed in Pollack, I. F. (1994)].   
Chemotherapy had been used as a standard treatment of cancers for many years, the 
outcome after chemotherapy is however still minimal success. Combined treatment of various 
chemotherapeutic drugs is normally applied to treat patients to avoid multidrug resistance, 
which is a major problem in cancer treatment and cause of tumour relapse. Multidrug 
resistance in cancers has been extensively studied in many aspects to understand the biology 
of drug resistant cancers and improve treatment. Nevertheless, multidrug resistance in 
cancer cells has not been conquered yet. Novel chemotherapeutic agents have been 
developed and new derivatives synthesised to improve the quality of treatment and reduce 
drug toxicity. Many chemotherapeutic agents that have been used to treat brain tumours and 
chemotherapeutic drugs for CNS cancers, which had been developed within the last two 
decades, are shown in Table 1.7. With respect to the study undertaken in this thesis 4 
common chemotherapeutic drugs (etoposide, cisplatin, irinotecan and methotrexate), which 
are known to be the substrates of ABC transporters [Szakács, G et al (2006)], are described 
in detail with respect to general information or drug history, chemical structures, mechanisms 
of action and resistance mechanisms to drugs. 
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1.2.1 Etoposide 
Etoposide (VP-16) belongs to the podophyllin group, which has been used in folk medicine for 
over a thousand years to treat many diseases. Toxicity of podophyllotoxins however was a 
limitation to their use. The most effective derivative from the Indian Podophyllum plant was 
¶-demethylepipodophyllin benzylidene glucoside (DEPBG). Later, etoposide (VP-16) and 
Teniposide (VM-26) were successfully synthesised in 1966 and 1967, respectively. These 2 
analogues of DEPBG effectively preserve antineoplastic activity better than previous 
derivatives [Reviewed in Hande, K. R. (1998)].  
 
Table 1.7 Chemotherapeutic drugs used to treat CNS cancers [Bredel, M. (2001)] 
 
Chloroethylnitrosoureas 
(CENUs) 
Antimetabolites Protein kinase C (PKC) 
inhibitors 
Carmustine (BNCU) Methotrexate (MTX) Tamoxifen 
Lomustine (CCNU) Edatrexate Bryostatin 
Nimustine (ACNU) 5-Fluorouracil (5-FU) 7-Hydroxystaurosporine (UCN-01) 
Semustine (MeCCNU) Cytosine arabinoside (Ara-C)  
PCNU 6-Tioguanine (6-TG)  
HeCNU 5-Fluorocytosine (5-FC) Miscellaneous agents 
NB-Fotemustine Bromodeoxyuridine (BrdU) Difluoromethylornithine (DFMO) 
 Iododeoxyuridine (IUDR) Mechlorethamine 
 Methylprednisolone (MPred) Nitrogen mustard (HN2) 
Vinca alkaloids   
Vincristine (VCR) Alkylating agents Mitoxantrone 
Vinblastine (VBL) Temozolomide  Topotecan 
 Procarbazine (PCB) Etanidazole (ETA) 
Epipodophyllotoxins Dacarbazine (DTIC) Misonidazole (MISO) 
Etoposide (VP-16) Thiotepa Irinotecan (CPT-11) 
Teniposide (VM-26) Chlorambucil Lovastatin 
 Busulfan Methylglyoxal bisquanylhydrazide 
 Melphalan Benznidazole 
Platinum compounds Hydroxyurea (HU) Didemnin B 
Cisplatin (CDDP) Gemcitabine Acivicin 
Carboplatin Spirohydantoin mustard (SHM)  
  Boswellic acids 
Phosphamides Antibiotics Thalidomide 
Cyclophosphamide (CPA) Doxorubicin Eflornithine 
Ifosfamide Iradrubicin Piroxantrone 
Mafosfamide Epirubicin  
 Actinomycin D  
Taxanes Bleomycin (Bleo) Hexitol derivatives 
Paclitaxel Aziridinylbenzoquinon (AZQ) Dibromodulcitol (DBD) 
Docetaxel KRN8602 (MX-2) Dianhydrogalactitol (DAG) 
 
The four drugs that are the focus of this thesis are highlighted. 
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The structure of etoposide 
Etoposide is one of the most common drugs used to treat many tumours. It is a semi-
synthetic epipodophyllotoxin. Etoposide having molecular weight 588 is weakly soluble in 
water. Therefore, etoposide phosphate had been developed to improve the solubility. 
Etoposide phosphate, the prodrug of etoposide which is converted by alkaline phosphatase 
action in blood, is water soluble. Etoposide phosphate shares the same pharmacokinetics and 
toxicities as etoposide [Reviewed in Hande, K. R. (1998)]. The chemical structures of the 
parental compound (podophyllotoxin) including other derivatives; etoposide, etoposide 
phosphate and teniposide are shown in Figure 1.6. 
 
The mechanism of action 
In all cells, the processes of DNA replication, transcription, chromosomal segregation and 
DNA recombination require DNA topoisomerase, which comprises 2 types; topoisomerase I 
and topoisomerase II. Topoisomerase I is required for single strand cuts in DNA whilst 
topoisomerase II is essential for cutting and passing an intact double helix through a 
transient double-stranded DNA break (Figure 1.7) [Wang, J. C. et al (1971) and Gellert, M. et 
al (1976)]. The main target of etoposide is nuclear topoisomerase II enzyme, which is a  
 
 
Figure 1.6 The chemical structure of the podophyllotoxin and derivatives; etoposide, 
etoposide phosphate and Teniposide. The figure shows the chemical structures of the 
original compound (podophyllotoxin) and its derivatives (etoposide, etoposide phosphate and 
Teniposide) [Adapted from Joel, S. (1996)]. 
Podophyllotoxin Etoposide Etoposide phosphate Teniposide 
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KRPRGLPHUFRQVLVWLQJRI IRUPVWRSRLVRPHUDVH,,ĮN'DDQGWRSRLVRPHUDVH,,ǃ
N'D7RSRLVRPHUDVH,,ĮDFWLYLW\LVKLJKO\LQFUHDVHGGXULQJ'1$UHSOLFDWLRQGHWHFWHGLQ
particular during S and G2 phases of cell cycle and has been correlated with DNA replication 
ZKLOVWWRSRLVRPHUDVH,,ǃH[SUHVVLRQLVGHWHFWHGDWDORZOHYHOWKURXJKRXWDOOSKDVHVRIFHOO
cycle [Joel, S. (1996)].  
 
7KHPHFKDQLVPRIHWRSRVLGH¶VDQWLQHRSODVWLFHIIHFWVLVVWLOOSRRUO\XQGHUVWRRG7RSRLVRPHUDVH
II function requires ATP for catalytic activity and modulation of DNA topology. Etoposide 
inhibits topoisomerase II function by directly binding to a covalent DNA and topoisomerase II 
complex resulting in stabilising of this complex. To inhibit topoisomerase II, etoposide 
interacts with the closed-gate state of topoisomerase II (Figure 1.7) [Chen, A. Y. and Liu, L. 
F. (1994)]. Stabilisation of the covalent complex toxin causes DNA breaks resulting in cell 
death.  
 
In 2003, Bromberg and colleagues postulated that there were 2 possible models for etoposide 
mechanism; one-drug model and two-drug model (Figure 1.8) [Bromberge, K. D. et al 
(2003)]. In the one-drug model etoposide affected on only one scissile bond of DNA but due 
to a strong communication between the active site of each topoisomerase II promoter, this 
was effective to cause double-stranded DNA breaks. In contrast, the two-drug model 
postulated that etoposide was required on both sites of scissile bonds to effectively lead to 
double-stranded DNA breaks. Drug action on each site worked independently and there was 
the slightest communication between these 2 topoisomerase II promoters. Therefore, if 
etoposide action occurs on a single scissile bond, this results in single-stranded DNA breaks 
[Bromberge, K. D. et al (2003)]. In addition, in 1985, DNA breakage and repair were studied 
in human lung adenocarcinoma cells in vitro and the investigators found that single- and 
double- stranded DNA breakage were detected shortly after both etoposide and Teniposide 
exposure. After cells were incubated with both drugs for 1 hour then drugs were removed, 
approximately half of all single- and double- stranded DNA breakages were repaired within 1 
hour [Long, B. H. (1985)]. 
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Figure 1.7 Topoisomerase II function. Topoisomerase II enzyme is composed of an ATP 
XQLW\HOORZFRORXUDQ$¶VXEIUDJPHQWEOXHFRORXUDQGD%¶VXEIUDJPHQWUHGFRORXUD
When G-segment DNA (grey rod), which contains the DNA gate, binds to topoisomerase II, it 
results in modification of the topoisomerase II structure (b) then T-segment DNA passes 
through (c). Due to binding of ATP unit, G-VHJPHQW '1$ LV VSOLW LQWR  SDUWV E\ WKH $¶
subfragment (d) then the ATP domain dimerises and transported T-segment DNA (green rod) 
is allowed to pass through the broken G-segment DNA into the central hole (e). G-segment 
DNA is resealed again and T-VHJPHQW '1$ LV WUDQVSRUWHG WKURXJK WKH RSHQLQJ RI $¶
subfragment (f). Etoposide inhibits topoisomerase II function by directly binding to DNA and 
topoisomerase II complex during the close gate stage [d and e] resulting in stabilisation of 
DNA and DNA breakes [Adapted from Burger, J. M. et al (1996)]. Red circles indicate the 
stage that etoposide binds to topoisomerase II enzyme.  
 
ATP 
T-segment 
ADP+Pi 
(a) (b) (c) 
(d) (e) 
(f) 
Etoposide 
binds 
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Resistance mechanisms to etoposide 
Two mechanisms of resistance to etoposide have been described; decreased intracellular 
accumulation of drug and atypical multidrug resistance (at-MDR) [Joel, S. (1996)]. A 
significant factor, which leads to decreased intracellular accumulation of drug, is the 
multidrug resistance gene (MDR1) and its product P-glycoprotein (ABCB1) [Endicott, J. and 
Ling, V. (1989)]. Drug resistance has been shown to develop by increasing the expression of 
P-glycoprotein after cells have been exposed to even one drug and this often results in cross 
resistance to other drugs of unrelated structure. at-MDR describes any drug resistance 
 
 
Figure 1.8 One- and two-drug model of etoposide mechanism. Etoposide is 
represented as red rods and blue arrows indicate active sites, to which etoposide binds (a). In 
the one-drug model etoposide binds to a single scissile (b), which is effective enough to cause 
double stranded DNA break due to strong communication between 2 scissiles. Whilst the two-
drug model proposed that etoposide binds to both scissiles resulting in double stranded DNA 
break (c). If etoposide binds to a single scissile, this results in single stranded DNA break (b) 
[Adapted from Bromberg, K. D. et al (2003)]. 
(a) 
(b) 
(c) 
5' 
5' 3' 
3' 
5' 
5' 3' 
3' 
5' 
5' 3' 
3' 
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5' 
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mechanism which does not involve overexpression of P-glycoprotein. Any alteration of 
topoisomerase II with regard to either a lower level of topoisomerase II enzyme or a 
mutation of topoisomerase II, which alters ATP binding, can lead to drug resistance [Bugg, B. 
Y. et al (1991)]. This decreases the amount of covalent DNA complex resulting in decreasing 
etoposide activity. Additionally, lengthening of the cell cycle can reduce etoposide efficacy 
since etoposide action is specific to S and G2 phases of cell cycle, which contain a very high 
level of topoisomerase II enzyme [Long, B. H. et al (1991)]. Increased DNA repair also leads 
to drug resistance whereby single- or double-stranded DNA breakage resulting from 
etoposide treatment can be repaired quickly when etoposide is removed. 
 
1.2.2 Cisplatin 
Cisplatin is also known as Dichloroplatinum azanide, Cisplatinum, Cis-
diamminedichloroplatinum (II) (CDDP) or cis-DDP. There are 3 antitumour drugs, which 
belong to the platinum group, including cisplatin, carboplatin and oxaliplatin. cis-DDP were 
first synWKHVLVHG LQ DQG LV JHQHUDOO\ NQRZQ DV 3H\URQH¶V FKORULGH ,Q WKH V Cis-
diamminedichloroplatinum (II) and cis-DDP forms of platinum were successfully used in 
treatment of cancer [Reviewed in Lippard, S. J. (1982)]. Later, cisplatin was identified as the 
main anti-proliferative agent among the platinum group, and was generally used to treat 
cancer [Review in Cepeda, V. et al (2007)].   
 
The structure of cisplatin 
The platinum atom contains 2 nitrogen atoms of the ammine ligands and 2 chloride atoms of 
cis-DDP. The structures of cisplatin and other forms of platinum group including carboplatin, 
oxaliplatin and biologically inactive transplatin are shown in Figure 1.9. Oxaliplatin is the only 
member of the platinum group claimed to be able to overcome cisplatin resistance in tumours 
such as colorectal carcinoma [Reviewed in Cepeda, V. et al (2007)].  
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 The mechanism of action 
The main target of cisplatin is gDNA and the N7 atoms of guanine and adenine, which are 
located on the major groove of the double helix (Figure 1.10, D). There are 2 different forms 
of binding kinetics between cisplatin and DNA: monofunctional formation (cis-
[Pt(NH3)2(H2O)]:DNA adducts) (Figure 1.10, C) and bifunctional formation (cis-
[Pt(NH3)2]:DNA) (Figure 1.10, A and B). Bifunctional formation can occur by either 
interstrand (Figure 1.10, B) or intrastrand cross-links (Figure 1.10, A). The majority of 
cisplatin and DNA formation (60-65%) are 1, 2-d(GpG) intrastrand cross-links although 
d(ApG) intrastrand cross-links do occur (20-25%). Monofunctional and bifunctional 
formations result in inhibition of DNA replication and transcription [Payet, D. et al (1993)]. 
Cisplatin results in cell death or inhibition depending on the concentration applied. The effects 
of cisplatin in G2 arrest and DNA double-strand breaks were studied in murine leukaemic 
L1210 cells and the results demonstrated that cells were transiently inhibited at G2 phase for 
24-48 hours at a lower concentration of cisplatin (1.67 µM) then cells were recovered after 
drug removal. Whilst the higher concentration of cisplatin (26.67 µM) led to cells arresting at 
the G2 phase and double stranded DNA breakage, which could not be recovered within 96 
hours [Sorenson, C. M. and Eastman, A. (1988)].     
 
 
 
Figure 1.9 The chemical structures of the platinum group. The chemical structures of 
the active derivatives of platinum compound including cisplatin, carboplatin and oxaliplatin 
and the inactive derivative: transplatin [Cepeda, V. et al (2007)]. 
 
 
Carboplatin Cisplatin Oxaliplatin Transplatin 
 31 
Resistance mechanism to cisplatin  
The resistance of tumour cells to cisplatin treatment is still an unresolved problem in many 
types of cancers. At present, many studies have tried to investigate the mechanisms of 
cisplatin resistance, however, the exact mechanisms to explain cisplatin resistance in tumour 
cells are not fully understood. Three mechanisms were postulated to be important in cisplatin 
resistance: decreasing intracellular cisplatin accumulation [Richon, V. M. et al (1987), 
Teicher, B. A. et al (1987) and Waud, W. R. (1987)] e.g. overexpression of transporter 
membrane protein e.g. SQM1 identified in human squamous carcinomas [Bernal, S. D. et al 
(1990)] and CPR-200 identified in murine thymic lymphoma sublines [Kawai, K. et al (1990)], 
increasing levels intracellular thiols inactivating cisplatin [Andrews, P. A. et al (1985),  
 
 
Figure 1.10 Cisplatin and DNA formation. Figure demonstrates various binding forms 
between cisplatin and DNA; bifunctional formation consisting of 2 binding sites of cisplatin 
within the same DNA strand [intrastrand cross-link (A)] or between 2 DNA strands 
[interstrand cross-link (B)], monofunctional formation composing one binding site of cisplatin 
on one DNA strand (C) and the N7 position of Guanine, which is the specific site for cisplatin 
binding to DNA (D) [Adapted from Cepeda, V. et al (2007)]. 
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Hromas, R. A. et al (1987), Dabholkar, M. et al (1992) and Schilder, R. J. et al (1990)] and 
an increase in DNA repair [Parker, R. J. et al (1991), Eastman, A. and Schulte, N. (1988) and 
Sheibana, N. et al (1989)]. However, evidence of these 3 main mechanisms of cisplatin 
resistance is inconsistent and has not been convincingly confirmed. 
 
1.2.3 Irinotecan 
Irinotecan is also known as CPT-11, Camptosar® and 7-ethyl-10-[4-(1-piperidino)-1-
piperidino] carbonyloxycamptothecin, which is a semisynthetic water soluble analogue of 
camptothecin. In 1983, camptothecin was primarily discovered and synthesised in Japan 
[Rothenberg, M. L. (2001)]. Irinotecan, which has a broad spectrum of anticancer treatment, 
was discovered earlier and applied to treat cancers for many years before the mechanisms of 
irinotecan action in cancer treatment were revealed [Wall, M. E. et al (1966)]. At present, 
irinotecan is widely used to treat many types of cancers such as colorectal cancers, 
oesophageal cancers, gastric cancers, non-small-cell and small-cell lung cancers, leukaemia, 
lymphomas, and CNS cancers [Reviewed in Rothenberg, M. L. (2001)]. Currently, the 
metabolism of irinotecan is very complicated and it has been extensively studied due to the 
many enzymes, which are involved in the process of metabolising and conventing irinotecan 
to various forms.    
 
The structure of irinotecan 
The chemical structure of irinotecan is illustrated in Figure 1.11 including its metabolites. 
Several enzymes metabolise irinotecan to either active or inactive metabolites including 
cytochrome P450 3A (CYP3A), carboxylesterases (CES) and uridine diphosphate-
glucuronosyltransferase 1A (UGT1A). In humans, irinotecan is catalysed by CES to the most 
potent metabolite: SN-38 (7-ethyl-10-hydroxycamptothecin), which has 100 ± 1,000 fold 
higher potency than the parental compound [Kawato, Y. et al (1991)]. CYP3A also plays an 
important role in the metabolic pathway of irinotecan converting it to inactive metabolites 7-
ethyl-10-[4-N-(5 aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) (APC) and 7-
ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin (NPC). Additionally, NPC might 
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also be metabolised by CES and converted back to SN-38, which is an active metabolite 
again [Santos, A. et al (2000)]. UGT1A is an important enzyme in glucuronidation of SN-38 
ZKHUHE\ǃ-glucuronic acid is conjugated to SN-38 resulting in formation of 10-O-glucuronyl-
SN-38 (SN-38G) (Figure 1.11, e). This is the main mechanism to detoxify SN-38 [Iyer, L et al 
(1998)].  
 
 
Figure 1.11 Metabolism pathway of irinotecan. There are several enzymes involving in 
metabolism of irinotecan. Irinotecan (a) is converted to an active metabolite (SN-38) (d) by 
Carboxylesterase (CES). Cytochrome P450 3A (CYP3A) functions to metabolise irinotecan to 
inactive metabolites; 7-ethyl-10-[4-N-(5 aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin) (APC) (b) and 7-ethyl-10-(4-amino-1-piperidino) 
carbonyloxycamptothecin (NPC) (c). To detoxify SN-38, which is the most potent metabolite 
of irinotecan, SN-38 is glucuronised by UGT1A whereby SN- LV FRQMXJDWHG ZLWK ǃ-
glucuronic acid resulting in the formation of 10-O-glucuronyl-SN-38 (SN-38G) (e) [Adapted 
from Smith, N. F. et al (2006)].  
APC NPC 
Irinotecan 
(a) 
(b) (c) 
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The mechanisms of action 
The main target of irinotecan is DNA topoisomerase I enzyme, which is an important enzyme 
in reducing DNA twisting and supercoiling, consequently, it is an essential enzyme in the 
process of DNA transcription, replication and repair recombination. Irinotecan binds reversibly 
to the DNA-topoisomerase I complex resulting in its stabilisation. This process inhibits 
resealing of single stranded DNA breaks and prevents accession of the replication folk leading 
to double stranded DNA breaks ultimately causing cell death. However, irinotecan can only 
effectively target the DNA-topoisomerase I complex while cells are in the G2 or S phase 
[Hsiang, Y. H. et al (1989)]. Therefore, irinotecan effectively targets proliferating cells 
particularly in rapidly dividing tissues such as bone marrow cells and intestinal mucosa. 
Significant adverse effects of irinotecan are myelosuppression and diarrhoea, which limit 
irinotecan dose for treatment [Rowinsky, E. K. et al (1994)]. For excretion of irinotecan and 
all of its metabolites, the ABC transporter superfamily is the main transporter via a 
hepatobiliary pathway in faeces [Slatter, J. G. et al (2000)]. 
 
Resistance mechanisms to irinotecan 
Four general mechanisms have been postulated to be involved in irinotecan resistance. The 
first mechanism is an alteration of pharmacokinetics and metabolism of irinotecan. Any 
factors, which favour the production of inactive metabolites, result in irinotecan resistance 
such as overexpression of UGT1A [Takahashi, T. et al (1997)] or CYP3A [Gupta, E. et al 
(1997)] and decreasing CES level [van Ark-Otte, J. et al (1998)]. The second mechanism is 
active drug transporters. Many studies have demonstrated that ABC transporters play a role 
in irinotecan resistance including ABCB1, MRP [Chu, X. Y. et al (1999)], cMOAT, MRP2 [Koike, 
K. et al (1997)] and ABCG2 [Maliepaard, M. et al (2001)]. The third mechanism is 
topoisomerase I level, one study reported that a low level of topoisomerase I activity 
correlated with irinotecan resistance in a resistant cell line compared to parental cell line 
[Giovanella, B. C. et al (1989)]. The last mechanism is topoisomerase I mutations: any 
mutations that reduce the affinity of irinotecan binding. Mutations of topoisomerase I have 
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been detected in murine cell lines resistant to irinotecan [Reviewed in Saleem, A. et al 
(2000)]. 
 
1.2.4 Methotrexate 
Methotrexate, a IRODWHDQWDJRQLVWLVDOVRNQRZQDV$PHWKRSWHULQĮ-Methopterin or MTX. In 
1948, aminopterin (2, 4-diaminopteroyl glutamic acid), the original folate antagonist 
compound, was used to treat lymphocytic leukaemia in children [Farber, S. et al (1974)]. 
Methotrexate is not only used as an antineoplastic but also as anti-inflammatory in treatment 
of rheumatoid arthritis (RA) [Weinblatt, M. E. et al (1985) and Williams, H. J. et al (1985)] 
and psoriasis [Weinstein, G. D. et al (1990)]. Additionally, it is used to suppress immune 
reaction in the prophylaxis of acute graft-versus-host disease (GVHD) [Storb, R. et al 
(1986)]. Currently, methotrexate is extensively used to treat many types of cancers.   
 
The structure of methotrexate 
Basically, polyglutamation occurs intracellularly to convert physiological folates to 
polyglutamate storage forms in the liver, erythrocytes and various tissues. Folylpolyglutamate 
synthetase (FPGS) functions to add glutamate groups in gamma linkage to the end carboxyl 
group of the neighbouring folyl glutamate. Similarly, methotrexate, a folate analogue, is also 
converted to polyglutamate form (7-hydroxy methotrexate) by polyglutamation in the liver 
and erythrocytes (Figure 1.12, d) [Baugh, C. M. et al (1973) and Jacobs, S. A. et al (1977)]. 
There are other 2 metabolic forms of methotrexate, which have less efficiency in inhibition of 
DHFR: DAMPA (Figure 1.12, a) and polyglutamated metrotrexate (Figure 1.12, c). The 
importance of polyglutamation of methotrexate is 1) to intracellularly store any excess 
methotrexate after binding to dihydrofolate reductase enzyme (DHFR) and thus maintain a 
high degree of DHFR inhibition even after drug removal [White, J. C. et al (1975)] and 2) to 
increase the affinity of binding to DHFR [Jacobs, S. A. et al (1975)]. Unbound methotrexate 
(MTX-Glu1) or MTX-Glu2 and MTX-Glu3 are removed from cells, however, MTX-Glu4 and MTX-
Glu5 are retained in cells for at least 24 hours after drug removal [Jolivet, J. et al (1983)].  
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The mechanisms of action 
The main target enzyme of methotrexate is DHFR, which is an essential enzyme for 
intracellular folate metabolism. Methotrexate is a potent inhibitor for DHFR resulting in 
inhibition of DNA synthesis [White and Goldman, (1976)]. The effect of methotrexate has 
been proposed to depend on the concentration and the stage in the cell cycle. Studies in 
human peripheral T cells in vitro demonstrated that cells were inhibited in their proliferation 
but were not induced to undergo apoptosis at a high concentration (100 µM) or a low 
concentration (0.01 µM) of methotrexate [Genestier, L. et al (1998)]. Whilst Chinese hamster 
ovary cells underwent apoptosis in response to 128 µM methotrexate [Barry, M. A. et al 
(1990)]. Therefore, the correlation between methotrexate concentration and cell apoptosis 
 
 
Figure 1.12 Methotrexate chemical structure and intracellular metabolic form of 
methotrexate. Methotrexate (b) is metabolised by intestinal bacteria to Diamino-2,4-N-10-
methylpteroic acid (DAMPA) (a) and hydroxylated at 7-position of the pterine ring in 
hepatocytes to form 7-Hydroxy-methotrexate (7-OH-MTX) (d). The polyglutamation of 
methotrexate occurs by adding 1 ± 4 new glutamyl groups into an unusual gamma-peptide 
linkage (c) [Reviewed in Genestier, L. et al (2000)]. 
Diamino-2,4 N10 méthylptéroïc acid (DAMPA) 
Methotrexate 
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remains unclear due to the fact that methotrexate concentrations from these 2 studies 
were similar but provided different effects. Cells were only effectively induced to undergo 
apoptosis by methotrexate while they were in S or G2 phases of cell cycle. Peripheral T cells 
were induced to stay in G1 phase when they were treated with methotrexate resulting in 
resistance to methotrexate-induced apoptosis [Genestier, L. et al (1998)]. Studies in 
peripheral blood lymphocytes suggested that the maximum effect of apoptosis were detected 
after 8 hours of methotrexate exposure and the half-life of methotrexate was approximately 3 
days [Genestier, L. et al (1998)]. 
 
Resistance mechanisms to methotrexate 
There are 3 main mechanisms, associated with resistance to methotrexate. An overproduction 
of DHFR resulting from gene amplification is a common mechanism for acquired methotrexate 
resistance after drug exposure [Schimke, R.T. (1988) and Srimatkandada, S. et al (1989)]. 
However, an alteration of the ability of methotrexate to bind to DHFR is primarily believed to 
result in intrinsic resistance, and has been found in different methotrexate resistant cell lines 
 [Jackson, R. C. et al (1976)]. Decreasing drug accumulation or increasing drug efflux is the 
final significant mechanism leading to methotrexate resistance, which correlates with several 
transporters. Reduced or impaired folate carrier (RFC), an important transporter of folates 
DQG IRODWHDQDORJXHV OHDGV WRPHWKRWUH[DWH UHVLVWDQFH >6LURWQDN)0DQG2¶/HDU\ D. F. 
(1991)]. Overexpression of ABC transporters such as ABCC1, MRP2 [Hooijberg, J. H. et al 
(1999)], ABCB1 [Gifford, A. J. et al (1998)] and ABCG2 [Volk, E. L. et al (2000)] also plays 
an important role in increasing methotrexate efflux resulting in reduction of methotrexate 
cytotoxicity. Additional minor mechanisms include impaired polyglutamation resulting from 
alteration or mutation of FPGS and failed polyglutamation [Chabner, B. A. et al (1985)]. 
 
In summary, etoposide, cisplatin, irinotecan and methotrexate are common chemotherapeutic 
drugs used to treat paediatric brain tumours. They have different mechanisms to attack 
cancer cells causing inhibition of proliferation or apoptosis. However, all chemotherapeutic 
drugs similarly target proliferating cells. Currently, chemotherapy is still a common treatment 
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for paediatric brain tumours and it is particularly in children aged less than 2 years, to 
avoid destroying the developing nervous system with radiation. Chemotherapy regimens 
commonly comprise more than one drug to attack cancer cells each with different 
mechanisms, to increase the effectiveness of treatment. However, the outcome of 
chemotherapy is not as good as expected partially due to the fact that cancer cells develop 
multidrug resistance. Hence, cancer cells are resistant to many drugs regardless of the types 
of drugs or drug chemical structure. At present, multidrug resistance in cancers is an 
unconquered enigma resulting in tumour recurrence, poor prognosis and unsatisfactory 
treatment outcome. One of the most important mechanisms playing a role in multidrug 
resistance is active drug efflux by transporters. The ABC transporter family is currently 
believed to initiate multidrug resistance in many cancers and has been extensively studied 
and discovered to correlate with multidrug resistance in tumours resulting in failure of 
chemotherapy.     
 
1.3 ATP-binding cassette (ABC) transporters 
 
Drug resistance in cancers is a multifactorial phenomenon since there is possibly more than 
one mechanism involved in drug resistance with regard to overexpression of active drug 
efflux transporters, improved DNA repairing, increased detoxification of drug, decreased drug 
uptake and altered cell cycle. Overexpression of active drug transporters has been found in 
many drug resistant cancer cells and it causes resistance to many drugs in different groups or 
chemical structures. This is known as multidrug resistance. ABC transporters are currently 
postulated as the most important drug resistance mechanism since these transporters have a 
broad spectrum of specificity to many substrates and also chemotherapeutic drugs resulting 
in multidrug resistance. At present, 49 ABC transporters, which correlate with substrate 
efflux, have been identified in the human genome [Dean, M. et al (2001)]. Most ABC 
transporters have a role in cellular transportation to excrete substrates from cells. Currently, 
15 ABC transporters are correlated to chemotherapeutic drug efflux, but only 3 main ABC 
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transporters (ABCB1, ABCC1 and ABCG2) have been extensively studied and proposed as 
important in active drug efflux in brain tumours [Schinkel, A. H. et al (2003)].  
 
These transporters were named ABC transporters because the structure contains an ATP-
binding cassette region which provides energy for this transporter to export intracellular 
substrates to extracellular spaces [Bunting, K. D. (2002)]. ABC transporters mainly comprise 
2 components: transmembrane domain (TMDs) and nucleotide-binding domain (NBD) or ATP-
binding region. General ABC topology is demonstrated in Figure 1.13, a. The full length of the 
ABC transporter structure is normally composed of two homologous halves each containing a 
6TMDs and a NBD with the exception of some ABC transporters, which have distinct 
topologies, such as ABCC1 and ABCG2 described in more detail later. Each domain connects 
to the other via a flexible linker region, an important part involved in the catalytic activity of 
the transporter [Bunting, K. D. (2002)]. The NBD is an important unit which hydrolyses 
adenosine triphosphate (ATP) to provide energy for the transporter to transport substances 
across membranes. The NBD, an ~200 amino acid residue region, contains 2-domain 
architecture; a RecA-like catalytic domain and a smaller helical domain. The NBD also 
comprises a highly conserved region consisting of a Walker A motif, a Walker B motif, and a 
signature motif (linker peptide or LSGGQ motif) used to classify ABC transporters into seven 
types which are detected in both normal and malignant cells (ABCA through to ABCG), D-
loop, H-loop and Q-loop as shown in Figure 1.13, b [Reviewed in Kos, V. and Ford, R. C. 
(2009)]. Human ABC transporters involved in drug transportation are as shown in Table 1.8 
[Leonard, G. D. et al (2003)]. TMDs are the functional unit which selectively effluxes specific 
substrates including sugars, amino acids, glycans, cholesterol, phospholipids, peptides, 
proteins, toxins, antibiotics, and xenobiotics [Gottesman, M. M. and Ambudkar, S. V. (2001)]. 
ABC transporters are not only involved in the efflux of many of these substrates from cells, 
but are also involved in the excretion of toxic substances from liver, kidneys and the 
gastrointestinal tract. Furthermore, such transporters protect vital organs, including brain, 
placenta and testis, from toxic agents penetrating through to these organs [Leonard, G. D. et 
al (2003)].  
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1.3.1 ABCB1  
ABCB1 also known as MDR1 or P-glycoprotein (P-gp) was initially discovered in colchicine 
resistant Chinese hamster ovary cells but it was not present in the wild type cells. These cells 
also showed cross-resistance to other drugs. This transporter was named P-glycoprotein 
because it was a glycoprotein that had the ability to alter permeability of cell membrane 
[Juliano, R. L. and Ling, V. (1976)]. ABCB1 is a large membrane protein comprising more 
than 1,200 amino acid which has a molecular weight of approximately 170 kDa. ABCB1 is a 
product of the ABCB1 (MDR1) gene which is located on chromosome 7p21 in humans. The 
MDR1 gene is a member of the MDR gene family including MDR2 and MDR3 genes.  
 
In normal tissues, ABCB1 is detected in human brain located on the luminal membrane of 
endothelial cells in the blood brain barrier (BBB) and had a very important role in protecting 
vital organs (brain and spinal cord) from toxic agents [Regina, A. et al (2001)]. Additionally, 
ABCB1 was also located on the transport epithelium of liver, kidney and gastrointestinal tract 
[Reviewed in Szakács, G. et al (2006)].   
 
The structure of ABCB1 
The 1,280 amino acid polypeptide of ABCB1 consists of two NBDs, two transmembrane 
domains (TMDs) linked by a 60-70 amino acid linker region with multiple phosphorylation 
sites and glycosylation sites (GS) [Figure 1.14]. Individual TMDs comprised 6 helices, 
therefore, ABCB1 consists of 12 helices in total [Loo, T. W. and Clarke, D. M. (1997)]. The 
current crystal structure of ABCB1 is demonstrated in Figure 1.15 and shows that the ABCB1 
structure is an inverted V. Transmembrane helixes (TMHs) of ABCB1 correlating to drug efflux 
are TMH4 and TMH5 associated with TMD2 and TMH10 and TMH11 associated with TMD1. 
These TMHs are close to the extracellular site contributing to substrate transport [Ravna, A. 
W. et al (2009)]. Transmembrane domains are the regions, which bind to ABCB1 substrates 
or anticancer drugs and these are hydrophobic (either neutral or positively charge). This 
binding stimulates ATPase activity of ABCB1 and the 2 ATP binding domains were required for 
the transport mechanism but these 2 ATP domain did not work simultaneously. The first 
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ATPase event is proposed to be transport drug across the membrane whilst the second 
ATPase event is proposed to alter ABCB1 structure ready for the next round of transportation 
[Ambudkar, S. V. et al (1999), Senior, A. E. and Bhagat, S. (1998) and Sauna, Z. E. and 
Ambudkar, S. V. (2000)].   
 
ABCB1 and multidrug resistance 
ABCB1, the first ABC transporters discovered in both normal tissues and many cancers, has 
physiological function in the blood brain barrier (BBB) to prevent cytotoxic drugs entering 
vital organs e.g. brain and spinal cord [Regina, A. et al (2001)], and also plays a role in 
multidrug resistance by efflux of a broad spectrum of drugs in cancer cells overexpressing 
ABCB1. Therefore, both physiological function and active drug efflux may initiate multidrug 
resistance in brain tumours. ABCB1 was hence extensively studied with regard to the 
correlation between ABCB1 and multidrug resistance in brain tumours. Many studies revealed  
 
 
Figure 1.13 General topology of ABC transporters and 3D figure of NBD. General 
topology of ABC transporters comprises two TMDs located in membrane and two NBDs 
located in cytoplasm (a). ABC region of ABC transporters is composed of three highly 
conserved regions including Walker A, B motifs and signature C motif including D, H and Q-
loop. The highly conserved signature C motif lies between Walker A and B regions (b) [(a): 
Adapted from Ravna, A. W. et al (2009) and (b): Obtained from Kos, V. and Ford, R. C. 
(2009)].  
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Table 1.8 ABC transporters involved in drug resistance [Adapted from Dean, M. et al (2005), Gottesman, M. M. et al (2002), 
Dean, M. et al (2001) and Szakacs, G. et al (2006)] 
Genes Protein 
/alias 
Location Chemotherapeutic drugs effluxed by 
transporter 
Other drugs and substrates Normal 
location 
ABCA2 ABCA2 9q34 Estranustine Steroid derivatives, lipids Brain, monocyte 
ABCB1 ABCB1 
(MDR1) 
7p21 Doxorubicin, daunorubicin, vincristine, 
vinblastine, actinonycin-D, paclitaxel, 
doetaxel, etoposide, teniposide, 
bisantrene, homoharmingtonine (STI-571) 
Digoxin, saquinivir, neutral and 
cationic organic compounds, many 
commonly used drugs 
Intestine, liver, 
kidney, blood-
brain barrier 
ABCB4 MDR2 7q21.1 Phophatidylcholine, some hydrophobic 
drugs 
Paclitaxel, vinblastine Liver 
ABCB11 BSEP, 
SPGP 
2q24 Paclitaxel Bile salts Liver 
ABCC1 ABCC1 16p13.1 Doxorubicin, epirubicin, daunorubicin, 
vincristine, etoposide, colchicine, 
camptothecins, methotrexate 
Glutathione and other conjugates 
and other conjugates, organic 
anions, rhodamine, leukotriene C4 
Widespread all 
tissues 
ABCC2 MRP2 
(cMOAT) 
10q24 Vinblastine, cisplatin, doxorubicin, 
methotrexate, etoposide, vincristine 
Similar to ABCC1, non-bile salt 
organic anions, sulfinpyrazone 
Liver, kidney, 
intestine 
ABCC3 MRP3 
(MOAT-D) 
17q21.3 Teniposide, etoposide, methotrexate, 
cisplatin, vincristine, doxorubicin 
Glucuronate and glutathione 
conjugates, anti-folates, bile acids 
Pancreas, 
kidney, intestine, 
liver, adrenal 
ABCC4 MRP4 
(MOAT-B) 
13q32 Methotrexate, thiopurine, 6-
mercaptopurine, 6-thioguanine and 
metabolites 
Nucleoside analogues, organic 
anions, PMEA, cAMP, cGMP 
Prostate, testis, 
ovary, intestine, 
pancreas, lung 
ABCC5 MRP5 
(MOAT-C) 
3q27 6-mercaptopurine, 6-thioguanine and 
metabolites 
Nucleoside analogues, cyclic 
nucleotides, organic anions, PMEA, 
cAMP, cGMP 
Widespread 
ABCC6 MRP6 
(MOAT-E) 
16p13.1 etoposide Anionic cyclic pentapeptide Liver, kidney 
ABCC10  6p21 Vinblastine, vincristine, docetaxel, 
paclitaxel 
Cyclosporin, MK571  
ABCC11 MRP8 16q11-
q12 
5-fluorouracil PMEA, cAMP, cGMP  
ABCG2 MXR, 
BCRP, 
ABC-P 
4q22 Estramustine, mitoxantrone, topotecan, 
doxorubicin, daunorubicin, irinotecan, 
imatinib, methotrexate 
Anthracyclines, steroid derivatives, 
lipids, pheophorbide A, Hoechst 
33342, rhodamine 
Placenta, 
intestine, breast, 
liver 
BCRP=breast cancer resistance protein, cAMP=cyclic adenosine monophosphate, cGMP=cyclic guanine monophosphate, 
MDR=multidrug resistance, MRP=multidrug-resistance-associated protein, MXR=mitoxantrone-resistance protein, PMEA=9-[2-
(phosphonomethoxy)ethyl]adenine 
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Figure 1.14 ABCB1 structure. ABCB1 structure in cell membranes comprises two ABC 
segments (ATP binding domains or nucleotide binding domains: NBDs), two 6TMDs and 
glycosylation sites. There are 2 glycosylation sites indicated by branching black lines, which are 
located in extracellular part of ABCB1. Two 6TMDs are connected by NBDs comprising Walker A 
(    ), Walker B (    ) and a signature C motif (     ) [Adapted from Löscher, W. and Potschka, H. 
(2005)]. 
 
Figure 1.15 Crystal structure of ABCB1 transporter. Three dimension structure of ABCB1 
is an inverted V shape. In the arm of V shape, NBD1 is associated with TMH1, 2, 3 and 6 of 
TMD1 and TMH10 and 11 of TMD2 and NBD2 are associated with TMH4 and 5 of TMD1 and 
TMH7, 8, 9 and 12 of TMD2 [Adapted from Ravna, A. W. et al (2009)].  
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a relationship between ABCB1 and multidrug resistance in many cancer types. However, the 
multidrug resistance mechanism of ABCB1 in brain tumours is not fully understood. One study 
demonstrated that ABCB1 was intensely expressed on the luminal surface of endothelial cells of 
human gliomas, and these endothelial cells expressing ABCB1 probably formed a brain tumour 
barrier (BTB) which restricts the entrance of chemotherapeutic agents to targeted cells. 
Therefore, active drug efflux was increased to remove xenobiotics from the brain tumour cells 
[Tanaka, Y. et al (1994)]. A study to investigate the relationship between ABCB1 expression 
and a grading of astrocytic tumours showed that ABCB1 expression was detected in 31% of low 
grade astrocytomas and 88% of high grade astrocytomas. This study suggested that ABCB1 
expression influenced the prognosis of gliomas, whereby a high expression of ABCB1 may 
result in increasing chemoresistance [von Bossanyi, P. et al (1997)]. In addition, the study of 
mdr1a (-/-) mice found that the accumulation of neurotoxic drugs in brain increased up to 80-
100 fold when compared with the wild type mice exposed to digoxin, ondancetron, loperamide, 
paclitaxel, vinblastin and doxorubicin [Schinkel, A. H. et al (1994)]. Therefore, a great deal of 
evidence confirmed that ABCB1 correlated with multidrug resistance. Hence, it was proposed 
that ABCB1 was overexpressed in drug resistant cancer cells and it reduced drug cytotoxicity 
by increase drug export into extracellular spaces resulting in decreased intracellular drug 
accumulation. Additionally, a high level of ABCB1 detected in cancers was associated with high 
level of chemoresistance resulting in a worse treatment outcome [Ling, V. (1997) and Regina, 
A. et al (2001)].  
 
Hence, ABCB1 is believed to be one of the active drug efflux transporters correlating with 
multidrug resistance in brain tumours. The function of these transporters is to export cytotoxic 
drugs to extracellular spaces regardless of the type or structure of drugs resulting in resistance 
to many chemotherapeutic drugs. This is the reason why the treatment outcome is still poor 
even though many drugs having different mechanisms of actions are combined in a 
chemotherapeutic regimen. The mechanism to explain how ABCB1 is able to efflux a broad 
spectrum of drugs is still unclear. However, 3 mechanisms have been proposed to explain the 
efflux function of ABCB1. Firstly, the hydrophobic vacuum cleaner model describes that many 
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lipophillic substrates penetrated into lipid bilayers (outer or inner leaflet) of the cell 
membrane then these substrates were absorbed by the TMDs of ABCB1 and effluxed into the 
extracellular spaces prior to the substrate penetrating into cytoplasms (Figure 1.16, a) 
[Higgins, C. F. and Gottesman, M. M. (1992), Raviv, Y. et al (1990, Homolya, L. et al (1993) 
and Shapiro, A. B. et al @7KHVHFRQGµµIOLSSDVH¶¶PRGHOGHVFULEHVKRZ$%&%IXQFWLRQV
to translocate substrates from the inner leaflet to the outer leaflet of lipid bilayers resulting in a 
concentration gradient between the outer and the inner leaflet (Figure 1.16, b). Drug binding 
sites of ABCB1 can then be exposed to the extracellular medium therefore, drugs are released 
into extracellular space depending on their hydrophobicity [Higgins, C. F. and Gottesman, M. M. 
(1992) and Margolles, A. et al (1999)]. Finally, the membrane partitioning model explains three 
different factors involved in drug efflux of ABCB1 transporter: the lipid-waterpartition 
coefficient (Klip), the apparent binding affinity (Kd) and the intrinsic binding affinity (Kdlip). 
Substrates bind to ABCB1 within the membrane (Figure 1.16, c and d). The lipid-waterpartition 
coefficient (Klip) indicates the ability of the aqueous phase of substrates to penetrate into the 
lipid bilayers. Therefore, the Klip value indicates the ability of the membrane to concentrate 
substrates in the lipid bilayers. The Klip of ABCB1 is approximately 300 ± 20,000 fold that of the 
substrates concentration in the aqueous solution. The intrinsic binding affinity (Kdlip) indicates 
the ability of substrates in binding to the transporter within the membrane. These 2 
parameters; Klip and Kdlip, are an important factors, which influence the apparent binding affinity 
or the dissociation constant (Kd), which is the product of substrates penetrating to the lipid 
bilayers and the substrates binding to the transporter within the membrane [Eytan, G. D. et al 
(1997)]. Therefore, to overcome drug resistance, drug (lipophillicity) should be reduced 
resulting in a decrease in drug efflux by ABCB1 and hence the drug will be accumulated in cells. 
 
1.3.2  ABCC1 
ABCC1 is also known as MDR-associated protein1 (MRP1). The MRP1 gene spans 2.8 kb of 
DNA, which encodes an approximately 180-195 kDa membrane protein. Currently, 6 other 
human MRPs have been identified. ABCC1 (ABCC1) is the first MRP member and is located on 
chromosome 16 at band p13.13-13.12. It is expressed in the plasma membrane of several cells 
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including erythrocytes and many MDR tumours [Reviewed in Regina, A. et al (2001) and 
Bredel, M. (2001)]. In 1992, Cole and colleagues cloned ABCC1 from the human lung cancer 
cell line H69AR, which was selected by doxorubicin. Doxorubicin-selected H69AR cells had 
cross-resistance to many chemotherapeutic drugs but did not express ABCB1 [Cole, S. P. C. et 
al (1992)].   
 
 
 
Figure 1.16 The hydrophobic vacuum cleaner model, flippase model and membrane 
partitioning model. The hydrophobic vacuum cleaner model postulated that TMDs of ABCB1 
bound to substrates while they penetrated into the lipid bilayers but not into the cytoplasm 
then the substrates were exported into the extracellular spaces (a). Whilst the flippase model 
suggests that ABCB1 only translocates the substrates from the inner leaflet to the outer leaflet 
of lipid bilayers of cell membrane (b). The membrane partitioning model shows 2 different 
substrates. Kdlip is an intrinsic binding affinity, which is determined by the concentration of the 
substrates in the membrane and is relatively low. Substrates with a high Klip were able to get 
into the lipid bilayers with a high concentration compared to the aqueous solution but they will 
have a low Kd resulting from a low intrinsic binding affinity (c). Whilst the substrates with a low 
Klip results in a low concentration of the substrates in the membrane but they will have a high 
Kd resulting from a high intrinsic binding affinity (d) [Adapted from Eckford, P. D. W. and 
Sharom, F. J. (2009)].  
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ABCC1 expression is detected in most normal tissue types throughout our body, however, 
some normal tissues express a high level of ABCC1 including the adrenal gland, bladder, 
choroid plexus, colon, erythrocytes, kidney, lung, placenta, spleen, stomach, testis, helper T- 
cells, and both skeletal and cardiac muscle [Flens, M. J. et al (1996)]. ABCC1 is also detected 
in sensitive normal tissues with this protein being located on basal membranes of sertoli cells in 
testis to protect the germline cells from toxicity and on basolateral membranes in the choroid 
plexus to protect nervous system tissues from drugs in blood circulation getting into 
cerebrospinal fluid [Regina, A. et al (2001) and Bredel, M. (2001)]. A study in ABCC1 knockout 
mice found that mrp-/- mice were viable and fertile with no physiological abnormalities. These 
mice were more susceptible to etoposide (2 fold) and had increased levels of glutathione (GSH) 
in tissues of breast, lung, heart, kidney, muscle, colon, testes, bone marrow cells, blood 
mononuclear leukocytes, and blood erythrocytes. This study indicated that ABCC1 is not 
essential for growth and development but it does play an important role in drug detoxification 
and GSH metabolism [Lorico, A. et al (1997)].  
 
Structure of ABCC1 
The structure of the ABCC1 transporter is similar to MRP2/3/6. It consists of two 6 TMDs, two 
ATP binding sites, glycosylation sites and an additional amino N-terminal domain with 5TMDs 
(Figure 1.17). The additional 5TMDs located on the N-terminal domain is a distinct 
characteristic of the ABCC1 transporter. The 2 ATP binding sites contain highly conserved ABC 
regions comprising a Walker A, a Walker B and a signature C motif. The two N-linked 
glycosylation sites are located on the extracellular loops. [Bakos, É. et al (1996)]. 
 
ABCC1 and multidrug resistance 
ABCC1 was found to associate with multidrug resistance similar to ABCB1. It has been 
proposed that the level of MRP mRNA expression in glioma cells lines relates to the degree of 
anticancer sensitivity. High levels of MRP expression results in a poor response of cells to many 
anticancer agents such as etoposide, vincristine and adriamycin. On the contrary, cell lines are 
less chemoresistant when the level of MRP expression is low. The level of MRP expression might 
 48 
therefore indicate the degree of chemoresistance. Both ABCB1 and MRP have an influence on 
the acquired multidrug resistance phenotype [Abe, T. et al (1994)]. 
 
ABCC1 transports many substrates similar to ABCB1 however, the proposed mechanism of 
ABCC1 is distinct and different from ABCB1. Both ABCC1 and MRP2 have been studied and it is 
known that these two proteins are involved in MDR. MRP transporters are organic anion 
transporters which transport anionic drugs and neutral drugs by conjugating these drugs to 
acidic ligands (e.g. glutathione (GSH) and glucuronate of sulphate) and exporting them into the 
extracellular space [Jetlitschky, G. et al (1996)]. The principle functions of ABCC1 have been 
described; first, both hydrophobic and hydrophilic compounds are transported via ABCC1; 
second, it has an important role in normal physiology in the transportation of drugs across the 
 
 
Figure 1.17 The structure of ABCC1. ABCC1 structure is similar to ABCB1 (two 6TMDs and 2 
NBDs) but ABCC1 consists of an additional 5TMD, which is of unknown function and an 
extracellular N-terminus whilst the C-terminus of ABCC1 is located intracellularly. There are N-
linked glycosylation sites (indicated by black branching lines) on extracellular loops of TMDs. 
Intracellular NBDs comprise Walker A (    ), Walker B (     ) and a signature C motif (    ) 
[Adapted from Löscher, W. and Potschka, H. (2005)].  
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placenta and intestine; third, it is a vital component of the BBB and blood tumour barriers 
(BTBs) [Reviewed in Bredel, M. (2001)]. A recent mechanism of ABCC1 multidrug resistance 
was proposed whereby MRP interacted with the gluthatione (GSH) -linked enzyme system in 
drug efflux function. ABCC1 worked as an active anticancer efflux pump by conjugating with 
GSH called GSH conjugate export pump (GS-x). When drugs enter the cells, they were 
detoxified by conjugating with GSH-GST to form drug/GSH complexes. These drug/GSH 
complexes were then removed from cells via the GS-X pump resulting in chemoresistance 
[Jetlitschky, G. et al (1996)]. 
 
1.3.3 ABCG2  
ABCG2 initially known as the breast cancer resistance protein (BCRP)/mitoxantrone-resistance 
protein (MXP)/ABC transporter in placenta (ABCP) is located on chromosome 4q22 
[Sparreboom, A. et al (2003)]. ABCG2 is a membranous transporter protein, which is a 72-kDa 
protein and comprises 655 amino acids [Bunting, K. D. (2002)]. ABCG2 was initially isolated 
from the placenta, and is also expressed in many tissues such as the liver, small intestine, 
colon, lung, kidney, adrenal gland, sweat gland and endothelial of vein and capillaries [Ozvegy-
Laczka, C. et al (2005)]. ABCG2 is highly expressed in the trophoblast cells of the placenta 
where it is believed to eliminate toxic metabolites from the foetus and transport nutrients and 
useful compounds to the foetus via the foetal blood supply [Dean, M. et al (2001)]. The ABCG2 
knockout study showed that abnormal functions occurred in several tissues such as altered BBB 
function, intestinal drug absorption, foetal drug exposure and drug induced damage in 
testicular tubules, choroid plexus epithelium and oropharyngeal mucosa [Sparreboom, A. et al 
(2003)]. 
 
The ABCG2 transporter is able to transport large, hydrophobic, both positively and negatively 
charged molecules. Some substrates transported by ABCG2 are overlapping with ABCB1 and 
MRP transporters. However, ABCG2 can be distinguished from ABCB1 and ABCC1 in the fact 
that there are some substrates, which are transported by these two transporters, but are not 
transported by ABCG2 such as vinblastine, paclitaxel and verapamil (transported by ABCB1), 
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and calcein (transported by ABCC1) [Huang, Y and Sadee, W. (2006)]. Additionally, 
mitoxantrone resistant cell lines expressed ABCG2 but did not express ABCB1 or ABCC1 [Dean, 
M. et al (2001)]. 
 
Structure of ABCG2 
ABCG2 is called an ABC half transporter because of its structure, which is different from other 
ABC transporters. ABCG2 structure consists of only one 6TMD and one ATP-binding region 
(Figure 1.18). The ATP-binding region is located on the amino-terminal side (N) of the TMD 
whilst in ABCB1 and ABCC1 the NBD is located on caboxy-terminal side (C) of TMD. The half  
 
 
Figure 1.18 ABCG2 structure. ABCG2 is a half transporter, which comprises only one 6TMD 
with a glycosylation site and one ATP-binding region. The ATP-binding region, which provides 
energy to transport compounds, is located on the N-terminal side in cytoplasm. The position of 
ATP-binding region of ABCG2 is different from the other ABC transporters, which have this 
region on C-terminal side. Functional ABCG2 works as a homodimer. There are N-linked 
glycosylation sites (indicated by black branching lines) on extracellular loops of TMDs. 
Intracellular NBDs comprise Walker A (   ), Walker B (    ) and a signature C motif (   ) 
[Adapted from Löscher, W. and Potschka, H. (2005)].    
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transporter structure of ABCG2 lacks the required 4 domains for function [Gottesman, M. M. 
et al (2002)]. So dimerisation of ABCG2 is believed to be essential to function [Ozvegy-Laczka, 
C. et al (2005)]. 
 
ABCG2 and multidrug resistance 
ABCG2 was postulated to play a role in chemosistance in many cancers. Resistant cell lines 
overexpressing ABCG2 were serially selected for a high level of mitoxantrone resistance, these 
cell lines also had cross-resistance to anthracyclines but they were susceptible to vinca 
alkaloids or taxanes [Ross, D. D. et al (1999)]. ABCG2 is an important multidrug resistant 
transporter in many cancers [Reviewed in Robey, R. W. et al (2007)]. Since, human ABCG2 has  
been shown to confer resistance to various compounds such as mitoxantrone, methotrexate, 
topotecan, SN38 and flavopiridol, which are commonly used chemotherapeutic drugs. ABCG2 
was also found to be an important identified marker for the stem cell subpopulation; it was 
overexpressed in human hemotopoietic stem cells (HSCs) and rapidly downregulated with 
differentiation [Zhou, S. et al (2001)]. ABCG2 was therefore proposed as an important 
mechanism to protect HSCs from cytotoxic agents [Zhou, S. et al (2002)]. Also in breast 
cancer, ABCG2 was functionally overexpressed and played an important role in 
chemotherapeutic resistance in breast cancer cell lines and hence multidrug resistance in this 
cancer [Doyle, L. A. et al (1998)]. In vivo studies also demonstrated that mice with ABCG2 
knockout were more sensitive to chemotherapy and depletion of ABCG2 gene did not affect 
growth and fertility [Jonker, J. W. et al (2002) and Zhou, S. et al (2002)]. ABCG2 is another 
important ABC transporters associating with multidrug resistance in many cancers. Human 
ABCG2 has recently been found to interact with a high binding affinity with tyrosine kinase 
inhibitors (TKIs), Gleevec/Imatinib (STI-571) and Iressa (ZD 1839). These 3 newly developed 
anticancer drugs specifically to inhibit malignant cell growth and metastasis formation. Hence 
inhibition of ABCG2 can enhance the ability of these drugs to kill malignant cells [Reviewed in 
Sarkadi, B. et al (2004)]. 
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At present, ABCG2 drug resistance mechanisms are still unclear, with little known compared 
to ABCB1 and ABCC1 transporters. There are many unclear issues about ABCG2, and further 
study is required with regard to the characteristics of the ATP hydrolytic pathway, the location 
of drug interaction sites, transitions of the protein during translocation of drug and regions 
involved in conformational coupling. Residue 482 is believed to be situated on the binding site 
of ABCG2 and to be involved in increased drug recognition by driving mutation of arginine to 
either glycine or threonine. In a study of R482G, which is an isoform of ABCG2, by Clark et al 
the results obtained that there are 2 different drug binding sites on ABCG2: the first one is for 
rhodamine 123 and the second one is a [3H]-daunomycin site, which is able to recognise at 
least four other compounds [Clark, R. et al (2006)]. 
 
1.3.4 Substrates and inhibitors of ABCB1, ABCC1 and ABCG2 transporters 
ABCB1, ABCC1 and ABCG2 are polyspecific because they were able to interact with many 
substrates. In general, the substrates for ABCB1 are large organic molecules (200-1,900 Da), 
amphipathic and lipid-soluble in nature with an aromatic ring system. However, not all of 
ABCB1 substrates have these properties for example some of them have an uncharged or 
positively charge N atom. ABCC1 has 2 regions for substrate binding; the first one for 
amphipathic molecules, which is similar to ABCB1 and the second one (a more hydrophilic site) 
for free gluthatione or drug conjugated to glutathione. Similar to ABCC1, ABCG2 is able to 
transport both positively and negatively charged drugs including sulphates and drugs 
conjugated to glucuronide. Substrates and inhibitors of ABCB1, ABCC1 and ABCG2 are 
summarised in Table 1.9 (Reviewed in Eckford P. D. W. and Sharom, F. J. (2009)]. 
 
To summarise this section, 3 main ABC transporters (ABCB1, ABCC1 and ABCG2) are confirmed 
to correlate with multidrug resistance in many cancers. These 3 ABC transporters are 
overexpressed in resistant cell lines and lead to insensitivity of chemotherapy [Chen, C. J. et al 
(1986), Cole, S. P. C. et al (1992) and Doyle, L. A. et al (1998)]. Additionally, depletion of 
either the ABCB1, ABCC1 or ABCG2 gene resulted in increased chemotherapeutic susceptibility 
but growth and fertility of mice were not affected indicating that these genes were not essential  
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Table 1.9 Chemotherapeutic drugs and other compounds that interact with ABCB1, ABCC1 and ABCG2 transporters [Derived from Eckford P. D. W. and 
Sharom, F. J. (2009), Sparreboom, A. et al (2003), Nies, A. T. (2007) and Gottesman, M. M. et al (2002)] 
ABC subfamily NCBI 
protein 
accession 
no. 
Number of 
amino acids 
and gene 
location 
Tissues Substrates Inhibitors Physiological 
substrates 
ABCB1 
(MDR1/ABCB1) 
NP_000918 1280 amino acid, 
chromosome 
7p21 
Intestine, 
liver, 
kidney, 
placenta, 
BBB 
Anticancer drugs: 
bisantrene, mitoxantrone, doxorubicin, daunorubicin, 
topotecan, etoposide, teniposide, paclitaxel, docetaxel, 
vinblastine, vincristine 
Fluorescent dyes: 
Calcein-AM, H33342, rhodamine 123, 
tetramethylrosamine 
Natural products: 
Colchicine, curcuminoids 
Tyrosine kinase inhibitors: 
Gefitinib, imatinib mesylate 
Biricodar, 
cyclosporine A, 
elacridar 
(GF120918), 
LY335979, 
R101933, 
Valspodar 
(PSC833), 
Verapamil, 
tariquidar 
(XR9576) 
 
MRP1 
(ABCC1) 
NP_004987 1531 amino acid, 
chromosome 
16p13.13-13.12 
All tissues Anticancer drugs: 
Doxorubicin, daunorubicin, topotecan, irinotecan, 
etoposide, teniposide, vinblastine, vincristine, 
methotrexate 
Fluorescent dyes: 
BCECF, calcein, fluo-3 
Glucuronide conjugates: 
Estradiol-17-ǃ-D-glucuronide, etoposide glucuronide, 
glucuronosylbilirubin, NS-38-glucuronide 
Natural products: 
curcuminoids 
Sulfate conjugates: 
Dehydroepiandrosterone-3-sulfate, estrone-3-sulfate, 
sulfatolithocholyl taurine 
Tyrosine kinase inhibitors: 
Gefitinib, imatinib mesylate 
 
Biricodar, 
Cyclosporin A, 
Glutathione 
ethacrynic acid, 
clotrimazole 
Estrone 3-sulfate, 
ǃ-Glucuronosyl 
estradiol, 
GSHd+vincristine, 
Leukotriene C4 
ABCG2 
(BCRP/MXR/ABCP) 
NP_004818 655 amino acid, 
chromosome 
4q22 
Placenta, 
intestine, 
breast, liver 
Anticancer drugs: 
topotecan, irinotecan, etoposide, teniposide, 
Methotrexate, flavopiridol 
Fluorescent dyes: 
BODIPY-prazosin, H33342 
Glucuronide conjugates: 
Estradiol-17-ǃ-D-glucuronide 
Natural products: 
curcuminoids 
Sulfate conjugates: 
Acetaminophen sulfate, dehydroepiandrosterone-3-
sulfate, estrone-3-sulfate 
Tyrosine kinase inhibitors: 
Gefitinib, imatinib mesylate 
 
CI1033, 
Fumitremorgin 
C, GF120918, 
Ko134, 
Reserpine, 
Diethylstilbestrol 
Dehydroepiandrost
erone sulfate 
(DHEAS), Estrone 
3-sulfate 
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for mice viability [Jonker, J. W. et al (2002), Schinkel, A. H. et al (1994) and Zhou, S. et al 
(2002)]. Hence, ABC transporters are a major mechanism for multidrug resistance in cancers. 
Presently, cancers resistant to chemotherapy are believed to result from a small subpopulation 
of cells, which can survive after treatment and initiate new tumours resulting in tumour 
recurrence. This small subpopulation of cells resistant to chemotherapy could be correlated 
with expression of drug efflux transporters from the ABC transporter family, which protects 
cancer cells from drug cytotoxicity. A small subpopulation of stem-like cells has recently been 
discovered in many cancers and these cells may be a significant target for treatment to cure 
cancers, as discussed in the rest of section. 
 
1.4 Cancer stem cells 
 
Most malignant neoplasms have the capabilities of invasion, progression and metastasis. 
Current available treatments do not completely eradicate all cancer cells, consequently, many 
cancers recur within a few or several years after a complete course of treatment. Presently, 
most patients diagnosed with malignant cancer ultimately have a poor prognosis and fatal 
outcome. In light of this, many types of cancers have been extensively studied in order to 
develop a deeper understanding of the pathology of cancer and improve treatment by attacking 
the right targets. The origin of cancer cells is still obscure and complicated by the fact that 
cancer populations consist of heterogeneous cells. Studies have shown that not all cancer cell 
populations are able to sustain formation or growth of tumours. In the last decade, there have 
been several studies focused on the risk of stem cells in cancer. These aberrant stem-like cells 
DUH NQRZQ DV µFDQFHU VWHP FHOOV &6&V¶ RU µWXPRXU LQLWLDWLQJ FHOOV¶ 6HYHUDO VWXGLHV KDYH
hypothesised that CSCs, small populations of cancer cells, are the cell of origin from which the 
primary cancer initiates [Ignatova, T. N. et al (2002), Hemmati, H. D. et al (2003), Tan, B. T. 
et al (2006), Galli, R. et al (2004), Singh, S. K. et al (2003 and 2004)]. It is still unknown 
where cancer stem cells themselves originate from. Importantly, however, cancer stem cells 
have been hypothesised to be the chemoresistant population resulting in failure of 
chemotherapy and tumour recurrence.  
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  1.4.1 Normal stem cells and cancer stem cells 
Normal stem cells and CSCs have many shared characteristics such as self-renewal, indefinite 
proliferation and differentiation (although in the case of CSCs this is limited). Therefore, it is 
important to understand what mechanisms in CSCs, which regulate self-renewal and 
differentiation, are different from normal stem cells and drive these cells to proliferate and fail 
to fully differentiate hence forming tumours. The two most likely possible sources from which 
CSCs originate are normal stem cells and progenitor cells. Due to their observed sharing of 
many similar characteristics with normal stem cells, CSCs have been proposed to originate 
from normal stem cells. Normally, stem cells self-renew to maintain themselves and generate 
restricted progenitors, which ultimately differentiate into the mature cells composing a 
particular tissue. Genetic mutations are an important factor participating in tumour formation. 
Normal stem cells have ability to indefinitely proliferate throughout their life span resulting in 
these cells have been through proliferation process more frequent than progenitor cells which 
have less ability to proliferate. Therefore, normal stem cells have a higher risk to accumulate 
genetic mutations than progenitor or differentiated cells. Hence, genetic aberrations occurring 
in normal stem cells could cause tumour initiation [Reya, T. et al (2001) and Pardal, R. et al 
(2003)]. A model of tumour progression in normal stem cells and progenitor cells is showed in 
Figure 1.19 [Dean, M. et al (2005)]. Studies in leukaemia supported the fact that stem cells 
isolated from acute leukaemia expressed similar markers to normal stem cells and isolated 
leukaemic cells could differentiate into multiple mature cell lineages similar to normal stem 
cells [Lapidot, T. et al (1994)]. Later studies postulated that CSCs arose from progenitor cells, 
which acquired the self-renewal capability of stem cells. Hence, CSCs were proposed to be 
derived from progenitor cells able to generate both self-renewing and non self-renewing 
progenitor cells [Wagner, K. et al (2006)].       
  
1.4.2 Discovery of cancer stem cells 
In 1997, the first evidence was discovered that CSCs studied in acute myeloid leukaemia (AML) 
were a significant component of the tumour bulk [Bonnet, D. and Dick, J. E. (1997)]. Minor 
populations of leukaemic cells were derived and identified by side-population analysis. This 
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side-population not only expressed the specific surface marker CD34+ but also was pluripotent. 
CD34+/CD38- populations were established in NOD-SCID mice and new tumours were 
generated. Additionally, these tumours could be serially established. Furthermore, the 
phenotypes of these leukaemic-initiating cells (LICs) were very similar to normal hemopoietic 
stem cells (HSC) [Bonnet, D. and Dick, J. E. (1997)]. Therefore, it is possible that LICs might 
be derived from normal HSCs. Since then CSCs have also been studied in solid tumours such as 
breast cancers [Al-Hajj, M. et al (2003)], prostate cancers [Collins, A. T. et al (2001)] and 
brain tumours [Singh, S. K. et al (2003 and 2004) and Hemmati, H. D. et al (2003)]. CSCs of 
solid tumours express different stem cells markers, for example, tumour-initiating cells of 
 
     
Figure 1.19 A model of cancer stem cells and tumour progression in normal stem cells 
and progenitor cells. Normal stem cells generate progenitors that ultimately differentiated 
into mature cells. When a mutation occurs in normal stem cells, this results in abnormal 
proliferation of stem cells leading to a pre-malignant lesion. If further mutation(s) occur in 
these stem cells or progenitor cells, these cells have more aberrations and acquire more stem 
cell-like charateristics resulting in increased proliferation, evasion of the immune system, self-
renewal and decreased apoptosis. Hence, aberrant normal stem cells or progenitor cells can 
initiate malignant tumours [Dean, M. et al (2005)]. 
Normal 
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Proliferation 
Cell death 
Immune evasion 
Self-renewal 
Stem cells Multipotent 
progenitors 
Committed 
progenitors 
Mature cells 
Mutation in stem cells 
Additional mutation(s) in stem cells or in 
progenitor cells 
 57 
breast cancers express CD44+CD24-, CD29hiCD24+ and CD49f+CD24+Sca-1low 
immunophenotypes  [Tan, B. T. et al (2006)].  
 
The first evidence that supported the existence of stem cell-like cells in human brain tumours 
was a study that isolated cells from a post-surgery specimen of human glioblastoma 
multiforme. Isolated cells could be induced to form neurospheres which expressed both 
neuronal and astroglial markers and had stem cell capacities [Ignatova, T. N. et al (2002)]. 
Hemmati et al (2003) also discovered that paediatric brain tumours (PBTs), including 
medulloblastomas and gliomas, contained stem cell-like cells. Cells derived from these PBTs 
could be induced to generate neurospheres and when these neurospheres were transplanted 
into immunodeficient mice, they could initiate tumours, which were able to be serially 
transplanted, and had the ability to self-renew. These cells could differentiate into both neurons 
and glial cells (multilineage differentiation) under differentiation conditions and after xenograft 
into neonatal rat brain. Genes expressed in neural and other stem cells (CD133, SOX2, 
musashi-1 bmi-1, maternal embryonic leucine zipper kinase, and phosphoserine phosphatase) 
could be detected in these stem cell-like neurospheres. However, the characteristics of these 
cells were not exactly the same as normal neural stem cells. Cancer stem-like cells occasionally 
differentiated into abnormal cells which expressed multilineage markers, hence a 
heterogeneous tumour might result from these cells [Hemmati, H. D. et al (2003)]. Galli et al 
(2004) studied neural-like stem cells derived from adult human glioblastoma multiforme. They 
found that neural-like stem cells derived from tumour specimen had characteristics of stem 
cells in terms of multilineage differentiation, capability of neurosphere formation and initiation 
of tumours recapitulating the original tumours when they were transplanted into 
immunodeficient mice.  Additionally, these neural-like stem cells could be repeatedly isolated 
and used to initiate neurospheres and new tumours indicating their self-renewal characteristic 
in vivo [Galli, R. et al (2004)].  
 
1.4.3 Identification of cancer stem cells 
Many techniques have been developed to effectively identify and isolate brain tumour stem  
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cells. However, cancer stem cells are still difficult to isolate due to the fact that they are a small 
population of the tumour. There is no specific antibody to detect these cells at present and 
none of techniques exclusively isolates cancer stem cells. Cancer stem cells can be identified by 
the neurosphere assay, side population analysis or stem cell markers. However, the most 
convincing method to prove the existence of cancer stem cells is serial transplantation by 
orthotopic transplantation. Cells containing cancer stem cells should be able to re-established 
tumours, which recapitulate the original tumours, and these cells should preserve self-renewal 
ability on serial passages.  
 
The neurosphere assay is the simplest method to identify, isolate and expand neural stem cells. 
The principle of neurosphere assay is that cells are dissociated into single cells in serum free 
tumour media supplemented with growth factor. Most cells die but only cells, which are 
responsive to the growth factors, can survive and proliferate to form floating clusters of cells 
defined as neurospheres. This assay examines the ability of cells to self-renew and proliferate 
[Reynolds, B. A. and Weiss, S. (1992)].  
 
Side population analysis is based on the principle that cancer stem cells have the capability to 
extrude the DNA binding dye Hoechst 33342 and flow cytometry is used to detect the level of 
dye accumulation in cells. Cells with a low level of dye accumulation are identified as side 
population cells (the putative stem-like population) [Komuro, H. et al (2007) and Hadnagy, A. 
et al (2006)]. 
  
Markers for cancer stem cells have been generally used to identify and characterise cancer 
stem cells in multiple solid tumour types. Due to the extensive study of cancer stem cells, 
many cell surface markers have proved to be effective in identifying populations enriched with 
cancer stem cells such as CD133 (PROM1), CD44 (PGP1), CD24 (HSA), epithelial cell adhesion 
molecule [EpCAM (epithelial specific antigen: ESA or TACSTD1)], ALDH1, THY1 (CD90) and 
ATP-binding cassette B5 (ABCB5) [Reviewed in Visvader, J. E. and Lindeman, G. J. (2008)]. 
SOX2 is also generally used to identify neural stem cells since SOX2 is an important gene 
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involving in the maintenance of self-renewal and proliferation of human embryonic stem cells 
[Fong, H. et al (2008)]. SOX2 gene deletion in glioblastoma lead to loss of proliferation and 
tumourigenicity [Gangemi, R. M. R. et al (2009)]. CD133 and SOX2 were hence used to identify 
cancer stem-like cells in our study. 
 
1.4.3.1 CD133 
CD133 was formerly known as human AC133 or human PROML-1 (prominin-1, named after its 
location on protrusions of the plasma membrane). Human prominin-1 was first isolated from 
hematopoietic stem cells using a monoclonal antibody to CD34+ and identified as AC133 
(CD133). CD133 belongs to a pentaspan transmembrane glycoprotein family including 
prominin-2, recently discovered and originally known as prominin related protein (prom-rp). 
Prominin-2 has also been shown to be expressed in human lung cancer and tumours of the 
CNS [Mizrak, D. et al (2008)]. Human CD133 has 37 exons and encodes a 865 amino acid (aa) 
protein with a total molecular weight of 120 kDa [Shmelkov, S. V. et al (2005)].  
 
CD133 has been used to isolate and study cancer stem cells in many studies.  Singh et al 
(2003) sorted CD133+ and CD133- cells by magnetic cell sorting and characterised the 
properties of these cells. Their results showed that brain tumours originate from cells 
expressing CD133, with these cells being able to form clusters of neurosphere-like cells, self-
renew, proliferate and initiate new tumours which recapitulated the original tumour phenotypes 
in vivo. Normal neural stem cells were also found within CD133+ populations so it is possible 
that these normal stem cells are the candidate cells that initiate brain tumours [Singh, S. K. et 
al (2003)]. Singh et al (2004) went on to study tumour-initiating cell characteristics from 
CD133+ cells isolated from medulloblastoma and glioblastoma. Their study showed that only 
the CD133+ subpopulation cells (100 cells were sufficient) could be xenografted into NOD-SCID 
mice and initiate new tumours which display similar histological features to the original 
tumours. Additionally, these cells also could be consecutively transplanted. In contrast, CD133- 
cells could not form nodules or masses even after a large number of these cells (100,000 cells) 
were injected into mouse brain. This demonstrates the self-renewal and recapitulation capacity 
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of CD133+ cells. The tumours initiated by CD133+ cells comprised a small proportion of CD133+ 
cells (19-22%) and a large proportion of CD133- cells (78-81%). This suggested that CD133+ 
cells may produce both CD133+ and CD133- cells in new tumours. Furthermore, xenografted 
and transplanted tumours expressed similar markers to the original tumours using antibodies 
WR QHVWLQ DQG YLPHQWLQ QHXUDO SUHFXUVRU FHOO PDUNHU ǃ,,,-tubulin and MAP2 (neuronal 
markers), and GFAP (astrocyte marker). This demonstrated the multilineage differentiation 
capability of these tumour initiating cells (CD133+ cells). The immunofluorescent results of their 
study showed that CD133+ positive cells accounted for 9-29% of GBM and 6-21% of 
medulloblastoma which was in accordance with the assay of primary sphere formation in vitro 
[Singh, S. K. et al (2004)]. These two studies support the fact that neural stem cell surface 
marker CD133 can be used to effectively identify cancer stem cells in brain tumours. However, 
one study revealed that CD133 could not identify cancer stem cells in the C6 glioma cell line 
since both CD133+ and CD133- cells had characteristics of cancer stem cells. Hoechst 33342 
also could not identify side population due to its toxicity to this cell line. Therefore, they 
concluded that both CD133 and Hoechst 33342 have limitations in identification of cancer 
stem-like cells in C6 glioma cell line [Shen, G. et al (2008)].  
 
CD133 structure 
The structure of CD133 [Figure 1.20] consists of an extracellular N-terminal domain, two large 
glycosylated extracellular loops of 255 and 290 aa, five transmembrane domains, two small 
intracellular loops of 30 aa each and a cytoplasmic C-terminal domain [Sakariassen, P. et al 
(2007)]. The extracellular loops have eight potential N-glycosylation sites with five located on 
the first loop and three located on the second loop. The two large extracellular loops and the 
cytoplasmic C-terminal can be detected by antibodies and epitope insertion analysis [Corbeil, 
D. et al (2001)]. Transcription of CD133 is regulated by five alternative promoters (P1-P5) 
[Figure 1.21]. Three are located within a CpG-island suggesting that they can be controlled by 
PHWK\ODWLRQ7KH¶-untranslated region (UTR) comprises 10 exons (A, B, C, D1-3 and E1-4). 
CD133 transcription is regulated by at least five alternative promoters. There are 8 isoforms of 
CD133 transcribed depending on which promoters regulate this process. Therefore, different 
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DOWHUQDWLYH SURPRWHUV UHVXOW LQ WKH LQFOXVLRQ RI GLIIHUHQW ¶-UTR exons which may have an 
influence on splicing of the coding regions. Consequently, different alternative promoters play a 
role in the expression of prominin-1 isoforms [Shmelkov, S. V. et al (2005)]. Due to this 
variation CD133 isoforms, it is difficult to select an appropriate antibody to identify CD133 in a 
tissue/tumour of interest. 
  
 
 
Figure 1.20 Schematic diagram of murine CD133 structure. The structure of murine 
CD133 consists of five transmembrane domains which are located in lipid bilayers of the 
plasma membrane. Extracellular components of CD133 comprise an 85 aa N-terminal domain 
and two large glycosylated extracellular loops of 255 and 290 aa which have eight potential N-
glycosylation sites (orange-blue forks). Five glycosylation sites exist on the 255 aa loop and 
three are located on the 290 aa loop. In addition, there are two small intracellular loops of 30 
aa each and a cytoplasmic 50 aa C-terminal domain. Red scissors indicates the sites where 
trypsin can cut CD133 when it is exposed for too long to trypsin solution [Adapted from 
Sakariassen, P. et al (2007)].  
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CD133 as a marker 
CD133 is normally used as a marker for human haematopoietic stem cells. It is also a very 
useful marker for normal neural stem cells. Additionally, many undifferentiated cells also 
express CD133, such as endothelial progenitor cells, foetal brain stem cells, embryonic 
epithelium, prostatic epithelial stem cells and myogenic cells. Moreover, prominin-1 protein, 
detected by mAb AC133, is not only restricted to human neural or haematopoietic stem cells 
but it is also expressed in adult human tissues such as kidneys, mammary gland, trachea, 
salivary gland and placenta [Florek, M. et al (2005)]. Furthermore, some other cancers express 
CD133 such as retinoblastoma [Maw, M. A. et al (2000)], teratocarcinoma [Miraglia, G. et al 
(1997)] and leukaemia [Baersch, G. et al (1999)]. CD133, as described previously, has been used 
 
 
 
Figure 1.21 Genomic organisation of the promoter region of human AC133 and 
DOWHUQDWLYHVSOLFLQJZLWKLQLWV¶-UTR. The diagram shows eight CD133 isoforms due to the 
regulation of alternative promoters. Five alternative promoters (P1 - P5) influence which 
particular isoform of CD133 is expressed with alternative promoters being transcription 
initiation points. The detection of five alternative first exons indicated the existence of these 
five alternative promoters, P1 (upstream of exon 1A), P2 (upstream of 1B), P3 (upstream of 
1C), P4 (upstream of 1D1) and P5 (upstream of 1E1) [Shmelkov, S. V. et al (2005)]. 
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as a marker to detect stem cells in several studies [Singh, S. K. et al (2003 and 2004) and 
Hemmati, H. D. (2003)]. In addition, CD133 has been used to study the biology and plasticity 
of CD133+ haematopoietic stem cells by Handgretinger et al (2003). CD133+ stem cells were 
isolated using magnetic activated cell sorting (MACS) from peripheral blood cells of healthy 
adults. These isolated CD133+ cells had a high capacity of xenograftment into NOD-SCID mice 
and gave rise to both adherent and non-adherent cells in vitro. Interestingly, the adherent cells 
lacked CD34 expression and could be induced to develop into stem cells which had a high 
capability of NOD-SCID engraftment, similar to the original cells. Adherent CD133+CD34- cells 
could also produce CD133+CD34+ cells after a short time of culture in vitro [Handgretinger, R. 
et al (2003)]. 
 
CD133 function and application 
The functions of CD133 are not completely understood. One study found that single nucleotide 
deletion of prominin-1 resulted in retinal degeneration since morphogenesis of photoreceptor 
disk was impaired [Maw, M. A. et al (2000)]. CD133 was proposed to have a function in cell 
membrane protrusions and be inherited with the apical membrane during asymmetric cell 
division [Reviewed in Corbeil, D. et al (2001)]. This might give a clue to CD133 function. 
Several studies have characterised CD133 and showed that CD133+ cells are able to 
differentiate into both neurons and glial cells, can form neurospheres and be serially 
transplanted into NOD-SCID mice. Such properties reflect self-renewal and multilineage 
differentiation of stem cells [Singh, S. K. et al (2003 and 2004), Uchida, N. et al (2000) and 
Hemmati, H. D. et al (2003)]. CD133 expression has also been used as a prognostic factor or 
an indicator in cancers. Recently, Zeppernick and colleagues were the first group to 
demonstrate the correlation between CD133 expression and clinical outcome of glioma 
patients. They revealed that the proportion of CD133 expressing cells and the presence of 
positive cell clusters were prognostic factors for glioma patients. Whereby a high proportion of 
positive cells or a presence of the clusters associated with a high grade of tumour. These 2 
prognostic factors also can indicate tumour recurrence, patient survival and tumour progression 
in particular for WHO grade II and III tumours [Zeppernick, F. et al (2008)]. CD133 reactivity 
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might therefore identify cells with increased tumourigenicity. High CD133 reactivity cells have 
also been found in the active phase of cell cycle whilst low CD133 reactivity cells were detected 
in G1-G0 phase suggesting an association with proliferating cells. Therefore, CD133 is a good 
marker to reflect mitotic activity indicating increasing tumourigenicity as well as identifying a 
distinct cancer stem cell-like subpopulation. However, recent studies have indicated that the 
AC133 epitope is not a stable marker whereby high AC133 reactivity cells generate less 
reactivity of AC133 cells after many passages of culture whilst low AC133 reactivity cells can 
generate high AC133 reactivity cells after prolonged cultivation [Jaksch, M. et al (2008)]. 
Another complicating factor is the sensitivity of CD133 to cell harvesting agents such as trypsin 
(Figure 1.20). 
 
1.4.3.2 SOX2 
SOX2, encodes a SRY-related high mobility group (HMG) box transcription factor, which has 
90% aa residue identity in its HMG-DNA binding domain to SOX1 and SOX3. SOX2 is a member 
of the superfamily of SOXB1 transcription factors, consisting of closely related genes including 
SOX1 and SOX3. SOX2 is normally expressed in neural progenitors and stem cells, which can 
be found throughout the vertebrate CNS [Graham, V. et al (2003)].  
 
SOX2 function and application 
SOX2 protein is expressed in embryonic stem cells (ESCs) and neural stem cells (NSCs), but its 
function remains unclear. Graham et al (2003) studieG 62;¶V DELOLW\ WR PDLQWDLQ QHXUDO
progenitor identity. They found that SOX2 plays a role in maintenance of general stem cell 
properties including self-renewal, proliferation and differentiation into varying progenies 
[Graham, V. et al (2003)]. Similar to human embryonic stem cells, SOX2 is also involved in 
regulation of self-renewal and pluripotency studied in human embryonic stem cell lines: H1 and 
H9 [Fong, H. et al (2008)]. When SOX2 was knocked down in glioblastoma cell lines, they lost 
the capability of self-renewal and tumourigenicity [Gangemi, R. M. R. et al (2009)]. In addition, 
inhibition of SOX2 function results in promotion of differentiation of neural progenitor cells, but 
the inhibitory mechanism of neuronal differentiation by SOX2 is still unclear. A possible 
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mechanism of SOX2 inhibition of cell differentiation has been proposed whereby SOX2 
regulates cells to continuously be maintained in the cell cycle resulting in no differentiation 
[Graham, V. et al (2003)]. SOX1, SOX2 and SOX3 are normally co-expressed in neuroepithelial 
cells and regulate the development of neural stem cells. SOX2 however, plays a very important 
role in the regulation of neural development because SOX2 knockout embryos fail to develop 
embryonic or trophectoderm lineages. Conversely, SOX1 and SOX3 knockout mice can survive 
and have no defects in the CNS [Episkopou, V. (2005)]. SOX2 has been found to be a marker 
for ESCs and NSCs. Additionally, SOX2 functionally co-operates with transcription enhancer 
regions including SOX2 regulatory region 1 (SRR1) and SRR2 identified from ESCs. The 
function of SRR2 is to enhance the Oct-3/4-SOX2 or Oct-6-SOX2 complex (Oct-SOX enhancers) 
in ESCs resulting in maintenance of the multipotent capacity of both ESCs and NSCs [Miyagi, S. 
et al (2004)]. SOX2 therefore plays an important role in maintenance of the undifferentiated 
stage of stem cells.  
 
Masui et al (2007) hypothesized that SOX2 collaborates with OCT3/4 to maintain pluripotency 
of ESCs whereby SOX2 acts as a cofactor of OCT3/4 [Masui, S. et al (2007)]. Avilion et al 
(2003) found that SOX2 and OCT4 are co-expressed in early embryonic cells including morula, 
inner cell mass (ICM), epiblast and germ cells. Therefore, both SOX2 and OCT4 might have a 
role in the regulation of cell differentiation. Their results showed that the presence of both 
SOX2 and OCT4 induced epiblast formation whilst their absence resulted in the formation of 
trophectoderm. In addition, single expression of SOX2 is required to maintain an 
undifferentiated property of the epiblast whilst extraembryonic endoderm is developed when 
OCT4 is individually expressed. Furthermore, SOX2 shuttles between nuclei and cytoplasm 
depending on the stage of cell development. SOX2 is located in nuclei in the early stage of 
embryogenesis whilst SOX2 is exported to the cytoplasm when embryonic cells progressively 
develop. SOX2 was stained in both nuclei and cytoplasm [Avilion, A. A. et al (2003)]. In the 
early mouse embryo, SOX2 mRNA expression has been detected in some embryonic cells 
including inner cell mass, epiblasts, germ cells and trophoblast cells. SOX2 expression was 
found to be restricted to cells having stem cell characteristics rather than more differentiated 
 66 
cells [Miyagi, S. et al (2004)]. Hence, SOX2 is expressed in cells having stem cell properties 
whilst being downregulated in cells differentiating into terminal specific mature cells. SOX2 
functions to maintain pluripotency and undifferentiated stage of stem cells. Additionally, SOX2 
is also one of the important transcription factors involved in reprogramming mature cells 
(mouse fibroblast) to embryonic stem-like cells alongside Oct3/4, c-Myc and Klf4. These cells 
had characteristics of embryonic stem (ES) cells in terms of morphology and growth properties, 
expression of ES markers and initiation of tumour after transplantation [Takahashi, K. and 
Yamanaka, S. (2006)]. 
 
CD133 and SOX2 identify both stem cells and progenitor cells. The location of CD133 and SOX2 
expression in brain was not obviously stated because these two markers are expressed in the 
developing brain and they are down regulated when brain is developed. In both human fetal 
brain and embryonic mouse brain, it was revealed that both CD133 and SOX2 were expressed 
in the subventricular zone [Uchida, N. et al (2000), Ferri, A. L. M. et al (2004) and Pfenninger, 
C. V. et al (2007)]. In human fetal brain, there is evidence revealing that CD133 was 
expressed in the roof and floor plate of the ventricle and surrounding the central canal [Uchida, 
N. et al (2000)]. In postnatal mouse brain, CD133 and SOX2 co-staining was positive in the 
ventral wall whereas the dorsal wall of the ventricle expressed SOX2 without CD133 (Figure 
1.22) [Ferri, A. L. M. et al (2004) and Pfenninger, C. V. et al (2007)].  
 
1.4.4 The model for tumour heterogeneity and propagation 
The identity of the cells which initiate and develop brain tumours is not fully understood at 
present. Currently, there are two models which explain the heterogeneity, initiation and 
development of tumours [Figure 1.23]. The clonal evolution model describes that any cell 
(stem cell/progenitor or mature) is able to acquire mutations that provide a growth advantage 
hence allowing selection of these cells which will continually proliferate and maintain the 
tumour population (Figure 1.23, a) [Visvader, J. and Lindeman, G. J. (2008)]. This model is 
similar to the stochastic model in some aspects. The stochastic model suggests that all cancer 
cells are heterogeneous and have a similar tumourigenic potential to initiate and sustain 
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tumours. Cells accumulate mutations over a considerable period of time and are induced into 
CSCs which have capabilities of self-renewal and maintenance of tumour cells [Vescovi, A. L. et 
al (2006)]. The cancer stem cell model or hierarchical model proposes that only a small 
population of tumour cells, cancer stem cells, is able to generate and sustain the tumour 
population due to their self-renewal capacity and proliferation whilst the remaining cancer cells 
are either short-lived progenitors or terminally differentiated cells without stem cell-like 
characteristics, and with a low potential for continued proliferation (Figure 1.23, b) [Visvader, 
J. and Lindeman, G. J. (2008)]. The progression of tumours might be based on both of these 
models of tumourigenesis. Initially, CSC1 generates and maintains the tumour population. 
When progression of the tumour occurs, CSC2 is selected due to the clonal evolution of CSC1. 
CSC2 acquires more mutations or epigenetic modifications resulting in generation of a more 
aggressive tumour. This might indicate that cancer stem cells will gain more and more 
mutations after many rounds of treatment and these severely aberrant cancer stem cells will 
generate increasingly aggressive tumours (Figure 1.23, c) [Visvader, J. and Lindeman, G. J. 
(2008)]. 
 
 
 
 
Figure 1.22 The location of CD133 and SOX2 expression in postnatal mouse brain. 
CD133 and SOX2 expression was present in the subventricular zone (SVZ) of postnatal mouse 
brain. CD133 and SOX2 co-expression was found in the ventral wall of the ventricle whilst the 
dorsal wall is positive for SOX2 only.  
 
SOX2 expression 
CD133 & SOX2 co-
expression 
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At present, many genetic mutations have been shown to correlate with brain tumour formation. 
In astrocytoma, aberrations of INK4A, CDK4, RB and TP53, which regulate cell cycle, and 
EGFR, PDGFR and PTEN, which are growth factor receptor signalling, have all been shown to 
initiate astrocytoma in mouse models [Reviewed in Furnari, F. B. et al (2007)]. Additionally, 
one study revealed that both neural stem cells and progenitor cells were able to be 
transformed into high grade glioma cancer cells by depletion of specific tumour suppressor 
genes. A tamoxifen-inducible Nestin-cre-ERT2 transgene was used to induce these cells to form 
tumours in mice model. This study confirmed the hypothesis that loss of tumour suppressor 
genes could lead to tumour formation from both neural stem cells and progenitor cells 
[Llaguno, S. A. et al (2009)].       
 
Figure 1.23 The heterogeneity and propagation of tumours. The clonal evolution model 
proposes that all cells have a similar potential to generate a tumour. Cells that have acquired 
mutations that provide a growth advantage are selected to propagate tumours (a). Whilst the 
cancer stem cell model postulates that only cancer stem cells can generate and maintain a 
tumour population (b). For tumour progression, clonal evolution of CSC1 occurs therefore, 
CSC2 therefore acquires more mutations and is selected to be the prominent population of 
tumours. The more mutated CSC2 population can then initiate a more aggressive tumour (c) 
[Visvader, J. and Lindeman, G. J. (2008)].  
CSC 
CSC1 
CSC2 
Progression 
(a) 
(b) 
(c) 
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  1.4.5 Cancer stem cells and drug resistance 
Drug resistance of cancer cells can occur by either intrinsic or acquired resistance. Drug 
resistance in cancer cells, which contain a resistant population in the absence of previous 
exposure to chemotherapeutic drugs, is called intrinsic resistance. Whilst the process whereby 
a resistant population is developed after chemotherapy resulting from mutation or 
overexpression of drug target, inactivation or detoxification of drugs or drug removal from 
cells, is defined as acquired resistance. Cancer stem cells, a small population of tumours, are 
an important target of treatment since these cells are believed to be chemoresistant and have 
the ability to re-initiate tumours after treatment. Four models of drug resistance in tumours are 
presented in Figure 1.24.   
 
The conventional model of acquired drug resistance in cancer cells hypothesised that tumours 
contained one cell or a small proportion of the tumour population, which gained genetic 
alterations or mutations after chemotherapy. Consequently, these drug selected resistant cells 
developed a growth advantage after drug selection resulting in rapid repopulation of tumours 
and taking over of the whole tumour population (Figure 1.24, a). Stem cells are now widely 
believed to be responsible for drug resistance in cancer. The second model therefore postulates 
that tumours contain a small number of cancer stem cells, which are resistant to chemotherapy 
due to either their quiescent properties, ability to undergo DNA repair or active drug efflux 
capability by ABC transporters (or a combination of all). Therefore, they are able to survive and 
reform tumours, which are heterogeneous and share characteristics with the parental tumour 
(Figure 1.24, b). The third model describes acquired drug resistance, which can be found in 
patient who have been treated with radiation or exposed to carcinogens for a long period of 
time or undergone tumour recurrence after chemotherapy. Consequently, cancer stem cells 
have accumulated genetic mutations or alterations. After treatment, surviving genetically 
mutated cancer stem cells regenerated progenitor cells containing these genetic mutations. 
Hence, initiated tumours have different characteristics from the parental tumours (Figure 1.24, 
c). The final model describes intrinsic drug resistance whereby tumours contain cancer stem 
cells and various stages of differentiating cells, which are all inherently drug resistant.  
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Figure 1.24 Models of drug resistance in cancer cells. The conventional model of drug 
resistance in cancer cells proposes that a small population of cancer cells (blue) containing a 
genetic alteration (yellow) survives after treatment and regenerates a new tumour (a). A drug 
resistance model based on cancer stem cells (red) is shown in (b) whereby cancer stem cells 
survive after treatment and regenerate cancer stem cells and progenitors. The acquired drug 
resistance model proposes that cancer stem cells (pale yellow) acquire genetic mutations after 
prolonged treatment resulting in regenerating cancer stem cells containing that genetic 
mutation and various differentiating progenitors with the same genetic alteration (purple) (c). 
The last model describe intrinsic drug resistance whereby both cancer stem cells (yellow) and 
cancer cells (purple) are completely resistant to chemotherapy, consequently, there is no effect 
on these cells   [Dean, M. et al (2005)]. 
MDR cells 
Tumours 
Therapy 
(a) 
Therapy 
Tumour stem cells (b) 
Therapy 
Mutation 
(c) 
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Therefore, chemotherapy will not have any effect on these cells and tumour will continue to 
progress (Figure 1.24, d) [Dean, M. et al (2005)]. The cancer population is heterogeneous. It is 
proposed that a large proportion of the cancer population is comprised of non-tumourigenic 
cells, which are sensitive to chemotherapy resulting in shrinkage of tumour mass after 
treatment. However, a small proportion of the cancer population, is chemoresistant and 
survives after treatment. This small proportion of cancer cells is cancer stem cells. Cancer stem 
cells were initially identified in acute leukaemia. They were also detected in many brain 
tumours. An overexpression of ABC transporters in cancer stem cells increased DNA repair and 
their quiescent nature are important factors in resistance to therapy. With these main 
characteristics, cancer stem cells surviving after treatment self renew and proliferate to re-
initiate the tumour population resulting in tumour relapse. Therefore, cancer stem cells are 
currently believed to cause chemoresistance in many cancers and hence represent the main 
target of treatment to ultimately cure malignant diseases in the future.   
 
1.5 What is the contribution of drug resistance CSCs to 
paediatric brain tumours? 
 
Paediatric brain tumours (PBTs) are the second most common malignant disease in children 
after leukaemia [Pollack, Ian F. (1994), and Stewart, E.S. and Cohen, D.G. (1998)]. Most PBTs 
are still devastating diseases since the treatment outcome is not impressively successful and 
patients also have adverse sequelaes after treatment. Although, many treatment options are 
currently available and new improved drugs are included in chemotherapeutic regimens, the 
survival rate of patients and prognosis of disease remains poor for many tumour types 
[Stewart, E.S. and Cohen, D.G. (1998) and Gupta, N. et al. (2004)]. Several chemotherapeutic 
drugs with different mechanisms of action are used in a single regimen to treat patients, 
however, the clinical outcome is only slightly improved and less effective than expected. The 
phenomenon whereby PBTs are/become resistant to chemotherapy and commonly have cross-
resistance to many chemotherapeutic drugs is currently known as multidrug resistance (MDR). 
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During the last few decades, MDR has been extensively studied in many malignant diseases. 
One important drug resistance mechanisms, predominantly found in many drug resistant 
cancers, involves the ABC transporter family. These transporters function as pumps to 
extracellularly export many cytotoxic drugs resulting in decreased cellular accumulation of 
drugs. ABCB1 [Chen, C. J. et al (1986)], ABCC1 [Cole, S. P. C. et al (1992)] and ABCG2 
[Doyle, L. A. et al (1998)] have been shown to be predominantly overexpressed in many drug 
resistant brain tumours and these three transporters have ability to transport various 
substrates and chemotherapeutic agents regardless of their drug categories or chemical 
structures. These 3 transporters are therefore obvious candidate for the acquisition of 
multidrug resistance.  
 
More recently, cancer stem cells (CSCs) have been confirmed to exist as a small proportion of 
the tumour population [Ignatova, T. N. et al (2002), Hemmati, H. D. et al (2003), Tan, B. T. et 
al (2006), Galli, R. et al (2004), Singh, S. K. et al (2003 and 2004)]. The hypothesis being 
tested here is that CSCs are chemoresistant and they are able to re-initiate tumours after 
treatment due to their self-renewal and proliferative capability. It is proposed that the main 
mechanism of MDR in CSCs is active drug efflux by ABC drug transporters although other 
mechanisms may also protect CSCs from cytotoxic drugs including their quiescent property and 
capability of DNA repair. Therefore, CSCs are postulated to contribute to MDR in cancers via 
active drug efflux by ABC drug transporters. As a result, CSCs might be the real target for 
treatment in many malignant diseases.     
 
The hypothesis being tested in this thesis postulates that paediatric brain tumour cell lines 
contain a subpopulation of cancer stem cells that use ABC multidrug transporters to efflux 
chemotherapeutic agents.  
 
The aim of this thesis were therefore to  
x characterise newly derived paediatric brain tumour cell lines to demonstrate their clinical 
relevance 
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x characterise the cancer stem cell component of these lines 
x determine the expression of ABCB1, ABCC1 and ABCG2 in cancer stem cell enriched 
cultures/cancer stem cells 
x test whether it was possible to enrich for ABC expressing cancer stem cells using 4 
different chemotherapeutically applied drugs 
x test if ABC transporter function can be detected and if inhibition restores 
chemosensitivity  
. 
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Chapter 2: Materials and Methods 
 
2.1 Cell culture 
 
Generating cell lines from paediatric brain tumours is difficult and often is limited by the size 
of the tumour tissue available and the ability of dissociated cells to grow under cell culture 
conditions. This has resulted in a dearth of appropriate model cell lines in which to 
investigate prognostic targets and develop potential therapies. For several tumour types, 
VXFK DV HSHQG\PRPD WKHUH DUH QR µFRPPHUFLDOO\¶ DYDLODEOH FHOO OLQHV 2WKHUV DUH PRUH
readily available, but their relationship to the tumour of origin has not been studied, nor has 
their retention of CSCs and degree of tumourigenicity. Brain tumour cell lines were derived 
DW WKH &KLOGUHQ¶V %UDLQ 7XPRXU 5HVHDUFK &HQWUH &%75& (31-1, EPN-2, MED-1, MED-2, 
Oig-1 and SPNET-1) and at the University of Birmingham (BT-4) as approved by the Local 
Research Ethics Committee. The tumours of origin were graded and classified by a 
pathologist (Professor James Lowe) according to the World Health Organisation (WHO) 2007 
classification. All material was obtained and used in accordance with the human tissue act. 
Additionally, a commercial cell line which is CNS PNET (PFSK-1) was also studied in this 
project. EPN-2, MED-2 and SPNET-1 cells were successfully cultured in tumour media, 
whereas PFSK-1 cells were grown in PFSK media as recommended by the ATCC* (media 
recipes in appendix B1, Table B1.1). Apart from paediatric brain tumour cells, control cells 
were also grown to provide positive controls for Western blotting analysis, Fluorescence-
activated cell sorting (FACS) and co-staining immunofluorescence. NTERA-2, a commercial 
cell line derived from a teratocarcinoma, were grown in NTERA media (appendix B1). This 
cell line was used as a positive control for CD133 expression in Western blotting analysis. 
HEK cells stably transfected with pcDNA encoding ABCB1, ABCC1, ABCG2 or empty pcDNA 
were also used as positive and negative controls for Western blotting analysis, FACS and 
immunofluorescence. These control cell lines were kindly provided by Dr. Ian Kerr. These  
* www.lgcpromochem-atcc.com 
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cells were grown in tumour media containing 500 µg/ml of G418. All cell lines were grown in 
75 cm2 vented flasks containing 20 ml of media and incubated in a standard humidified 5% 
CO2 ±air incubator at 37°C. Cells were cultured as monolayer cells and subcultured twice a 
week when cells reached subconfluency. In addition, cells were screened regularly for 
mycoplasma infectionusing Venor®GEM-Mycoplasma detection kit (11-1050, Minerva 
biolabs). The other cell lines, which are EPN-1 (ependymoma), MED-1 (medulloblastoma), 
BT-4 (glioblastoma multiforme) and Olig-1 (oligodendroglioma), were grown by Dr. Deema 
Hussein, who kindly provided snap frozen pellets and fixed cells for some experiments.  
 
Monolayers and neurospheres from all cell lines were collected as pellets, snap frozen in 
liquid nitrogen, then stored at -80°C. A large number of cell pellets were routinely prepared 
and frozen for future experiments from early, middle and late passage of monolayers and 
neurospheres. Additionally, the earliest passage numbers of each cell line were frozen by 
resuspending at one million cells/ml in 10% dimethyl sulfoxide (DMSO) in FBS, and stored in 
liquid nitrogen for future culture.  
 
2.1.1 Cell recovery from liquid nitrogen 
Cryovial tubes containing the designated cell line were removed from the liquid nitrogen 
bank and rapidly thawed at 37°C. Cells were then immediately transferred to a 75 cm2 flask 
containing fresh 20 ml of the appropriate cell culture media and incubated overnight. The 
media was replaced with fresh media the next day, and cells were incubated until ready for 
subculture.  
 
2.1.2 Deriving neurospheres from monolayers 
Monolayers were induced to form neurospheres by culturing in stem cell media. After 
trypsinization of monolayers with 1xT/E [1xTrypsin/Ethylene diamine tetracetic acid 
(EDTA)], 1:20 dilution of trypsinized cells was transferred into 75 cm2 flask with 20 ml of 
stem cell media. Neurospheres were usually formed within 48 hours. 
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2.1.3 Subculturing cells 
Cells were subcultured when cells were approximately subconfluent. Normally, this was 
about 72-96 hours after subculturing when cells were passaged at a 1:20 dilution.  
2.1.3.1 Monolayer cells 
Cells were detached from flask using 1xT/E (Fisher, VX15400-054). Cells were washed with 
+DQNV¶ %DODQFHG 6DOW Solution (HBSS) (Invitrogen, 14025-050) before adding 2 ml 1xT/E 
into each flask then incubated in trypsin solution for 5 minutes at 37 °C. Trypsinized cells 
were harvested by tapping the flask before transferring a small proportion of cells to a new 
75 cm2 flask at a 1:10 or 1:20 dilution with appropriate media.  
2.1.3.2 Neurospheres  
  2.1.3.2.1 Using TrypLETM select 
To dissociate neurospheres into single cells, neurospheres were centrifuged at 70xg for 3 
minutes then washed with 5 ml of HBSS and centrifuged again to pellet cells. The pellet was 
resuspended in 1 ml of TrypLETM select (Invitrogen, 12563-029) for 1 minute with gentle 
swirling to gently dissociate neurospheres. Dissociated neurospheres were passaged as 1:2 
or 1:5 or 1:10 into fresh stem cell media (see appendix B1). Fibroblast growth factor (FGF) 
(Invitrogen, PHG0026) and epidermal growth factor (EGF) (Invitrogen, 13247-051) were 
replenished to promote neurosphere growth every 3 or 4 days.  
2.1.3.2.2 Using mechanical dissociation 
Neurospheres were also dissociated by mechanical dissociation using pipette. Dissociated 
neurospheres were filtered through a 40 µm cell strainer (BD Sciences, 352340) into fresh 
stem cell media.  
 
These two different methods for neurosphere dissociation have different advantages and 
disadvantages and there was no evidence to confirm which method is better for cell 
dissociation. Chemical dissociation using TrypLETM select is a gentle and fast method to 
dissociate cells. However, the chemical effect of TrypLETM select might cause cell membrane 
and protein damage for long term use. This is a very important issue since the protein of 
interest is located on cell membrane (CD133 and ABC transporters). Mechanical dissociation 
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using mechanical pipette also effectively singularised cells. However, this method is slightly 
harsh to cells and probably causes cells lysis resulting in increasing number of death cells. 
Additionally, cells were required to filter through cell strainer to ensure that they were 
separated into single cells, therefore, this method is time consuming compared to chemical 
dissociation method. To avoid taking risk of disadvantages and receiving some advantages 
of each method, these two different dissociation methods were hence used alternately to 
dissociate cells. Neurospheres tested in this study were obtained after their first passage 
from neurospheres.  
 
  2.1.4 Snap freezing cells  
   2.1.4.1 Snap frozen cells for general purposes 
Monolayers and neurospheres were harvested as described in section 2.1.3. After 
trypsinization, cells were washed once with HBSS then centrifuged at 70xg for 3 minutes. 
Cell pellets were resuspended in 1 ml of HBSS and transferred to new eppendorfs. Cells 
were centrifuged again at 70xg for 3 minutes. HBSS was removed and cell pellets were 
dropped in liquid nitrogen for snap freezing. Snap frozen pellets were stored at -80 °C until 
required. 
   2.1.4.2 Snap frozen cells for microsomal membrane extraction 
    2.1.4.2.1 Attached cells 
Cells were detached using a scraper and transferred into 50 ml Falcon tube. Cells were 
centrifuged at 70xg for 3 minutes then media was removed. Cells were resuspended in fresh 
media and incubated at 37 °C for 30 minutes to recover surface protein expression. Cells 
were centrifuged again at the same speed then washed twice with filtered PBS. Cells were 
resuspended with 1 ml of filtered PBS in an eppendorf tube and centrifuged again. PBS was 
removed then the pellet was snap frozen in liquid nitrogen and stored at -80 °C until 
required.   
    2.1.4.2.2 Neurospheres (cells grown in suspension) 
Cells were transferred into a 50 ml Falcon tube and washed twice with filter PBS. Cells were 
centrifuged at 70xg for 3 minutes to remove PBS. Cells were then resuspended in filtered 
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PBS and transferred into an eppendorf tube. Cells were centrifuged again at the same speed 
to pellet and snap frozen in liquid nitrogen then stored at -80 °C until required.    
 
2.2 Immunofluorescence assay 
Indirect immunofluorescence was performed to detect stem cell-like populations and ABC 
transporter expression in newly established paediatric brain tumour cell lines. This method 
detects emitted fluorescence from species specific secondary antibodies bound to epitope 
specific primary antibodies.  
 
2.2.1 Immunofluorescent staining of monolayers  
2.2.1.1 Plating monolayer cells on chamber slides 
Monolayers were subcultured as mentioned in section 2.1.3.1. Cells were stained using 
trypan blue and counted using a haemocytometer. Cells were resuspended in appropriate 
tumour media and plated at a density of 1,000 cells/ml in 500 µl of media into each 
chamber of an 8 well slide (VWR international, 734-2126). Cells were incubated for 3 or 4 
days until subconfluence before fixation.  
2.2.1.2 0.4% Paraformaldehyde (PFA) fixation 
Cells were washed with HBSS then fixed with 200 µl of 0.4% Paraformaldehyde (PFA) for 30 
minutes at room temperature. After fixation, 0.4% PFA was removed and fixed cells were 
covered with 500 µl of HBSS. Fixed cells were stored at 4°C until required. 
   2.2.1.3 Single immunofluorescent staining 
Fixed cells were washed once with PBS. Non-specific antigens were blocked by incubating 
cells in 150 µl of an appropriate blocking solution (appendix B2) for 1 hour at room 
temperature. Blocking solution was removed and cells were incubated in the appropriate 
primary antibody (Table 2.1) at 4 °C overnight. Following primary antibody incubation, cells 
were gently washed 3 times with PBS then incubated with the appropriate secondary 
antibody (Table 2.2) at room temperature for 1 hour. Cells were washed gently twice with 
PBS. Chambers and gaskets were then removed, and slides were mounted with Vectashield 
containing 4¶, 6-diamidino-2-phenylindole (DAPI) (Vector, H-1,200) to stain nuclei. Cells  
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Table 2.1 Primary antibodies used in immunofluorescent staining 
Primary antibody Host species Dilution Suppliers 
1. CD133 antibody Rabbit 1:200 Abcam 
(ab19898) 
2. CD133 (C24B9) Rabbit 1:75 Cell signaling 
(3663) 
3. Human/Mouse SOX2 MAb (Clone 245610) Mouse 1:75 R&D system 
(MAB 2018) 
4. Anti-P-Glycoprotein Mouse mAb (C219)  Mouse 1:50 Calbiochem 
(517310) 
5. P glycoprotein antibody (4E3)  Mouse  1:50 Abcam 
(ab10333) 
6. Multidrug Resistance Associated Protein 
(MRPr1) Monoclonal Antibody 
Rat 1:50 Signet     
(SIG-38760) 
7. Anti-MultiDrug Resistance Related Protein 
(clone MRPm6) 
Mouse 1:50 Chemicon 
(MAB4122) 
8. BCRP/ABCG2 antibody (BXP-21) Mouse 1:50 Abcam 
(ab3380) 
 
Table 2.2 Secondary antibodies used in immunofluorescent staining 
Secondary antibody Dilution Suppliers 
1. Alexa fluor® 555 goat anti-mouse antibody 1:500 Invitrogen, A21424 
2. Alexa fluor® 488 goat anti-rabbit antibody 1:500 Invitrogen, A11008 
3. Alexa fluor® 555 goat anti-rat antibody 1:500 Invitrogen, A21434 
 
were covered with coverslips and sealed with tosylamide-formaldehyde resin (nail varnish). 
Slides were wrapped in foil and stored at 4 °C up to 4 weeks until microscopically analysed. 
 
2.2.2 Immunofluorescent staining of neurospheres  
2.2.2.1 0.4% Paraformaldehyde (PFA) fixation  
Neurospheres were transferred into 50 ml Falcon tubes and left for 30-40 minutes to 
naturally settle down at room temperature. Media was carefully removed and neurospheres 
were washed with 5 ml of HBSS and allowed to settle down again. HBSS was then carefully 
removed. Neurospheres were then fixed with 0.4% PFA at room temperature for 30 minutes. 
After fixation, 0.4% PFA was removed and neurospheres were resuspended in 1 ml of 30% 
sucrose in HBSS. Fixed neurospheres were transferred to new eppendorfs using 10 ml 
pipette to preserve intact neurosphere and stored at 4 °C until required. 
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2.2.2.2 Cryostat sectioning of neurospheres  
The Leica CM 1850 cryostat machine was set below -20qC, and the chuck holder gap was 
filled with optimal cutting temperature (OCT) compound (BDH, 361603E) then left until set. 
To create a neurosphere block, 10 µl of fixed neurospheres were added to the middle of a 
ǋOGURSof OCT on the coated chuck holder then left to set. The neurosphere block was 
cut at a thickness of 8 µm and neurosphere sections were picked up onto 3-
Aminopropyltriethoxysilane (APES) coated slides. Neurosphere sections were stored at -20 
qC until required. 
   2.2.2.3 Single immunofluorescent staining 
Cryostat sections of neurospheres were removed from -20 qC and left at room temperature 
until defrosted. An immunoedge pen (Vector, H-4000) was used to create a border around 
neurosphere sections. Sections were incubated with an appropriate blocking reagent 
(appendix B2, Table B2.2) for 1 hour at room temperature. The blocking reagent was 
removed and sections were incubated with the appropriate primary antibody (Table 2.1) at 4 
°C overnight. Following primary antibody incubation, sections were gently washed 3 times 
with PBS. Sections were then incubated with the appropriate secondary antibody (Table 2.2) 
at room temperature for 1 hour. Sections were washed gently twice with PBS and mounted 
with Vectashield containing DAPI (Vector, H-1,200) to stain nuclei. Sections were covered 
with coverslips and sealed with nail varnish. Slides were wrapped in foil and stored at 4 °C 
until microscopically analysed.  
 
2.2.3 Double immunofluorescent staining 
The process of double staining IF in both monolayer cells and neurospheres is similar to that 
of single staining. However, the blocking reagent and antibody solution used for double 
staining are different as mentioned in appendix B2, Table B2.2. Two primary antibodies were 
added together as were the anti-mouse or anti-rat and anti-rabbit secondary antibodies. 
 
 
 
 82 
2.2.4 Image processing 
Immunofluorescence slides were observed under a Leica DMRM fluorescent microscope 
[Nikon: Digital sight-USB (H)] fitted with filters to detect fluorescence omitted by DAPI 
(blue), Texas red (red) and FITC (green). A Nikon camera and the NIS elements software 
was used to capture images. Positive cells stained for specific markers (total counted cells 
range from 600-1,000 cells) were counted by using Adobe Photoshop elements 3.0 with x40 
and x100 magnification for monolayer and neurospheres, respectively.  
 
2.3 Western blotting analysis 
Western blot analysis was performed to detect the level of protein expression, semi-
quantitatively. Proteins were separated based on size by SDS gel electrophoresis, 
transferred to a membrane and then incubated with a primary antibody. The membrane was 
then incubated with a secondary antibody, directed against the primary antibody, 
conjugated to horseradish peroxidase enzyme (HRP). The emitted light from the HRP activity 
was detected by Enhanced Chemiluminescence (ECL) detection. This technique is fairly 
effective because of the combination of enzyme label and chemiluminescent detection of 
peroxidase labelled proteins resulting in a highly sensitivity assay. The HRP enzyme complex 
bound to the primary antibody catalyzes oxidation of Lumigen PS-3 Acridan substrate in the 
ECL detection kit, resulting in the generation of acridinium ester intermediates. These 
intermediates react with peroxide under slight alkaline conditions to produce a sustained, 
high intensity chemiluminescent signal with maximum emission at 430 nm. This 
chemiluminescent emission was detected on chemiluminescent film, Kodak® BioMax light 
film (Sigma, Z373508). 
 
2.3.1 Protein extraction  
 2.3.1.1 Standard method for protein extraction from cell pellets  
Cell pellets, as mentioned in section 2.1.4.2, were removed from -80°C freezer and stored 
on dry ice. Cells were then resuspended in an appropriate volume (depends on number of 
cells pelleted, 100-200 µl for 1-5 x 106 cells) of ice cold lysis buffer containing 1:50 protease 
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cocktail inhibitor (appendix B3, Table B3.1). Cells were homogenised using Fisher Scientific 
PowerGen Model 125 Homogeniser (Fisher Scientific, 14-359-250) for a minute on ice and 
then incubated at 4°C for 20 minutes on a rocker. After incubation, the cell lysate was 
centrifuged at 12,470xg for 30 minutes at 4°C then the supernatant solution comprising of 
extracted protein was transferred into a fresh eppendorf tube and stored at -80°C or the 
protocol continued with a Bradford assay. 
2.3.1.2 Isolation of microsomal membrane from cell pellets 
Cell pellets prepared by the method described in section 2.1.4.2 were removed from -80 °C 
freezer and placed on dry ice.  Cells were resuspended with 250 µl of ice cold lysis buffer 
containing 1:50 protease cocktail inhibitor (see appendix B3, Table B3.1) and homogenised 
using the Fisher Scientific PowerGen Model 125 Homogeniser for a minute on ice. 
Homogenised cells were incubated at 4°C for 20 minutes with agitation. Gentle 
centrifugation was then performed to remove cell debris at 300xg, 4°C for 3 minutes. 
Supernatants were transferred to ultracentrifuge tubes for membrane separation. An 
ultracentrifugation machine (OptimaTM Max Ultracentrifuge 130,000 rpm, Beckman 
CoulterTM) was used to centrifuge the supernatant at 100,000xg, 4 °C for 1 hour. After 
ultracentrifugation, the cytosolic component was transferred to a fresh eppendorf. The 
microsomal membrane pellets were then resuspended in ice cold PBS containing 1:50 
protease cocktail inhibitor and stored at -80°C until used. 
   2.3.1.3 Total cell lysate 
The initial steps of total cell lysate are similar to the standard method for protein extraction. 
After incubation on ice, the centrifugation step was omitted to ensure that the protein 
extracted contained the nuclear fraction. Total cell lysates were used for SOX2 detection and 
stored at -80 °C until used. 
 
2.3.2 Protein quantification (Bradford assay) 
The concentration of protein was quantified by using a Bradford assay. A range of bovine 
serum albumin (BSA) standards from 1, 5, 10, 15, 20, 30 and 40 µg/ml (total volume is 1 
ml) were prepared using 2 mg/ml stock of BSA (Sigma, B4287) diluted with 1:5 Bio-Rad 
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protein assay dye reagent (Bio-Rad, 500-0006). To prepare the sample for protein 
quantification, 5 µl of sample was added into 995 µl of 1:5 Bio-Rad protein assay dye 
reagent. Individually, 200 µl of the BSA standards and samples were added into 96-well 
SODWHDQGWKHDEVRUEDQFHZDVPHDVXUHGDWǊXVLQJDVSHFWURSKRWRPHWHU05;,,'<1(;
technology). Revelation software for MRX® version 5.1.2600.2180 was used to analyse and 
calculate protein concentration. 
  
Before loading proteins on the gel, protein samples were mixed with sample buffer so that at 
least 20% volume is sample buffer (appendix B3, Table B3.1). The maximum volume for 
loading was 15 µl when using 0.75 mm spacers or 50 µl when using 1.5 mm spacer from 
Bio-Rad Mini-Protean III system. The sample buffer must have 1:20 ǃ-mercaptoethanol 
freshly added prior to use. 
 
2.3.3 Preparation of Polyacrylamide gel electrophoresis (PAGE)  
The Bio-Rad mini Protean III glass plates and spacers were cleaned with 1.5% trigene and 
70% ethanol before use. Glass plates and spacers were set into the glass plate casting 
frame and the casting frame was clamped tightly into the casting stand. Distilled water was 
added first to ensure that there was no leakage. The lower gel (appendix B3, Table B3.2) 
then was prepared and immediately added between the glass plates to 2 cm below the top 
of the smaller glass plate. Butanol was added on top of the lower gel to ensure a smooth 
surface on setting. The percentage of lower gel prepared for gel electrophoresis depends on 
the expected size of the proteins to be detected as shown in Table 2.3. The gel was allowed 
to set at room temperature for approximately 30 minutes then the butanol was removed. A 
4% acrylamide upper gel (upper stacking gel, appendix B3, Table B3.3) was prepared and 
rapidly layered over the top of the lower gel. The comb was carefully inserted into the upper 
gel and the gel was allowed to polymerize at room temperature for 30 minutes.  
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Table 2.3 Effective range of separation of SDS-Polyacrylamide gels (Sambrook, J. 
and Russell, D.W. 2001) 
Acrylamide concentration (%) Linear range of separation (kD) 
15 10 ± 43 
12 12 ± 60 
10 20 ± 80 
7.5 36 ± 94 
5 57 - 212 
Molar ratio of bisacrylamide:acrylamide is 1:29 
 
2.3.4 Sample preparation for gel electrophoresis 
The set gel was placed in an electrode assembly with the smaller glass plate facing inwardly 
then the assembly was filled with electrode buffer (appendix B3, Table B3.1). If only one gel 
was to be run, a dummy plate was placed in the opposing slot. To prepare samples for 
loading, 40 µg ± 100 µg of protein was mixed with sample buffer and boiled on a 99°C hot 
plate for 3 minutes (for microsomal membrane samples, samples were incubated at 37°C for 
30-45 minutes (CD133 detection) or at 70°C for 10 minutes (ABC transporters detection). 
Samples were centrifuged at 12,470xg for 1 minute. The combs were carefully removed and 
each well was flushed of any gel debris using a needle filled with electrode buffer. Then 12 µl 
of See blue size marker (Invitrogen, LC5925) was loaded into the first well and 15 µl (for 
0.75 mm spacer) or 50 µl (for 1.5 mm spacer) of protein samples was loaded into each 
subsequent well. The gel was then electrophoresed at 120-150 V until markers in the size 
range of expected protein were sufficiently separated (approximately 2 or 3 hours at room 
temperature). 
 
2.3.5 Protein transfer to membrane 
HybondTM±P PVDF membrane (Amersham, RPN303F) was activated in 1) methanol for 10 
seconds, 2) distilled water for 5 minutes and 3) ice cold transfer buffer (appendix B3, Table 
B3.1) for at least 10 minutes. The gel was carefully detached from the glass plates and 
upper gel was removed. The transfer cassette was arranged in the transfer buffer as follow, 
1) black gel holder, 2) 2 sponges soaked in transfer buffer, 3) 2 pieces of filter paper, 4) gel, 
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5) the membrane, 6) 2 pieces to filter paper, 7) 2 sponges soaked in transfer buffer, and 8) 
white gel holder. Negatively charged proteins (SDS) migrate toward the anode. To transfer 
the protein to the membrane, the transfer cassette was placed inside the transfer tank with 
black and white holders facing the negative electrode (black) and the positive electrode 
(red), respectively. The tank was filled with transfer buffer until the transfer cassette was 
fully immersed. The transfer was carried out at 100 mA and 25 V overnight at 4°C.  
 
2.3.6 Ponceau staining 
Ponceau staining was performed to test whether protein had been successfully transferred to 
the membrane. If the proteins are transferred onto the membrane, pink bands will appear 
on the membrane after incubating in the Ponceau solution. The membrane was removed 
from the transfer cassette and incubated in the 0.1% Ponceau S solution for approximately 1 
minute until the pink bands were detected. The membrane was then washed with TBS-T 
(appendix B3, Table B3.1). Due to the fact that the size markers may fade during incubation 
steps, the position of markers on the membrane was marked using non-soluble ink. 
 
2.3.7 Primary and secondary antibody treatment 
To block non-specific antigens, the membrane was incubated in blocking solution, 5% Marvel 
milk in TBS-T (appendix B3, Table B3.1), for 1 hour at room temperature on a rocker, then 
rinsed twice with TBS-T solution. For primary antibody treatment, the membrane was 
incubated in primary antibody diluted in blocking solution (Table 2.4) overnight at 4°C on 
the rocker. The membrane was then washed as follows: 1) rinsed twice in 5% Marvel milk in 
TBS-T, 2) 10 minutes in 5% Marvel in TBS-T, 3) 5 minutes in 5% Marvel in TBS-T twice, and 
4) TBS-T for 5 minutes, all performed on the rocker. The membrane was then incubated in 
secondary antibody diluted in TBS-T (Table 2.4) for 1 hour at room temperature on the 
rocker. The membrane was then washed as follow: 1) rinsing twice in 5% Marvel in TBS-T, 
2) 10 minutes in 5% Marvel in TBS-T, 3) 5 minutes in 5% Marvel in TBS-T twice, 4) TBS-T 
for 5 minutes and finally, 5) in 1xTBS (appendix B3, Table B3.1) for 5 minutes all performed 
on the rocker. 
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2.3.8 ECL detection 
Peroxidase activity of secondary antibody bound to primary antibody on the membrane was 
detected by the ECL plus western blotting detection kit (Amersham Bioscience, RPN2132). 
For 1 blot, the ECL detection reagent was prepared by adding 50 µl of solution B to 2 ml of 
solution A (Lumingen). The ECL reagent was pipetted to cover the surface of the membrane 
(protein side up) and incubated for 5 minutes. Excess reagent was removed by blotting the 
edge of the membrane with tissue paper. The membrane was placed facing side down on 
asmooth sheet of Saran wrap. Another piece of Saran wrap was placed over the membrane 
and carefully smoothed to ensure no creases or bubbles were present. The sealed 
membrane was transferred to a photography cassette. Kodak® BioMax light film (Sigma, 
Z373508) was placed on top of the membrane under dark room condition. Exposure time 
 
Table 2.4 Primary and secondary antibodies used in Western blot analysis 
Primary antibody Host 
Species 
Dilution Secondary antibody Dilution 
CD133 (Abcam, ab19898) 
: detected size 110 kDa 
: predicted size 97 kDa 
Rabbit 1:400 Anti-rabbit HRP 
(Universal biologicals, 
A120-101P) 
1:2,000 
CD133/1 (W6B3C1) pure 
(Miltenyi Biotec, 130-092-395) 
: detected size 120 kDa 
: predicted size 95 kDa 
Mouse 1:100 Anti-mouse HRP  
(Cell signaling NEB, 
7076) 
1:2,000 
SOX2 (R&D system, MAB2018) 
: detected size 37 kDa 
: predicted size 34 kDa 
Mouse 1:150 Anti-mouse HRP  
 
1:2,000 
SOX2 (Cell signaling, 2748) 
: detected size 35 kDa 
: predicted size 35 kDa 
Rabbit 1:1,000 Anti-rabbit HRP  1:2,000 
C219 (Calbiochem, 517310) 
: detected size range from 140 ± 
170 kDa 
Mouse 1:100 Anti-mouse HRP  
 
1:2,000 
MRPr1 (Signet, SIG-38760) 
: detected size range from 140 ± 
190 kDa 
Rat 1:100 Anti-rat HRP 
(Cell signaling NEB, 
7077) 
1:2,000 
BXP-21 (Abcam, ab3380) 
: predicted size 72.3 kDa 
Mouse 1:500 Anti-mouse HRP 1:2,000 
ǃ-tubulin  
(Cell signaling, 2128) 
Rabbit 1:1,000 Anti-rabbit HRP 1:2,000 
varied from approximately 15 seconds to 30 minutes. Finally, the film was developed using 
an automatic developer machine (Curix 60, Agfa) or manual developing.  
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 2.4 DNA extraction 
DNA extraction was performed for single nucleotide polymorphism (SNP) array and TRF 
(terminal restriction fragments) assay. DNA was extracted from both monolayer and 
neurosphere cell pellets. Live cell pellets were for SNP array whilst frozen cell pellets were 
extracted for TRF assay. 
 
  2.4.1 DNA extraction from frozen cell pellets 
Frozen cell pellets removed from -80°C and kept on dry ice. 500 µl DNA lysis buffer 
(appendix B4, Table B4.1) containing 2 mg proteinase K (Sigma, P2308) was added to cell 
pellets. Cell pellets were homogenised for a minute using Fisher Scientific PowerGen Model 
125 Homogeniser then incubated on a Thermomixer (Eppendorf) at 37°C, 450 rpm 
overnight. 700 µl Phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma, 77617) was added 
to homogenised cells and transferred into the mixtured precentrifuged 2.0 ml Phase Lock Gel 
(PLG) (5 PRIME, 2302830) tubes. Samples were centrifuged at 16,000xg for 5 minutes 
allowing the PLG to separate the solution into 2 parts: an upper phase containing nucleic 
acid and a lower phase. The upper phase solution was transferred into fresh eppendorfs. 100 
µg RNase A (Sigma, R6513) was added to upper phase solution and samples were incubated 
on thermomixer at 37°C for 30 minutes. An equal volume of isopropanol (Fisher, P/7508/17) 
was added to precipitate DNA then samples were centrifuged at 12,000xg for 5 minutes. The 
supernatant was removed avoiding the DNA pellet and the pellet was washed twice with 500 
µl of 70% ethanol then centrifuged at 12,000xg for 5 minutes. Supernatant was discarded 
and DNA pellets were left to dry at room temperature. DNA pellets were resuspended with 
100 ± 200 µl of ultra pure sterile water (UPSW) then incubated on the Thermomixer at 60°C, 
450 rpm for 15 minutes then at 37°C, 450 rpm for 1 hour. DNA concentration was 
determined using Nanodrop (NanoDrop Technologies, INC, NanoDrop® ND-1000 
Spectrophotometer). Five micro litres of extracted DNA was mixed with 5 µl gel loading 
buffer (Sigma, G2526) and run on a 1% agarose MP (Multi purpose agarose) gel (Roche, 
11388991001) at 120 V. for 20 minutes to test the quality of DNA and for contaminations. 
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10 kb hyperladder was loaded as a DNA marker. If there is no contamination, extracted DNA 
was stored at -80°C. 
 
  2.4.2 DNA extraction from live cell pellets 
Live cells were collected from a T75 cm2 flask using a scraper and washed twice with HBSS. 
500 µl DNA lysis buffer (appendix B4, Table B4.1) and 2 mg proteinase K were added to live 
cell pellets. Pellets were homogenised using the Fisher Scientific PowerGen Model 125 
Homogeniser for a minute and incubated on a thermomixer at 37°C, 450 rpm overnight. 
From this point DNA extraction was the same as from frozen cell pellets as mentioned in 
section 2.4.1.   
 
 2.5 Terminal restriction fragment (TRF) assay or telomere length 
assay 
The telomere length assay was performed to measure any alteration of telomere length in 
EPN-2, MED-2, SPNET-1 and PFSK-1 cell lines at early, middle and late passages in 
comparison to normal human stem cell (hNSC) and adult glioblastoma (U87 and U373 cell 
lines). There is significant difference in doubling time at early passage compared to later 
passage of neurospheres. It was opposed that alteration of telomere length might be 
responsible for the longer doubling time of late passage neurospheres. 
 
2.5.1 DNA digestion 
The required DNA amount for this assay was 3 µg resuspended in distilled water (total 
volume is 16 µl) and mixed with 9 µl of the master mix containing 30 units of Hinf I*, 30 
units of Rsa I*, 2.5 µl of NEBuffer 2 (Biolabs, B7001S) and 0.5 µl of Rnase A (Sigma, 
R5000). Samples were incubated at 37°C overnight. This step results in cutting of genomic 
DNA into small pieces but telomeric DNA and sub-telomeric regions remain intact. 
[* Supplied with Telo TAGGG Telomere Length assay kit (Roche, 12209136001)] 
2.5.2 TRF gel electrophoresis 
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0.75% agarose gel in 1x TAE solution (appendix B5, Table B5.1) was prepared in gel tray 
with a 20 lane comb. DIG marker*, Digoxygenin labelled telomere-specific probe, had to be 
activated prior to use. Thereby 4 µl of DIG marker was mixed with 12 µl of distilled water 
and 4 µl of gel loading buffer then the mixtured solution was incubated at 65°C for 10 
minutes. Digested DNA was mixed with 3 µl of loading buffer before loading and DIG marker 
also was loaded at the first and last lanes of gel. The gel was initially run at 100 V for 20 
minutes then 30 V overnight at room temperature.  
(* Supplied with Telo TAGGG Telomere Length assay kit) 
 
2.5.3 Denature of DNA 
The gel was cut at left upper corner and transferred into the tray. Gel was incubated in 0.25 
M HCL for 10 minutes to separate double strands of DNA. All steps were performed on 
shaker at room temperature. The gel was rinsed twice with distilled water before incubating 
in denaturing solution (appendix B5, Table B5.1) for 15 minutes twice. The gel was rinsed 
twice with distilled water and incubated in neutralising solution (appendix B5, Table B5.1) 
for 15 minutes.  
 
2.5.4 TRF Southern blot 
DNA was transferred to a positively charged nylon membrane (Roche, 11417240001) in 20x 
SSC (1.5 litres, appendix B5, Table B5.1). The order of transferring was arranged as 
following; 1) long blotting paper soaked in 20x SSC prior to used and placed on top the hard 
plate, 2) gel inverted prior to transfer, 3) Nylon positive charge membrane (cut the same 
corner as gel), 4) Saran wrap cut around gel border then peeled off to leave the remain on 
edges of gel, 5) two pieces of soaked 20cm x 20cm blotting paper, 6) two pieces of 10cm x 
20cm blue tissue paper, 7) two packs of blue tissue paper placed on top each 10cm x 20cm 
blue tissue paper, and 8) heavy weight. Bubbles were removed by rolling a pipette across 
each layer. DNA was transferred overnight at room temperature. 
 
2.5.5 Hybridization 
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The membrane was placed DNA side up and DNA was linked to membrane using UV cross 
linker at 120 mJ/cm2 for 1 minute. The membrane was washed in 50 ml 2x SSC before 
prehybridisation. The membrane was rolled in the roller bottle and prehybridised in 15 ml 
DIG Easy (Roche) Hyb TRF solution* for 1 hour at 42°C in hybridisation machine. For 
hybridisation, the membrane was incubated in 15 ml DIG Easy (Roche) Hyb TRF solution 
containing 3 µl of Telomere TTAGGG probe* (1 µl/5 ml) at 42°C overnight.    
(* Supplied with Telo TAGGG Telomere Length assay kit) 
 
2.5.6 Washing, blocking and anti-DIG-AP treatment 
The membrane was washed as follows; 1) twice in 50 ml of 2x SSC containing 0.1% SDS for 
5 minutes on shaker at room temperature, 2) twice in 50 ml of 0.2x SSC containing 0.1% 
SDS for 15 minutes in the roller bottle at 50°C and 3) once washing buffer (appendix B5, 
Table B5.1) for 5 minutes on shaker at room temperature. The membrane was blocked in 
100 ml of blocking solution (appendix B5, Table B5.1) for 30 minutes then incubated in 100 
ml of anti-DIG-AP solution (appendix B5, Table B5.1) for 30 minutes on shaker. The 
membrane was washed twice in 100 ml of washing buffer for 15 minutes on shaker. 
 
  2.5.7 Detection 
The membrane was incubated in 100 ml of detection solution (appendix B5, Table B5.1) for 
5 minutes on shaker at room temperature. 
 
  2.5.8 Substrate treatment 
The membrane was placed on Saran wrap then CDP substrate solution (supplemented with 
TRF assay kit) was dropped to cover the membrane. The membrane was wrapped with 
another piece of Saran wrap then excess solution, bubbles and creases were removed. The 
sealed membrane was transferred to a photography cassette. Kodak® BioMax light film 
(Sigma, Z373508) was placed on top of the membrane under dark room condition. Exposure 
time varied from approximately 15 seconds to 30 minutes. Finally, the film was developed 
using an automatic developer machine (Curix 60, Agfa) or manual developing. 
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2.6 Haematoxylin and Eosin (H&E) staining 
H&E staining was performed on formalin-fixed paraffin embedded (FFPE) tumours to study 
histological features of tumours. Sections were dewaxed in solutions as following; 1) xylene 
(Fisher Scientific, X/0250/PB17) for 15 minutes, 2) 100% ethanol for 5 minutes twice and 3) 
95% ethanol for 5 minutes twice. Slides were incubated in running tap water to get rid of 
ethanol and wax. Slides were placed in the rack and agitated in Harris haematoxylin for 7 
seconds then washed in running tap water until clear. Slides were agitated in Lithium 
carbonate until turning blue then washed in running tap water until clear. Slides were 
soaked in Eosin (Nustain, Department of Pathology, Nottingham, AD046) for 10 seconds 
then washed in running tap water until clear. Sections were dehydrated in 95% ethanol, 
100% ethanol and xylene respectively and sections were mounted by using DePex. 
 
2.7 Telomere Repeat Amplification Protocol (TRAP) assay 
The TRAP assay was performed to measure telomerase activity in each cell lines at early, 
middle and late passage number.  
 
2.7.1 Protein extraction 
Snap frozen pellets as mentioned in section 2.1.4 were placed on dry ice. Total protein was 
extracted by adding 50 µl 1x CHAPS buffer* containing 200 units/ml RNase inhibitor (Roche, 
03335399001). Cell pellets were resuspended by gently pipetting then incubated on ice for 
30 minutes. Extracted proteins were snap frozen on dry ice and prepared for protein 
measurement or stored at -80°C. Protein extraction was diluted with CHAPS buffer at a 
FRQFHQWUDWLRQRIǋJǋOIRU3RO\PHUDVH&KDLQ5HDFWLRQ3&5DVVD\ 
 
[* Supplied with TRAPeze® Telomerase Detection Kit (Chemicon, S7700)] 
 
2.7.2 Protein quantification 
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To determine protein concentration, a BSA standard curve was prepared by serial dilution as 
shown in Table 2.5. BSA standard concentration from tube A-F was loaded as 25 µl into 96-
well plate. Both BSA standard concentrations and samples were prepared as duplication and 
loaded in 96-well plate. To prepared samples for protein quantification, 1 µl from each 
sample was diluted in 9 µl of 1x CHAPS buffer then transferred to each well of a 96-well 
plate. 250 µl of 1:12 diluted Coomassie reagent (appendix B6, Table B6.1) was added into 
each well of 96-well plate then the absorbance value of protein was analysed using a 
spectrophotometer at 595-600 nm. Protein concentration was determined from the BSA 
standard curve using the equation from linear graph. 
 
2.7.3 Addition and amplification of telomere repeats by telomerase 
A PCR method was performed to add and amplify telomere repeats in samples. The required 
amount of protein for each PCR reaction is 0.1 µg. 1 µl of 0.1 µg/µl protein extraction was 
resuspended in 40.6 µl of nuclease-free water. PCR master mix as shown in Table 2.6 was 
prepared and 8.4 µl was added to each sample. Samples were run in PCR machine as the 
following cycle conditions: 
- 30°C for 30 minutes: 1 cycle (Telomere extension) 
- 94°C for 30 seconds, 59°C for 30 seconds: 31 cycles (Amplification of Telomere 
repeats) 
 
Table 2.5 Preparation of BSA standard concentration for protein quantification 
Tube BSA volume (µl) 
from 2mg/ml 
stock 
CHAPS diluent volume 
(µl) 
Total protein 
(µg) 
A 25 µl BSA stock 25 µl 25 
B 25 µl from tube A 25 µl 12.5 
C 25 µl from tube B 25 µl 6.25 
D 25 µl from tube C 25 µl 3.12 
E 25 µl from tube D 25 µl 1.55 
F 25 µl from tube E 25 µl 0.775 
 
Table 2.6 PCR Master Mix 
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Solutions Volume (µl) 
1. 10x TRAP buffer 5 
2. Ts primer 1 
3. Primer mix 1 
4. 50x dNTP 1 
5. Taq Polymerase 0.4 
Total 8.4 
 
2.7.4 Telomerase detection 
A 10% polyacrylamide gel (appendix B6, Table B6.1) was cast between gel plates and left to 
set for 30 minutes. Gel plates were set into electrophoresis tank and filled with gel running 
buffer (appendix B6, Table B6.1). DNA molecular marker (appendix B6, Table B6.1) was 
loaded as 10 µl in the first lane of gel. 25 µl of samples were loaded on gel which was run 
240 Volts for 90 minutes. The gel was incubated in staining solution (appendix B6, Table 
B6.1) and agitated on the shaker for 30 minutes in dark. The gel was scanned with FL-2000 
gel imager (FUJIFILM) to detect telomerase activity. 
 
2.7.5 Quantification of telomerase activity 
The Quantity One software was used to analyse the density of telomerase activity. The 
density of telomerase activity was assessed by the summation of density measuring from 
divided 6 boxes covering the telomerase activity and the internal bands were also measured 
density. The total product of telomerase activity was calculated from the formula as 
followed.  
 
2.8 Metaphase spread analysis 
The total product 
(units) 
A = the density of samples 
B = the density of negative control 
C = the density of TSR8 
DA = the density of A internal control band 
DB = the density of B internal control band 
(ȈA- ȈB)/ DA 
(ȈC- ȈB)/ DB 
X 100 = 
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The result from Telomere length assay showed 2 different lengths of telomeres (short and 
long telomere) in both monolayer and neurosphere samples. Long and short telomere 
lengths are approximately 15 and 4 Kbp respectively. Therefore, cell spread analysis was 
performed to investigate whether long telomere length resulted from end-fusion of 
chromosome. 
  2.8.1 Nocodazole treatment 
Cells were subcultured into T75 flasks and incubated until 50-70% confluency 
(approximately 2x106 cells). Cells were treated with 0.1 µg/ml Nocodazole (Sigma, M1404) 
for 16 hours to induce cells in metaphase. 
  2.8.2 Preparation of metaphase spreads from cell culture 
Mitotic rounded cells were collected by tapping the flask several times and checked under 
the microscope to ensure that all mitotic cells were collected.  Floating mitotic cells were 
transferred to a 50 ml Falcon tube and centrifuged at 800xg for 5 minutes then the 
supernatant was discarded. Freshly prepared 10 ml of 0.6% Tri-Sodium citrate (Fisher, 
S/P500/53) (hypotonic solution) was added to pellets while vortexing and incubated at room 
temperature for 15 minutes to allow cells to absorb the solution and swell. Cells were 
centrifuged at 800xg for 5 minutes and supernatant was removed. Pellets were fixed 3 times 
with 6 ml of freshly prepared fixative solution, 3:1 methanol: acetic acid, which was added 
drop wise while vortexing to each pellet then cells were centrifuged at 800xg for 5 minutes. 
The process was repeated 3 times before cell pellets were resuspended in 500 µl of fixative 
and stored at -Û& 
  2.8.3 Slide preparation 
Slides were incubated in 70% ethanol overnight prior to performing metaphase spread 
analysis. Slides were washed in distilled water then polished with blue roll paper. Slides were 
KHOGDWDÛDQJOHWRWKHEHQFK then fixed cells were dropped from approximately 5 inches 
above slides. Three drops of fixed cells were dropped on each slide then slides were 
incubated at room temperature until dry. Metaphase cells were examined under the light 
microscope.  
2.9 Clonogenic assay 
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EPN-2, MED-2 and SPNET-1 cell lines 
(70-80% confluency) 
Plate 100 cells/well 
Plate 40 cells/well 
Fix and crystal violet 
staining after 8 days 
incubation 
- Colony counting 
-  repeat x3 
experiments 
  Treat cell with  
- Etoposide and Cisplatin for 2 hrs.      
± Irinotecan for 96 hrs.                        
± Methotrexate for 8 days                    
  Incubate for 8 days 
Just 1 experiment 
 
For double staining IF 
- B1/C1 or G2 with CD133 co-staining 
- compare co-staining between 
clones in each well 
B1            C1           G2 
Treated cells 
Control cells 
Eto.   Cisp.  Irino.  MTX 
-  Treat with vehicle or drug 
concentration that gives 30-40% 
- Eto. and Cisp.: tx. 
for 2 hrs. and 
change media 
-  Irino.: tx. for 96 
hrs. and change 
media 
Incubate for 
8 days 
-  Fix with 0.4% PFA 
-  Co-staining IF: B1, C1 and G2 with 
CD133 
B1            C1           G2 
-  Plate totally: 3 chamber slides x 3 
cell lines = 9 chamber slides 
-  compare co-staining between 
clones within each well 
Result 
-  From the result of co-staining IF, can 
determine which transporters and the 
corresponding drug treatment to 
examine by FACS. 
-  The result can also show whether 3 
different control clones (DMSO, 0.9% 
NaCl and NaOH in 0.9% NaCl) have 
different expression of ABC transporters 
and CD133. If there is no difference 
between 3 different clones, only 1 
control clone will be selected to carry on 
-  Just 1 experiment 
-  Select 3 clones from the 
vehicle control well and well 
with 30-40% surviving cells 
-  plate in 6-well plate in 
tumour media 
-  Treat cells exactly the same 
way as start to select resistant 
cells ie. Use vehicle or drug 
concentration that gives 30-
40% survival 
-  Plate totally: 1 plate x 4 
drugs x 3 cell lines = 12x 6-
well plates -  when cells reach sub-
confluency, trypsinise and 
passage to T25 flasks   
-  Treat cells exactly the same 
way as start 
-  when cells reach sub-
confluency, trypsinise and 
passage to T75 flasks with 
tumour media 
-  Treat cells exactly the same 
way as start 
= 6 wells x 12 plates  
= 72 x T25 flasks 
= 72 x T75 
flasks 
**At this stage, 
make cell stocks 
from those not 
selected to carry 
on** 
Freeze cells 
and store 
at -80°C 
for stock 
Passage for 
experiment 
FACS analysis 
-  Functional 
analysis 
-  Co-staining 
Clonogenic plan 
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Clonogenic assay was performed to select drug resistant cells after cells were exposed to 
chemotherapeutic drugs and examine the ability of surviving cells following treatment to 
form colonies. 
 
2.9.1 Optimisation of cell density in monolayer cells 
Cells were plated in 6-well plates at different cell densities to find the most appropriate 
number of cells to form sufficient countable colonies after 8 day incubation. Cells were 
trypsinised using 1x Typsin/EDTA to dissociate cells into single cells. Cells were seeded in 
tumour media at different cell numbers: 50, 100, 200, 300, 500 and 1,000 cells/well into a 
6-well plate. Cells were incubated in 5% CO2 ±air incubator at 37°C for 8 days to allow each 
single cell to form a colony. Cells were then fixed with 0.4% PFA for 20 minutes and stained 
with 0.1% crystal violet. A cell density of 100 cells/well provided sufficient well separated 
single clone for all cell lines and was selected to be used for seeding. 
 
2.9.2  Drug treatment 
To determine inhibitory concentration (IC50) of chemotherapeutic drugs in paediatric brain 
tumour cell lines: EPN-2, MED-2 and SPNET-1, cells were treated with 4 different drugs: 
Cisplatin, Etoposide, Irinotecan and Methotrexate with different concentration. Four different 
drugs were tested on each of the 3 cell lines in order to identify the appropriated clonogenic 
range. Several different ranges of drug concentration were tested until a single ranges was 
identified that would allow the full range of drug response to be determined ideally including 
IC0, IC30, IC50, IC70 and IC90. Resistant clones were picked from the well giving 30-40% 
survival and cultured for further investigations: co-expression of ABC transporters and 
CD133 and functional analysis of ABC transporters using Fluorescence Activated Cell Sorting 
(FACS).   
2.9.2.1 Plating cells 
Monolayer cells were detached using 1xTrypsin/EDTA then passed through the cell strainer 
to separate cells into single cells. Cells were plated in 6-well plate at 100 cells/well in 3 ml of 
tumour media and incubated for 4-6 hours in an incubator to allow them attaching the flask. 
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2.9.2.2 Drug Treatment 
Cells were observed under a microscope to ensure that cells had attached before treatment. 
Each cell line was treated with different concentration of Cisplatin, Etoposide, Irinotecan and 
Methotrexate as shown in Table 2.7 and incubated for 8 days. Each 6-well plate contained 
the control well and 5 different concentrations of each drug.  
 
2.9.3 Fixation and Counting 
After 8-day incubation, cells were fixed with 4% PFA for 20 minutes and stained with 0.1% 
crystal violet for 5 minutes. Cells were then washed 3 times with distilled water to remove 
crystal violet. Only well separated surviving colonies containing more than 50 cells were 
counted.  
 
2.9.4  Derivation of IC50  
GraphPad Prism 5 software was used to draw dose-response curve and determine the IC50 
value. 
 
Table 2.7 Drug treatment for clonogenic assay 
Drug 
EPN-2 MED-2 SPNET-1 
Drug exposure 
duration Control 
Conc. 
(µM) 
Control 
Conc. 
(µM) 
Control 
Conc. 
(µM) 
1. Etoposide 
(Sigma, E1383) 
 
 
 
0.08% 
DMSO 
5  
10  
20  
40  
80  
0.04% 
DMSO 
3  
6  
12  
20  
40  
0.04% 
DMSO 
3  
6  
12  
20  
40  
Cells treated with 
either Etoposide or 
Cisplatin were 
incubated for 2 
hours then tumour 
media were 
replaced with fresh 
media. 
2. Cisplatin 
(Cisplatin 1 mg/ml 
Injection from TEVA 
UK limited) 
1.6x10-5% 
NaCl 
 
 
 
0.3  
0.75  
1.5  
3  
6  
1.6x10-5% 
NaCl 
 
 
 
0.3  
0.75  
1.5  
3  
6  
2.2x10-5% 
NaCl 
0.5  
1  
2  
4  
8  
3. Irinotecan 
(Sigma, I1406) 
0.02% 
DMSO 
0.5  
4  
8  
12  
24  
0.012% 
DMSO 
0.75  
1.5  
3  
6  
12  
0.012% 
DMSO 
0.75  
1.5  
3  
6  
12  
Cells treated with 
Irinotecan were 
incubated for 96 
hours then tumour 
media was 
replaced with fresh 
media. 
4. Methotrexate 
(100mg/ml, 
Pharmacy, DBL) 
 
1.2x10-5% 
NaCl 
+0.42M 
NaOH 
1 nM 
5 nM 
10 nM  
20 nM 
30 nM 
1.2x10-5% 
NaCl 
+0.42M 
NaOH 
1 nM 
5 nM 
10 nM  
20 nM 
30 nM 
1.2x10-5% 
NaCl 
+0.42M 
NaOH 
1 nM 
5 nM 
10 nM  
20 nM 
30 nM 
Cells treated with 
Methotrexate were 
continuously 
treated for 8 days. 
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2.10 Cells co-expressing ABC transporters and CD133 detected by 
FACS analysis 
Co-staining CD133 and ABC transporters immunofluorescence by FACS was performed to 
confirm the data of co-staining immunofluorescence and Western blotting analysis in 
resistant selected clones. Both immunofluorescence and Western blotting analysis results 
indicated that resistant selected clone expressed higher proportion of cells expressing CD133 
and either ABCB1 or ABCC1. Unfortunately, FACS analysis results showed inconsistent 
proportion of CD133 and ABC transporters co-stained cells when the experiments were 
repeated. Therefore, the data from co-staining immunofluorescence FACS were unreliable.  
 
2.10.1 Harvesting cells 
Cells were subcultured as monolayers and neurospheres in sufficient T75 flasks to achieve 2 
x 107 cells/ml for each assay. HEK cells stably transfected with pcDNA encoding either 
ABCB1 or ABCC1 or ABCG2 were used as positive controls and HEK cells stably transfected 
with empty pcDNA were used as negative control. 
2.10.1.1 Monolayer cells 
Cells were washed with 'XOEHFFR¶V 3KRVSKDWH %XIIHUHG 6DOLQH (DPBS) without CaCl2 and 
MgCl2 (Sigma, D8537) and detached from flasks with 2 ml of 10 mM EDTA in DPBS. Cells 
were incubated for 15 minutes in standard cell culture incubator then gently dissociated 
using 10 ml pipette to singularise cells. Cells were centrifuged at 800xg for 3 minutes then 
DPBS was removed. Cells were resuspended in 500 µl of DPBS.  
2.10.1.2 Neurospheres 
Neurospheres were centrifuged at 800xg for 3 minutes then media were removed. 
Neurospheres were washed with 5 ml DPBS then 5 ml of 10 mM EDTA was added into 
neurospheres to dissociate cells into single cells. Neurospheres were incubated at 37°C on 
an orbital shaker for 20 minutes. To ensure that cells are singularised, cells were pipetted up 
and down using 10 ml pipette and centrifuged at 800xg for 3 minutes to remove EDTA. Cells 
were resuspended in 500 µl of DPBS.  
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2.10.2 Fixation 
Cells were fixed with 2% PFA for 30 minutes at room temperature. Cells were gently 
vortexed while PFA was dropped into the tube. Then 2 x 106 cells were equally transferred 
into FACS tube for ABCB1, ABCC1, ABCG2 detection and also negative controls for each one.  
 
2.10.3 Blocking 
Cells were centrifuged at 250xg for 3 minutes then PFA was discarded. Cells were blocked 
with appropriate blocking buffer as described in Table 2.8. Cells were blocked for 15 minutes 
at room temperature then centrifuged at 250xg for 3 minutes and blocking buffer was 
removed. Cells were then resuspended in 100 µl of DPBS.  
 
2.10.4 Co-staining immunofluorescence by FACS 
2.10.4.1 Primary antibody treatment 
Cells were incubated in the appropriate primary antibody made up in the appropriate 
blocking buffer (co-staining between ABC transporters and CD133) (Table 2.9) for 1 hour at 
room temperature. Cells were centrifuged at 250xg for 3 minutes then the primary antibody 
solution was removed. To remove excess primary antibody, cells were washed once with 100 
µl blocking buffer. 
2.10.4.2 Secondary antibody treatment 
Cells were resuspended in 100 µl of DPBS and incubated with secondary antibody (Table 
2.9) made up in appropriate blocking buffer. For ABCG2 detection, cells were incubated with 
conjugated ABCG2 primary antibody at this stage. Cells were incubated for 30 minutes at 
room temperature in dark. After which cells were washed once with 100 µl of DPBS then 
resuspended in 300 µl of DPBS. 
Table 2.8 Blocking buffer 
ABC transporters Blocking buffer 
1. ABCB1 2% NGS in DPBS 
2. ABCC1 2% NGS + 0.2% Triton X-100 in DPBS 
3. ABCG2 2% NGS in DPBS 
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Table 2.9 Primary and secondary antibody for FACS co-staining 
immunofluorescence 
Primary 
antibody 
Supplier Working 
concentration 
Secondary 
antibody 
Supplier Working 
concentration 
1. ABCB1: 4E3     
   
    CD133  
 
Abcam 
(Ab10333) 
Cell signaling 
(3663) 
1:50 
 
1:100 
Anti-Mouse 
Alexa 647 
Anti-Rabbit 
Alexa 488 
Invitrogen 
(A21235) 
Invitrogen 
(A11008) 
1:1,000 
 
1:500 
2. ABCC1: MRPR1 
 
    CD133 
Signet  
(SIG-38760) 
Abcam 
(Ab19898) 
1:10 
 
1:400 
Anti-Rat Alexa 
647 
Anti-Rabbit 
Alexa 488 
Invitrogen 
(A21247) 
Invitrogen 
(A11008) 
1:1,000 
 
1:500 
3. ABCG2*: 5D3 
 
    CD133 
 
R&D system 
(FAB995P) 
Cell signaling 
(3663) 
1:100 
 
1:100 
- 
 
Anti-Rabbit 
Alexa 488 
- 
 
Invitrogen 
(A11008) 
- 
 
1:500 
 
*ABCG2 primary antibody is conjugated with PE therefore this antibody will be added later 
when cells reaches secondary antibody treatment step. 
 
2.10.5 Analysis 
ABC transporters co-stained with CD133 were detected using FACS machine (Cytomics 
FC500, Beckman Coulter). FACS data were analysed using WinMDI version 2.8 software. 
 
2.11 Functional ABCB1 analysis by FACS  
Immunofluorescence and Western blotting analysis results showed that the ABCB1 
transporter was enriched after drug treatment and consistently expressed at a high level 
after prolonged treatment. Therefore, functional analysis using FACS was performed to 
determine whether high level of ABCB1 expression correlated with an increase in function. 
 
2.11.1 Harvesting cells 
Sufficient cells were subcultured as monolayers to achieve 2 x 107 cells/ml for each assay. 
Cells were washed with DPBS then detached by incubating in 10 mM EDTA in DPBS for 15 
minutes in a standard incubator. To ensure that cells are singularised, a 10 ml pipette was 
used to dissociate cells. Cells were centrifuged at 250xg for 3 minutes then EDTA was 
removed. Cells were washed once with DPBS and resuspended in FACS buffer (appendix B7, 
Table B7.1) to achieve 2 x 107 cells/ml.   
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2.11.2 Substrate, inhibitor and primary antibody treatment 
100 µl of cells (2 x 106 cells) were transferred as into each FACS tube as described in figure 
2.1 and incubated with Rhodamine123 (ABCB1 substrate), Verapamil (ABCB1 inhibitor) or 
4E3 (anti P-glycoprotein) which were made up in FACS buffer, for 30 minutes at 37°C with 
periodic inversion every 10 minutes. Working concentration of all reagents and testing set 
were described in Table 2.10 and figure 2.1. Cells were washed twice with FACS buffer and 
were centrifuged at 250xg for 3 minutes to removed FACS buffer. Then cells were 
resuspended in 100 µl FACS buffer. 
Table 2.10 Reagents for ABCB1 functional analysis by FACS 
Reagents Supplier Aim Working 
concentration 
1. Rhodamine 123 Sigma 
(R8004) 
Substrate 2 µM 
2. Verapamil Sigma 
(V4629) 
Inhibitor 20 µM 
3. 4E3 (anti P-glycoprotein) 
 
Abcam 
(ab10333) 
Primary 
antibody 
1:20 
4. Alexa Fluor® 647 goat 
anti-mouse IgG (H+L) 
Invitrogen 
(A21235) 
Secondary 
antibody 
1:1,000 
 
                            (1)          (2)          (3)          (4)          (5)           (6) 
                                         
                               647                             Rh                              VP 
 
Figure 2.1 Testing set for ABCB1 functional analysis. Cells (2 x 106 cell) were equally 
transferred to each FACS tubes. Each tube was added with different chemicals for different 
aims: 1st tube for background staining of secondary antibody, 2nd tube for co-staining 
detection, 3rd tube for Rhodamine123 (Rh) accumulation or efflux determining, 4th tube for 
determining cells, which effluxed Rh and expressed ABCB1, 5th tube for determining 
Verapamil effect and last tubes for determining inhibition effect of Verapmil on cells, which 
expressed ABCB1 and effluxed Rh.     
Rh+4E3+
647 
4E3+647   Rh+4E3+
647+VP 
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2.11.3 Secondary antibody treatment 
Cells were incubated with the secondary antibody as described in Table 2.10 for 30 minutes 
on ice in dark. Then cells were washed twice with 100 µl FACS buffer and resuspended in 
300 µl FACS buffer. 
 
2.11.4 Analysis 
ABCB1 function was determined by FACS (Cytomics FC500, Beckman Coulter). FACS data 
was analysed using WinMDI version 2.8 software. 
 
2.12 ABCB1 RNAi transfection 
Previous results showed that the ABCB1 transporter was primarily enriched after first 
treatment in the selected clones and consistently expressed at a high level after prolonged 
treatment. To prove that ABCB1 transporter is the major mechanism that protects cells from 
chemotherapeutic cytotoxicity, ABCB1 transporter function was inhibited using Ribonucleic 
acid interference (RNAi) transfection. After transfection, messenger RNA (mRNA) of ABCB1 
will be degraded and protein expression will be absent. If ABCB1 is the major mechanism to 
protect cells from cytotoxicity, ABCB1 siRNA transfected cells should respond better to drug 
treatment. Unfortunately, this technique was unsuccessfully optimised to find the 
appropriate condition for ABCB1 SiRNA transfection into our cell lines. As a result, the 
clonogenic assay was performed to investigate the effectiveness of ABCB1 inhibition in drug 
treatment as mentioned later.  
 
  2.12.1 Plating cells for transfection 
Cells were plated in 24-well plate (EPN-2 cell line and EPN-2 C1 (DMSO) clone = 20 x 103 
cells/well and EPN-2 T1 Etoposide and Irinotecan clones = 25 x 103 cells/well in 1 ml of 
tumour media) for 24 hours in a standard culture incubator before transfection to achieve 
50%-70% confluency.  
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  2.12.2 ABCB1 SiRNA transfection 
SiPORT Amine (Ambion, AM4503) and Opti-MEM® ,  *OXWD0$; , *LEFR -026) 
were warmed to room temperature and mixed together as different concentrations (Table 
2.11). The mixture of SiPORT Amine and Opti-MEM was incubated at room temperature for 
10-15 minutes. GAPDH or ABCB1 SiRNA was mixed with Opti-MEM as described in Table 
2.12. 25 µl of both SiPORT Amine and SiRNA mixture was mixed properly using pipette and 
incubated at room temperature for 10-15 minute to allow them to form RNA induced 
silencing complex (RISC). Cells with 450 µl tumour media were added with 50 µl of different 
concentration of the SiPORT Amine and SiRNA mixture while plate was tilting to avoid 
directly contact of the mixture to particular cell area. Transfected cells were incubated in 5% 
CO2 ±air incubator at 37°C for 24 hours. After 6-8 hour incubation, tumour media was 
replaced with fresh tumour media to avoid cytotoxicity from SiPORT Amine. After 24-hour 
transfection, cells were harvested and extracted RNA to determine ABCB1 expression using 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).      
 
To optimise the condition for ABCB1 transfection, the transfection experiment was 
performed to knockdown known highly expressed gene. Therefore, Silencer® GAPDH SiRNA 
(human) (Ambion, AM4605) (forward GAPDH: TCTGGCCCCCTCTGCTGATGC and reverse 
GAPDH: GGTGGCAGTGATGGCATGGAC) was used to knockdown GAPDH, which is house 
keeping gene generally expressed in all cells, to optimise the appropriate condition for 
ABCB1 transfection. Once the appropriate concentration of GAPDH SiRNA and SiPORT Amine 
condition can be optimised. The optimised concentration will be applied for ABCB1 
transfection.  
 
There are 3 different ABCB1 SiRNAs used to optimise for knocking down ABCB1 expression; 
si_ABCB1 $$&888**&8*&&$8&$8&&$ ><DJǖH ( et al (2007)], si_ABCB1.1 
(GCAAAGAAAUAAAGCGACU) and si_ABCB1.2 (AGAAAGAACUUGAAAGGUA) from Eurogentec. 
The condition optimised from GAPDH knockdown however did not effectively knockdown 
ABCB1 expression in our cell lines. The concentration of SiPORT Amine and ABCB1 SiRNA  
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Table 2.11 Mixture of SiPORT Amine and Opti-MEM 
 
Concentration of 
SiPort Amine 
(%v/v) in 500 µl 
20 µM SiPort 
amine (µl) 
Opti-MEM 1 
(µl) 
0.1 2.75 135 
0.2 5.50 132 
0.4 11.00 126.5 
0.6 16.5 121 
0.8 22 115.5 
1.6 44 93.5 
 
Table 2.12 Mixture of ABCB1 SiRNA and Opti-MEM 
 
SiRNA (nM) in 500 µl 1 nM 5 nM 10 nM 20 nM 40 nM 80 nM 100 nM 
20 µM Stock SiRNA (µl) 0.08 0.41 0.83 1.65 3.3 6.6 8.25 
Opti-MEM (µl) 82.4 82.1 81.7 80.9 79.2 75.9 74.3 
 
was hence increased up to 1.6%v/v and 100 nM, respectively. Unfortunately, ABCB1 
expression in our cell lines could not be knocked down at all. Consequently, drug inhibition, 
Verapamil, was used to inhibit ABCB1 function instead of SiRNA knockdown.   
 
2.13 RNA extraction 
RNA extraction was performed to extract RNA from cells after transfection. RNA was used to 
determine ABCB1 messenger RNA expression using RT-PCR. 
 
  2.13.1 Dissociation of nucleoprotein complex   
After 24-hour transfection, tumour media was removed then 200 µl of RNA STAT-60TM (TEL-
TEST, INC, CS-110) was used to harvest cells. Cells were passed through pipette several 
times and incubated at room temperature for 5 minutes to complete the dissociation of 
nucleoprotein complexes. 
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  2.13.2 RNA extraction 
To extract RNA, 1:50 chloroform was added into the homogenate. The homogenate was 
vigorously vortexed for 15 seconds and incubated at room temperature for 2-3 minutes. The 
homogenate was centrifuged at 12,000xg for 15 minutes at 4°C as resulting in separation 
into 2 phases: a lower red phenol chloroform phase and the colourless upper aqueous phase 
containing RNA.  
 
  2.13.3 RNA precipitation 
The upper aqueous phase was transferred into fresh eppendorf tube and RNA was 
precipitated by adding and equal volume of 1:2 isopropanol. Samples were incubated at 
room temperature for 5-10 minutes and centrifuged at 12,000xg for 10-15 minutes at 4°C. 
A tiny pellet of RNA should be seen at this step. 
 
  2.13.4 RNA washing 
Supernatants were discarded and RNA pellets were washed once with 200 µl of 75% 
ethanol. Samples were centrifuged at 7,500xg for 5 minutes at 4°C. Supernatants were 
removed then RNA pellets were dried by air-drying at room temperature. RNA pellets were 
resuspended in 25 µl of Diethylpyrocarbonate (DEPC) treated RNase-free water and 
incubated at 55-60°C for 10-15 minutes to effectively dissolve RNA pellets. RNA 
concentration was determined by using Nanodrop. RNA samples were stored at -80°C until 
required. 
 
2.14 Reverse transcriptase Polymerase Chain Reaction (RT-PCR) 
 
2.14.1 DNase treatment 
Required RNA amount to process cDNA synthesis is 1,000 ng. Required RNA amount was 
topped up with DEPC water to 8 µl and mixed with 1 µl of 10x reaction buffer supplied with 
DNaseI. 1 µl of RQ1 RNase free DNaseI (Promega, M6101). Once DNase was added into RNA 
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samples, samples were strictly incubated for 15 minutes at room temperature. To stop 
DNaseI activity, 2 µl of stop solution supplied with DNaseI was immediately added into RNA 
samples, which were then incubated at 65°C for 10 minutes to inactivated DNase.   
  
2.14.2 Primer annealing and reverse transcription (cDNA synthesis) 
DNase treated RNA samples were combined with 1 µl of Oligo (dT)18 primer, 4 µl of 5x 
reaction buffer, 2 µl of dNTP Mix (10 mM each), 1 µl of RibolockTM RNase inhibitor and 1 µl of 
RevertAidTM M-MuLV Reverse Transcriptase [all reagents are supplied in 5HYHUW$LG )LUVW
Strand cDNA Synthesis Kit (Fermentas, K1622)]. To synthesise cDNA, RNA samples were 
incubated at 42°C for 1 hour and 70°C for 5 minutes. Finally, cDNA samples were diluted by 
the addition of 40 µl of DEPC water and stored at -20°C until needed. 
 
2.14.3 Polymerase chain reaction (PCR)  
3 µl of cDNA template was mixed with the master mix solution consisting of 1.5 µl of DEPC 
water, 1.5 µl of forward primer (10 µM), 1.5 of reverse primer (10 µM) and 7.5 µl of Taq (2x 
Biomixred) (Bioline: Bio-Bio-25005). The mixture was properly mixed and briefly centrifuged 
before running the PCR programme. The PCR programme used in this study is described 
below. 
- Normal PCR programme: initial denaturation at 94Û&IRUPLQXWHDWÛ&IRU
 VHFRQGV DW Û& DQQHDOLQJ WHPSHUDWXUH IRU  VHFRQGV DW Û& IRU 
VHFRQGVDQGILQDOH[WHQVLRQDWÛ&IRUPLQXWHV 
x GAPDH detection: annealing temperature = 60°C, 30 cycles  
x ABCB1 detection: annealing temperature = 56°C, 35 cycles 
- Gradient PCR programme: LQLWLDOGHQDWXUDWLRQDWÛ&IRUPLQXWHDWÛ&
IRUVHFRQGVDWÛ&ƩÛ&JUDGLHQWWHPSHUDWXUHIRUPLQXWHDWÛ&IRU
VHFRQGVDQGILQDOH[WHQVLRQDWÛ&IRUPLQXWHV 
x Optimisation for ABCB1: gradient temperature = 53.8°C, 54.3°C, 
55.1°C, 56.1°C, 56.8°C, 57.6°C, 58.2°C, 59.6°C, 60.2°C, 61.3°C, and 
62.2°C. 
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2.14.4 Gel electrophoresis 
PCR product (7 µl) and ladder marker (10 µl) [HyperLadder marker (Bioline: Bio-33025) 
were loaded into 2% agarose gel (Invitrogen: 15517-022) containing ethidium bromide (5 
µl/40 ml). Gel was dissolved and run in 1x TAE buffer at 150 volts for 20 minutes. DNA 
bands were observed and photographed using the UV light machine (GENEFlash, syngene 
bioimaging).  
 
2.15 Clonogenic assay: Drug treatment combined ABCB1 inhibition 
Previous results showed that our cell lines contain approximately 10-12% of cancer stem-
like cells in monolayer cells and they were enriched in neurosphere condition. After 
treatment with drugs, the majority population which survived after treatment was co-stained 
CD133 and ABCB1 cells. Therefore, ABCB1 transporter probably is the major mechanism 
which protects these tumour cells from drug toxicity. To prove whether ABCB1 transporter is 
an essential mechanism for these cells to survive after treatment, verapamil was used as a 
combined treatment with drug to inhibit ABCB1 function. If the ABCB1 transporter is a major 
mechanism for these cells to survive, drug treatment combined with verapamil should 
provide much more effective result than single drug treatment. Based on the FACS result, 
EPN-2 cell line was selected to be studied. The schematic plan is shown in the next page. 
 
2.15.1 Plating cells for treatment 
Monolayer cells were harvested using 1x Trypsin/EDTA to detach cells and passed through 
the cell strainer to ensure that cells were separated into single cells. Cells were counted 
using trypan blue and plated into 6-well plate at 100 cells/well in 2 ml of tumour media. 
Cells were incubated in 5% CO2 ±air incubator at 37°C for 2-4 hours to allow them to attach 
on plate properly before treatment.   
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EPN-2, EPN-2 C1 (DMSO), EPN-2 T1 Etoposide and 
EPN-2 T1 Irinotecan (70-80% confluency) 
Plate 100 cells/well 
EPN-2 and EPN-2 C1  
= 4 x 6-well plates  
(2 for Eto. tx. and 2 for Irino. 
tx.) 
EPN-2 T1 Eto. & Irino.  
= 2 x 6-well plates 
Cytospin assay 
-  Harvest cells 
and fix with 4% 
PFA 
-  Cytospin cells 
and process co-
-  Fix NS with 
4% PFA and 
take a photo 
-  
Etoposide
: treat for 
2 hours 
-  
Irinotecan
: treat for 
-  fix 
with 
4% 
PFA 
NS forming assay 
-  select 5 clons 
from vehicle 
tx., drug tx., 
and VP+drug 
tx. 
-  grow 
selected clone 
Counting 
surviving 
colonies 
Clonogenic assay: Drug treatment combined with ABCB1 inhibition 
1st exp. 2nd exp. 3rd exp. 
-  Detect B1 & 
EPN-2 and EPN-2 C1  
= 2 x 6-well plates  
(1 for Eto. tx. and 1 for Irino. 
tx.) 
EPN-2 T1 Eto. & Irino.  
= 1 x 6-well plates 
-  
Etoposide
: treat for 
2 hours 
-  
Irinotecan
: treat for 
-  fix with 4% PFA and 
stain with 0.1% 
Counting 
surviving 
colonies 
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2.15.2 Drug Treatment 
Cells were observed under the microscope to ensure that they had attached before 
treatment. There are 8 different conditions of treatment as shown in Table 2.13. Each 
condition was prepared in 1 ml of tumour media (total tumour media/well = 3 ml) and 
transferred into each well of 6-well plate as shown in the figure 2.13. Cells treated with 
Etoposide were incubated for 2 hours whereas cells treated with Irinotecan were incubated 
for 96 hours, each in a 5% CO2 ±air incubator at 37°C, then tumour media were replaced 
with fresh media. Cells were incubated until each colony contained at least 50 cells (6 cell 
divisions) approximately 6-8 days.    
 
2.15.3 Harvesting cells 
After 6-8 day incubation, when colonies were properly formed (contain more than 50 
cells/clone). There were 3 different assays performed: colony counting to determine the 
effectiveness of drug treatment combined with verapamil, cytospin for co-staining 
immunofluorescence to investigate whether surviving clones express ABCB1 or not and 
neurosphere forming assay to examine the ability of cells to form neurospheres which is one 
of the CSC characteristics.  
 
               Etoposide treatment                    Irinotecan treatment   
        
 
 
 
 
 
 
 
 
Figure 2.2 Schematic treatment plan on 6-well plate for clonogenic assay 
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2.15.3.1 Colony counting 
To compare the effectiveness of treatment between single drug treatment and drug 
treatment combined with verapamil, clonogenic assay was performed. Surviving colonies 
were counted to determine the effectiveness of drug and combined verapamil treatment.  
 
After 6-8 day incubation, cells were fixed with 4% PFA for 20 minutes and stained with 0.1% 
crystal violet for 5 minutes. Surviving colonies containing more than 50 cells were counted 
and compared single drug treatment or drug combined with verapamil treatment with 
vehicle treatment.  
 
2.15.3.2 Cytospin for co-staining immunofluorescence 
To determine the expression of ABCB1 after drug and verapamil treatment, cytospin and co-
staining immunofluorescence were performed. We hypothesised that surviving colonies 
probably are 1) cells expressing ABCB1 because of insufficient Verapamil concentration, 2) 
cells expressing ABCB1, which turn on another mechanism of protection and 3) cells without 
ABCB1 expression. Therefore, this experiment could not distinguish the population of 1) and 
2) resulting in the future study should be performed to further investigate to distinguish 
these 2 populations. To prove whether surviving cells after drug treatment combined with 
Table 2.13 Drug treatment combined with ABCB1 inhibition  
Treatment Concentration 
1. Vehicle for Etoposide (DMSO) 1:4,000 
2. Vehicle for Irinotecan (DMSO) 1:12,500 
3. 20 µM Verapamil treatment 20 µM 
4. 10 µM Verapamil treatment 10 µM 
5. 20 µM Verapamil + 10 µM Etoposide Verapamil = 20 µM 
Etoposide = 10 µM 
6. 10 µM Verapamil + 8 µM Irinotecan Verapamil = 10 µM 
Irinotecan = 8 µM 
7. 10 µM Etoposide 10 µM 
8. 8 µM Irinotecan 
 
8 µM 
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verapamil are ABCB1 positive cells or ABCB1 negative cells, that does not need ABCB1 
function to protect them but they have different mechanism to survive from drug treatment. 
 
Clonogenic assay for drug treatment combined with verapamil was performed and incubated 
for 6-8 days. Cells were harvested using 1x Trypsin/EDTA and washed once with HBSS. Cells 
were centrifuged at 800xg for 5 minutes then HBSS was removed. Cells were fixed with 
0.4% PFA for 20 minutes at room temperature then PFA was removed, as much as possible, 
and cells were resuspended in HBSS. Cytospin was performed using Cytospin machine 
(Centurion Scientific LTD, 4050 series). Filter papers with a hole and APES slides were fit 
into the cytospin bucket and locked with clips. To soak filter paper, 200 µl of HBSS was 
added into each bucket and centrifuged at 1,000 rpm for 1 minute. 500 µl of fixed cells were 
then transferred into the cytospin bucket and centrifuged at 1,000 for 2 minutes. Slides 
were left to dry at room temperature and stored at -20°C until required. Co-staining CD133 
and ABCB1 IF was performed as described in section 2.2.1.    
 
2.15.3.3 Neurosphere formation assay  
 This assay was performed to determine the ability of surviving cells after chemotherapeutic 
drugs (Etoposide and Irinotecan) and ABCB1 inhibitor (verapamil) treatment to form 
neurospheres which is one of significant characteristics of stem cells.  
 
Clonogenic assay was performed as mentioned earlier in section 2.15. After 6-8 days 
treatment, 5 clones weUHPLFURVFRSLFDOO\LGHQWLILHGDQGVHOHFWHGXVLQJD3*LOVRQ¶VSLSHWWH
from each condition. Selected clones were induced to form neurospheres in 24-well plates 
containing 1 ml of stem cell media with EGF and FGF for 3-4 days. To ensure that cells were 
inLWLDOO\GLVVRFLDWHG LQWRVLQJOHFHOOVD3*LOVRQ¶VSLSHWWHZDVXVHGWRVLQJXODULVHFHOOV
Neurospheres were fixed with 0.4% PFA for 20 minutes. Neurosphere forming images were 
captured using a dissecting microscope by Digital Sight D3 U1, Nikon camera and ACT-2U 
software, Version 1.61.136.292. 
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Chapter 3: Basic characteristics of the primary cultured paediatric cell 
lines and their original tumours 
 
3.1 Introduction 
 
The most common solid neoplasms in children are tumours of the central nervous system 
(CNS) accounting for approximately one third of childhood cancers and they are the second 
most common paediatric cancers behind leukaemia [Pollack, I. F. (1994), and Stewart, E.S. 
and Cohen, D.G. (1998)]. The most common paediatric brain tumours (PBTs) are low grade 
astrocytomas accounting for 52% and the embryonal tumours (the majority of which 
medulloblastomas) are the second most common, accounting for 21%. The less frequently 
occury PBTs are glioblastoma multiforme and ependymoma accounting for 15% and 9%, 
respectively [Baldwin, R.T. and Martin, S.P. (2004) and Jay, V. et al (2003)]. PBTs studied in 
this project were newly established from 5 different tumour types, which were obtained from 
patients diagnosed with ependymomas (EPN-1 and EPN-2), medulloblastomas (MED-1 and 
MED-2), CNS PNETs (SPNET-1), giant cell glioblastoma multiformes (BT-4) and 
oligodendrogliomas (Olig-1). The commercial cell line (PFSK-1) was also included. The five 
different tumour types studied in this project are all common PBTs, many of which show drug 
resistance after treatment leading to tumour relapse. All high grade tumours (WHO grade IV) 
including medulloblastoma, CNS PNET and GBM have less susceptibility to treatment and 
have high mortality rate. Low grade tumours (WHO grade II) include ependymomas, which 
have a tendency to recur locally, and oligodendrogliomas, which are sensitive to 
chemotherapy. Oligodendrogliomas were included to compare with the other tumours, which 
are frequently resistant to chemotherapy. Ependymomas and medulloblastomas comprised 
both primary (EPN-2 and MED-1) and recurrent tumours (EPN-1 and MED-2), although these 
are unpaired (i.e. the recurrent cell line EPN-1 and the primary EPN-2 are derived from 
different patients). To confirm the diagnosis, Haematoxylin and Eosin staining is performed 
on all tumour samples after surgery.   
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Histological features are able to indicate the cellular characteristics of tumours and are 
important in the tumour grading system. Each type of tumour demonstrates different 
hallmarks of histological features for example the hallmarks of ependymomas are 
perivascular pseudorosettes and true ependymal rosettes whereas common histological 
features of medulloblastomas are pseudorosettes or Homer-Wright rosettes and rhythmic 
palisading cells [Hart, M. N. et al (1973)]. Details of common histological features of each 
tumour type are described in the General Introduction.  
 
Haematoxylin and Eosin staining confirmed the tumour type from which the cell lines were 
established and analysis of their genomic variability was established with a chromosomal 
count. Normal somatic cells normally have 46 chromosomes (diploidy) whilst normal sex cells 
contain only 23 chromosomes (haploidy). Cancer cells, which are aberrant cells, are expected 
to have variable number of chromosomes. Cytogenetic analysis in children brain tumours 
have been less frequently carried out than in adult brain tumours due to many limitations 
[Bhattacharjee, M. B. et al (1997)]. Specific genetic abnormality patterns were observed in 
some brain tumours. Isochromosome 17q and loss of chromosome 22 were commonly 
observed in PNETs whilst there were no convincing evidence to support a specific genetic 
alteration in ependymomas [Bhattacharjee, M. B. et al (1997)]. Karyotyping of chromosomes 
is a major method to screen for chromosome abnormalities and highly specialised assay, and 
was not performed in our study. To get a basic idea how variable our cell lines with respect to 
a variation of chromosome numbers, metaphase spread analysis was performed on 
monolayers from all cell lines at early passage. To determine variation of chromosome 
numbers, chromosomes were counted from 100 cells and means of chromosome numbers 
were calculated. This gave some inspection of a degree of chromosome number variation in 
our cell lines. Therefore, basic characterisation of newly established paediatric brain tumour 
cell lines were assessed in term of Haematoxylin and Eosin staining to describe histology of 
tumours and metaphase analysis to determine a variation of chromosome numbers.  
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3.2 Results 
 
3.2.1 Descriptive data of all primary cultured paediatric and commercial cell 
lines 
Primary cultured cell lines EPN-1 and EPN-2 (ependymoma), MED-1 and MED-2 
(medulloblastoma), SPNET-1 (CNS PNET) and Olig-1 (oligodendroglioma) were obtained from 
WKH &KLOGUHQ¶V %UDLQ 7XPRXU 5HVHDUFK &HQWUH &%75& FHOO OLQH EDQN 8QLYHUVLW\ RI
Nottingham. BT-4 (glioblastoma multiforme) was donated by Dr. Andrew Peet, University of 
Birmingham. The commercial cell line, PFSK-1, was obtained from LGC promochem (CRL-
2060TM). Details of all cell lines are described in Table 3.1 and Table 3.2. EPN-2, MED-1, 
SPNET-1, BT-4 and Olig-1 cell lines were obtained from first surgery (primary tumours) while 
EPN-1 and MED-2 cell lines are from recurrent tumours which relapsed after treatment. Dr. 
Lisa Storer who has the responsibility to produce and maintain the CBTRC cell line bank 
kindly provided all cell line stocks for this study.  
 
Table 3.1 PFSK-1 commercial cell line details [Product description from 
www.lgcpromochem-atcc.com (cited 17 November 2007)] 
Name of cell 
line 
 
Diagnosis 
 
Source 
 
Characteristics of cells 
1. PFSK-1 Malignant primitive 
neuroectodermal tumour 
- male Caucasian, 22 
months of age 
- tumour located in 
cerebral hemisphere 
- obtained from LGC 
promochem 
Comments: express the intermediate 
filament protein, nestin, and are positive for 
neuron specific enolase (NSE). 
               : lack characteristics of terminally 
differentiated neurons or glia. 
               : loss of heterozygosity for multiple 
loci on chromosome 17. 
               : neither c-myc nor N-myc is 
amplified or re-arranged. 
Doubling time: 30 hours 
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Table 3.2 Description of clinical characteristics of the paediatric brain tumours from which cell lines were derived  
Name of cell 
line 
Diagnosis 
Age at 
diagnosis 
Origin of tumour Surgical resection status and treatment 
Follow up 
(months) 
Outcome 
Metastatic 
status 
1. EPN-1 
[Figure 3.1] 
Recurrent 
ependymoma,  
WHO grade II 
13 years  
6 months 
- located in right parietal lobe 
- sample was obtained from 
3rd surgery 
- complete surgical resection 
- repeat surgery at relapse 
- 3 cycles of CT: Vincristine, Cyclophosphamide 
and Etoposide and focal RT then 3 cycles of PCV 
prior to 3rd surgery 
111 
(from 1st 
operation) 
Deceased M0 
2. EPN-2 
[Figure 3.2] 
Ependymoma,  
WHO grade II 
3 years  
6 months 
- located in fourth ventricle 
- primary tumour 
- Macroscopic resection 
- UKCCSG infant ependymoma study 
20 Alive M0 
3. MED-1 
[Figure 3.1] 
Medulloblastoma, 
WHO grade IV 
3 years  
5 months 
- located in cerebellum 
- primary tumour 
- partial surgical resection 
- High dose Cyclophosphamide. UK infant 
Medulloblastoma protocol posterior fossa RT 
8 Deceased M0  
4. MED-2 
[Figure 3.1] 
Recurrent 
medulloblastoma, 
WHO grade IV 
10 years 
 6 months 
- metastatic to supratentorial 
compartment (bilateral frontal 
lobes) 
- partial surgical resection 
- POG 3021 regimen: CT and craniospinal RT 
prior to surgery from which this line was derived 
42 
(from 1st 
operation) 
Deceased M2 at 
relapse 
5. SPNET-1 
[Figure 3.1] 
CNS PNET,  
WHO grade IV 
5 years  
1 month 
- located in left frontal lobe  
- primary tumour 
- partial surgical resection 
- Headstart CT and high dose 
Carboplatinum+Thiotepa after surgery 
- Local relapse at 13 months after the 1st 
operation: repeat surgery and craniospinal RT. 
Further local relapse 4 months post RT 
21 Deceased M0 
6. Olig-1 
[Figure 3.2] 
Oligodendroglioma, 
WHO grade II 
6 years  
7 months 
- located in right fronto-
tempero-parietal lobe 
- primary tumour 
- Subtotal  surgical resection 
- PCV: Procarbazine, CCNU and Vincristine  
- progression high dose Carboplatin+Etoposide 
- Repeat surgery ± Focal RT 54Gy) 
24 Alive M0 
7. BT-4 
[Figure 3.1] 
Giant cell 
glioblastoma 
multiforme,  
WHO grade IV 
4 years 
 3 months 
- located in frontal lobe of 
cerebral hemisphere 
- primary tumour 
- partial surgical resection  
- Cisplatin ± Temozolomide x 6 courses (Partial 
response)  
- Repeat surgery ± focal RT 
52 Alive M0 
CT=Chemotherapy, RT=Radiotherapy, PCV=Procarbazine, CCNU (Chloroethylcyclohexylnitrocourea) (eg. Lumustine) and Vincristine 
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3.2.2 Histopathological features of the original tumours from which 7 cell lines 
were derived 
Haematoxylin & Eosin staining was performed on sections from all original brain tumours to 
identify type of tumour and evaluate grading based on WHO criteria 2007. EPN-1 and EPN-2 
cell lines were derived from WHO grade II ependymomas. EPN-2 was derived from a primary 
tumour. The EPN-1 cell line was however obtained from the 3rd surgery after the second 
tumour relapse. Hence, this cell line was derived after the patient had been treated with focal 
radiotherapy and 3 cycles each of two chemotherapy regimens prior to the third surgery (Table 
3.2). The EPN-1 tumour was originally diagnosed as an ependymoma but tumour Haematoxylin 
and Eosin staining from the 3rd surgery showed dense networks of branching capillaries (Figure 
3.1, a) which are a predominant characteristic of oligodendroglioma. Therefore, electron 
microscopy (EM) was performed to confirm the original diagnosis. This showed ependymal cillia 
(Figure 3.1, b) which is the characteristic electron microscopic feature of ependymoma. EPN-2 
tumour Haematoxylin and Eosin staining showed monomorphic nuclear morphology 
FKDUDFWHULVHG E\ URXQG WR RYDO QXFOHL ZLWK µVDOW DQG SHSSHU DSSHDUDQFH¶ )LJXUH  D ,Q
addition, perivascular pseudorosettes (Figure 3.2, b) and ependymal rosettes (Figure 3.2, b), 
typical histological features of ependymoma were observed. Neuroblastic rosette or 
perivascular pseudorosette (Figure 3.2, c) are described as vessels surrounded by ependymal 
tumour cells with a nuclear-free zone which has thin ependymal processes directed toward the 
walls of vessels. 
 
MED-1 and MED-2 tumours were diagnosed as medulloblastoma tumours, WHO grade IV. MED-
1 was derived from a primary tumour located in cerebellum. Haematoxylin and Eosin staining 
of MED-1 showed classical features of medulloblastoma described as densely packed round to 
oval or carrot shaped cells with highly hyperchromatic nuclei surrounded by scanty cytoplasm 
(Figure 3.1, g). MED-2 was a recurrent tumour and surgical and radiological evidence found 
that this tumour had metastasised to supratentorial compartment. MED-2 patient had been 
treated with POG 3021 regimen (chemotherapy and craniospinal radiotherapy) prior to surgery. 
Haematoxylin and Eosin staining showed round to oval hyperchromatic nuclei surrounded by 
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scanty cytoplasm. Additionally, a rhythmic palisading of tumour cells (Figure 3.1, c) defined as 
arrangement of tumour cells into parallel rows was observed. Neuroblastic rosettes (Homer 
Wright rosettes) which are observed in less than 40% of cases (Figure 3.1, d) were also 
observed in this patient. 
 
The SPNET-1 cell line was derived from a CNS PNET, WHO grade IV. This tumour was located in 
left frontal lobe.  Histological features of SPNET-1 tumour from Haematoxylin and Eosin 
staining showed cells with round regular nuclei and high nucleus:cytoplasm ratios (Figure 3.1, 
e). Furthermore, mitotic cells labelled with arrows were observed (Figure 3.1, f).  
 
The BT-4 cell line was derived from a giant cell glioblastoma multiforme, WHO grade IV 
tumour. This tumour was located in frontal lobe of the cerebral hemisphere. Haematoxylin and 
Eosin staining of BT-4 tumour showed a high degree of nuclear polymorphism with 
multinucleated giant cells and vascular proliferation (Figure 3.1, h). 
 
The Olig-1 tumour of origin was diagnosed as oligodendroglioma tumour, WHO grade II. This 
tumour was located in the right fronto-tempero-parietal lobe. Haematoxylin & Eosin staining of 
Olig-1 tumour showed monomorphic cells with uniform round nuclei and perinuclear halos 
(Honeycomb appearance) (Figure 3.2, d). Dense networks of branching capillaries were also 
observed (Figure 3.2, e) in this tumour, as were microcalcifications (Figure 3.2, f). 
 
 
 
 
 
 
 
 
 
 
 120 
 
 
Figure 3.1 Histological features of the original tumours from which EPN-1, MED-2, SPNET-
1, MED-1 and BT-4 cells were derived. EPN-1 tumour Haematoxylin and Eosin staining showed 
dense networks of branching capillaries, a classical feature of oligodendroglioma tumour at x20 
magnification (a). Therefore, electron microscopy was performed and showed ependymal cilia which 
is hallmark feature for ependymoma indicated by arrows (b). MED-2 Haematoxylin and Eosin 
staining at x40 magnification showed a rhythmic palisading of tumour cells (c) and neuroblastic 
rosettes (d) indicated by blue boxes. Haematoxylin and Eosin staining of SPNET-1 tumour showed 
cells with regular round nuclei and high nucleus:cytoplasm ratios (e) and mitotic cells (f) indicated 
by arrows at x40 magnification. MED-1 Haematoxylin and Eosin showed densely packed round to 
oval or carrot shaped cells with highly hyperchromatic nuclei surrounded by scanty cytoplasm (x40) 
(g). BT-4 Haematoxylin and Eosin staining showed significant histological features for diagnosis of 
giant cell glioblastoma multiforme comprising of nuclear polymorphism, multinucleated giant cells 
(black boxes) and vascular proliferation (arrows) (x40) (h). 
x20 
x40 x40 
x40 x40 
x4
 
x40 
a b 
c d 
e f 
g h 
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Figure 3.2 Histological features of tumours from which EPN-2 and Olig-1 were 
derived. EPN-2 Haematoxylin and Eosin staining is shown in the top row (a ± c). The classical 
histological features of ependymoma are clearly visible; salt and pepper appearance (a), 
perivascular pseudorosettes (*, b and c) and ependymal rosettes (     , b). Histological features 
of Olig-1 tumour were showed in the bottom row (d ± f). Haematoxylin and Eosin staining of 
Olig-1 showed a honey comb appearance (d), branching capillaries (e) and microcalcification 
indicated by arrows (f).  
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3.2.3 Metaphase spread analysis 
To study chromosomal variation in cultured tumour cell lines, metaphase spread analysis was 
performed on EPN-2, MED-2, SPNET-1 and PFSK-1 cell lines. Cells cultured as monolayers were 
blocked in metaphase using Nocodazole. Metaphase cells then were harvested and dropped 
onto slides and observed under the microscope. Chromosome numbers were counted from 100 
cells for each cell line. Metaphase spread analysis results are shown in Table 3.3 and Figure 
3.3. Primary cultured cell lines (EPN-2, MED-2 and SPNET-1) demonstrated less variation of 
chromosome number when compared to the commercial cell line (PFSK-1) (Table 3.3 and 
Figure 3.3). When the size of chromosomes was evaluated, all 3 primary cultured cells 
contained the expected range in chromosome size whereas PFSK-1 cell line mostly contained 
chromosomes of the same size (Figure 3.3).  
 
Metaphase analysis results from EPN-1, MED-1, BT-4 and Olig-1 cells shown in Figure 3.3 were 
produced by Dr. Deema Hussein. These 4 primary cell lines also showed a low level of variation 
of chromosome numbers (Figure 3.3); EPN-1 (20-82), MED-2 (22-84), BT-4 (33-113) and Olig-
1 (30-89) and the majority of cells contained 40-45 chromosomes/cell. Therefore, our 7 
primary cultured cells had less variation of chromosome numbers when compared to the 
commercial cell line.   
 
Table 3.3 The variation of chromosome number from metaphase spread analysis 
 
Cell line 
Chromosome number 
STDEV 
Max. Min. Median Mean 
EPN-2 76 23 45 44.73 7.04 
MED-2 62 27 38 39.55 6.78 
SPNET-1 66 25 44 44.28 4.88 
PFSK-1 132 7 47 45.26 21.76 
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Figure 3.3 Metaphase spread analysis of EPN-1, EPN-2, MED-1, MED-2, BT-4, Olig-1, 
SPNET-1 and PFSK-1 cell lines. Monolayers were treated with Nocodazole to block cells in 
metaphase. After treatment, cells were fixed and observed under the microscope. The result 
showed that metaphase cells from EPN-2 (23-76, mean = 44.73, STDEV = 7.04), MED-2 (27- 
62, mean = 39.55, STDEV = 6.78) and SPNET-1 (25-66, mean = 44.28, STDEV = 4.88) have a 
less variable chromosome number than those from PFSK-1 (7-132, mean = 45.26, STDEV = 
21.76). The majority of chromosome numbers from the other 4 cell lines range from 40-50.  
0
5
10
15
20
25
30
35
1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137
Chromosome numbers
Fr
eq
ue
nc
y
EPN-2 
0
5
10
15
20
25
30
35
1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137
Chromosome numbers
Fr
eq
ue
nc
y
 SPNET-1 
0
5
10
15
20
25
30
35
1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137
Chromosome numbers
Fr
eq
ue
nc
y
 PFSK-1 
0
5
10
15
20
25
30
35
1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137
Chromosome numbers
Fr
eq
ue
nc
y
MED-2 
Fr
eq
u
en
cy
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 
BT-4 
Chromosome numbers 
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 
Fr
eq
u
en
cy
 
MED-1 
Chromosome numbers 
 
 
 
 0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 
Fr
eq
u
en
cy
 
EPN-1 
Chromosome numbers 
 
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 
Olig-1 
Fr
eq
u
en
cy
 
Chromosome numbers 
 124 
3.3 Discussion 
 
High and low grade tumours were included in this study 
 
Seven primary cultured cell lines; EPN-1, EPN-2, MED-1, MED-2, SPNET-1, BT-4 and Olig-1 
were included in this study as well as the commercial cell line; PFSK-1. All 8 cell lines were 
categorised into 5 types of tumours; Ependymoma (EPN-1 and EPN-2), Medulloblastoma 
(MED-1 and MED-2), CNS PNET (SPNET-1 and PFSK-1), Glioblastoma multiforme (BT-4) and 
Oligodendroglioma (Olig-1). These 5 different brain tumours covered the most common 
malignant CNS tumours which occur in children and they were also defined as different 
grading by WHO criteria 2007 into high grade tumours; WHO grade IV (MED-1, MED-2, 
SPNET-1, BT-4 and PFSK-1) and lower grade tumours; WHO grade II (EPN-1, EPN-2 and 
Olig-1). Although ependymomas are classified as grade II tumours, they behave 
aggressively in terms of high rate of recurrence after treatment and having chemoresistance 
[Messahel, B. et al (2009)]. Cell lines derived from Ependymoma and Medulloblastoma were 
generated from both primary tumours (EPN-2 and MED-1) and recurrent tumours (EPN-1 
and MED-2) whilst SPNET-1, BT-4 and Olig-1 were established from the corresponding 
primary tumours. Only 3 cell lines; EPN-2, MED-2 and SPNET-1 were the focus of this PhD. 
The others were studied by Dr. Deema Hussein and have been included for completeness so 
that comparisons can be made. 
 
The high grade tumours; medulloblastoma, CNS PNET and glioblastoma multiforme were 
selected to study because they are common types of paediatric brain tumours (PBTs) which 
are still resistant to chemotherapy and relapse after complete treatment resulting in poor 
prognosis. Medulloblastoma is the most common brain tumour occurring in children 
accounting for 25% of all PBTs and it has a poor prognosis. However, the 5-year survival 
rate has currently been increased because of improved treatment resulting in 60% of cases 
were cured with a combination treatment of neurosurgery and adjuvant radiotherapy and 
chemotherapy [Polkinghorn, W. R. and Tarbell, N. J. (2007)]. Nevertheless, the survivors 
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still have long sequelae resulting from treatments. At least 30% of those, who do not 
respond to treatment, present with disseminated lesion and the majority of cases are 
younger children [Packer, R. J. and Vezina, G. (2008)]. 10-15% of these cases have no 
response to therapy and die within 2 years of diagnosis. Hence, it is believed that these 
high-risk medulloblastoma patients are intrinsically resistant to chemotherapy [Johnsen, J. I. 
et al (2009)]. Both patient tumours, which generated the MED-1 and MED-2 cell lines, were 
classified as a high risk medulloblastoma with regard to partial surgical resection (MED-1 
and MED-2), metastasis to supratentorial compartment (MED-2) and young age at diagnosis 
(MED-1). CNS PNET rarely occurs in children and locates in different region compared with 
medulloblastoma but they share some similar histological features. However, CNS PNET is 
more aggressive and unsusceptible to current chemotherapy resulting in far worse prognosis 
compared to medulloblastoma [Johnsen, J. I. et al (2009)]. GBM is also a very aggressive 
tumour and patients have a very poor prognosis. The median survival time was 
approximately 1 year after diagnosis and only 29% - 37% of patients survived for 18 month 
[Shapiro, W. R. et al (1989)]. This tumour is still highly resistant to combination treatment 
between chemotherapy and radiotherapy. These high grade tumours are very high 
malignant brain tumours and have aggressively metastatic characteristics within the 
neuroaxis. Particularly, CNS PNETs are recognised to have more locally aggressive invasion 
than medulloblastoma and the outcome of treatment is worsen in CNS PNET. Glioblastoma 
also rapidly spread through the contralateral hemisphere resulting in a very poor prognosis. 
Therefore, these highly resistant tumours were studied and characterised to provide useful 
data to overcome drug resistance in the future.     
 
Low grade tumours were also included in this study. Ependymomas were included because 
these have a tendency to recur locally. This tumour is the third most common of PBTs 
accounting for 12%. Although advanced diagnosis using neuroimaging and treatments 
including neurosurgery and adjuvant therapy are available, the overall survival rate in 
ependymoma patients is still poor (39-64% for 5-year survival rate) [Zacharoulis, S. et al 
(2007)]. The prognosis is poorer after relapse and only 25% of patients survive after a first 
 126 
relapse [Messahel, B. et al (2009)] indicating the acquisition of drug and radiotherapy 
resistance in this tumour. Oligodendrogliomas were included because these tumours respond 
well to therapy, and these will provide a comparison of the characteristics of tumours 
susceptible to chemotherapy with chemoresistant tumours. Therefore, this study included 
both high and low grades tumours for downstream analysis. Studying the characteristics in 
several types of tumours provides much more useful data and describes basic information 
from representative cell lines. The comparison of the similarities and differences among cell 
lines will hopefully promote understanding of the differences between high grade and low 
grade tumours or between primary and recurrent tumours. 
 
All primary cultured cell lines demonstrated common histological features of 
tumours from which they were established.  
 
It was important prior to undertaking this analysis to make sure that the cell lines being 
studied were representative of these tumour types and had not been altered in culture. At 
the beginning, all cell lines were basically characterised (>30 in the CBTRC bank) then the 
most interesting cell lines were further investigated. Haematoxylin and Eosin staining is a 
reliable standard method and simple to perform. The classification of tumour presently still 
relies on Haematoxylin and Eosin staining observed under the light microscope. This 
technique is an initial screening and routinely used in the pathological department for 
diagnosis of tumour samples. Therefore, Haematoxylin and Eosin staining was performed on 
our original tumours to classify and confirm the original diagnosis. Histological features from 
each cell line are shown in Figure 3.1 and 3.2 and the descriptions of Haematoxylin and 
Eosin results are also mentioned in section 3.2.2. All primary cultured cell lines showed 
classical histological features of the corresponding tumours from which they were derived 
with the exception of EPN-1 cell line. This cell line was derived from the third surgery and 
the patient had been treated with several complete courses of chemotherapy and radiation 
prior to surgery. Haematoxylin and Eosin staining, which was processed on the 
corresponding formalin-fixed, paraffin-embedded (FFPE) sample from the third surgery, did 
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not show classic ependymoma histological features. In contrast, the histological feature 
showed capillary branching, which is commonly found in oligodendroglioma (Figure 3.1, a). 
However, specific characteristic of ependymoma was observed using EM assay, which 
showed ependymal cilia (Figure 3.1, b). Hence, EM assay result confirmed that ependymoma 
is the final diagnosis for this tumour. Haematoxylin and Eosin results therefore indicated that 
all 7 cell lines would be expected to present specific representative characteristics of each 
tumour type hence justifying their inclusion in this study. 
 
Huge variation of chromosome number was observed in PFSK-1 whilst all 
paediatric primary culture cell lines contained less variation.   
 
Human chromosome number was first described in 1923 by Painter, T. However, the right 
chromosome number (46) was discovered by Tjio, J. H. and Levan, A. in 1956. In 1958, 
human chromosome number was studied in different 13 human samples from different 
organs and also derived samples, which were grown in vitro. Tjio and Puck found that 
chromosome numbers of 46 were found in 99.9% from almost 2,000 cells whilst the 
frequency of tetraploidy was observed at less than 3% [Tjio, J. H. and Puck, T. T. (1958)]. 
Therefore, normal human chromosome number is stable at 46 and has a very narrow range 
of chromosome number. Many previous studies found a variation of chromosome number in 
brain tumours. Griffin, C. A. and colleagues studied the chromosome abnormalities in 
paediatric brain tumours; 6 astrocytomas, 10 CNS PNETs, 2 atypical teratoid tumours, 1 
mixed glioma, 1 ependymoma and 1 meningioma. Their data showed that chromosome 
numbers of CNS PNET and ependymoma ranging from 41-100 and 43-46, respectively 
[Griffin, C. A. et al (1988)]. Additionally, karyotype data studied in paediatric brain tumours 
found that there were a variation of chromosome numbers in tumour cells; 50-285 in 
glioblastoma multiforme, 36-91 in medulloblastoma [Aganamolis, D. P. and Malone, J. M. 
(1995)], 50-77 in ependymoma [Sainati, L. et al (1996)]. A huge variation of chromosome 
numbers and chromosomal abnormalities were found in aggressive tumours such as 
glioblastoma multiforme or medulloblastoma while low grade tumour or untreated tumour 
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have normal karyotype and less variation of chromosome numbers [Aganamolis, D. P. and 
Malone, J. M. (1995), Sainati, L. et al (1996) and Bhattacharjee, M. B. et al (1997)]. So 
cancer cells are expected to have abnormal chromosome numbers compared to normal cells. 
Hence, a simple metaphase spread analysis was performed to investigate the range of 
chromosome numbers in our cell line when they were cultured in standard tumour media for 
a certain period (early passage, < 25) compared to the commercial cell line. All cell lines 
were cultured as monolayer cells in standard tumour media supplemented with 15% fetal 
bovine serum apart from PFSK-1 cell line, which was cultured in specific media, 
recommended by ATCC. Analysis results showed that chromosome numbers of our 7 primary 
cell lines have less variation than the commercial cell line, PFSK-1 (Figure 3.3) and the 
descriptive statistical data for EPN-2, MED-2, SPNET-1 and PFSK-1 are shown in Table 3.3. 
The majority of cells are diploid giving a mean of 40-50, some cells are in the lower range 
but the majority are higher. This was particularly the case for BT-4, the giant cell GBM, and 
is in-keeping with Griffins results [Griffin, C. A. et al (1988)]. Additionally, the PFSK-1 line 
data was much more widely spread with more homogeneity in chromosome length indicating 
that this line had altered greatly in culture whilst our cell lines retained the expected 
variation in chromosome length. 
 
Metaphase analysis results revealed that all 7 paediatric primary cultured cell lines had a 
narrow range of chromosome number whilst PFSK-1 had a huge variation of chromosome 
number (7-132, STDEV = 21.76). Hence, a variation of chromosome numbers commonly 
occurred in tumour cells, the results from metaphase analysis of our cell lines correlated to 
the previous studies. The majority of chromosome numbers from our primary cell lines 
ranged from 30-50 while the chromosome numbers of PFSK-1 cell line generally spread from 
7 to 132. Therefore, our cell lines contained much narrow range of chromosome numbers 
than the commercial cell line. Although PFSK-1 cells were able to form colonies (17%) in 
agar [Fults, D. et al (1992)] and also initiated new tumours when they were transplanted 
into mice brain within 4 weeks [Fults, D. et al (1992)], this cell line had been continuously 
cultured in RPMI medium supplemented with 10% fetal calf serum for over 2 years (85 
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passages) after establishment from patient. However, it was not clear what passage was 
provided commercially. Additionally, PFSK-1 was described as hypotetraploid at passage 59 
(karyotype: 81, XXYY, t(Xp;8q), del(1)(p22), -2, -3, del(4)(p14), -5, -8, -9, -9, -13, -13, -
14, -16, -20, -22, +mar and at passage 75: 84, XXY, -Y, t(Xp;8q), del(1)(p22), -3, 
del(4)(p14), -9, -10, -13, -14, -14, -16, -22) with loss of chromosome 17 occurring during 
establishment [Fults, D. et al (1992)]. Based on the establishment history of PFSK-1 and our 
findings, this indicated that PFSK-1 were unstable in culture condition whilst our cell lines 
were more stable in preserving a narrow chromosome number range. Hence, PFSK-1 was 
not a good cancer cell line model for PBT research. To complete this assay and extract more 
useful information, karyotype assay should be performed to determine the abnormalities of 
chromosomes from each tumour type and define whether the increase in chromosome 
numbers is hyperdiploidy or tetraploidy. 
 
Monolayers from all cell lines preserved alterations of chromosomal copy number 
from the corresponding original tumours. 
 
Single nucleotide polymorphism analysis (SNP; Affymetrix 500K arrays) was performed on 
monolayers from 5 primary paediatric cell lines (EPN-1, EPN-2, BT-4, MED-2 and SPNET-1) 
including the corresponding original tumours and were analysed by Dr. Deema Hussein to 
determine whether monolayer culture conditions are able to preserve a significant DNA copy 
number aberration, which is detected in the original tumour samples from which they were 
derived. The SNP results demonstrated that significant DNA copy number aberrations 
detected in the original tumours were present in both monolayer and neurosphere culture 
conditions of all cell lines (Figure 3.4, and data not shown). The chromosomal copy number 
of the recurrent ependymoma derived EPN-1 cell lines showed gain in regions 1q32.1, 
2q32.1, 6p21.33, 11q23.3, 14q11.2, and 17q21.2, which have been reported previously that 
these aberrations were found in ependmoma tumour [Taylor, M. D. et al (2005)]. The 
primary ependymoma derived EPN-2 cell line demonstrated gain of chromosomal copy 
number in regions 2p23.1, 2q14.2, 3p14.2, 6q25.3, 7q32.3, 17q12, and loss in 15q11.2. 
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Ependymoma tumour has been reported to contain an amplification of 3p14.2 [Taylor, M. D. 
et al (2005)]. Chromosomal copy number aberrations in region 1q32.1 and changes in 
chromosome 7, which were detected in BT-4 cell lines, have also been reported to be found 
in other glioblastoma tumours [The Cancer Genome Atlas Research Network (2008)]. Gain 
of chromosomal copy number in region 1p34.2 and loss in 8p23.1 were recently reported as 
an aberration in medulloblastoma and were present in MED-2 cell line [Northcott, P. A. et al 
(2009)]. The aberrations of chromosome copy number, which are commonly detected in 
CNS PNETs, are gain of 1q21.3, 2p24.1, and 6p22.1 (unpublished data Suzanne Miller). 
These aberrations were also preserved in SPNET-1 cell line.  In accordance with 
Haematoxylin and Eosin, metaphase analysis and SNP results, our cell lines were able to 
preserve important characteristics from the original tumours from which they were derived 
and they were stable in culture conditions. 
 
In summary, patient tumours showed the hallmark of histological features of the 
corresponding tumours which they were diagnosed. Our cell lines contained less variation of 
chromosome number than the commercial cell line and they also preserved significant 
genetic aberrations from the corresponding original tumours from which they were derived. 
To examine the existence of CSCs in our cell lines, characterisation of CSCs was studied in 
Chapter 4.  
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Figure 3.4 SNP analysis. SNP analysis was performed on monolayers (M) from EPN-1, 
EPN-2, BT-4, MED-2 and SPNET-1 cell liens at early passages (less than 25 passages) 
compared with the original tumours (T) from which they were derived. The results 
demonstrate that a significant DNA copy number aberrations detected in the original 
tumours were present in both monolayer culture conditions of all cell lines [The results 
obtained from Dr. Deema Hussein]. 
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Chapter 4: Characterisation of cancer stem cells 
 
4.1 Introduction 
 
The previous chapter described basic characterisation of 5 different paediatric brain tumours 
including ependymomas, medulloblastomas, CNS PNETs, GMBs and oligodendrogliomas that 
had been successfully established in tumour media supplemented with serum. Additionally, 
the results from Chapter 3 demonstrated that Haematoxylin & Eosin staining from tumour 
specimens, from which paediatric brain tumour cell lines were generated for this study, 
displayed significant histological features of tumours that they were diagnosed. SNP analysis 
results also confirmed that significant genetic abnormalities found in the original tumours 
were preserved in culture. Additionally, our cell lines were more stable in culture than the 
commercial cell line (PFSK-1) in term of having less variation of chromosome numbers 
demonstrated by metaphase analysis.  
 
At present, a major unresolved problem of malignancy including paediatric brain tumours is 
multidrug resistance resulting in tumour relapse and high mortality. Causes of drug 
resistance in malignancy have been extensively studied. Cancer stem cells, discovered a 
decade ago, were postulated to be an important cause of drug resistance. Cancer stem cells 
are a small population of tumour cells and currently are believed to resist to chemotherapy 
resulting in surviving after treatment and initiating new tumours causing tumour relapse. 
Cancer stem cells were firstly discovered in a small population of acute myeloid leukaemia 
(AML) using side-population analysis. These cells initiated new tumours when they were 
transplanted into NOD-SCID mice [Tan, B. T. et al (2006)]. The first evidence supporting the 
existence of cancer stem cells in brain tumours was discovered in human glioblastoma 
multiforme. The isolated cells resembled normal neural stem cells in formation of clones and 
neurospheres and expressing neuronal and astroglial markers [Ignatova, T. N. et al (2002)]. 
In later studies, medulloblastomas and gliomas were also shown to contain cancer stem-like 
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cells, which were induced to form neurospheres. These neurospheres initiated new tumours 
when they were transplanted into mouse brain and they were able to be serially passaged. 
Neurospheres could be induced to differentiate into both neurons and glial cells under 
differentiation conditions. These cells shared some characteristics with normal neural stem 
cells and they occasionally differentiated into abnormal cells possibly explaining tumour 
generation [Hemmati, H. D. et al (2003)]. Neural stem-like cells have also been discovered 
in adult glioblastoma multiforme. These cells had multilineage differentiation and generated 
new tumours after transplantation. These neural stem-like cells isolated from initiated 
tumours were used to form neurospheres, which were serially transplanted into mice and 
formed new tumours [Galli, R. et al (2004)].  
 
To study cancer stem cells, many studies used different stem cell markers to identify and 
isolate these cells and methods used to isolate cells were also different. Singh and 
colleagues used CD133 to isolate cancer stem-like cells using magnetic cell sorting. CD133+ 
cells were able to initiate tumour, which was recapitulate the original tumours when they 
were transplanted, these cells had the abilities to form neurospheres, self-renew and 
proliferate [Singh, S. K. et al (2003)]. In a later study, Singh and colleagues found that 
tumours, which were initiated from CD133+ cells, contained a small proportion of CD133+ 
cells (19-22%) and a majority population of CD133- cells (78-81%). Therefore, they 
suggested that CD133+ cells were able to produce both CD133+ cells and CD133- cells in 
initiated tumours [Singh, S. K. et al (2004)]. SOX2 is also generally used as a stem cell 
marker due to the fact that SOX2 is a nuclear transcriptional factor, which is normally 
expressed in embryonic stem cells and neural stem cells [Graham, V. et al (2003)].  Since 
then, many laboratories extensively studied cancer stem cells in brain tumours to 
understand the mechanisms of drug resistance, which may open the door to overcoming 
drug resistance in adult and paediatric brain tumours. 
 
The aim of this Chapter is to characterise cancer stem cells in newly established paediatric 
brain tumour cell lines. One of the significant characteristics of cancer stem cells is 
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neurosphere formation [Tan, B. T. et al (2006), Ignatova, T. N. et al (2002) and Galli, R. et 
al (2004)]. To test ability in formation of neurospheres, all cell lines normally grown as 
monolayers in tumour media were induced in stem cell media to form neurospheres at early, 
middle and late passages. CD133 and SOX2 were used as stem cell markers to identify 
cancer stem cells in our cell lines by co-staining immunofluorescence and Western blotting 
analysis. Since CD133 [Singh, S. K. et al (2003) and (2004)] and SOX2 [Graham et al 
(2003) and Miyagi, S. et al (2004)] have been generally used as a stem cell markers. 
Identification of cancer stem cells was performed in both monolayer and neurospheres 
conditions to compare the proportion of cancer stem cells in different culture conditions. 
Additionally, the assay was performed at early, middle and late passages to determine any 
alteration of cancer stem cell proportion when cell lines were serially passages. Western 
blotting analysis was performed to investigate CD133 and SOX2 expression at protein level 
and validate the immunofluorescence data.  
 
Telomerase activity and telomere maintenance have been postulated as significant factors to 
preserve immortality in cancer cells. Telomerase activity is also a feature of normal stem 
cells. Telomeres are usually maintained in malignant cells and 85-90% of these cells are 
telomerase positive [Bryan, T. M. and Cech, T. R. (1999)]. To demonstrate activation of 
telomerase in our cell lines, the Telomeric Repeat Amplification Protocol (TRAP) assay was 
performed in both monolayers and neurospheres from all cell lines. Telomere length was 
also assessed using the Terminal Restriction Fragment length (TRF) assay in our cell lines in 
both monolayers and neurospheres at early, middle and late passages to investigate 
telomere maintenance and determine any alteration of telomere length at different time 
points.  
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4.2 Results 
4.2.1 Primary cultured monolayers and neurospheres of paediatric brain 
tumour cell lines at early, middle and late passage 
There were 7 cell lines studied in the overall project. However, only 3 cell lines were the 
subject of my experiments; EPN-2, MED-2 and SPNET-1. The remainder were studied by Dr. 
Deema Hussein, a Post Doctoral researcher. Cell line stocks from the CBTRC liquid nitrogen 
bank were recovered as described in section 2.1.1 and cultured as monolayers in tumour 
media. All cell lines were successfully grown in tumour media. PFSK-1 cells were initially 
cultured in the standard tumour media however, they failed to survive in this media. They 
had to be cultured in media specifically recommended by LGC Promochem for this cell type.  
 
All primary culture paediatric cell lines used in this study were serially subcultured as 
monolayers in standard tumour media supplemented with serum up to at least 80 passages. 
Neurospheres were continuously re-established from monolayer cells and cells from both 
growth conditions were collected at different passages for experiments. Morphological 
features of cultured monolayers and neurospheres from each cell line at early, middle and 
late passage are shown in Figure 4.1. When PFSK-1 cells were cultured in stem cell media, 
they attached to the flask and did not form neurospheres even after 7 days of incubation. 
Therefore, under these conditions the PFSK-1 cell line could not be induced to form 
neurospheres. The morphological features of all cell lines were not visibly changed even 
when they were serially subcultured at late passage. All cell lines were also still able to be 
induced to form neurospheres even at late passage number. The passage numbers of 
monolayers and neurospheres were matched as close as possible prior to analysis. The 
passage number was separated into 3 categories; early passage (less than 25), middle 
passage (26-50) and late passage (more than 50). The number next to cell line names 
indicates the passage number, which is continually counted when cells are subcultured. For 
neurospheres, the passage number, which is initially induced from monolayers, is designated 
as primary neurosphere (1° NS) and when 1° NS was passaged, they are called secondary 
neurospheres (2° NS). All experiments were always performed on 2° NS.  
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Figure 4.1 The morphology of serially cultured EPN-2, MED-2 and SPNET-1 cell lines as 
monolayer and neurosphere condition at early, middle and late passage and PFSK-1 cell 
line. This figure shows the morphology of cultured cell lines at different time points when they 
were serially subcultured as monolayers. All cell lines were stably grown in tumour media even at 
very late passages and the morphology did not obviously change when the passage number 
increased. Primary neurospheres were formed when monolayers were induced in stem cell media 
at any passage number. Secondary neurospheres were also able to be properly formed when 
primary neurospheres were passaged. Neurosphere sizes range from 30 ± 100 µm.    
EPN-2 
P6 P37 P56 1° NS 1° NS 1° NS 
 
Early passage Middle passage Late passage 
2° NS 2° NS   2° NS 
Early passage Middle passage Late passage 
MED-2 
P8 P40 P68 1° NS 
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1° NS 
2° NS 
1° NS 
 2° NS 
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SPNET-1 
P16 P28 P68 1° NS 1° NS 1° NS 
2° NS 2° NS  2° NS 
PFSK-1 
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form NS 
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4.2.2 Doubling time 
EPN-2, MED-2 and SPNET-1 cell lines were serially subcultured as monolayers and passaged 
to form neurospheres whereas PFSK-1 monolayers were unable to be induced to form 
neurospheres. To determine the growth characteristic of cultured cell lines when they were 
continually passaged for a long period of time, a doubling time assay was performed on both 
monolayers and neurospheres (with the exception of PFSK-1). The doubling time of all cell 
lines was determined at early, middle and late passage number to study the variation in 
doubling time when cells were serially subcultured for a long period of time. The doubling 
time is the amount of time that cells require to double in number. The doubling time results 
are shown in Figure 4.2. The formula used to calculate the doubling time is shown below. 
 
                          Td = (T2 ± T1) x     log2 
                                                                  (Q2 - Q1) 
 
  Td = Doubling time (hour) 
  T1 = Time when cells were plated 
  T2 = Time that cells reached subconfluency 
  Q1 = Original cell numbers that were plated 
  Q2 = Final cell numbers 
 
Doubling times of all cell lines were examined at early, middle and late passage number in 
both monolayers and neurospheres. To compare the difference of the doubling time at 
different passages or between monolayers and neurospheres, unpaired student T-test was 
performed. PFSK-1, a commercial cell line, had the longest doubling time (mean ± SEM) 
32.1±1.2 hours when compared to other monolayers ranging from 20.3 - 23.5 hours (Figure 
4.2). One way Anova was used to compare the difference in doubling time at early, middle 
and late passage number. Doubling times at early, middle and late passage of this cell line 
were not significantly different (p = 0.158). Therefore, this cell line had a consistent growth 
rate even when they were serially subcultured for a long period of time.  
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The results in Figure 4.2 show that each cell line has a different characteristic growth 
pattern.  The average doubling times of EPN-2 monolayers and neurospheres were 20.6±1.1 
and 38.4±2.3, respectively and they were significantly different (p < 0.001). As passage 
numbers increased, the doubling time of monolayers remained constant at all passages (p > 
0.05) as shown in Figure 4.2 (a). On the contrary, the doubling time of neurospheres 
apparently increased when passage numbers increased and they are significantly different 
between early, middle and late passages (p = 0.001). At all passage numbers of EPN-2 cells, 
the average doubling time of neurospheres was significantly higher than the monolayers 
[Figure 4.2, (a)] (unpair student T-tests, p < 0.01).  
 
The average doubling times of MED-2 monolayers and neurospheres were 23.5±1.6 and 
25.4±2.4, respectively. The average doubling time of neurospheres was higher than that of 
monolayers however there was no significant difference (p > 0.05) and the average doubling 
times of neurospheres were not consistently higher than monolayers at early, middle and 
late passages. Monolayer doubling times remained constant when passage numbers 
increased (p > 0.05). Whilst, the doubling time of neurospheres increased when passage 
numbers increased and they were significantly different (p < 0.001) at early, middle and 
late passages [Figure 4.2, (b)].  
 
The average doubling time of SPNET-1 monolayers and neurospheres were 20.3±1.5 and 
24.9±2.0, respectively and there was no difference between them (p > 0.05). The average 
doubling times of neurospheres at early, middle and late passages were not consistently 
higher than that of monolayers. The doubling times of both monolayers and neurospheres 
decreased when passage numbers increased. The doubling times among monolayer group at 
early, middle and late passages were not different (p > 0.05) whilst there were significant 
difference in neurosphere group (p < 0.001) [Figure 4.2, (c)].  
 
Each paediatric cell line showed different characteristics and patterns in doubling time when 
these cells were serially subcultured over a long period of time. However, the average 
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doubling times showed a similar pattern among EPN-2, MED-2 and SPNET-1 cell lines when 
compared between monolayers and neurospheres [Figure 4.2 (a-c)]. The average of 
doubling times of neurospheres was higher than monolayer cells. However, only the EPN-2 
cell line showed significantly different doubling time in neurospheres compared to 
monolayers (p < 0.001). Additionally, the average of doubling times at early, middle and 
late passages in monolayers from all cell lines was consistent whilst they were variable in 
neurospheres.  
 
When merging the data from all 7 cell lines (Figure 4.3), it can be seen that the mean 
doubling time in neurospheres was higher than monolayers in all cell lines. However, only 
EPN-1, EPN-2, MED-1 and Olig-1 neurospheres had significantly higher mean of doubling 
times compared to monolayers. 
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Figure 4.2 Doubling times at early, middle and late passage number of monolayer 
and neurosphere from primary cultured cell lines. Doubling times of EPN-2, MED-2, 
SPNET-1 and PFSK-1 cell lines at early, middle and late passage are shown in (a), (b), (c) 
and (d), respectively [      = monolayers,       = neurospheres]. The average doubling time 
of all cell lines showed similar patterns whereby neurospheres had longer doubling times 
than monolayers. The doubling times of neurospheres from EPN-2 were significantly higher 
than monolayers at all passages (a). This was not the case for the MED-2 (b) and SPNET-1 
(c) cell lines since the comparison between monolayers and neurospheres at different 
passages was variable. However, doubling times of monolayers from all cell lines were fairly 
stable at all passage numbers. PFSK-1 cell line also showed a constant growth rate 
throughout all passages (d). 
** 
(a) (b) 
(c) (d) 
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Figure 4.3 Doubling time means of monolayers and neurospheres from all primary 
paediatric cell lines. This graph shows doubling time means from all 7 cell lines including 4 
data sets obtained from Dr. Deem Hussein. Neurosphere doubling times of all cell lines were 
higher than monolayers however, only the doubling times of EPN-1, EPN-2, MED-1 and Olig-
1 cell lines were significantly longer than that of monolayers (** = p < 0.01, * = p < 0.05). 
PFSK-1 cell line had the longest doubling time than the other cell lines among monolayers 
whereas the longest neurosphere doubling time was found in EPN-2 cell line. Interestingly, 
the pattern of neurosphere growth rate was distinctively observed in EPN-1 and EPN-2 cell 
lines. Neurospheres of ependymoma from which EPN-1 and EPN-2 cell lines were derived 
had a significant slower growth rate than that of monolayers.      
 
 
 
 
Monolayers 
Neurospheres 
Doubling time of monolayer cells and neurospheres of 
primary paediatric cell lines 
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[**] 
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4.2.3 Co-staining CD133 and SOX2 immunofluorescence analysis 
Co-staining immunofluorescence was performed to study the existence of a cancer stem 
cell-like population in primary cultured cell lines under both monolayer and neurosphere 
conditions. For monolayer conditions, cells were grown in serum supplemented tumour 
media which supported cells to normally proliferate whilst neurosphere conditions, serum-
free media, promoted cells to proliferate without differentiation. Neurosphere conditions 
were expected to contain a higher percentage of stem cell-like cells since many studies 
supported that these conditions can preserve characteristics of cancer stem cells [Reynold, 
B. A. and Weiss, S. (1992) and Lee et al (2006)]. Co-staining immunofluorescence was also 
performed at different time points: early, middle and late passage to determine whether 
increasing passage number affects the proportion of stem cell-like cells in each condition or 
not. CD133 and SOX2, which are commonly used to study cancer stem cells, were used as 
stem cell markers.   
 
The immunofluorescence results shown in Figure 4.4 are representative images from each 
cell line. Positive co-staining CD133 and SOX2 immunofluorescence was defined as obvious 
membranous staining of CD133 antibody (green signal) and nuclear or cytoplasmic staining 
of SOX2 antibody (red signal).  Positive co-staining cells were counted as stem cell-like cells 
as shown in Figure 4.4. Cells were counted at x40 and x100 magnification for monolayers 
and neurospheres, respectively and more than 600 cells were counted to determine the 
proportion of stem cell-like cells in each condition for all cell lines. Immunofluorescence 
results showed no CD133 positive cells in PFSK-1 monolayer cells (Figure 4.4). As previously 
mentioned, PFSK-1 monolayer cells could not be induced to form neurospheres, which is one 
of significant characteristic of stem-like cells, when they were grown in stem cell media. 
Therefore, it was concluded that based in these criteria there was no stem cell-like 
population in PFSK-1 cell line. 
 
Co-staining immunofluorescence results in primary cultured cell lines (EPN-2, MED-2 and 
SPNET-1) showed that positive co-staining cells were observed in both monolayer and   
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Figure 4.4 Co-staining CD133 and SOX2 immunofluorescence in monolayers and 
neurospheres of primary cultured cell lines and PFSK-1. Co-staining 
immunofluorescence results of EPN-2, MED-2 and SPNET-1 cells showed typical double 
staining cells described as membranous staining of CD133 (1:200, green signal) and nuclear 
staining of SOX2 (1:75, red signal). PFSK-1 cells were negative for CD133 and SOX2 
staining. Approximately 40-50% of co-stained CD133 and SOX2 cells were detected in 
neurospheres as shown in the right column whereas in monolayer cultured cells co-staining 
CD133 and SOX2 represented only 10-15% of the total (left column).  
100 µm 
EPN-2 
MED-2 
  
Monolayers Neurospheres 
100 µm 
100 µm 100 µm 
100 µm 100 µm 
100 µm 
 SPNET-1 
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neurosphere conditions (Figure 4.4). However, monolayer conditions for all of the cell lines 
contained a smaller proportion of co-staining cells (~10-15%) (Figure 4.4, left column) than 
neurosphere conditions where almost half of neurosphere population were positive for 
CD133 and SOX2 (~30-45%) (Figure 4.4, right column). Hence, the neurosphere population 
comprised a larger proportion of cells co-staining CD133 and SOX2 than monolayers. 
Therefore, cells grown under neurosphere conditions were enriched with stem cell-like cells 
when compared to monolayer conditions.  
 
All 3 primary cell lines (EPN-2, MED-2, SPNET-1) showed a similar pattern of co-staining 
CD133 and SOX2 with increased passage number, namely that the proportion of positive co-
staining cells decreased (Figure 4.5). The proportion significantly decreased in EPN-2 cell 
line (monolayers p < 0.05, neurospheres p < 0.01) and SPNET-1 cell line (monolayers and 
neurospheres p < 0.05), whilst there was no significant decreasing in both monolayers and 
neurospheres of MED-2 cell line (monolayers p = 0.40, neurospheres p = 0.21). The 
percentage of positive co-staining cells was higher in neurospheres (almost 4 fold) when 
compared to monolayers; EPN-2 (monolayer = 10.3±1.3, neurosphere = 37.5±4.0), MED-2 
(monolayer = 10.6±1.1, neurosphere = 37.9±2.5) and SPNET-1 (monolayer = 9.6±1.1, 
neurosphere = 35.6±2.8).  
 
To study the proportion of stem cell-like cells in paediatric brain tumour cell lines, not only 
the main 3 cell lines were investigated but the other 4 cell lines at early passage (EPN-1, 
MED-1, BT-4 and Olig-1) were also included in this assay to determine the proportion of 
cancer stem-like cells in all primary cell lines (Figure 4.6). The average proportion of positive 
co-staining cells across all 7 cell lines was then evaluated. The proportion of positive cells 
was significantly higher in neurospheres (p < 0.01) ranging from 30-40% compared to 
monolayers comprising of 8-12% positive cells (Figure 4.6). Additionally, there was no 
correlation between the proportion of stem cell-like population and types of tumours 
(primary or recurrent) or grading in both monolayers and neurospheres (Figure 4.6). 
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Figure 4.5 The percentage of CD133 and SOX2 co-staining cells at early, middle 
and late passage from monolayers and neurospheres. CD133 and SOX2 co-staining 
was performed at early, middle and late passage number of EPN-2, MED-2 and SPNET-1 
monolayers (    ) and neurospheres (   ). All cell lines expressed similar characteristics of 
CD133 and SOX2 expression with increasing passage number. The percentage of CD133 and 
SOX2 co-expressing cells slightly decreased in both monolayer culture and neurosphere 
culture when passage numbers increased. Monolayer cells and neurospheres expressed 
CD133 and SOX2 in approximately 10% and 35-45%, respectively.  Decline of co-staining 
cells was clear in neurospheres when passage number increased. The proportion of cells co-
expressing CD133 and SOX2 in neurospheres was nearly 4 fold higher than monolayers from 
all cell lines at any passages.  
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Figure 4.6 The percentage of positive co-staining cells in all 7 primary cell lines. 
This graph shows the average percentage of positive co-staining CD133 and SOX2 cells from 
EPN-1, EPN-2, MED-1, MED-2, BT-4, Olig-1 and SPNET-1 cell lines in both monolayer and 
neurosphere culture at early passage. Neurospheres from all cell lines contained 30-45% 
positive co-staining cells whilst there were only 8-12% positive cells in monolayers. EPN-1 
and MED-2 cell lines were recurrent tumours (R) whereas the others were primary tumours 
(P). The percentage of co-staining cells either in monolayers or neurospheres from all cell 
lines had no correlation with the grading (I-IV) or type of tumour (primary or recurrent 
tumour). 
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4.2.4 CD133 and SOX2 expression detected using Western blotting analysis 
To validate the data from co-staining immunofluorescence, Western blotting analysis was 
performed to detect CD133 and SOX2 expression in the 3 primary cultured cell lines (EPN-2, 
MED-2 and SPNET-1) and the commercial cell line (PFSK-1) in both monolayer and 
neurosphere conditions at early passage. This assay was performed to confirm whether 
neurospheres expressed higher level of CD133 and SOX2 than monolayers. CD133 
expression was detected from the membranous fractions whilst SOX2 expression was 
detected from total cell lysates retaining the nuclear and cytoplasmic fractions.  
 
NTERA-2 cells, which expressed a high level of CD133 at ~120 kDa (Figure 4.7) were used 
as a positive control and were compared to the CD133 expression in monolayers and 
neurospheres of EPN-2, MED-2, SPNET-1 and PFSK-1 cell lines. The detected size of CD133 
in our cell lines was ~140 kDa probably due to additional glycosylation. Western blotting 
analysis showed that neurospheres from all 3 primary cultured cell lines expressed higher 
levels of glycosylated CD133 when compared to their monolayers. In the light of the 
negative immunofluorescence for PFSK-1, it seems possible that the bands observed on 
Western blotting analysis may represent non-specific reaction of the antibody.  
 
NTERA-2 cells were also used as a positive control for SOX2 expression. A SOX2 band of 37 
kDa was detected in NTERA-2 cells as expected. SOX2 expression was detected at a very 
low level in all cell lines including the positive control (NTERA-2) whereas PFSK-1 cells gave 
a strong positive band of SOX2 (Figure 4.7). The protein extraction process was optimised 
and different methods to extract the appropriate fraction enriched with nuclei and cytoplasm 
were attempted. Additionally, different SOX2 antibodies were tested. Unfortunately, despite 
these changes the level of SOX2 detected in our cell lines and the NTERA-2 control remained 
too low for effective detection by Western blotting.   
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Figure 4.7 Detection of CD133 and SOX2 expression using Western blotting 
analysis in primary paediatric cell lines. NTERA-2 cells were used as positive control and 
highly expressed CD133 when detected with the Miltenyi CD133 antibody (1:100). CD133 
expression was detected in the membrane fraction and CD133 expression in neurospheres 
(NS) showed stronger intensities than monolayers (M). This data correlated to co-staining 
immunofluorescent data. NTERA-2 cells were also used as a positive control for SOX2. SOX2 
antibody, R&D system (1:150), detected an equally low level of SOX2 expression in all 
samples. However, PFSK-1 cells highly expressed SOX2 when compared to other cell lines. 
Loading controls detected by ß-tubulin are also shown. The membrane fraction samples 
were loaded 60 µg/well and total cell lysate samples were loaded 100 µg/well whilst NTERA-
2 cell extraction was loaded 5 µg/well. Membranes were incubated in primary antibody for 
overnight at 4°C.         
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4.2.5 Telomeric Repeat Amplification Protocol (TRAP) assay 
Maintenance of telomere length is an important mechanism for tumour cells to survive 
beyond the limited cell division that occurs in normal cells. A significant factor that extends 
the length of telomere in cancer cells is the enzyme telomerase. This enzyme is activated in 
cancer cells to extend telomere length, thus these cancer cells can escape from senescence 
and apoptosis resulting in indefinite cell division. Telomerase may also remain active if a 
stem cell has been transformed [Lee, J, et al (2006)]. Therefore, the TRAP assay was 
performed to study telomerase activity. Positive telomerase activity will indicate that the 
active telomerase is maintaining telomere length in these cancer cells.  
 
The TRAP assay was performed to determine the degree of activation of telomerase activity 
in monolayers and neurospheres from all 7 primary cultured cell lines; EPN-1, EPN-2, MED-
1, MED-2, BT-4, Olig-1 and SPNET-1 at early passage (Figure 4.8). Human neural stem cells 
(hNSCs), adult glioblastoma cells (U87), PFSK-1 and the positive control supplied with the 
TRAP kit were all used as positive controls. The TRAP assay was independently repeated 3 
times then telomerase activity was quantified using the Quantity One software to analyse 
the level of telomerase activity (Figure 4.9). A representative figure is shown in Figure 4.8. 
Telomerase products were seen as incremental 6 bp ladder bands starting from 50 bp 
(Figure 4.8). Internal positive control bands detected at 36 bp were also seen in individual 
samples (Figure 4.8, bottom bands). All positive controls expressed high telomerase activity 
and telomerase processivity was also detected in all cell lines, both monolayers and 
neurospheres. The quantitative data shown in Figure 4.9 allows comparison of processivity 
between monolayers and neurospheres from each cell line. The TRAP assay showed that the 
telomerase activity was present in both monolayers and neurospheres of all cell lines with 
EPN-1, EPN-2 and MED-1 cell lines showing high processivity of telomerase in both 
monolayers and neurospheres. Neurospheres from BT-4 and SPNET-1 cell lines have visibly 
higher telomerase processivity than that of monolayers, whilst MED-2 (grade IV recurrent 
tumour) and Olig-1 (grade II primary tumour) have low levels of telomerase activity in both 
conditions. However, telomerase activity was consistently active in both monolayers and 
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neurospheres of all cell lines in all 3 individual experiments. There is no significant difference 
in telomerase activity between monolayers and neurospheres from all cell lines (unpaired 
student T-test). Tumour grade and recurrence status suggests that there is no correlation 
with the degree of telomerase processivity.  
 
Figure 4.8 Telomerase activity is present in monolayers and neurospheres of all 7 
primary cultured cell lines. Telomerase products are shown as incremental 6 bp ladder 
bands starting from 50 bp. The positive controls were human neural stem cells (hNSCs), 
adult glioma cells (U87) and PFSK-1 all of which have high telomerase processivity. 
Telomerase was consistently active in monolayers (M) and neurospheres (NS) derived from 
EPN-1, EPN-2, MED-1, MED-2, BT-4, Olig-1 and SPNET-1 cell lines in 3 individual 
experiments (a representative figure is shown). Additional controls were the telomerase 
positive cells (+), TSR8 PCR control template and the lysis buffer only sample (Neg.). The 
internal positive control product is seen at 36 bp. Samples were loaded 0.01 µg/well.  
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Figure 4.9 The quantification of telomerase activity in EPN-1, EPN-2, MED-1, MED-
2, BT-4, Olig-1, SPNET-1 and PFSK-1 cell lines at early passages. Telomerase activity 
was quantified from the density of telomerase processivity using the Quantity one software. 
The quantification data of telomerase activity from all cell lines are shown in the graph to 
allow comparison of the processivity between monolayers and neurospheres. Monolayers of 
the EPN-1 cell line, a recurrent (R) ependymoma, have the highest telomerase activity while 
the MED-2 cell line, a recurrent medulloblastoma, has the lowest level of telomerase activity. 
Neurospheres from EPN-2, a primary (P) ependymoma, BT-4 and SPNET-1 cell lines have a 
higher telomerase processivity than that of monolayers but it is not statistically significant (p 
value = 0.738, 0.199 and 0.167, respectively). Additionally, the processivity compared 
between monolayers and neurospheres from all cell lines was not significantly different 
(unpair student T-test, p value > 0.05). The analysis of the total product was described in 
section 2.7.5.    
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4.2.6 Terminal Restriction Fragments (TRF) assay or Telomere length assay 
Telomere length of normal somatic cells is shorter after each round of the cell cycle and this 
mechanism limits the number of cell division [Harley, C. B. and Futcher, A. B. (1990)]. 
When the length of telomere becomes too short (crisis), cells will go into senescence or 
undergo apoptosis. However, this mechanism is aberrant in tumour cells where tumourigenic 
cells can escape from senescent and apoptotic processes. The Terminal Restriction Fragment 
(TRF) assay complements the TRAP assay and was performed to investigate whether the 
telomere length is maintained in our primary cultured cell lines.  
 
The TRF assay was performed on monolayers and neurospheres of EPN-2, MED-2, SPNET-1 
and PFSK-1 cell lines at early, middle and late passage number. hNCS, U87 and U373 (both 
adult glioblastoma cells) were used as positive controls. Telomere length was detected as a 
smear shown in Figure 4.10. Mean telomere length was analysed using the Quantity One 
software and the data are shown in table 4.1. hNSC had the longest telomere length (8.6 
kbp) while telomere length of U87 and U373 was 5.7 and 3.9 kbp, respectively. The 
telomere length in our cell lines ranged from 4-8 kbp. Mean telomere length of neurospheres 
(NS) was shorter than monolayers (M) in EPN-2 (M=5.8kb±0.2 and NS=4.5kb±0.2) and 
MED-2 cell lines (M=6.3kb±0.8 and NS=6kb±0.6) (Table 4.1), whilst a shorter mean 
telomere length was observed in monolayers from SPNET-1 compared to neurospheres 
(M=6kb±0.51 and NS=6.62kb±0.85) (Table 4.1). However, this did not reach statistical 
significance (Table 4.1).  Telomere length was maintained in both monolayers and 
neurospheres of all cell lines at all passages. Thus, consistent with the TRAP assay data it 
appears that the 7 cell lines are all able to perpetuate their telomeres at a length suitable for 
cell survival.   
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Table 4.1 Mean telomere length of EPN-2, MED-2 and SPNET-1 cell lines 
 
Cell line Telomere length  
(kb) 
Independent student 
t-test (p value) 
Monolayer Neurosphere 
EPN-2 5.8±0.2 4.5±0.4 0.055 
MED-2 6.3±0.8 6.0±0.6 0.801 
SPNET-1 6.0±0.5 6.6±0.8 0.572 
PFSK-1 5.4±0.2 - - 
 
 
Figure 4.10 TRF assay in monolayers and neurospheres at early, middle and late 
passages of PFSK-1, SPNET-1, EPN-2 and MED-2 compared with hNSC, U87 and 
U373 cell lines. Telomere length was determined in monolayers and neurospheres (NS) 
from EPN-2, MED-2, SPNET-1 and PFSK-1 at early (E), middle (M) and late (L) passages. 
hNSC has the longest length of telomeres whereas the other cell lines have telomere length 
range between 3.6 ± 7.4 kbp. Telomere length was still maintained in all cell lines even at 
late passages. White dotted lines indicate mean of telomere in each cell line as assigned by 
Quantity One. 
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4.3 Discussion 
 
Our cell lines cultured as standard monolayers were more stable than neurosphere 
conditions.  
 
Cell lines studied in this project were derived from paediatric patients diagnosed with brain 
tumours; ependymoma (EPN-2), medulloblastoma (MED-2) and CNS PNET (SPNET-1), which 
were the main focus of this project. The commercial cell line, PFSK-1, was also included in 
this project. The PFSK-1 cell line however needed specialised culture media, recommended 
by LGC Promochem, because they could not survive in the much simpler tumour media and 
they could not be induced to form neurospheres in stem cell media. Due to the limitation of 
consecutive subculture in neurospheres, we could not serially subculture cells as 
neurospheres for prolonged propagation. They could be continuously subcultured with our 
experiment terminating at passage number 6. At this stage they became harder to 
dissociate and re-establish, a feature also recognised by other groups and prolonged culture 
of neurospheres also caused changes in proliferation kinetics, gene expression and cell 
adhesion [Morshead, C. M. et al (2002)]. All cell lines hence were cultured as monolayers 
and they have been continually passaged for up to 80 passages with regular growth rate 
(constant doubling times) and similar cellular morphology with increasing passage numbers 
(Figure 4.1.). Additionally, neurospheres were routinely generated from monolayers and 
monolayers were effectively induced to form neurospheres within 48 hours even at late 
passages (Figure 4.1.). The immunofluorescence results also demonstrated that all cell lines 
expressed stem cell markers (CD133 and SOX2) in both monolayer and neurosphere 
conditions at all passages. The proportion of cells co-expressing CD133 and SOX2 in 
monolayers was consistent even in late passage (up to 80 passages) (Figure 4.4 and 4.5). 
In addition, significant genetic abnormalities commonly found in the original tumours were 
preserved in our cell lines both monolayers and neurospheres from SNP analysis (Chapter 
3). Metaphase spread analysis results from Chapter 3 also demonstrated that our 
monolayers had less variation of chromosome numbers compared to PFSK-1 indicating more 
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stability of cell lines. Therefore, these results suggested that our cell lines were stably 
preserved during prolonged culture under monolayer conditions, standard tumour media 
supplemented with serum.  Monolayer conditions also conserved the characteristic of cancer 
stem cell in neurosphere formation and preserved significant characteristics of the original 
tumours. A previous study also demonstrated that human neural stem cells, which were 
grown as adherent monolayer cells, had stem cell characteristics and their property was 
stable even when they were continuously subcultured as adherent cells for long periods 
[Daadi, M. M. et al (2008)]. 
 
The failure to establish neurospheres from PFSK-1 monolayer cells is probably explained 
from the study of Lee, J. et al (2006). They proposed that there are de novo genetic and/or 
epigenetic changes in cells which have been cultured in serum condition (DMEM media 
containing 10% FBS) for a long period. PFSK-1 is a commercial cell line, which was 
established from a 22-month old boy diagnosed with undifferentiated PNET. These cells had 
been cultured in RPMI media supplemented with 10% fetal calf serum for over 2 years (85 
passages). Initially, PFSK-1 cells were able to form neurospheres in gel and initiate new 
tumours when they were transplanted into mice brain. It was concluded therefore that the 
PFSK-1 cell line had characteristics of neuroepithelial stem cells. However, this cell line had 
lost the heterozygosity on chromosome 17 at passage 39 and 73 during an establishment in 
culture [Fults, D. et al (1992)]. These findings suggest instability of the PFSK-1 cell line and 
also supported the findings of Lee et al study. In our hands, PFSK-1 could not form 
neurospheres in stem cell media and they were negative for CD133. Based on the evidence 
from Fults et al and our findings, it is concluded that PFSK-1 was not stable in prolonged 
culture and they had lost a property of stem cells during continuous subculture in media 
supplemented with serum. Hence, our cell lines were more stable in monolayer conditions 
than the commercial cell line, PFSK-1.  
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Neurosphere grew slower than monolayers indicating containing more quiescent 
cells. 
 
To determine any alteration of growth rate with increasing passage numbers, doubling time 
analysis was performed at early, middle and late passage numbers of monolayers and 
neurospheres. Our results demonstrated that monolayer doubling time was constant even 
when passage number increased whilst neurosphere doubling time was variable. 
Additionally, neurosphere doubling time was longer than monolayer although this was not 
significant in many cases. These findings indicated that neurospheres grew slower than 
monolayers possibly due to increasing CSCs, which are spending longer time in G0G1 phase 
of the cell cycle. Cell cycle analysis performed by Dr. Deema Hussein, a post doctoral 
researcher, showed that the proportion of cells in G0G1 phase was significantly increased in 
neurospheres (p < 0.001) when compared to the monolayers, with a corresponding 
decrease  in S phase cells (p < 0.001) (Figure 4.11). Hence, the presence of a larger  
 
Figure 4.11 An alteration of cell cycle profile in cells grown as neurospheres 
compared to monolayers. Monolayers (M) and neurospheres (NS) from EPN-1, EPN-2, 
MED-1, MED-2, BT-4, Olig-1 and SPNET-1 cell lines were examined cell cycle profile using 
flow cytometry. Cell cycle profile results demonstrated that a proportion of cells in G0G1 
phase had increased in neurospheres compared to the corresponding monolayers. An 
increase in a proportion of cell in G0G1 is consistent with the slower growth in neurospheres 
[The result was obtained from Dr. Deema Hussein].     
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proportion of neurosphere derived cells in the G0G1 phase of the cell cycle suggests the 
presence of an increased proportion of quiescent cells, a recognised feature of stem cells 
[Cotsarelis, G. et al (1990) and Li, L. et al (2010)]. Previous studies also supported the 
finding of slower growing neurospheres in neural stem cells derived from a subventricular 
zone of a newborn mouse. Nestin positive cells, which indicated neural stem cells present in 
a quiescent state, were found in neurosphere culture condition indicating slow cycling cells. 
They hence concluded that neural stem cells cultured as neurospheres remained in quiescent 
state [Ma, B. F. et al (2006)]. Our findings were similar to the previous study performed by 
Alam and colleagues. They studied a murine neural stem cell line and found that 
neurospheres were slowly cycling cells and the majority (65-70%) population were in G1 
state whist a very small proportion of cells were found in G2/M state. 20% of population 
were always observed in G0 phase. They also discovered that prolonged continuous culture 
(more than 60 days) affected the cell cycle kinetics. The proportion of cells in G2/M phase 
increased in the later passage [Alam, S. et al (2004)]. Quiescent cells or slow cycling cells 
(G0) are important cells in maintenance of self-renewal property of stem cells or preserve 
stemness in hematopoietic stem cells. These cells were normally located in niche when they 
were activated to be active cycling cells, they moved out of the niche [Arai, F. et al (2004)]. 
Another possibility for slower growth is different cell growth form. These 2 conditions were 
due to growth in different media; monolayers were grown in media supplemented with 
serum and neurospheres were grown as floating clusters of cells in serum free media 
supplemented with EGF and FGF. Large neurospheres may have an inadequate oxygen and 
nutrient supply to the centralized cells. As a result, apoptosis and necrosis could occur in the 
neurospheres, resulting in slowing down and termination of neurosphere growth [Zhdanov, 
V. P. and Kasemo, B. (2004)]. Monolayer cells grown as single layers should not have 
depletion of oxygen and nutrients. We did however try to control for this by routinely 
culturing neurospheres ever 3-4 days in order to keep their size minimal (< 100 µm in 
diameter). Additionally, the difficulty of dissociation in neurospheres leads to clumping of 
cells. Therefore, these cells were not included when they were counted using 
hemocytometer. When the doubling time was calculated using the formula in page 141, this 
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underestimated cell number of neurospheres resulted in longer doubling time compared to 
monolayers. 
 
Neurosphere conditions were enriched for CSCs but CSCs were maintained in 
monolayer conditions. 
 
It has been generally accepted that the tumour cell population is heterogeneous and not all 
tumour cells have the characteristics of cancer stem cells, which are able to regenerate new 
tumours. Only a subpopulation of cells is capable of initiating tumours and this population is 
believed to resist chemo- or radiotherapy [Guo, W. et al (2006), Nakano, I. et al (2006) and 
Singh, S. K. et al (2004)]. Therefore, to investigate whether our paediatric primary cell lines 
contain cancer stem cells, co-staining immunofluorescence and Western blotting analysis 
were performed.  
 
Immunofluorescence results confirmed a consistent proportion of cells co-expressing CD133 
and SOX2 (8-12%) in monolayers at early, middle and late passages (Figure 4.4 and 4.5) 
and these cells were effectively induced to form neurospheres at any passages. Therefore, 
monolayer conditions can constantly maintain the proportion of cancer stem-like cells at all 
passages for a long period. This was true of all the 3 tumour types under analysis in this and 
the wider study (ependymoma, medulloblastoma, CNS PNET, Oligodendroglioma and 
malignant glioneuronal tumour). A previous study demonstrated that human neural stem 
cells, which were grown as adherent monolayer cells, express molecular features of stem 
cells such as nestin, vimentin and radial glial markers and have a symmetrical mode of cell 
division. The stem cell characteristics of these adherent cells were stable even when they 
were continuously subcultured as adherent cells for long periods [Daadi, M. M. et al (2008)]. 
Additionally, neural stem cells derived from embryonic stem cells, fetal forebrain and adult 
forebrain, were successfully cultured as adherent monolayer cells. These adherent cells 
rapidly grow and maintain the characteristics of stem cells including clonogenicity, 
homogeneity and symmetrical division. They are also an enrichment resource of pure stem 
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cells [Pollard, S. M. et al (2006)]. However, there was a discrepancy between adherent and 
non-adherent culture in maintenance of cancer stem cell characteristics. Several previous 
studies used neurospheres to study the characteristics and properties of cancer stem cells 
[Shiras, A. et al (2007), Chen, L. et al (2007), Merkel, F. T. et al (2004), Lee, J. et al 
(2006), Calabrese, C. et al (2007), Inagaki, A. et al (2007), Hansford, L. M. et al (2007), 
Singh, S. K et al (2003 and 2004)]. These studies found that neurospheres have the 
properties of stem cells including self-renewal, proliferation, multilineage differentiation and 
expression of several stem cell markers. In addition, isolated neurospheres express 
neuroepithelial stem cell markers including nestin, an intermediate filament protein. The 
characteristics of stem cells could be maintained while culturing the cells as floating cell 
clusters (neurospheres) [Reynold, B. A. and Weiss, S. (1992)]. Cells, derived from a primary 
GBM and grown as neurospheres under serum free neurobasal media supplemented with 
bFGF and EGF, can maintain their potential of self-renewal and ability of multiple lineage 
differentiation. Additionally, these cells expressed similar genes to NSCs and parental GBM 
cells, and maintained genetic stability over serial culture for a long period. In contrast, 
adherent cells cultured under DMEM media containing 10% FBS lost the properties of stem 
cells and could not maintain tumourigenic characteristics. The genetic profiles of these cells 
were totally different from NSCs and their parental tumour cells [Lee, J. et al (2006), Yuan, 
X. et al (2004)]. In addition, Fael Al-Mayhani et al claimed that the Cambridge protocol, 
which comprised 2 phases; derivation and propagation phases, was an effective method to 
derive tumour initiating cells from glioblastoma. They combined spheroid and monolayer 
culture in the Cambridge protocol to achieve the most effective yield of derivation and they 
revealed that this method successfully derived cell lines from glioblastoma (100%) and 
these cell lines also conserved parental genomic profiles [Fael Al-Mayhani, T. M. et al 
(2009)]. However, when the underlying metabolic events and biological features were 
analysed to investigate the maintenance of stem cell properties of both adherent and non-
adherent cultured cells. It was found that both adherent and non adherent cells could 
preserve the stem cell characteristics over several passages [Inagaki, A. et al (2007)]. 
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Hence, there are two different methods; monolayer and neurosphere conditions, to maintain 
stem cell characteristics in culture.  
 
Additionally, neurospheres, induced from adherent (monolayer) cells, were enriched with 
stem-like cells. Approximately 35-45% of neurospheres were positive for stem cell markers; 
CD133 and SOX2 (Figure 4.4 and 4.5). The proportion of CD133 and SOX2 co-stained cells 
was significantly higher in neurospheres (35-45%) than in monolayers (8-12%) (p < 0.001). 
The presence of an increased proportion of cells expressing CD133 in neurospheres 
compared to monolayers was confirmed by Western blotting analysis (Figure 4.7) whereas 
SOX2 expression detected by Western blotting analysis was low and did not appear to alter 
in any of the cell lines. In addition, a 4-fold increase in cells co-expressing CD133 and SOX2 
was correlated with the immunofluorescence and FACS data performed by Dr. Deema 
Hussein. These FACS and immunofluorescence data also showed that a higher proportion of 
cells expressing nestin was observed in neurospheres from EPN-1 and EPN-2 cell lines 
(18±1.6 and 16.7±3.1, respectively) compared to monolayers (4.9±0.6 and 4.6±0.6, 
respectively). Similarly, flow cytometry data also demonstrated a higher proportion of nestin 
positive cells in neurospheres (11.1±2.2) compared to monolayers (3.8±0.7). Taken these 
all data together, it was convincingly confirmed that neurosphere conditions were enriched 
with cancer stem-like cells approximately 4-fold compared to monolayer conditions.  
 
The PFSK-1 cell line failed to form neurospheres and immunofluorescence showed that there 
were no positive CD133 cells in PFSK-1 cells (Figure 4.4) (also confirmed by Dr. Deema 
Hussein, personal communication). However, the adherent PFSK-1 cells that grew in stem 
cell media were not examined for the expression of stem cell markers. Due to that fact that 
there were no CD133 positive cells present under monolayer growth conditions, however, 
PFSK-1 cells grown under neurosphere condition should be negative for CD133.          
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Co-stem cell marker (CD133 and SOX2) effectively identified CSCs in our cell lines. 
 
Based on the hypothesis of cancer stem cell characteristics, appropriate stem cell markers 
should identify a subpopulation, which has the capabilities of self-renewal, multilineage 
differentiation and tumour initiation in vivo. CD133 was originally recognized as a marker for 
human haematopoietic stem cells and neural stem cells. However, CD133 mRNA is also 
expressed in normal human tissues including mammary gland, trachea, salivary gland, 
placenta pancreas, digestive tract and testes [Mizrak, D. et al (2008)]. Currently, CD133 has 
been generally used as stem cell marker to identify the cancer stem cell subpopulation and 
many studies have provided evidence to support the effectiveness of CD133 in cancer stem 
cell identification. For example a study in human epithelial basal cells, supported the fact 
that AC133 identified a rare population, which showed 2 essential characteristics of epithelial 
stem cells in terms of higher proliferation in vitro and complete differentiation into prostatic 
like-acini in vivo [Richardson, G. D. et al 2004)]. AC133+CD34+CD3- cells, sorted from 
human fetal liver cells, had the capability to differentiate into astrocytes and neural cells 
[Hao, H. N. et al (2003)]. Additionally, CD133 antigens were rapidly down regulated when 
Caco-2 cells (colon carcinoma cell line) differentiated [Corbeil, D. et al (2000)]. Cells 
expressing AC133 isolated from human brain tumour cell lines significantly increased the 
capability of cells to initiate tumour when they were transplanted into non-obese diabetic-
severe combined immunodeficient (NOD-SCID) mouse brain [Singh, S. K. et al (2004)] 
whereas cells without AC133 or AC141 expression had less tumourigenic capacity [Günther, 
H. S. et al (2008)]. In addition, AC133 co-expressed with other stem cell markers was used 
in many studies to specify cancer stem cells. Uchida et al found that cells expressing AC133 
and AC141 but not CD34 and CD45 isolated from human fetal brain tissues formed 
neurospheres and differentiated into both neurons and glial cells in vitro. When these cells 
were transplanted into immunodeficient neonatal mice, they had high potential of tumour 
initiation, proliferation, migration and neural differentiation [Uchida, N. et al (2000)]. There 
were, however, also some findings revealed a weakness and limitation of using CD133 to 
identify cancer stem cells. Sakariassen et al examined the reliability of each technique in the 
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detection of stem cells and stated that false positive and a wide range of data could occur. 
For example, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
showed a huge variance of CD133 mRNA expression probably due to the presence of 
multiple isoforms and immunofluorescent results showed unexpected staining location in 
positive cells. CD133 staining is difficult possibly due to the presence of trypsin sensitive 
cytoplamic loops and the high levels of intracellular expression. [Sakariassen, P. et al 
(2007)]. Beier et al revealed that CD133+ and CD133- cells, which sorted from primary and 
secondary glioblastoma tumours by FACS, showed similar tumourigenic potential when they 
were engrafted into nude mice. They found that CD133- subpopulation also had infinite self-
renewal and pluripotency capacity where these cells were able to differentiate into neurons, 
astrocytes and oligodendrocytes [Beier, D. et al (2007)]. Clément et al also studied CD133 
in glioblastoma and they supported that CD133+ and CD133- cells sorted by flow cytometry 
showed similar stem cell potential. They also suggested that FACS technique was not 
effective enough to isolated cancer stem cells, which can preserve long term self-renewal 
capacity, and CD133 was insufficient to detected entire cancer stem cells [Clément, V. et al 
(2009)]. Hence, there is a controversy in using CD133 alone to identify cancer stem cell 
population. However, there are several currently available stem cell markers for detection of 
cancer stem cells. For example SOX2 (MAB2018 R&D system®) was raised against 
recombinant human SOX2 at 135-317 amino acids. SOX2 is a transcription factor, which is 
important in the designation of neural stem cell fate. In addition, SOX2 is highly expressed 
in neuroepithelial stem cells and neural stem/progenitor cells. It was recognised as 
embryonic or neural stem cell marker [Miyagi, S. et al (2006)]. Nestin, which is neural stem 
cell marker, is also commonly used to identify cancer stem cells [Singh, S. K. et al (2004) 
and Wu, A. et al (2008)]. Nestin was used to identify CSCs in brain tumours 
(medulloblastoma and glioma) [Hemmati, H. D. et al (2003)]. Therefore, double staining of 
two stem cells markers is probably more convincing than single staining of one stem cell 
marker. Co-staining CD133 and SOX2 hence were used as stem cell markers to identify 
cancer stem-like cells in our primary cell lines. Co-staining immunofluorescence analysis was 
performed and the data were also validated by Western blotting analysis. CD133 antibody 
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(ab19898 abcam®) binds to C-terminus of human CD133. In our study, immunofluorescence 
staining of CD133 and SOX2 showed the correct sites of staining whereby positive signal was 
identified from membranous staining and nuclear or cytoplasmic staining, respectively. Our 
immunofluorescence data were consistent with co-staining immunofluorescence data 
performed by Dr. Deema Hussein using CD133 co-stained Nestin to identify cancer stem 
cells. CD133 co-stained with Nestin was also used to identify cancer stem cells in brain 
tumours [Singh, S. K. et al (2004) and Wu, A. et al (2008)]. The results showed high 
enrichment of CSCs in neurospheres almost 4 fold than in monolayers. Therefore, using 2 
stem cell markers in CSC identification provided convincing results and CD133 and SOX2 
effectively identified CSCs in our cell lines. 
 
Telomere length was maintained and telomerase was activated in our cell lines at 
any passages.  
 
The TRAP assay, which determined the level of telomerase activity, was performed on 
monolayers and neurospheres from 7 primary paediatric cultured cell lines. The TRAP results 
showed that telomerase processivity was positive in both monolayers and neurospheres 
from all cell lines (Figure 4.8 and 4.9). Telomerase activity is negative in normal brain 
tissues [Siyuan, L. et al. (1998) and Nakatani, K. et al. (1997)]. Although, to obtain more 
convincing results, normal brain samples should have been included in the TRAP assay as a 
negative control. Our results showed further that there was no correlation between 
telomerase activity and tumour progression or tumour grading in our cell lines and there was 
no consistent correlation between TRAP processivity and culture conditions between 
monolayers and neurospheres. Currently, the correlation between telomerase activity and 
tumour progression or tumour grading is not confirmed and remains controversial. One 
previous study showed that telomerase activity in gastric carcinoma was detected in large 
size tumours, those at an advanced stage and metastatic whereas at an early stage of 
gastric cancer telomerase activity was negative. In addition, telomerase positive cases had a 
shorter survival time than negative cases. However, telomerase activity was not always 
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positive in advanced stages of gastric cancer [Hiyama, E. et al. (1995)]. In contrast, in brain 
tumours, telomerase activity was detected in both high and low grade tumours 
(glioblastoma multiforme, oligodendroglioma and anaplastic astrocytoma). Positive 
processivity detected in anaplastic astrocytoma indicated that a tumour was more likely to 
transform to a higher grade tumour; glioblastoma multiforme. This study concluded that 
telomerase activity was associated with tumour progression [Langford, L. A. et al. (1995)]. 
Our TRAP results indicated that there was no correlation between a degree of telomerase 
activity and tumour grading of tumour progression, however, to make a strong conclusion, 
the TRAP assay should be performed on the same cell lines derived from the original 
tumours at different stage of tumour progression in term of primary tumour and relapse 
tumour. So that the level of telomerase activity can be compared when tumours have 
progression. These samples were, however, not available for us to compare the level of 
telomerase activity at different stages of tumours. It would also be important to increase the 
sample size for each type of tumour under analysis. 
 
A TRF assay was also performed to determine telomere length in monolayers and 
neurospheres from EPN-2, MED-2, SPNET-1 and PFSK-1 cell lines at early, middle and late 
passages (Figure 4.10 and Table 4.1). Although, TRF assays were independently repeated 
many times, however, good quality results were only derived from 2 experiments. The TRF 
assay confirmed that telomeres were maintained in monolayers and neurospheres from all 
cell lines at all passages. Didiano et al. determined telomere length in PNET cell lines and 
found that telomere length ranged from 5 ± 12.1 kbp [Didiano, D. et al. (2004)]. This data is 
consistent with our findings, which showed the telomere length ranging from 4.78 ± 7.6 kbp 
in SPNET-1 and MED-2 cell lines. Another study revealed that all recurrent ependymomas 
demonstrated a high level of telomerase activity and telomere lengthening was observed in 
the majority (71%) of these tumours compared to the corresponding primary tumours 
[Ridley, L. et al (2008)]. However, we could not indicate whether the maintenance of 
telomere length in our cell lines are shortening or lengthening since data on the original 
tumour or the primary tumour specimens were not available to make a comparison. Based 
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on evidence that telomere length detected in fetal brain and adult brain (32 ± 76 years) was 
11.9±1.5 and 10.5±0.5 kbp, respectively [Allsopp, R. C. et al. (1995)], telomere length was 
maintained at a short length in our cell lines since it was shorter than 10 kbp. The pattern of 
telomere length smear of our cell lines was different from the controls, hNSC, U87 and 
U373. The TRF results showed heterogeneous telomere length smears, which contained 
short and long telomere length. The heterogeneous telomere length pattern, which is the 
characteristic of ALT cell lines, was previously found in late passages where cells have gone 
through crisis [Yeager, T. R. et al. (1999)]. Therefore, this evidence suggested that our cell 
lines have gone through crisis since early passages (< 25) and ALT probably was the major 
mechanism to maintain telomere length in our cell lines. As a result, our cell lines still 
survived with no change of cellular morphology even they have been passaged up to 80 
passages. Additionally, Didiano et al. found that telomerase positive PNET cells had shorter 
telomere length than telomerase negative cells. This data indicated that the maintenance of 
telomere length in PNET cells does not always depend on the upregulation of telomerase 
activity but it possibly resulted from ALT mechanism [Didiano, D. et al. (2004)]. Therefore, 
telomerase activation might not be the only mechanism to maintain telomere length in 
cancers. It is also possible that different mechanisms could be operating in different tumour 
subpopulation. 
 
The correlation between telomerase activity and telomere length was evaluated to see 
whether a high telomerase activity is found in cell lines having a short telomere length. A 
previous study, which determined telomerase activity and telomere length in cancer cells, 
revealed that telomere length of cancer cells was maintained at homeostasis was short 
where cancer cells had limiting amount of telomerase [Cristofari, G. and Lingner, J. (2006)]. 
However, telomerase activity did not correlate with telomere length in our cell lines with 
regard to tumour grading, tumour types whether primary or recurrence or history of 
treatment.  This might be because the different telomere length maintenance mechanisms 
possibly activated in different types of tumours. Didiano et al. also found that there was no 
correlation between telomerase activity and telomere length in PNET cell lines but their data 
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showed that human telomerase reverse transcriptase (hTERT) mRNA expression significantly 
correlated with telomerase activity [Didiano, D. et al (2004)]. In addition, telomere length is 
not the only factor, which determines telomeric function. It has also been found that 
telomeric dysfunction can be detected in cells with long telomere length [Hemann, M. T. et 
al (2001)]. Taking all the TRF and TRAP results together, the results indicated that 
telomeres were maintained and telomerase activity was present at all passages in all cell 
lines both monolayers and neurospheres. However, there was no correlation between 
telomere length and telomerase processivity.  
 
Due to the fact that telomerase activity and telomere length were not the main aim of this 
project, experiments were not performed to study in depth about these topics. However, 
there were several interesting points, which should be studied to complete the data. Firstly, 
normal childhood brain samples should be included in both the TRAP and TRF assay to 
compare the level of telomerase activity and the length of telomere. Secondly, a telomerase 
inhibitor could be used to inhibit telomerase activity then telomere length determined to see 
whether telomere length is affected when telomerase activity is absent. This will prove which 
cell lines use telomerase activity as a major mechanism to maintain telomere length. The 
TRF assay using Southern blotting analysis is standard method to determine telomere length 
where the black smear on the blot represents mean of telomere length from a whole DNA, 
which is extracted from samples. This is the limitation of this technique, which only shows 
the mean telomere length from all chromosomes. In fact, each chromosome contains 
variation of telomere length and the shortest telomere length will activate telomerase to 
elongate that telomere or other dysfunctional telomere [Hemann, M. T. et al (2001)]. For 
future study, Q-FISH technique could be performed to determine telomere length because 
this technique is able to show individual telomere length from each cell and distinguish 
between ALT pattern (variation of telomere length) and telomerase pattern (equal telomere 
length). Additionally, the TRF and TRAP assay should be performed on the original tumours 
obtained from patients to determine the preservation of original characteristic in cell lines, 
which have been serially passaged in tumour media. Pulse field electrophoresis could also 
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have been used to give better resolution of heterogeneous telomere length smears. Finally, 
clonal analysis could have been used to determine if different tumour subpopulation are 
using different mechanisms to maintain their telomeres.  
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Chapter 5: Identification and functional analysis of ABC transporters in 
the parental cell lines 
 
5.1 Introduction 
 
In Chapter 4, co-staining immunofluorescence analysis of the parental cell lines demonstrated 
that monolayers and neurospheres from our cell lines (EPN-2, MED-2 and SPNET-1) contained 
approximately 8-12% and 35-45% of cells co-expressing CD133 and SOX2, respectively, 
consistent with previous findings by Singh and colleagues in medulloblastoma [Singh, S. K. et 
al (2003)]. This indicated that neurosphere culture conditions were able to enrich for cells co-
expressing CD133 and SOX2 (cancer stem-like cells) when compared to the monolayers. 
Western blotting results also confirmed a higher expression level of CD133 detected in 
neurospheres compared to monolayers. Therefore, our cell lines contain a small but detectable 
proportion of cancer stem-like cells. To study drug resistance in our cell lines, these cell lines 
were investigated for the expression of functional ABC transporters.  
 
Conventional chemotherapy remains an essential treatment for several types of cancers.  In 
some types of cancer, patients diagnosed with malignancy and first treated with chemotherapy, 
are seen to respond to treatment, resulting in tumour mass being shrunken in size. 
Nonetheless, tumour relapse will occur in a sizeable proportion of patients within a few years or 
many years after the first treatment, resulting from drug resistance of targeted cells. 
Chemotherapeutic drug resistance occurring in cancer cells is broadly categorised as being 
either acquired and intrinsic drug resistance. Acquired drug resistance is observed after cancer 
cells are treated with many rounds of chemotherapeutic agents. It is believed to occur from 
accumulated genetic mutation or alteration after each cycle of chemotherapy resulting in these 
cells become resistant to drugs. Drug resistance which is originally present in cancer cells prior 
to treatment is intrinsic drug resistance.  Drug resistance in cancer cells is commonly multidrug 
resistance (MDR). A unique characteristic of MDR is that resistant cells are able to have cross-
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resistance to many chemotherapeutic drugs regardless of structure of drugs or drug exposure 
experience. Although, chemotherapeutic regimens comprise multiple drugs with different 
targets, effectiveness of treatment cannot be improved. Therefore, multidrug resistance is still 
a major problem of chemotherapeutic treatments resulting in failure of treatment and relapsed 
cancers.  At present, researchers are attempting to understand the mechanism of drug 
resistance of cancer. Many mechanisms lead to MDR, however, members of the adenosine 
triphosphate-binding cassette (ABC) transporter family are at least partly responsible for MDR 
[Goldie, J.H. (2001)].  
 
Current knowledge about drug transporters involved in drug resistance has been obtained from 
extensive studies into ABCB1, ABCC1 and ABCG2. ABCB1 was initially detected in several types 
of cancer, with colon, kidney, adrenocortical and hepatocellular cancers having high levels of 
expression [Fojo, A. T et al (1987)]. ABCC1 was also highly expressed in human cancers e.g. 
leukaemias, oesophageal carcinoma and non-small-cell lung cancers [Nooter, K. et al (1995)]. 
ABCG2 was discovered later and identified by methoxantrone resistance without ABCB1 or 
ABCC1 expression [Dean, M. et al (2001)]. ABCG2 was highly expressed in breast cancer and 
postulated to associate with drug resistance [Doyle, L. A. et al (1998)]. Therefore, the 
correlation between high levels of ABCB1, ABCC1 or ABCG2 expression and drug resistance was 
extensively studied in many types of cancers. In leukaemia, ABCB1 was detected in only one 
third of patients diagnosed with acute myelogenous leukaemia (AML), and highly expressed in 
approximately half of relapsed cases of AML. Additionally, it was found that a high level of 
ABCB1 expression was correlated with poor prognosis and ineffective response to treatment by 
patients [Gottesman, M. M. (2002)]. Poor treatment outcome of breast cancer [Trock, B. J. et 
al (1997)] and highly doxorubicin resistant sarcoma [Abolhoda, A. et al (1999)] were also 
correlated with high levels of ABCB1 expression. The level of ABCC1 mRNA expression also 
related to a degree of chemoresistance in glioma resulting in poor treatment outcome [Bredel, 
M. (2001)]. ABCG2 expression had an impact on prognosis and clinical chemoresistance studied 
in acute myeloid leukaemia (AML) [Wilson, C. S. et al (2006) and van den Heuvel-Eibrink, M. 
M. et al (2002)]. The patient having the poorest prognosis was found to have both ABCB1 and 
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ABCG2 co-expression [Benderra, Z. et al (2004)]. Therefore, ABCB1, ABCC1 and ABCG2 play 
an important role in drug resistance in many cancer types. 
 
CSCs, proven to exist in brain tumours, may be the population that survives following 
treatment hence targeting these cells could improve chemotherapy. We hypothesised that ABC 
transporters might be an important mechanism for drug resistance in cancer stem cells. 
Therefore, as part of our studies of drug resistance in our paediatric brain tumour cell lines, 
endogenous ABC transporter expression was determined by immunofluorescence, Western 
blotting and flow cytometry. The assays were performed in monolayers and neurospheres to 
compare the proportion of cells co-expressing CD133 and ABC transporters between these 2 
culture conditions. The existence of endogenous ABC transporter expression co-stained with 
CD133 was coupled with drug export assays to examine ABC transporter function. The 
presence of co-expressing cells with functional drug exporters would be consistent with our 
hypothesis regarding CSCs being able to survive drug treatment. 
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5.2 Results 
 
5.2.1 Co-staining ABC transporters and CD133 immunofluorescence analysis 
Co-staining immunofluorescence was performed on 3 primary cultured cell lines; EPN-2, MED-2 
and SPNET-1 at early passage (<25). Monolayers and neurospheres were co-stained with 
antibodies to CD133 and either ABCB1, ABCC1 or ABCG2. Human embryonic kidney (HEK) cells 
stably transfected with vector expressing ABCB1, ABCC1 or ABCG2 were used as positive 
controls. Positive control cells showed a high expression of ABC transporters defined as clear 
membranous staining with ABC transporter antibodies (Figure 5.1, 5.2 and 5.3). Positive 
ABCB1 or ABCC1 cells co-stained with CD133 were detected in both monolayers and 
neurospheres of all 3 cell lines. In general, monolayers showed a low level of co-expression 
whereas neurospheres expressed ABCs and CD133 at a higher level and also the proportion of 
co-expressing cells was larger in neurospheres compared to monolayers (Figure 5.1, 5.2 and 
5.3). However, there were some populations which singly stained for CD133 or ABC 
transporters in both monolayers and neurospheres of all cell lines. ABCG2 expression was not 
detected in any of the cell lines. Although, ABCG2 antibody positivity was detected in SPNET-1 
neurospheres, this positive signal was nuclear instead of membranous staining. Therefore, this 
positive signal was defined as non-specific for ABCG2 since only protein located on the plasma 
membrane could function as a drug transporter.                                                                                 
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Figure 5.1 Co-staining CD133 and ABCB1 immunofluorescence in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines at early passage number. 
HEK-B1 cells were used as a positive control and they highly expressed ABCB1, which clearly 
showed membranous staining. Monolayers and neurospheres from EPN-2, MED-2 and SPNET-1 
cell lines were detected with antibodies against CD133 and ABCB1 and images were captured 
at x40 magnification. Cells expressing membranous CD133 and ABCB1 were detected in both 
monolayers and neurospheres from all 3 cell lines. Co-staining CD133 and ABCB1 cells were 
detected at a higher proportion in neurospheres and were more intensely stained compared to 
monolayers. Single staining; DAPI staining nuclei (blue), CD133 (green) and ABCB1 (red), and 
merged images are shown. The white boxes in the merged images show an example of co-
staining cells and merged images are enlarged for clarity (x2-3). (Scale bars = 100 µM)  
 
 
 176 
 
DAPI CD133 ABCC1 Merged 
HEK-C1 
EPN-2 Monolayers 
EPN-2 Neurospheres 
MED-2 Neurospheres 
MED-2 Monolayers 
SPNET-1 Neurospheres 
SPNET-1 Monolayers 
100 µm 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
 177 
 
 
 
 
 
 
Figure 5.2 Co-staining CD133 and ABCC1 immunofluorescence in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines at early passage number. A 
high level of clear membranous staining of ABCC1 was detected in the HEK-C1 positive control 
cells. Both monolayer and neurosphere cells from all 3 cell lines were positive for antibodies 
against CD133 and ABCC1. In each case a higher proportion of CD133 and ABCC1 co-staining 
cells was detected in neurospheres when compared to monolayers. Similar to co-staining 
CD133 and ABCB1 results, cells grown as neurospheres had membranes which were entirely 
co-stained CD133 and ABCC1 antibodies. White boxes in each merged image show 
representative co-staining cells and merged images are enlarged for clarity (x2-3). 
Immunofluorescence results are shown as single staining images (DAPI [blue], CD133 [green] 
and ABCC1 [red]) and merged images; all images were captured at x40 magnification. (Scale 
bars = 100 µM) 
 178 
 
DAPI CD133 ABCG2 Merged 
HEK-G2 
 
EPN-2 Monolayers 
EPN-2 Neurospheres 
MED-2 Neurospheres 
MED-2 Monolayers 
SPNET-1 Neurospheres 
SPNET-1 Monolayers 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 100 µm 
100 µm 
        
100 µm 100 µm 100 µm 
        
         40 µm 50 µm 
100 µm 100 µm     40 µm 50 µm 
 179 
 
 
 
 
 
 
Figure 5.3 Co-staining CD133 and ABCG2 immunofluorescence in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines at early passage number. 
HEK-G2 cells were used as a positive control and they showed a high level of membranous 
staining detected with ABCG2 antibody. Monolayers and neurospheres from EPN-2, MED-2 and 
SPNET-1 cell lines were co-stained with antibodies against CD133 and ABCG2. CD133 
membranous staining was detected in both monolayers and neurospheres but ABCG2 staining 
was negative in all cell lines apart from SPNET-1 neurospheres. However, positive ABCG2 
staining in the SPNET-1 neurospheres was nuclear staining. The white box in the merged image 
shows co-staining cells. This figure shows single staining images of DAPI (blue), CD133 (green) 
and ABCG2 (red) and merged images. All images shown in this figure were captured at x40 
magnification apart from neurospheres from MED-2 and SPNET-1 cell lines which were captured 
at x100 magnification. (Scale bars = 100 µM and 40 µM) 
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5.2.2 Detecting cells co-stained for ABC transporters and CD133 by FACS 
The results from previous immunofluorescence analysis showed that neurospheres contained a 
larger proportion of cells co-expressing CD133 and ABCB1 or ABCC1 than monolayers. 
Additionally, no cells co-expressing CD133 and ABCG2 were detected in either monolayers or 
neurospheres. To validate the data from co-staining immunofluorescence, FACS was 
performed. 
 
The proportion of fixed cells co-stained with antibodies against CD133 and ABCB1, ABCC1 or 
ABCG2 was detected by flow cytometry in early passage monolayers and neurospheres from 
EPN-2, MED-2 and SPNET-1 cell lines. The assay was individually repeated 3 times and included 
either HEK-B1, HEK-C1 and HEK-G2 cells as positive controls or HEK-V cells as negative 
controls. Representative figures from each sample are shown in Figures 5.4 ± 5.6 and the 
percentage of co-expressing cells is shown in Figure 5.7. FACS results showed that our cell 
lines, especially when grown as neurospheres, were not well suited to this assay. Even in 
positive control cells, the percentage of co-expressing cells showed considerable variation. In 
addition, HEK-V cells (empty vector) sometimes displayed a high proportion of co-expressing 
cells similar to positive cells, in contrast to expectation. FACS results from 3 independent 
experiments showed a huge variation of co-staining percentage especially in neurospheres as 
shown in Figure 5.7. To illustrate the unreliability of FACS data, the proportion of cells 
expressing CD133 by FACS was compared to the proportion of co-staining CD133 and SOX2 by 
immunofluorescence. The immunofluorescence results showed that neurospheres were 
enriched 4-5 fold for cells expressing CD133 and SOX2. In contrast, over 50% of cells 
expressed CD133 detected by FACS in both monolayers and neurospheres (Figure 5.4 - 5.6) 
and, there is no 4 fold increase in the proportion of cells expressing CD133 in neurospheres 
compared to monolayers. The large degree of error (Figure 5.7) also indicated that this method 
was unreliable and Western blotting analysis was consequently performed to detect ABC 
transporter expression.          
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Figure 5.4 Co-expressing CD133 and ABCB1 cells detected by FACS in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines. Co-expression of CD133 and 
ABCB1 was detected in almost 50% in HEK-V cells similar to HEK-B1 cells on every occasion. 
Cells co-expressing CD133 and ABCB1 indicated in purple box sometimes were higher in 
neurospheres than monolayers (EPN-2) but sometimes they were higher in monolayers than 
neurospheres (MED-2 and SPNET-1). Cells expressing CD133 indicated in red box were 
detected at a very high proportion in all cell lines. Number of events included in the 
experiments was 5,000 ± 10,000. The results were gated based on the consistent negative 
controls of samples (secondary antibody alone) since the results from HEK-V and HEK-B1 
showed higher intensities of co-expression. Cells co-expressing CD133 and ABCB1 displayed in 
the right upper quadrant indicated cancer stem-like cells expressing ABCB1.    
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Figure 5.5 Co-expressing CD133 and ABCC1 cells detected by FACS in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines. This figure shows the best 
result of co-staining from HEK-C1 and HEK-V cells. CD133 and ABCC1 co-expressing cells of 
HEK-V were detected at similar proportion to HEK-C1 cells on some occasions. Cells co-
expressing CD133 and ABCC1 were detected at a very low proportion in all cell lines whereas 
CD133 expressing cells were detected at more than 50% in both monolayers and neurospheres 
from all cell lines.   
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Figure 5.6 Co-expressing CD133 and ABCG2 cells detected by FACS in monolayers and 
neurospheres from EPN-2, MED-2 and SPNET-1 cell lines. HEK-G2 cells used as a positive 
control contained approximately 80% ABCG2 expressing cells. There were no CD133 and 
ABCG2 co-expressing cells detected in HEK-V cells (negative control) as expected.  Co-
expression of CD133 and ABCG2 was negative in both monolayers and neurospheres from all 
cell lines and the result was consistent from 3 independent experiments. 
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Figure 5.7 The percentage of cells co-expressing CD133 and ABCB1 or ABCC1 in 
monolayers and neurospheres from EPN-2, MED-2 and SPNET-1 cell lines at early 
passage. Graph shows the mean percentage of cells co-expressing CD133 and ABCB1 or 
ABCC1 from 3 independent experiments but co-expression of CD133 and ABCG2 was 
consistently negative from all 3 experiments so the data are not included in this figure. The 
proportion of cells in neurosphere samples showed extensive variation and also less variation 
was observed in monolayers. Therefore, the data show unacceptable variation, as discussed in 
the text.  
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5.2.3 ABC transporters expression detected by Western blotting analysis 
Due to the dissimilarity between data obtained from immunofluorescence analysis and flow 
cytometry in detection of cells co-expressing CD133 and ABC transporters, Western blotting 
analysis was performed to validate the results. To confirm whether neurospheres express 
higher levels of ABC transporters than monolayers, ABC transporters expression was detected 
from the microsomal membrane fraction, where functional ABC transporters should be located, 
of both monolayers and neurospheres by Western blotting analysis. Microsomal membrane 
fractions had previously been shown to be enriched for CD133 expression (Figure 4.7, a, 
Chapter 4).   
 
The microsomal membrane fraction was extracted from monolayers and neurospheres of EPN-
2, MED-2 and SPNET-1 cell lines at early passage. HEK cells stably transfected with vector 
expressing ABCB1 (HEK-B1), ABCC1 (HEK-C1) or ABCG2 (HEK-G2) were used as positive 
controls whereas the negative control in each case was HEK cells stably transfected with empty 
vector (HEK-V). ABCB1 and ABCC1 proteins were detected at ~140 kDa in the appropriate 
controls and also in our cell lines (Figure 5.8, a and b).  Neurospheres of all 3 cell lines showed 
a higher intensity of ABCB1 and ABCC1 expression compared to monolayers in agreement with 
immunofluorescence analysis. ABCG2 protein was detected at ~72 kDa in controls whereas the 
only positive bands detected in our cell lines were ~200 kDa (Figure 5.8, c). This may have 
resulted from unresolved dimers of ABCG2 transporters or the aggregation of ABCG2 protein. 
As ABCG2 dimerisation is stabilised by an inter-chain disulphide bridge, additional steps were 
taken to investigate whether the 200 kDa species could represent ABCG2. Among these was 
the incubation of sample additionally containing urea, dithiothreitol (DTT) and higher than 
normal concentrations of ǃ-mercaptoethanol. However, the observed bands could not be 
reduced to 72 kDa and they were still detected at ~200 kDa in our cell lines. The sequence 
used to derive the ABCG2 antibody was screened against human protein databases using 
standard protein-protein BLAST (blast p) to find sequences with a high degree of similarity and 
hence other proteins that may have been detected. Eight different isoforms of human ABCG2 
protein, which have expected size ranging from 68-72 kDa, were identified as a number of 
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other members of ABC transporter subfamily G and several other proteins of unrelated function 
to ABC transporter. Under all electrophoresis conditions HEK-G2 showed a 72 kDa band 
whereas the cell lines did not show this reactivity. The identity of the 200 kDa sequences 
remains unknown but it seems impossible that it represents ABCG2 (in agreement with 
immunofluorescence analysis which showed no expression of ABCG2).  
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Figure 5.8 The expression of ABC transporters in monolayers and neurospheres of 
EPN-2, MED-2 and SPNET-1 cell lines by Western blotting analysis. ABCB1, ABCC1 and 
ABCG2 expression was detected in membranous fractions of all 3 cell lines in both monolayers 
(M) and neurospheres (NS). HEK cells stably transfected with ABCB1 (B1), ABCC1 (C1) or 
ABCG2 (G2) were used as a positive control for each blot. In each case 40 µg of membrane 
fractions was loaded alongside a much reduced amount of HEK control cells [2 µg B1, 5 µg C1 
and G2, and 10 µg of empty vector (-)].  Neurospheres showed higher intensity bands 
representing ABCB1 and ABCC1 expression compared to monolayers. Only the G2 control 
showed the expected 72 kDa band. A larger ~200 kDa protein was detected in both 
monolayers and neurospheres. This was deemed to be non-specific. A huge band at more than 
250 kDa in HEK-G2 was occasionally present in some blots resulting from protein aggregation. 
The ß-tubulin loading control is shown at the bottom of each blot.      
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5.2.4 Functional analysis of ABC transporters by FACS  
Both co-staining immunofluorescence and Western blotting results were consistent in that all 3 
cell lines; EPN-2, MED-2 and SPNET-1 contained a cancer stem cell-like population and 
expressed ABCB1 and ABCC1 in both monolayers and neurospheres. To prove cells are 
expressing functional ABC transporters, drug export analysis using FACS were performed. 
Initially, export assays for ABCB1 and ABCC1 was performed but parallel studies (described in 
Chapter 6) indicated that ABCB1 is the major functional efflux mechanism and thus only ABCB1 
data is presented here. Rhodamine 123 (Rh123), a fluorescence lipophillic cationic dye, was 
used as a fluorescent ABCB1 substrate and the extrusion of this by ABCB1 was inhibited using 
Verapamil (calcium channel blocker). Verapamil is believed to inhibit ABCB1 function by 
competitively binding to ABCB1 transporter or via an allosteric effect [Qian, X. D. and Beck, W. 
T. (1990)].   
 
ABCB1 functional analysis was performed on monolayers of EPN-2, MED-2 and SPNET-1 cell 
lines at early passage. HEK cells stably transfected with vector expressing ABCB1 (HEK-B1) and 
empty vector (HEK-V) were used as positive and negative controls, respectively. Cells 
harvested from monolayers were incubated with Rh123 to determine the proportion of cells 
able to extrude the dye. Cells expressing ABCB1 were able to extrude Rh123 and hence 
showed a low level of Rh123 accumulation by FACS (Figure 5.9, HEK-B1, Rh123), whereas non-
ABCB1 expressing cells accumulated Rh123 and showed a high level of Rh123 by FACS (Figure 
5.9, HEK-V, Rh123). If cells expressing ABCB1 are incubated with both Rh123 and Verapamil, 
export of Rh123 is inhibited and cells accumulate Rh123.  FACS analysis therefore detected a 
high level of Rh123 in these cells (Figure 5.9, HEK-B1, Rh123+VP). As expected, Verapamil 
does not affect the level of Rh123 in non-ABCB1 expressing cells (Figure 5.9, HEK-V, 
Rh123+VP). Similar data showed that EPN-2, MED-2 and SPNET-1 cell lines contained a 
population of cells which were able to extrude Rh123 and that this extrusion was inhibited after 
incubation in Verapamil resulting in Rh123 accumulation. The results demonstrated that the 3 
cell lines comprised a different proportion of functional ABCB1 cells; 34±5.2% in EPN-2, 
26.5±3.9% in MED-2 and 13.9±3.2% in SPNET-1 as shown in Figure 5.10 and 5.11.  
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Figure 5.9 ABCB1 functional analysis by FACS in control cells. ABCB1 function was 
analysed in HEK cells stably transfected with ABCB1 (HEK-B1, positive control) and empty 
vector (HEK-V, negative control). HEK-V cells clearly gave a negative result whereby all cells 
accumulated Rhodamine 123 (Rh123) and Verapamil (VP) had no effect on these cells. The 
majority of HEK-B1 cells (88%) had a low level of Rh accumulation after cells were incubated in 
Rh123 and this extrusion of Rh123 was inhibited by Verapamil resulting in cells accumulating 
Rh123 and shifting to the right panel. This figure shows date representative of 3 independent 
experiments. All experiment included 5,000 ± 10,000 events. Cells in the left panel indicate 
efflux function of ABCB1. For the positive control cells, the gate was set based on the results 
from HEK-V cells. 
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Figure 5.10 ABCB1 functional analysis by FACS in monolayers from EPN-2, MED-2 and 
SPNET-1 cell lines. Cells harvested from monolayers from the 3 cell lines were incubated in 
Rh123 with or without Verapamil. FACS results showed that all 3 cell lines contained cells 
extruding Rh123; 32.4% in EPN-2, 29.6% in MED-2 and 20% in SPNET-1 (left panel). All 
Rh123 extruding cells were inhibited by Verapamil as shown in the right panel. ABCB1 
functional analysis hence showed that all 3 cell lines contained functional ABCB1 cells which 
were completely blocked by Verapamil. This figure shows date representative of 3 independent 
experiments. For all cell lines, the gate was set based on the results from sample incubated in 
the secondary antibody only corresponding to each cell line.  
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Figure 5.11 Proportion of EPN-2, MED-2 and SPNET-1 cells showing functional ABCB1. 
The graph shows the percentage of cells extruding Rhodamine 123 (Rh123) detected by FACS 
from EPN-2, MED-2 and SPNET-1 cell lines. Data represents the (SEM) mean of 3 independent 
experiments. EPN-2 cell line contained the highest number of endogenous functional ABCB1 
cells whilst the lowest number was observed in SPNET-1 cell line.   
 
 
 192 
5.3 Discussion 
 
A low level of co-expression of CD133 and ABCB1 or ABCC1 suggests intrinsic drug 
resistance in parental paediatric brain tumour cell lines.  
 
Immunofluorescence results (CD133 co-stained with ABCB1, ABCC1 or ABCG2) 
demonstrated that monolayers from the parental EPN-2, MED-2 and SPNET-1 cell lines 
contained a small proportion of cells co-expressing a low level of CD133 and ABCB1 or 
ABCC1 (~10% by estimation) (Figure 5.1 and 5.2), whilst a larger proportion of cells co-
expressing a higher level of CD133 and ABCB1 or ABCC1 (~20-30% by estimation) (Figure 
5.1 and 5.2) was detected in neurospheres. Cells co-expressing CD133 and ABCG2 were not 
detected in any parental cell lines when grown both monolayers and neurospheres (Figure 
5.3). Calatozzolo and colleagues studied the expression of ABCB1 and ABCC1 in adult 
human glioma and found that glioma tissues derived from patients and primary cultures of 
gliomas as monolayers contained a high proportion of cells expressing ABCC1 whilst ABCB1 
was detected at a low proportion. They suggested that ABCC1 probably was a significant 
drug resistant transporter in glioma tumours [Calatozzolo, C. et al (2005)]. Based on our 
data at this stage, neither the proportion of cells expressing ABCB1 or ABCC1, nor the level 
of ABCB1 or ABCC1 expression is obviously different in our cell lines. Our data suggested 
that the parental cell lines contained a small proportion of cells expressing endogenous 
ABCB1 and ABCC1 at a similar low level. The difference in the level of ABC transporter 
expression after drug treatment is the focus of Chapter 6. A higher level of ABCB1, ABCC1 
and CD133 expression in neurospheres was confirmed by Western blotting analysis (Figure 
5.8, a and b and Figure 4.7, a) and a lack of ABCG2 expression was also confirmed as shown 
in Figure 5.8, c. For detection of ABCB1, different ABCB1 antibodies were used with respect 
to 4E3 antibody used in immunofluorescence and C219 antibody used in Western blotting 
analysis and the results from these 2 techniques were consistent. Similarly, MRPr1 and 
MRPr6 antibodies were available in our laboratory for ABCC1 detection. MRPr1 was used in 
immunofluorescence analysis whereas either MRPr1 or MRPm6 was used in Western blotting 
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analysis and these 2 antibodies showed similar results. The agreement of Western blotting 
and immunofluorescence analysis affords confidence in the conclusion that a low level of co-
expression is observed in monolayers and is enriched under conditions promoting 
neurosphere formation consistent with enrichment of a drug resistant cell population in 
neurospheres.  
 
In agreement with this, neurospheres from EPN-1, MED-1, BT-4 and Olig-1 cell lines 
contained a higher proportion of cancer stem-like cells (cells co-expressing CD133 and 
SOX2) than that of monolayers (Figure 4.6), and these neurospheres have greater etoposide 
resistance (Figure 5.12). Similarly, a higher proportion of cells co-expressing CD133 and 
ABCB1 or ABCC1 was detected in neurospheres when compared to monolayers. Hemmati 
and colleagues also studied neural stem-like cells in paediatric brain tumours including 
medulloblastomas and gliomas. They revealed similar results, which demonstrated that the 
large proportion of neurospheres derived from 4 different medulloblastoma tumours  
 
Figure 5.12 Drug resistance potential of EPN-1, MED-1, Olig-1 and BT4 to 
etoposide. The potential of drug resistance tested by clonogenic assay revealed that 
neurospheres from all cell lines were significantly more resistant to etoposide than 
monolayers with the exception of Olig-1 (EPN-1 p<0.001, BT-4 p<0.001 and MED-1 
p<0.001) (performed by Dr. Deema Hussein).   
EPN-1 MED-1 
BT-4 Olig-1 
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expressed the stem cell marker nestin (>45%; detected by immunocytochemistry), whilst 
differentiating conditions demonstrated a lower proportion of nestin positive cells (<20%) 
[Hemmati, H. D. et al (2003)]. Although they used a different stem cell marker (nestin 
rather than CD133 and SOX2) and a different technique (immunocytochemistry versus 
immunofluorescence) to detect stem-like cells in paediatric brain tumours, their results and 
our results demonstrated similar findings i.e. neurosphere growth conditions promote a 
higher proportion of cancer stem-like cells. Our ABC transporter expression here supports 
the presence of intrinsic drug resistance in EPN-2, MED-2 and SPNET-1. 
 
Quantification of the percentage of cells expressing CD133 and ABC transporters was 
attempted by FACS; however, a huge variation in the percentage of cells co-expressing 
CD133 and ABC transporters was detected in each independent experiment in particular for 
neurosphere samples (Figure 5.7). Therefore, the percentage of cells co-expressing CD133 
and ABC transporters detected by flow cytometry could not be reliably established. Since the 
principle of FACS is to detect the immunofluorescence signals from a single cells passing 
through the machine, both monolayers and neurospheres were required to be dissociated 
into single cells prior to processing FACS analysis. The difficulty in cell dissociation possibly 
results from the following factors. Since the proteins of interest are located on the 
membrane, cells need gentle dissociation to avoid destroying the antigens. In particular to 
CD133, this may be more critical as anti-CD133 antibodies can detect cytoplasmic CD133 
rather than membranous CD133, if the plasma membrane is broken down resulting from too 
harsh dissociation. As a result, our results showed a high proportion of cells expressing 
CD133 (Figure 5.4 ± 5.6), which is an overestimate compared to data from 
immunofluorescence (Figure 5.1 ± 5.3) and Western blotting analysis (Figure 4.7, a). 
However, if cells were too gently singularised to preserve membranous protein, clumped 
cells are present and these may not only conceal expression but they may be excluded from 
the FACS counter. Consequently, the number of cells expressing interesting protein will be 
underestimated. Gentle dissociation agent had been used to singularise cells e.g. 
Ethylenediaminetetraacetic acid (EDTA). Monolayers were easily dissociated into a single cell 
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using 10 mM EDTA in DPBS whilst neurospheres proved more difficult to singularise even 
after incubation in 10 mM EDTA in DPBS on a rotator for up to 30 minutes. EDTA is a strong 
chelator for calcium and other divalent cations such as magnesium resulting in digestion of 
the extracellular matrix or weakening of cell-dish adhesion. Using EDTA to detach cells from 
flasks is a gentle method and membranous antigens are preserved. However, a 
disadvantage of using EDTA is its slow action [Hara, M. et al (2001) and Corver, W. E. et al 
(1995)]. To improve the quality of dissociation in neurosphere samples, gentle enzymatic 
dissociation agents had been tried. Alfazyme and Accutase were both assessed to their 
ability to singularise cells for FACS analysis by Dr. Deema Hussein. However, these 2 gentle 
enzymatic dissociation agents failed to prepare a good quality of single cells. For the future 
study, an effective cell dissociation should be properly optimised to obtain a higher yield of 
viable single cells and a lesser destruction of membranous antigens.          
 
Parental cell lines contained endogenous functional ABCB1 
 
Since we hypothesised that cancer stem cells expressing ABC transporters play an important 
role in drug resistance of paediatric brain tumours, functional analysis by flow cytometry was 
performed. Based on the co-staining immunofluorescence data, it was only expected that 
around 15% of our cells would extrude Rhodamine 123 (Rh123). Since, parallel analysis of 
drug selected sublines/clones indicated that ABCB1 function was paramount (Chapter 7), 
only the function of this transporter was assessed. ABCB1 functional analysis demonstrated 
that parental cancer stem-like cells express functional endogenous ABCB1. The highest 
proportion was observed in EPN-2 (34±5.2) whilst SPNET-1 parental cells demonstrated the 
lowest proportion (13.9±3.2), and MED-2 parental cells contained 26.5±3.9 of cells 
extruding Rh123. The proportion of cancer stem-like cells and level of endogenous functional 
ABCB1 did not appear to correlate with tumour grade, type of tumour nor whether they were 
primary or recurrent. The grade II, primary EPN-2 cell line contained the highest proportion 
of endogenous functional ABCB1 whilst grade IV MED-2 and SPNET-1 cell lines contained a 
 196 
lower proportion. This could however only be properly assessed on a larger sample size to 
make a strong conclusion. 
 
An additional question is how appropriate the choice of substrate is?, van der Sandt and 
colleagues compared the specificity between doxorubicin and Rh123 in cell lines derived 
from a pig kidney and Caco-2 cell line derived from a human colon carcinoma. They found 
that Rh123 was able to be transported by both ABCB1 and the organic cation carrier system 
whilst doxorubicin was transported only by ABCB1. Therefore, the results from studying 
ABCB1 function in cell lines containing the organic cation carrier system using Rh123 as an 
ABCB1 substrate should be interpreted carefully. They suggested that doxorubicin seems to 
be more specific and appropriated to be a substrate for ABCB1 transporters in ABCB1 
functional analysis [van der Sandt, I. C. J. et al (2000)]. However, we do not know whether 
our paediatric cell lines contain the organic cation carrier system or not. In addition to this 
our initial analyses indicate that our cell lines are highly resistant to doxorubicin (Dr. Deema 
Hussein, personal communication). Currently, a third generation of ABCB1 inhibitors has 
been discovered and these inhibitors are more specific and have less toxicity. Additionally, 
they do not alter the level of other cytotoxic drugs, which are used as combined treatment. 
The third generation of ABCB1 inhibitors includes tariquidar and elacridar (GF120918). A 
third generation of ABCB1 inhibitors is also recommended to be used in future ABCB1 
functional analysis for more specificity.  
  
At this point, it has been known that the parental cell lines contained a small proportion of 
cancer stem-like cells expressing functional ABCB1 and neurosphere conditions enriched for 
CSCs expressing functional ABCB1. Active drug efflux transporters had been known to 
correlate with multidrug resistance in particular to ABC transporter family. Therefore, to 
prove that the endogenous functional ABCB1 expressed in the parental cell lines plays a role 
in drug resistance indicating intrinsic drug resistance, drug resistance analyses were 
performed and the results are shown in Chapter 6.  
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Chapter 6: Drug treatment selected resistant sublines expressing 
ABC transporters 
 
6.1 Introduction 
 
Although chemotherapy is a main standard treatment for brain tumours, a failure of 
treatment frequently occurs in patients resulting in tumour relapse and poor prognosis. Drug 
resistance frequently manifests as a resistance to many drugs, regardless of chemical 
structures, which is called multidrug resistance (MDR). Many mechanisms can lead to MDR, 
however, one important mechanism is active drug efflux pumps on the membranes of cancer 
cells. The ABC transporter family is currently postulated to be an important factor involved 
in the mechanism of drug resistance in cancer stem cells. Multidrug resistance is still a big 
obstacle and an unresolved problem for chemotherapy in many cancers. Currently, there are 
49 ABC transporter proteins identified in human [Reviewed in Dean, M. et al (2001)]. Only 3 
ABC transporters are overexpressed in both drug resistant cultured cell lines and drug 
resistant tumours in patients. ABCB1, ABCC1 and ABCG2 transporter are the main ABC 
transporters associated with MDR. P-gp (MDR1 or ABCB1) was first discovered in 1976 in 
Chinese hamster ovary cell lines selected for colchicine resistance. These cells were not only 
resistant to colchicine but they also had less permeability to other compounds [Juliano, R. L. 
and Ling, V. (1976)]. Later, a human small-cell lung cancer cell line (H69) that had been 
selected for doxorubicin resistance (but which did not express ABCB1) showed cross-
resistance to many anticancer agents including anthracyclines, vinca alkaloids and 
epipodophyllotoxins; leading to the identification of MRP1 (ABCC1) [Cole, S. P. C. et al 
(1992)]. More recently, the human breast cancer cell line (MCF-7) was selected for 
doxorubicin resistance in the presence of verapamil to inhibit ABCB1 function. However, this 
cell line was still resistant to doxorubicin without ABCB1 and ABCC1 expression [Chen, Y. N. 
et al (1990)]. Later, a drug resistant transporter in this cell line was identified by several 
groups independently as BCRP/ABCG2/MXR/ABCP [Doyle, L. A. et al (1998), Miyake, K. et al 
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(1999) and Allikmets, R. et al (1998)]. To study drug resistance in paediatric brain tumour 
cell lines, a clonogenic assay was performed to select sublines showing resistance to 
etoposide, cisplatin, irinotecan and methotrexate for ongoing drug resistance analysis. These 
4 drugs have different targets and mechanisms of actions. The main target of etoposide is 
nuclear topoisomerase II enzyme, which is homodimer, consisting of 2 forms; 
WRSRLVRPHUDVH ,,Į N'DDQG WRSRLVRPHUDVH ,,ǃ N'D7KHHIIHFWRIHWRSRVLGH 
involves in topoisomerase II since it is highly increased during DNA replication detected in 
particular to S and G2 phases of cell clycle [Joel, S. (1996)]. Cisplatin exert toxic effects 
through interacting with gDNA, although much of the drug binds to non-DNA target: the 
tripeptide glutathione (GSH) and other thiol-containing biomolecules such as 
metalothioneins (MT) [Reviewed in Cepeda, V. et al (2007)]. Irinotecan forms a covalent 
DNA-topoisomerase I complex by binding to this complex, which is a reversible reaction 
resulting in stabilisation of the DNA-topoisomerase I complex, preventing the processing of 
replication forks leading to double stranded DNA breaks and causing cell death [Hsiang, Y. 
H. et al (1989)]. Methotrexate is a potent inhibitor for DHFR, which results in inhibition of 
DNA synthesis [White and Goldman, (1976)]. All 4 drugs similarly target proliferating or 
cycling cells. Etoposide, irinotecan and methotrexate were known to be substrates for 
ABCB1, ABCC1 and ABCG2 transporters and these 3 drugs can be transported by these 
transporters. Whilst there was evidence supporting the fact that cisplatin was specifically 
transported by ABCC2 [Reviewed in Szakács, G. et al (2006)]. After drug treatment, the 
selected resistant sublines were investigated to determine whether ABC transporters were 
the major mechanisms of drug resistance. The expression of ABCB1, ABCC1 and ABCG2 and 
CD133 was assayed in the selected resistant sublines at different time points to determine 
whether alteration of expression occurred during prolonged drug treatment. The expression 
of these transporters was assayed by the immunofluorescence and Western blotting 
analysis. Additionally, the selected resistant sublines were induced in stem cell media to 
form neurospheres, to confirm retention of a key stem cell property.  
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Clonogenic assay plan 
 
 
 
Plate 100 cells/well 
-Fix and crystal violet 
staining after 8 days 
incubation 
-Colony counting for 
drug inhibitory graph to 
derive IC 
- repeat x3 
 Treat cell with etoposide, cisplatin, 
irinotecan and methotrexate 
 Incubate for 8 days 
 repeat once 
For double staining IF 
- B1/C1 or G2 with CD133 co-staining 
- Repeat once 
- compare co-staining between clones 
in each well 
B1            C1           G2 
Treated cells 
Control cells 
Eto.   Cisp.  Irino.  MTX 
- plate control and 30-40% surviving cells 
and initially treat with selected concentration 
-Eto. and Cisp.: tx. for 2 
hrs. and change media 
- Irino.: tx. for 96 hrs. and 
change media 
- MTX.: continuous tx. 
Incubate for 
8 days 
- Fix with 0.4% PFA 
- Co-staining IF: B1, C1 and G2 with CD133 
B1            C1           G2 
- Plate totally: 3 chamber slides x 3 cell 
lines = 9 chamber slides 
- compare co-staining between clones within 
each well 
Result 
- From the result of co-staining IF, the 
decision will be made to select an interesting 
sublines for on going drug resistant analysis 
- IF results showed that the control sublines 
(DMSO, 0.9% NaCl and NaOH in 0.9% NaCl) 
have similar co-staining results; therefore, 
the representative control sublines will be 
selected to carry on for negative controls. 
- Select 3 colonies from the control 
wells and 30-40% surviving wells and 
plate in 6-well plate as monolayer in 
tumour media 
- Plate totally: 3 cell lines x 4 drugs x 6 
(3 controls+3selected well) = 72 
sublines (36 sublines of controls and 
36 sublines of selected 30-40% 
survival) 
- Treat cells exactly the same way as 
start to select resistant sublines 
- when cells reach sub-confluency, 
passage cells to T25 flasks as 
monolayers with tumour media  
- Treat cells exactly the same way as 
start 
- when cells reach sub-confluency, 
passage cells to T75 flasks with tumour 
media 
- Treat cells exactly the same way as 
start 
= 72 sublines in T25 flasks 
= 72 x T75 flasks 
Freeze cells 
and store at -
80°C for stock 
(the remainder) 
Passage for 
experiment 
(selected sublines) 
FACS analysis 
- Functional analysis 
- Co-staining expression 
**At this stage, 
sublines were 
selected based on 
IF results ** 
EPN-2, MED-2 and SPNET-1 cell 
lines 
(70-80% confluency) 
Plate 40 cells/well 
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6.2 Results 
 
6.2.1 Condition optimised by clonogenic assay 
To study the contribution of ABCB1, ABCC1 and ABCG2 to drug resistance of cancer stem 
cells, 4 chemotherapeutic drugs commonly used to treat brain tumours and known to be 
substrates of ABC transporters; etoposide, cisplatin, irinotecan and methotrexate were 
applied to the 3 primary cultured cell lines; EPN-2, MED-2 and SPNET-1. All processes for 
clonogenic assay and immunofluorescence analysis for selection of on going resistant 
sublines are demonstrated in the schematic plan (page 202). A range of drug concentrations 
was selected, based on current literature, for the clonogenic assay [Cisplatin [Sorenson, C. 
M. and Eastman, A. (1988)], methotrexate [Barry, M. A. et al (1990)], etoposide 
[Ermakova, S. P. et al (2006)] and irinotecan [Pollack, I. F. et al (1999)]. The aim was to 
derive a concentration curve and indentify the inhibitory dose 0, 30%, 50%, 70% and 90%. 
Once the optimal range had been identified for each drug on each cell line, the experiment 
was repeated 3 times under these conditions. 
 
The percentage of surviving cells was plotted against log concentration of drug using 
GraphPad Prism software to determine IC30, IC50 and IC70 of each drug. Dose response 
curves for each cell line were obtained by fitting the data points to the linear quadratic 
equation and all graphs of etoposide, cisplatin, irinotecan and methotrexate are shown in 
Figure 6.1. All IC values are also summarised in Table 6.1.  From this assay, the 
concentration which achieved 30-40% surviving cells was selected to treat cells for 
downstream analysis. IC30, IC50 and IC70 values derived from drug inhibitory response graph 
are shown in Table 6.1. However, the concentrations, selected to treat cells for ongoing 
analysis, were those of the 30-40% survival well from the clonogenic assay shown in 
brackets in Table 6.1.  
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Figure 6.1 Drug inhibitory graphs of etoposide, cisplatin, irinotecan and 
methotrexate treatment in the EPN-2, MED-2 and SPNET-1 cell line. To find the IC30, 
IC50 and IC70 values of these drugs in the EPN-2, MED-2 and SPNET-1 cell line, they were 
treated with an appropriate range of concentrations of etoposide, cisplatin, irinotecan and 
methotrexate and percentages of surviving cells were plotted against log[drug 
concentration]. All 3 IC values are described in table 6.1. Error bars represent the SEM of 3 
independent experiments.  
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Table 6.1 Summary of IC30, IC50 and IC70 of etoposide, cisplatin, irinotecan and 
methotrexate treated in EPN-2, MED-2 and SPNET-1 cell lines 
Drug 
treatment 
IC 
IC value 
EPN-2  MED-2  SPNET-1 
Etoposide IC30 4.7 µM 2.6 µM 2.2 µM 
IC50 8.6 µM 4.95 µM 3.5 µM 
IC70 15.8 µM (20 µM) 8.8 µM (6 µM) 5.7 µM (6 µM) 
Cisplatin IC30 0.75 µM 0.39 µM 1.3 µM 
IC50 1.39 µM 0.73 µM 2.58 µM 
IC70 2.43 µM (3 µM) 1.3 µM (1.5 µM) 5.0 µM (4 µM) 
Irinotecan IC30 3.6 µM 1.7 µM 2.4 µM 
IC50 5.36 µM 2.56 µM 3.46 µM 
IC70 7.6 µM (8 µM) 3.8 µM (3 µM) 4.9 µM (6 µM) 
Methotrexate IC30 7.3 nM 8.2 nM 9.3 nM 
IC50 9.78 nM 10.35 nM 11.34 nM 
IC70 12.9 nM (15 nM) 12.6 nM (15 nM) 14.0 nM (15 nM) 
 
6.2.2 Neurosphere formation assay after drug treatment 
Surviving colonies were initially examined for their ability to form neurospheres as this is 
one of the characteristics of cancer stem cells. Six selected colonies from the clonogenic 
assay were dissociated into single cells in stem cell media. Neurosphere formation was 
observed under the microscope and counted. Both colonies from the vehicle treated and the 
drug treated well were able to form neurospheres following etoposide, cisplatin and 
irinotecan treatment (Figure 6.2 and 6.3). Methotrexate treated surviving colonies, however, 
formed smaller neurospheres (containing 10-20 cells) when compared to the other 
conditions. The average number of neurospheres formed was determined from the 6 
dissociated colonies. Since each colony selected to form neurospheres contained different 
cell numbers ranging from 50-200 cells, it is difficult to carry out statistical analysis on the 
data. However, an attempt was made to select equal size colonies from each condition. Drug 
treated cells generally formed smaller colonies than the control especially methotrexate 
treated cells which formed very small colonies containing less than 50 cells even after 
incubating for 8 days. The average number of neurospheres formed from each condition is 
shown in Figure 6.4. Control treated cells of SPNET-1 cell line formed the highest number of 
neurospheres while methotrexate treated cells formed the lowest number of neurospheres. 
Both control and treated conditions could form neurospheres apart from methotrexate 
treated cells which probably required a longer time to form proper neurospheres.  
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Figure 6.2 Neurosphere formation derived from the vehicle control colonies, 
etoposide and cisplatin treated colonies from EPN-2, MED-2 and SPNET-1 cell lines. 
This figure shows neurospheres, which were formed from microscopically selected single 
colonies, dissociated into single cells and grown in stem cell media for 3-4 days. Colonies 
derived from all conditions, both the vehicle control and treated conditions, were able to 
form neurospheres. (Scale bar = 50 µm) 
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Figure 6.3 Neurosphere formation derived from the vehicle control colonies, 
irinotecan and methotrexate treated colonies from EPN-2, MED-2 and SPNET-1 cell 
lines. Both the vehicle control colonies and irinotecan treated colonies could readily form 
neurospheres after 3-4 days incubation which contained more than 50 cells/neurosphere. 
Whilst methotrexate treated colonies formed tiny neurospheres containing less than 50 cells. 
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Figure 6.4 Neurosphere formation of the vehicle control colonies and 4 drug 
treatments in EPN-2, MED-2 and SPNET-1 cell lines. The average number of 
neurospheres formed from each condition is demonstrated in the graph. All conditions were 
able to readily form neurospheres with the exception of methotrexate treated colonies which 
formed the lowest numbers of neurospheres. The average numbers of neurospheres could 
not be directly compared between the vehicle control and the treated conditions because 
each selected clone contained a different number of cells when they were dissociated in 
stem cell media. However, neurosphere formation ability was affected in irinotecan treated 
SPNET-1 colonies and methotrexate colonies of all cell lines since a number of neurosphere 
formation of these colonies was less than the control colonies.  
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6.2.3 Immunofluorescence analysis in the parental cell lines after the first 
round of drug treatment 
Previous results confirmed that the parental EPN-2, MED-2 and SPNET-1 cell lines contained 
a cancer stem cell-like population expressing functional ABCB1 transporter. To investigate 
whether these parental cell lines can be enriched for cells expressing ABC transporters after 
drug treatment, the clonogenic assay was performed in chamber slides and the parental 
cells seeded as single cells were treated with each of the drugs (etoposide, cisplatin, 
irinotecan and methotrexate) at the concentration determined to give 30-40% survival. 
CD133 and ABC transporter co-staining immunofluorescence was then performed to 
determine co-expression of CD133 and ABC transporters after the first round of drug 
treatment. Immunofluorescence results from selected sublines after the first round of 
treatment are shown in Figure 6.5 - 6.7 and non-selected subline results are shown in the 
appendix section (Figure A1.1 ±A1.3).   
 
Co-staining immunofluorescence in the parental cells of EPN-2, MED-2 and SPNET-1 cell 
lines showed a low level of CD133 and ABCB1 or ABCC1 co-expression and a low proportion 
of co-expressing cells whilst none of our cell lines was positive for CD133 and ABCG2 co-
expression (Chapter 5, Figure 5.1, 5.2 and 5.3). After the first round of drug treatment, co-
expression of CD133 and ABCB1 was detected in all drug surviving sublines from all cell lines 
treated with etoposide, cisplatin, irinotecan or methotrexate. Whereby a high level of co-
expression was observed in surviving cells treated with etoposide or irinotecan in EPN-2 cell 
line, irinotecan or methotrexate in MED-2 cell line and etoposide or methotrexate in SPNET-1 
cell line. Conversely, EPN-2 treated with cisplatin or methotrexate, MED-2 treated with 
cisplatin or etoposide and SPNET-1 treated with cisplatin or irinotecan co-expressed a low 
level of CD133 and ABCB1. A high level of CD133 and ABCC1 co-expression was only 
detected in SPNET-1 treated with irinotecan whilst EPN-2 treated with each of 4 drugs co-
expressed at a low level. On the contrary, co-expression of CD133 and ABCC1 was not found 
in any sublines of MED-2 cell line.   
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Figure 6.5 Co-staining immunofluorescence analysis in the parental cells of EPN-2 
after the first round of etoposide or irinotecan treatment. After the first round of 
etoposide or irinotecan treatment, the co-staining immunofluorescence results showed a 
large proportion of cells co-expressing CD133 and ABCB1 at a high level [a and b] whilst a 
low proportion of cells co-expressing CD133 and ABCC1 or ABCG2 were detected at a low 
level [c ± f]. The parental cells of EPN-2 were seeded as single cells (40 cells) in chamber 
slides then cells were treated with etoposide or irinotecan. Single cells were incubated for 8 
days to form colonies. For merged images, a co-staining cell has been enlarged (x2-3) for 
clarity. 
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Figure 6.6 Co-staining immunofluorescence analysis in the parental cells of MED-2 
after the first round of cisplatin or irinotecan treatment. After the first round of 
cisplatin or irinotecan treatment was applied to MED-2 parental cells, a large proportion of 
cells co-expressing CD133 and ABCB1 at a high level was observed in MED-2 treated with 
irinotecan [b] while a smaller proportion of cells co-expressing CD133 and ABCB1 was 
detected in MED-2 after cisplatin treatment [a]. Surviving MED-2 colonies after neither 
cisplatin nor irinotecan treatment were positive for CD133 and ABCC1 or ABCG2 co-
expression [d ± f]. For each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure 6.7 Co-staining immunofluorescence analysis in the parental cells of SPNET-
1 after the first round of cisplatin or irinotecan treatment. After cells were treated 
with the first round of cisplatin or irinotecan, cells co-expressing CD133 and ABCB1 were 
detected after either cisplatin or irinotecan treatment [a and b]. Surviving irinotecan SPNET-
1 colonies displayed co-expression of CD133 and ABCC1 at a high level [d] whilst surviving 
cisplatin SPNET-1 colonies demonstrated cells single expressing either CD133 or ABCC1 [c]. 
No surviving colonies of SPNET-1 were positive for CD133 and ABCG2 co-expression after 
cisplatin and irinotecan treatment [e and f]. For each treatment a co-staining cell has been 
enlarged (x2) for clarity. 
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Drug treatment of selected resistant sublines 
 
Control sublines 
Treated sublines 
      C1     C2     C3 
    T1    T2     T3 
Control 20-30% 40-50% 
60-70%  80-90% 100% 
Control sublines 
Resistant sublines 
    T1               T2              T3 
   C1               C2              C3 
Select 3 colonies from the 
control well and 30-40% 
surviving well 
Passages all sublines to T25 
flasks with tumour media 
Control sublines=3 cell lines x 4 
drugs x 3 colonies = 36 sublines 
Treated sublines=3 cell lines x 4 
drugs x 3 colonies = 36 sublines 
Total = 72 
sublines 
-Selected 2 drug treatments  
from each cell line based on IF 
results 
- control sublines 
EPN-2_E_T1 
EPN-2_I_T1 
EPN-2_I_T2 
EPN-2_I_T3 MED-2_I_T1 
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SPNET-1_I_T1 
SPNET-1_I_T2 
SPNET-1_I_T3 
SPNET-1_C_T1 
SPNET-1_C_T2 
SPNET-1_C_T3 
Total = 19 sublines 
The remainder were 
frozen in liquid nitrogen 
EPN-2_C 
MED-2_C 
SPNET-1_C 
3 cell lines: EPN-2, MED-2 
and SPNET-1 
4 drugs: etoposide, cisplatin, 
irinotecan and methotrexate 
E= etoposide 
I= irinotecan 
C= cisplatin or control 
IF= immunofluorescence 
B1            C1           G2 
Co-staining IF 
analysis in the 
parental cells 
after the first 
round of 
treatment (initial 
treatment) 
Control sublines 
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6.2.4 Drug treatment selected resistant sublines for downstream drug 
resistance analysis 
The schematic work plan as shown in previous page demonstrates that there are 72 sublines 
in total after colony selection from clonogenic assay. It was unmanageable to carry on 
analysis on all 72 sublines in parallel with regard to time limitation. Therefore, to slim down 
the number of sublines for on going drug resistance analysis, co-staining 
immunofluorescence analysis was performed to determine any alteration of CD133 and ABC 
transporters co-expression after the first round of drug treatment in the parental EPN-2, 
MED-2 and SPNET-1 cell lines. We were interested in studying drug resistant cells containing 
a high proportion of cells co-expressing CD133 and ABC transporters at a high level. 
Therefore, any drugs, which selected sublines enriched with cells co-expressing CD133 and 
any ABC transporters after the first round of treatment, were carried on to select drug 
resistant sublines for downstream drug resistance analysis. Since there was no CD133 and 
ABCG2 co-expression detected in any surviving colonies, sublines enriched with a high level 
of CD133 and ABCB1 and/or CD133 and ABCC1 co-expression were selected for downstream 
of drug resistance analysis. Hence, there were totally 16 sublines selected with respect to 
EPN-2_E_T1, EPN-2_I_T1-T3, MED-2_C_T1-T3, MED-2_I_T1-T3, SPNET-1_C_T1-T3 and 
SPNET-1_I_T1-T3 as shown in the schematic work plan. Since the immunofluorescence 
results of the control sublines treated with different vehicle controls were similar, a 
representative control subline was selected for each cell line with regard to EPN-2_C, MED-
2_C and SPNET-1_C.  
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6.2.5 Cellular morphologies of the selected sublines after multiple rounds of 
drug treatment 
EPN-2, MED-2 and SPNET-1 selected sublines were then serially passaged as monolayers in 
tumour media and treated with the designated drugs. Sublines were treated at every 
passage and the duration of the treatment depended on the drugs: 2 hours for etoposide 
and cisplatin and 96 hours for irinotecan.  
 
Since the cellular morphologies of the control sublines and the selected sublines from all cell 
lines showed similar features, only representative sublines are demonstrated in Figure 6.8 
and the other selected sublines can be found in the appendix (Figure A2.1 and A2.2). All 
control sublines were a homogeneous population, which contained cells of a similar size and 
regular shape, whilst all selected sublines comprised 2 different populations; one was 
homogeneous population, which was similar to the vehicle control sublines and another was 
large multinucleated cells with an irregular shape. Additionally, selected sublines grew 
slower than the control sublines. For etoposide treatment of the EPN-2 cell line, EPN-2_E_T2 
and T3 were effectively damaged and struggling to survive after treatment. Only EPN-
2_E_T1 was able to survive and be serially passaged although it grew slowly taking 3x 
longer to double the number of cells than the parental EPN-2 cells (Figure A2.1).       
 217 
 
Figure 6.8 The cellular morphology of a control subline and selected MED-2 sublines 
after multiple rounds of drug treatment. All selected MED-2 sublines survived and were 
serially passaged after cisplatin or irinotecan treatments. The control sublines comprised a 
homogeneous population similar to the control sublines from EPN-2 and SPNET-1 cell line. 
Whilst the major cell population in each selected MED-2 sublines consistent with both EPN-2 
and SPNET-1 cell lines was similar to the control subline and the remainder were large 
irregular cells as indicated by white arrows. 
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6.2.6 Co-staining immunofluorescence analysis in the selected sublines 
after multiple rounds of drug treatment (< 10 and > 10 passages) 
Previous results showed co-expression of CD133 and ABC transporters in the parental cell 
lines and the parental cell lines after the first round of drug treatment. After the first round 
of treatment, ABCB1 was obviously expressed at a high level in most surviving sublines and 
a large proportion of cells co-expressing CD133 and ABCB1 was observed. Low levels of 
CD133 and ABCC1 or ABCG2 co-expression and a small proportion of CD133 and ABCC1 or 
ABCG2 co-expressing cells were observed in some surviving sublines. Based on the 
immunofluorescence results after the first round of drug treatment, some surviving sublines 
were selected to study for on going drug resistance. To determine any alteration of CD133 
and ABC transporters co-expression after continual drug treatment at every passage, co-
staining immunofluorescence was performed on selected sublines at < 10 and > 10 
passages of drug treatment. All immunofluorescence results are shown in Figure A3.1 ± A3.9 
and A4.1 ± A4.9 of the appendix. The data are also summarised in tabular form (Table 6.2) 
and the subsection below references representative images.  The average score from 3 
selected sublines was presented ranging from (-) to (++++).The proportion of cells co-
expressing CD133 and ABC transporters was scored using a sliding scale such that the 
highest score is (++++), which indicated selected sublines containing more than 80% of 
cells co-expressing CD133 and ABC transporters whereas no co-expressing cells were scored 
as (±) as described below the table. Sublines indicated with black blocks were not selected 
for further analysis. 
 
After multiple rounds of drug treatment, all selected sublines were consistently enriched with 
a large proportion of cells co-expressing CD133 and ABCB1 at a high level throughout drug 
treatment. On the contrary, most selected sublines were negative for CD133 and ABCC1 co-
expression after the first round and < 10 passages of drug treatment then a large proportion 
of cells co-expressing CD133 and ABCC1 at a high level was detected in most selected 
sublines after > 10 passages of treatment. There were some selected sublines, which 
inconsistently co-expressed CD133 and ABCC1 during drug treatment including irinotecan  
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Table 6.2 Summary of CD133 and ABC transporters co-expression by 
immunofluorescence. 
 
Cell line Treatment 
Treatment 
ABCB1 ABCC1 ABCG2 
1st <10 >10 1st <10 >10 1st <10 >10 
EPN-2 Cisplatin +   -   -   
Etoposide ++++ ++++ ++++ - - ++++ + + ++ 
Figure 6.5 A3.1 A4.1 6.5 A3.2 A4.2 6.5 A3.3 A4.3 
Irinotecan ++++ ++++ +++ + - ++++ + + +++ 
Figure 6.5 A3.1 A4.1 6.5 A3.2 A4.2 6.5 A3.3 A4.3 
Methotrexate ++   +   -   
MED-2 Cisplatin ++++ +++ +++ - + - - - + 
Figure 6.6 A3.4 A4.4 6.6 A3.5 A4.5 6.6 A3.6 A4.6 
Etoposide ++   -   -   
Irinotecan ++++ ++++ +++ - - ++ - ++ +++ 
Figure 6.6 A3.4 A4.4 6.6 A3.5 A4.5 6.6 A3.6 A4.6 
Methotrexate +++   -   -   
SPNET-1 Cisplatin ++++ +++ +++ - - - - + +++ 
Figure 6.7 A3.7 A4.7 6.7 A3.8 A4.8 6.7 A3.9 A4.9 
Etoposide +++   -   -   
Irinotecan +++ ++++ +++ ++ - +++ - +++ ++++ 
Figure 6.7 A3.7 A4.7 6.7 A3.8 A4.8 6.7 A3.9 A4.9 
Methotrexate ++   -   -   
 
 
-    no CD133 and ABC transporters co-expression 
            +   very low co-expression (less than 10%) 
          ++   moderate co-expression (10-50%) 
                 +++   high co-expression (50-80%) 
      ++++  very high co-expression (more than 80%) 
                                    clones not selected for further analysis 
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EPN-2, cisplatin MED-2 and irinotecan SPNET-1 sublines. Noticeably, cisplatin SPNET-1 
sublines were negative for CD133 and ABCC1 co-expression throughout drug treatment. Co-
expression of CD133 and ABCG2 was detected in few selected sublines after the first round 
of drug treatment then a proportion of cells co-expressing CD133 and ABCG2 was gradually 
increased after multiple rounds of drug treatment. 
 
From Table 6.2, the overall results of the immunofluorescence with regard to alteration of 
the proportion of co-expressing cells after repeated treatment can be seen. ABCB1 was the 
only one transporter, which was consistently present in a high proportion of co-expressing 
cells throughout drug treatment whilst ABCC1 was inconsistently expressed in some selected 
sublines and ABCG2 was present later after multiple rounds of drug treatment. Due to the 
fact that co-staining immunofluorescence was performed once at each passage, to decide 
which transporter should be the focus of further drug resistance analysis, Western blotting 
results were simultaneously evaluated to select the most interesting transporter for 
downstream analysis, as demonstrated in the next section.       
  
6.2.7 The expression of ABC transporters examined by Western blotting 
analysis 
To validate the results from immunofluorescence assay, Western blotting analysis was 
performed to obtain a further qualitative measure of ABC transporter expression. Western 
blotting analysis was carried out after the immunofluorescence and the functional analysis 
by FACS, therefore, selected sublines treated with drug for more than 10 rounds were used 
to detect ABC transporters expression. The expression of ABC transporters was detected in 
microsomal membrane fraction extracted from snap frozen cell pellets of all 16 selected 
sublines including 3 control sublines. HEK-B1, HEK-C1 and HEK-G2 cells were used as 
positive controls and HEK-V was used as negative control (see section 5.2.1). 
Representative blots are shown in Figure 6.9.  
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In the EPN-2 cell line, a strong band representing ABCB1 was detected in HEK-B1 and all 
selected sublines at ~140 kDa [Figure 6.9, a, (i)]. Although, the positive ABCB1 bands 
detected by Western blotting in HEK-B cells and selected clones demonstrated 2 different 
sizes: 140 and 130 kDa [Figure 6.9, a-c, (i)], these 2 different sizes of ABCB1 were different 
forms of ABCB1. Due to the fact that C219 antibody can detect both glycosylated and 
nonglycosylated forms of ABCB1 [Arceci, R. J. et al (1993)]; fully glycosylated form was 
detected at 140 kDa (upper bands) and nonglycosylated form was detected at 130 kDa 
(lower bands). Noticeably, most of selected clones demonstrated doublets of glycosylated 
and nonglycosylated forms of ABCB1, whilst ABCB1 detected in the vehicle control clones 
was a single bands (nonglycosylated form, 130 kDa). The highest intensity of ABCB1 
expression was detected in EPN-2_I_T1. The level of ABCB1 expression detected in all 
selected EPN-2 sublines was higher than those of the control sublines, which displayed a low 
intensity band [Figure 6.9, a, (i)]. ABCC1 protein was also detected at ~140 kDa in both 
HEK-C1 control cells and in the all sublines. The ABCC1 blot shows that ABCC1 expression 
was detected in all selected sublines and also in the control subline [Figure 6.9, a, (ii)]. 
However, the intensity of ABCC1 expression detected in treated clones was visibly higher 
than that of the control subline. The highest intensity of ABCC1 expression was observed in 
EPN-2_E_T1. For ABCG2 expression, ABCG2 protein was detected at ~72 kDa in HEK-G2 
cells whereas only a non-specific 200 kDa band was detected in our sublines [Figure 6.9, a, 
(iii)].  
 
In selected MED-2 sublines, results from 3 independent experiments showed that the level 
of ABCB1 expression observed in the selected sublines was higher than that of the control 
sublines with the exception of the MED-2_C_T1 expressing at a very low level [Figure 6.9, b, 
(i)]. The highest level of ABCB1 expression was observed in the MED-2_C_T2. A number of 
different sized bands representing different degrees of ABCB1 glycosylation were detected in 
the HEK-B1 control and also in the selected sublines. The ABCC1 blot shows that all sublines 
expressed ABCC1 [Figure 6.9, b, (ii)], with the selected sublines expressing a higher level of 
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ABCC1 than the control subline. For ABCG2, non-specific bands at ~200 kDa were detected 
in all clones [Figure 6.9, b, (iii)].  
 
The Western blotting results showed that most selected SPNET-1 sublines expressed ABCB1 
and level of ABCB1 expression was higher than the control subline with the exception of the 
SPNET-1_C_T2, which did not express ABCB1 [Figure 6.9, c, (i)]. While the highest level of 
ABCB1 expression was observed in the SPNET-1_C_T1. ABCC1 expression was detected in 
all selected sublines and in each case was higher than that of the control subline [Figure 6.9, 
c, (ii)]. The SPNET-1_I_T1 and T2 expressed the highest level of ABCC1 expression. For 
ABCG2, non-specific bands were detected at ~200 kDa in all selected sublines, the control 
subline and even in HEK-V cells. Only HEK-G2 was positive [Figure 6.9, c, (iii)].  
 
The enrichment of ABCB1 in all selected sublines after multiple rounds of drug treatment 
was entirely confirmed by both Western blotting and immunofluorescence analysis. A high 
level of ABCC1 expression in all selected sublines was mostly consistent with the 
immunofluorescence results demonstrating ABCC1 enrichment after prolonged drug 
treatment in most selected sublines. On the contrary, ABCG2 expression detected by 
Western blotting analysis was inconsistent with the immunofluorescence results. Whereby, 
Western blotting results showed no ABCG2 expression in any selected sublines whilst 
immunofluorescence results demonstrated an enrichment of ABCG2 after multiple rounds of 
drug treatment.  
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Figure 6.9 ABCB1, ABCC1 and ABCG2 expression determined by Western blotting 
analysis in selected sublines. HEK-B1 (B1), HEK-C1 (C1) and HEK-G2 (G2) were used as 
positive controls for the expression of ABCB1, ABCC1 and ABCG2, respectively and HEK-
empty vector (V) was used as a negative control. Most selected EPN-2, MED-2 sublines 
expressed a higher ABCB1 than the control sublines [a and b, (i)] whilst only some selected 
SPNET-1 sublines demonstrated a higher ABCB1 [c, (i)]. A higher ABCC1 expression was 
detected in all selected sublines compared to the corresponding control sublines [a, b and c, 
(ii)]. Conversely, no ABCG2 expression was detected in any selected sublines [a, b and c, 
(iii)]. Microsomal membrane fractions were loaded 40 µg/lane with the exception of the 
positive controls loaded 5 µg/lane and the negative control loaded 10 µg/lane. 1:100 C219 
or MRPm6 and 1:500 BXP-21 antibodies (overnight incubation at 4°C) were used as primary 
antibody to detected ABCB1, ABCC1 and ABCG2, respectively. 1:2,000 corresponding 
secondary antibodies were incubated with samples for 1 hour at room temperature. 
Expected bands were indicated within the red boxes.  
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6.3 Discussion 
 
Co-staining immunofluorescence was the main assay used to determine which sublines were 
selected for on going drug resistance analysis and the decision was made based on an 
enrichment of CD133 and ABCB1 or ABCC1 in sublines after the first round of drug 
treatment since none of our sublines expressed ABCG2. The process of subline selection was 
described in page 216 and subline nomenclature is also explained. From the clonogenic 
assay, IC50 of etoposide, cisplatin, irinotecan and methotrexate was determined and it was in 
a similar range (nM - µM). Drug treatment selected surviving cells having cancer stem cell 
characteristic i.e. an ability to form neurospheres. Methotrexate affected the ability of 
surviving cells from all selected sublines to form neurospheres. Both immunofluorescence 
and Western blotting analysis confirmed that ABCB1 was consistently expressed at a high 
level in cancer stem-like cells of the selected sublines and it persisted at a high level 
throughout drug treatment, whilst ABCC1 was upregulated after multiple rounds of drug 
treatment. On the contrary, no CD133 and ABCG2 co-expressing cells were detected in any 
selected sublines. Additionally, cellular morphologies of all selected sublines after multiple 
rounds of drug treatment were heterogeneous.  
 
Paediatric brain tumours can be treated.  
 
The clonogenic assay or colony formation assay is extensively used to determine cell 
survival in vitro after drug treatment or radiation. The principle of the clonogenic assay is 
based on the ability of single cells in forming colonies containing at least 50 cells [Franken, 
N. A. P. et al (2006)]. The clonogenic assay was suitable for colony selection rather than the 
microtetrazoline (MTT) assay because surviving colonies after treatment can be achieved 
from clonogenic assay and these colonies can be selected to culture for further drug 
selection. In contrast MTT assay does not provide colonies because this technique 
determines cell survival by measuring the reduction of tetrazolium salts to a formazan end-
product and it requires a short incubation. Consequently, single cells do not have enough 
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time to form colonies and some drugs require a long period of time for treatment e.g. 96 
hours for irinotecan or continuous treatment for methotrexate [Berridge, M. V. et al (1996)]. 
Hence, the clonogenic assay was performed for colony selection in our study and cells were 
treated with chemotherapeutic drugs to select drug resistant sublines. Chemotherapeutic 
agents used to select drug resistant sublines in our study were etoposide, cisplatin, 
irinotecan and methotrexate, which are common chemotherapeutic drugs used in treatment 
of paediatric brain tumours [Grossman, S. A. et al (2003), Packer, R. J. et al (1999) and 
Grundy, R. G. et al (2007)] and they had been clinically used to treat brain tumours of the 
type from which our cell lines derived. Additionally, all these 4 chemotherapeutic drugs were 
known to be substrates of ABCB1, ABCC1 and ABCG2 transporters [Guo, A. et al (2002), 
Reviewed in Borst, P. et al (2000) and Reviewed in Szakács, G. et al (2006)]. Our selected 
sublines were selected by multiple rounds of treatment with each of these 4 drugs.   
 
The clonogenic assay results demonstrated that survival rates decreased when drug 
concentration was increased (Figure 6.1). Therefore, this indicated that there were some 
cancer cells susceptible to drug treatment and this might suggest that paediatric brain 
tumour can be treated. Colonies formed after drug treatment indicated that surviving single 
cells had proliferation capability. To evaluate a degree of drug resistance in our cell lines, 
IC50 values derived from drug treatment in our cell lines were compared to IC50 values from 
other studies. IC50 values of etoposide and methotrexate in lung cancer cell line (INER-51) 
grown as monolayers were 2.2 µM and 800 nM, respectively [Valeria, P. L. and Raúl, B. R. 
(2005)]. IC50 values of etoposide and methotrexate in our cell lines ranged from 3±9 µM and 
9-11 nM, respectively. Comparing IC50 values with this study, our cell lines were far more 
sensitive to methotrexate than INER-51 cell line whilst our cell lines and INER-51 had similar 
sensitivity to etoposide. IC50 values of irinotecan in 2 human glioma cell lines were 3.4 µM 
and 7.2 µM, respectively and these finding were consistent with the results from our cell 
lines (5.36 µM) [Gomez-Manzano, C. et al (2006)]. IC50 of cisplatin in endometrial 
adenocarcinoma cell lines 0.7 µM in prostate cancer cell lines 6.7 µM ± 16.7 µM, the findings 
in our cell lines (1.39 µM) were in between the ranges of these 2 studies [Rantanen, V. et al 
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(1994) and Cummings, M. et al (2006)]. Different cell lines from different laboratories found 
different ranges of IC50 values of drugs. These might depend on the characteristics of cancer 
cell lines with regard to the aggressiveness, grading or treatment history and analysis 
methods used to determine IC50. There seems to be no correlation between grade or type of 
tumours and the IC50 in our cell lines. Using the IC70 values drug resistant sublines were 
selected for downstream drug resistance analysis. Therefore, we have tried to imitate the 
situation, which occurs in patient when they are treated with chemotherapeutic drugs, in 
selecting a concentration that is effective enough to decrease the number of cancer cells but 
without accompanying toxic effects. The concentration, which gave 30-40% of survival, was 
hence designated to select resistant cells for ongoing drug resistance analysis.     
 
The results from clonogenic assay demonstrated that the number of surviving colonies was 
decreased with increasing concentration of drugs. This suggested that paediatric brain 
tumours can be treated by chemotherapy whereby sensitive cancer cells are killed by 
cytotoxic drugs, however, resistant cells can still survive after treatment and form colonies. 
Since our cell lines had intrinsic drug resistance from endogenous ABCB1 and ABCC1 
expression, any alteration of ABC transporters expression was determined after the first 
round and after multiple rounds of drug treatment. This topic is discussed later.  
 
ABCB1 was consistently expressed and persisted throughout drug treatment. 
 
The immunofluorescence results in Chapter 5 indicated that the parental cell lines (EPN-2, 
MED-2 and SPNET-1) contained a low proportion of cells co-expressing CD133 and ABCB1 or 
ABCC1 whereby a proportion of co-expressing cells was observed higher in neurospheres 
than monolayers. Cells co-expressing CD133 and ABCG2 were not observed in any parental 
lines. To study further drug resistance analysis, these cells were treated with drug to select 
drug resistant sublines. To determine any alteration of levels of CD133 and ABC transporters 
co-expression and proportions of co-expressing cells, co-staining immunofluorescence 
analysis was performed on the parental cell lines after the first round of treatment and the 
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selected sublines after multiple rounds of treatment with respect to < 10 rounds and > 10 
rounds (Appendix A3.1 ± A3.9 and A4.1 ± A4.9). Additionally, the immunofluorescence data 
were also validated by Western blotting analysis performed on the selected sublines after 
>10 rounds of treatment (Figure 6.9). Interestingly, only the ABCB1 transporter was 
primarily detected in all cell lines at a high level of expression but low proportion after the 
first round of treatment whilst ABCC1 or ABCG2 transporters were observed in some treated 
sublines at a very low proportion (Figure 6.5 ± 6.7 for selected sublines and Appendix 
section A1.1 ± A1.3 for non-selected conditions). After multiple rounds of drug treatment, 
ABCB1 was consistently expressed at a high level and persisted throughout drug treatment 
whilst the proportion of cells co-expressing CD133 and ABCC1 and the level of co-expression 
were increased after many rounds of treatment. In contrast, there was no ABCG2 expression 
detected in any selected sublines, which was confirmed by Western blotting analysis. These 
results might suggest that ABCB1 transporter expression was the major drug resistance 
mechanism in our cell lines. Taking all results together, these indicated that drug treatment 
selected for cancer stem-like cells expressing ABCB1 and/or ABCC1 and ABCC1 expression 
was also upregulated later in these sublines after many rounds of drug selection. However, 
we could not conclude whether resistant sublines contained cells co-expressing ABCB1 and 
ABCC1 after many round of treatment because ABCB1 and ABCC1 co-staining 
immunofluorescence was not performed in the resistant sublines. To select drug resistant 
sublines, cells were treated with a single cytotoxic drug. However, resistant cells expressed 
at least 2 ABC transporters, as previously observed [Reviewed in Szakács, G et al (2006)]. 
Although, there was no evidence to support a specific upregulation of ABCB1 in etoposide, 
cisplatin, irinotecan and methotrexate treatment, ABCB1 was the main transporter selected 
after multiple rounds of drug treatment in our cell lines and ABCC1 transporter was only 
upregulated after many rounds of treatment. A similar increase had been reported in breast 
carcinoma where ABCB1 expressing cells increased with increasing passages of drug 
treatment (doxorubicin and toxol) and correlated with poor clinical of drug resistance. 
[Mechetner, E. et al (1998)]. It might be concluded that ABCB1 transporter has an 
important role in drug resistance in our cell lines because of the consistently high expression 
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of ABCB1 seen throughout drug treatment. To prove that ABCB1 is an essential mechanism, 
which plays a role in drug resistance, in our cell lines, ABCB1 functional analysis now needs 
to be performed to examine whether ABCB1 expressed in our cell lines is functional. This 
analysis of ABCB1 is described and discussed in Chapter 7. For future study, to make a 
strong conclusion from the immunofluorescence analysis, the analysis should be repeated at 
least 3 times. Although the immunofluorescence analysis had no repetition (although it was 
carried out at different passages), Western blotting analysis was independently repeated at 
least 3 times to validate the results from the immunofluorescence analysis. 
 
Drug treatment selected cancer stem-like cells.  
 
The Neurosphere formation assay was performed to determine the ability of surviving cells 
after drug treatment to form neurospheres indicating stem cell-like behaviour [Bez, A. et al 
(2003)]. The number of neurospheres formed, which is shown in Figure 6.4, demonstrated 
that not only the selected sublines can form neurosphere, but the control sublines can also 
form neurospheres. Therefore, not only drug treatment can select resistant cancer stem cells 
but the clonogenic assay itself can also select stem cells. Due to the fact that clonogenic 
assay is based on an ability of single cells to form colonies, these single cells must have an 
ability to proliferate and produce at least 50 progenitor cells/colony [Franken, N. A. P. et al 
(2006) and Snyder, E. Y. et al (1992)]. Our data supported the fact that surviving colonies 
selected from the clonogenic assay have stem cell characteristics since all colonies selected 
from the clonogenic assay were able to form neurospheres. Additionally, co-staining 
immunofluorescence results also demonstrated that a proportion of CSCs co-expressing 
CD133 and ABCB1 was increased after multiple rounds of drug treatment. This also 
supported the fact that drug treatment selected CSCs.  
 
The neurosphere formation results also interestingly demonstrated that colonies surviving 
from methotrexate treatment could not form distinct neurospheres (Figure 6.3) whilst cells, 
which were treated with etoposide, cisplatin, irinotecan and also the vehicle control, were 
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able to form neurospheres (Figure 6.2 and 6.3). The size of neurospheres formed from 
methotrexate treated clones was smaller and there were many single cells in methotrexate 
treatment wells, which could not form neurospheres, floating in stem cell media (data not 
shown). This was potentially a selection effect of methotrexate on the growth of cancer stem 
cells. The surviving single cells might require a longer time to recover from methotrexate 
cytotoxicity. However, we did not prove this point. Hence, these results suggested that 
methotrexate possibly inhibited cancer stem cell behaviour in formation of neurospheres, 
ZKLOVW WKH RWKHU GUXJV GLG QRW KDYH DQ\ HIIHFW RQ FDQFHU VWHP FHOO¶V DELOLW\ WR IRUP
neurospheres. For future study, methotrexate sublines should be incubated longer in stem 
cell media to prove that these cancer stem cells can recover after drug removal and 
ultimately form neurospheres.  
 
Heterogeneity of tumour cell population after multiple rounds of drug treatment.   
 
Cellular morphologies of selected sublines from EPN-2, MED-2 and SPNET-1 cell lines (Figure 
6.1 and Figure A2.1 and A2.2) demonstrated that the control sublines from all of the cell 
lines showed a homogeneous population (Figure 6.1 and Figure A2.1 and A2.2, control) 
similar to monolayers from the parental cell lines (Chapter 4, Figure 4.1). On the contrary, 
the selected sublines contained a heterogeneous population; the majority of population was 
similar to the homogeneous population seen in the control sublines and a small proportion 
was large cells with an irregular shape and multinucleated (Figure 6.1 and Figure A2.1 and 
A2.2, T1 ± T3). Noticeably, an increasing a proportion of large cells was observed in later 
passage (data not shown). This indicated that drug affected the morphology of cells as it 
selected the resistant population after each round of treatment.  
 
For etoposide EPN-2 sublines, only the T1 subline survived and could be continuously grown 
whilst both T2 and T3 sublines were very sick with only a few huge irregular cells (data not 
shown), remaining alive but unable to proliferate even after 2 weeks. This result indicated 
that not all selected resistant sublines were similar. Each subline was possibly generated 
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from different cancer stem cell. The heterogeneity of cancer stem cells was observed in 
glioblastoma multiforme [Beier, D. et al (2007)] and breast cancers [Wright, M. H. et al 
(2008)]. The phenotype heterogeneity was found in primary glioblastoma multiforme, which 
comprised at least 2 different cancer stem cells with respect to CD133+ and CD133-. These 2 
CSCs had different genetic profiles and biological growth patterns [Beier, D. et al (2007)]. 
Additionally, Brca1-deficeint mouse mammary tumours comprised heterogeneous cancer 
stem cells with respect to CD44+CD24- and CD133+. These 2 different CSCs had no 
overlapping population [Wright, M. H. et al (2008)]. Therefore, these 2 sublines, which could 
not survive after drug treatment, might originate from drug sensitive cancer stem cells in 
which genetic alteration might occur during mitosis whilst drug resistant cancer stem cells 
generate surviving clones [Fukasawa, K. et al (1997)].  
 
Based on the results from immunofluorescence analysis at different time points and Western 
blotting analysis, the population of selected sublines after drug treatment was 
heterogeneous and we have hypothesised that there were at least 3 different populations of 
selected sublines. Firstly, a population, which was negative for both CD133 and ABC 
transporters, can survive after treatment by other drug resistance mechanisms without ABC 
transporters. Secondly, a population expressing CD133 indicating CSCs also used other 
mechanisms to survive from drug cytotoxicity. Thirdly, a population co-expressing CD133 
and ABCB1 indicating CSCs expressing ABCB1 and ABCB1 transporters functionally effluxed 
drug out of cells to survive after drug treatment. Drug resistant CSCs expressing ABCB1 can 
also upregulate ABCC1 when they were repeatedly treated for many rounds of treatment. 
Three different populations of selected clones after treatment are shown in Figure 6.10. 
 
This chapter demonstrated that multiple rounds of drug treatment selected cancer stem cells 
overexpressing ABCB1 and ABCC1 was also gradually upregulated. An overexpression of 
ABCB1 in surviving resistant sublines was confirmed by both co-staining 
immunofluorescence and Western blotting analysis. However, we have not known yet 
determined whether CSCs overexpressing ABCB1 are functional and lead to drug resistance 
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in our cell lines. Therefore, drug efflux function of ABCB1 in CSCs was examined in Chapter 
7 to prove that enrichment of ABCB1 in CSCs after drug treatment contributes to multidrug 
resistance.     
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Figure 6.10 Progression expression of ABC transporters by tumour cells after 
prolonged drug treatment. Originally, our cell lines already contained a low proportion of 
cells expressing ABCB1 (a). After the first treatment, almost half of the tumour cells co-
expressed a high level of CD133 and ABCB1 whilst ABCC1 was co-expressed with CD133 on 
a very few cells (b). Almost half of tumour cells comprised CD133- cells or CD133+ cells 
without ABC expression (b). When tumour cells had been repeatedly treated, the proportion 
of cells co-expressing CD133 and ABCB1 (c) was higher and tumour cells expressed ABCB1 
at a high level throughout drug treatment. Tumour cells also upregulated ABCC1 later in a 
smaller proportion of cells when compared to ABCB1 (d). 
The first round of treatment 
Treatment for < 10 passages Treatment for >10 passages 
The parental cells 
Very low 
proportion 
ABCB1 
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Chapter 7: Functional analysis on selected resistant sublines 
 
6.2 Introduction 
 
A major problem of cancers, including paediatric brain tumours, is the failure of 
chemotherapeutic treatment since cancer cells develop drug resistance to not only a single 
drug but also many drugs regardless to chemical structure or drug target. This phenomenon 
is known as multidrug resistance. There are many mechanisms leading to multidrug 
resistance in cancers however, one of the most important drug resistance mechanisms in 
many cancers is active drug efflux transporters. ABC transporters are the most significant 
active transporter mediating multidrug resistance in human cancers. The first ABC 
transporter discovered to correlate with drug resistance was ABCB1 (P-gp or MDR1). In 
normal tissues, ABCB1 is present in the blood brain barrier (BBB), which protects brain and 
spinal cord from cytotoxic drug [Regina, A. et al (2001)] and also in the luminal epithelium 
of liver, kidney and gastrointestinal tract [Cordon-Cardo, C. et al (1990)]. ABCB1 is a broad 
spectrum drug effluxor/effluxing agent capable of transporting natural agents and 
chemotherapeutic drugs such as vinblastine, paclitaxel, doxorubicin, mithoxantrone, 
etoposide, actinomycin D, methotrexate and topotecan [Reviewed in Schinkel, A. H. and 
Jonker, J. W. (2003)]. In the last few decades, attempts have been made to reverse MDR by 
developing drugs which have more specific inhibition of drug resistant transporters. Other 
methods to inhibit ABCB1 function had been developed, however, none of the current 
methods is able to completely reverse MDR. RNAi technology has offered some promise to 
improve treatment in multidrug resistant cancer cells. RNAi is based on a 21 ± 25 nucleotide 
long double stranded RNA (dsRNA), which is able to trigger a gene silencing mechanism in a 
specific sequence manner. The RNAi technique comprises 2 different methods; transient and 
stable RNAi. Transient RNAi is based on transfection of short interference RNA (siRNA) whilst 
stable RNAi can be achieved by introducing short hairpin RNA (shRNA), encoded by 
expression vectors, into mammalian cells. The RNAi technique has been extensively studied 
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both in vitro and in vivo and it might potentially be applied for cancer treatment. Therefore, 
RNAi had been attempted to reduce ABCB1 mRNA in our cell lines for investigation of ABCB1 
role in drug resistance. 
 
The results from previous chapter suggested that the majority of our cell lines were 
susceptible to in vitro drug treatment; etoposide, cisplatin, irinotecan and methotrexate. 
Neurosphere formation assay performed on selected resistant clones revealed that all 
resistant clones were able to form neurospheres with the exception of methotrexate treated 
clones. Additionally, ABCB1 was possibly the main drug resistance mechanism in our cell 
lines since ABCB1 was consistently expressed at a high level throughout drug treatment 
whilst cells expressing ABCC1 were increased after many rounds of treatment. None of the 
selected clones expressed ABCG2. As a result of a consistent high expression of ABCB1 after 
treatment, ABCB1 transporter was focused on for ongoing study in this chapter. In this 
chapter, ABCB1 transporter function was hence determined by FACS using Rh123 and 
Verapamil as a substrate and inhibitor for ABCB1, respectively. Although there are many 
inhibitors of ABCB1 such as verapamil, the phenothiazines, quinidine, quinacrine, quinine, 
amiodarone, several neuroleptics, tamoxifen, progesterone, cyclosporine A, dexverapamil, 
dexniguldipine, GF-902128, PSC-833 and VX-710, an assessment of the efficacy of ABCB1 
inhibition in vivo indicated that these drugs provided a weak potency in ABCB1 inhibition and 
caused side effect at a high dose [Reviewed in Gottesman, M. M. et al (2002)]. Since there 
is excellent evidence to support that Verapamil was able to successfully inhibit in vitro 
ABCB1 function [Tsuruo, T. et al (1981)], Verapamil was used to inhibit ABCB1 in our study.  
To demonstrate that the ABCB1 transporter was responsible for the observed drug 
resistance, inhibition of ABCB1 expression was also attempted using SiRNA transfection. 
Clonogenic assays were performed to compare the effectiveness of single drug treatment 
and combined drug treatment with Verapamil. Surviving resistant clones from the clonogenic 
assay were selected to determine the ability to form neurospheres. Finally, co-staining 
immunofluorescence was performed to determine the proportion of cells co-expressing 
CD133 and ABCB1 in surviving clones after treatment.  
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6.3 Results 
 
7.2.1 Functional analysis of ABC transporters by FACS 
ABCB1 functional analysis was optimised in the positive and negative controls 
ABCB1 functional analysis by FACS was performed on all selected sublines. Rhodamine 123 
(Rh123) and Verapamil were used as ABCB1 substrate and inhibitor, respectively. HEK-V 
cells stably transfected with empty vector and HEK-B1 cells stably transfected with vector 
expressing ABCB1 were included as negative and positive controls, respectively, for ABCB1 
transporter function, and allow simple illustration of the data. FACS results showed that all 
HEK-V cells accumulated Rh123 and hence showed a high level of Rh123 fluorescence 
[Figure 7.1, a, (ii)]. As expected, when such cells were incubated with both Rh123 and 
Verapamil, the Rh123 accumulation was unaffected [Figure 7.1, a, (iii)]. HEK-B1 cells on the 
other hand were able to efflux Rh123 and therefore the majority of cells failed to accumulate 
Rh123 [Figure 7.1, b, (ii)]. In contrast, when HEK-B1 cells were incubated in both Rh123 
and Verapamil, efflux function was inhibited resulting in all formerly extruding cells 
accumulating Rh123 and shifting to the right panel [Figure 7.1, b, (iii)]. The results for both 
the positive and the negative control therefore showed that ABCB1 functional analysis by 
FACS was fully optimised. 
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Figure 7.1 Optimisation of ABCB1 functional analysis by FACS using HEK-V and 
HEK-B1. HEK-empty vector (HEK-V) cells were used as a negative control (a). When HEK-V 
cells were incubated in Rhodamine 123 (Rh123), these cells could not efflux Rh123 resulting 
in Rh123 accumulation. Most of HEK-V cells hence shifted to the right panel [a, (ii)]. When 
HEK-V cells were incubated in Verapamil (VP), these cells were not affected [a, (iii)]. HEK-
B1 cells highly expressing ABCB1 transporter effluxed Rh123 when they were incubated in 
Rh123 therefore the majority of cells stayed in the left panel [b, (ii)]. When ABCB1 
transporter was inhibited by VP, most of HEK-B1 cells accumulated Rh123 and as a result 
these cells shifted to the right lower quadrant [b, (iii)]. 5,000-10,000 events of each sample 
were included in the functional analysis. Rh123 fluorescence wave length was 515 nm. The 
concentration of Rh123 and Verapamil used was 2 µM and 20 µM, respectively. The numbers 
in the red boxes indicates the proportion of cells extruding Rhodamine 123.    
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Cells 
Rh123 Rh123+VP Cells 
HEK-B1 
Rh123  
(a) 
(b) 
(i)  (ii) (iii) 
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ABCB1 functional analysis was performed on the selected resistant sublines 
ABCB1 functional analysis results showed that the control sublines from all 3 cell lines 
contained a small proportion of extruding cells, and that this extrusion was inhibited by 
Verapamil (Figure 7.2, 7.3 and 7.4, a). The highest proportion of cells expressing functional 
ABCB1 in the control sublines was found in EPN-2 (32.7±13.1%) and the proportions 
observed in MED-2 and SPNET-1 were 6.7±0.8% and 3.9±1.7%, respectively. The 
proportions of functional ABCB1 cells found in the control sublines were consistent with the 
corresponding parental cell lines (Chapter 5, Figure 5.10 and 5.11).    
 
ABCB1 functional analysis by FACS was also performed on selected sublines from EPN-2, 
MED-2 and SPNET-1 cell lines. Representative results of ABCB1 functional analysis in the 
control sublines and selected sublines are shown in Figure 7.2, 7.3 and 7.4. For the EPN-2 
cell line, the percentage of cells expressing functional ABCB1 transporters was increased 
approximately 2 fold in the selected etoposide and irinotecan EPN-2 sublines when compared 
to the parental cell line and the control sublines (Figure 7.2, b and c) from ~35% to >75% 
(Figure 7.2, a ± c and Figure 7.5). Similarly, the average percentage of Rh123 extruding 
cells from both selected MED-2 and SPNET-1 sublines was approximately 2 fold higher than 
the parental cells and the control sublines (Figure 7.3 ± 7.5). In this case there was 
apparently greater variability with the percentage of functional extrusion in selected MED-2 
and SPNET-1 sublines ranging from 19% to >60% and 8% to 35%, respectively, whilst 
constant percentage of these cells was found in the selected EPN-2 sublines ranging from 
75% - 85% (Figure 7.5). Noticeably, the proportion of extruding cells in the selected SPNET-
1 sublines was lower than that of both the selected EPN-2 and MED-2 sublines.   
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Figure 7.2 ABCB1 functional analysis in the control subline and selected etoposide 
and irinotecan EPN-2 sublines. This figure shows representative results from the control 
subline, EPN-2_E_T1 and EPN-2_I_T2 subline. The experiments were independently 
repeated 3 times as described in Figure 7.1. The proportion of extruding cells, which were 
inhibited by Verapamil (VP) in representative selected EPN-2 sublines [b and c, (i) and (ii)] 
was obviously higher than that of the control subline approximately 2 fold [a, (i) and (ii)]. 
The numbers in the red boxes indicates the proportion of cells extruding Rhodamine 123. 
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Figure 7.3 ABCB1 functional analysis in the control subline and selected cisplatin 
and irinotecan MED-2 sublines. A very low proportion of cells extruding Rh123, which 
were inhibited by Verapamil, was detected in the control subline [a, (i) and (ii)] whilst both 
selected cisplatin and irinotecan MED-2 subline comprised a higher proportion of extruding 
cells [b and c, (i) and (ii)] ~2 fold. All cells extruding Rh123, in the left panel, were inhibited 
by Verapamil resulting in they shifted to the right panel after they were incubated in Rh123 
and Verapamil [b and c, (i) and (ii)]. The numbers in the red boxes indicates the proportion 
of cells extruding Rhodamine 123. 
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Figure 7.4 ABCB1 functional analysis in the control subline and selected cisplatin 
and irinotecan SPNET-1 sublines. Representative SPNET-1_C_T1 and SPNET-1_I_T2 
sublines are shown. Similar to the results from selected EPN-2 and MED-2 sublines, a higher 
proportion of cells extruding Rh123, which were inhibited by Verapamil, were detected in all 
selected SPNET-1 sublines [b and c, (i) and (ii)] compared to that of the control subline [a, 
(i) and (ii)]. The numbers in the red boxes indicates the proportion of cells extruding 
Rhodamine 123.       
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Figure 7.5 ABCB1 functional analysis in the selected EPN-2, MED-2 and SPNET-1 
sublines. ABCB1 functional analysis by FACS was individually repeated 3 times. This graph 
shows the mean percentage of cells extruding Rh123, which were inhibited by Verapamil 
(VP). In EPN-2 cell line, the parental cells and the control subline contained a high 
proportion of extruding cells ~35% whilst the proportion almost doubled after drug 
treatment with etoposide or irinotecan (75-85%). The parental cells and the control sublines 
of MED-2 and SPNET-1 cell lines comprised a lower proportion of extruding cells than the 
control subline of EPN-2. However, the proportion of those cells was still increased almost 2 
fold after drug treatment compared to the parental cell lines although not to as great an 
extent as in EPN-2 cell line. The proportion of extruding cells was homogeneous in the 
selected EPN-2 sublines whilst there was a variation detected in the selected MED-2 and 
SPNET-1 sublines. EPN-2_E_T2 and T3 sublines were not included in this analysis because 
these 2 sublines failed to survive after the second round of etoposide treatment.  
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All cell lines contained cells expressing functional ABCB1 transporters and the proportion of 
cells was visibly upregulated after drug treatment. The selected EPN-2 sublines comprised 
the highest percentage of cells expressing functional ABCB1 whilst the lowest percentage 
was observed in the selected SPNET-1 subline. After drug treatment, the percentage of 
functional ABCB1 transporter was increased 2-3 fold in most selected sublines when 
compared to the parental cells or the control sublines. Interestingly, the EPN-2 cell line 
comprised a high endogenous percentage of cells expressing functional ABCB1 in the 
parental cells (34%) and the highest percentage (75-85%) was consistently found in all 
selected EPN-2 sublines whilst the percentage of those cells in the other 2 cell lines was 
largely varible. Therefore, the selected EPN-2_E_T1 and EPN-2_I_T1 sublines were selected 
for further drug resistance analysis. 
 
7.2.2 ABCB1 knockdown using RNAi 
To further substantiate that ABCB1 transporter function is an essential mechanism for our 
selected sublines to survive after multiple rounds of drug treatment, ABCB1 knockdown 
using RNAi was performed to inhibit ABCB1 function. The plan was then to treat with drug 
and determine the efficacy of treatment after ABCB1 inhibition. Three different SiRNAs; 
si_ABCB1, si_ABCB1.1 and si_ABCB1.2, were tested on the EPN-2_E_T1 and EPN-2_I_T1 
sublines using SiPort Amine as the transfection agent. Since the growth characteristics of 
each selected subline are different, transfection conditions were optimised independently for 
each selected subline. To optimise the appropriate condition for ABCB1 transfection in each 
cell line, GAPDH, a housekeeping gene generally found in all cells, was initially used to test 
the varying conditions for transfection (data not shown). The parental EPN-2 cells (EPN-2) 
and the control EPN-2 subline (EPN-2_C), which contained a low proportion of functional 
ABCB1 cells, were initially tested. 24 hours after GAPDH transfection, cells were harvested 
and RNA was extracted. The PCR results showed no expression of GAPDH in some conditions 
[(1) SiRNA of GAPDH = 10 nM, SiPORT = 0.1 %v/v and (2) SiRNA of GAPDH = 1 nM, 
SiPORT = 0.4 %v/v]. These 2 conditions were applied to transfect GAPDH SiRNA (as a 
control) and 3 different ABCB1 SiRNAs in the control subline of EPN-2. GAPDH and ABCB1 
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expression were however present in all conditions after the transfection. It was thought that 
therefore, each SiRNA probably required specific conditions to be transfected into each 
subline. All 3 ABCB1 SiRNAs (si_ABCB1, si_ABCB1.1 and si_ABCB1.2) were then transfected 
into EPN-2 cells and the EPN-2_C subline with vary concentrations of ABCB1 SiRNA (range 1 
± 20 nM) and SiPORT Amine (range 0.1 ± 0.4 %v/v). The concentration of SiRNA and SiPort 
Amine were varied in each well of a 24-well plate and a total of 30 different conditions were 
tested. 24 hours after transfection, cells were harvested and RNA was extracted. RT-PCR 
was performed to examine the level of ABCB1 knockdown. However, the representative 
results showed that ABCB1 expression was still detected in all samples (Figure 7.6). Even if 
the concentration of SiPORT Amine and SiRNA was further increased, ABCB1 transporter still 
could not be knocked down. Since, ABCB1 SiRNA transfection was unsuccessful, the 
clonogenic assay using drug combined with Verapamil was performed instead because 
Verapamil effectively inhibited ABCB1 function in functional analysis by FACS from the 
previous chapter.       
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Figure 7.6 Optimisation of ABCB1 knockdown using si_ABCB1, si_ABCB1.1 and 
si_ABCB1.2 in EPN-2 sublines. The parental EPN-2 cells were transfected with either 
si_ABCB1 or si_ABCB1.2 while the EPN-2_C subline was transfected with si_ABCB1. All 3 
different SiRNAs of ABCB1 transporters were transfected with different concentration of 
SiPORT Amine and SiRNA. A1 was the lowest concentration of both SiPORT Amine and SiRNA 
(0.2 %v/v and 10 nM, respectively) whereas C5 was the highest concentration (0.6%v/v 
and 100 nM, respectively). PCR results showed that the 80 bp bands representing ABCB1 
expression were still detected in all samples even in the highest concentration of SiPORT 
amine and SiRNA [C5 lanes, A, B and C (iii)]. Loading controls detected by GAPDH are 
shown at the bottom of each blot. [M = 100 bp ladder marker and P = control plasmid for 
ABCB1 cDNA].  
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7.2.3 Clonogenic assay: drug treatment combined with Verapamil 
Since ABCB1 knockdown could not be reduced reliably by SiRNA, functional knockdown with 
Verapamil was performed, because it was previously effective to inhibit ABCB1 function in 
functional ABCB1 analysis by FACS (as seen in Figure 7.2 ± 7.4), to determine whether 
reducing ABCB1 function affected the ability of cells to withstand drug in a clonogenic assay. 
This clonogenic assay was performed on the parental cells, the control sublines, EPN-2_E_T1 
and EPN-2_I_T1 sublines. This experiment essentially consisted of 3 assays; the clonogenic 
assay for surviving colony counting, a neurosphere formation assay and co-staining 
immunofluorescence. For the clonogenic assay, the parental cells, the control sublines and 
selected sublines were treated with vehicle (negative control), Verapamil alone ( ǋ0
drug alone (concentration which achieved 30- VXUYLYDO HWRSRVLGH    ǋ0 DQG
LULQRWHFDQ ǋ0DQGGUXJFRPELQHGZLWK9HUDSDPLOǋ07KHVXUYLYLQJFRORQLHVZHUH
counted to determine the efficacy of Verapamil when it was combined with drug treatment. 
The neurosphere formation assay was then performed to determine whether surviving 
resistant colonies have the characteristics of cancer stem cells. Additionally, co-staining 
CD133 and ABCB1 immunofluorescence was performed on resistant surviving colonies to 
investigate whether these surviving cells expressed the ABCB1 transporter and the neural 
stem cell marker (CD133).     
 
   7.2.3.1 Surviving colony counting from clonogenic assay 
The morphology of the colonies formed is shown in Figure 7.7 and 7.8. To determine the 
cytotoxic effect of Verapamil on colony formation, colony numbers and colony size of 
Verapamil treated cells were compared in preliminary experiments with cells treated with the 
YHKLFOH7ZRGLIIHUHQWFRQFHQWUDWLRQVDQGǋ0RIVerapamil were tested based on a 
previous study [Anderle, P. et al (1998)] and our own functional analyses (section 7.2.1). 
7KHUHVXOWVVKRZHGWKDWWKHUHZDVQRGLIIHUHQFHLQVXUYLYDOEHWZHHQǋ09HUDSDPLODQG
the vehicle treatment in any of the cell typHV>)LJXUHDQGLDQGLL@:KLOVWǋ0
Verapamil treatment resulted in cellular toxicity, consequently, colony numbers decreased 
ZKHQ FRPSDUHG WR WKH YHKLFOH WUHDWPHQW GDWD QRW VKRZQ 6LQFH  ǋ0 9HUDSDPLO
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treatment had no effect on cell survival or colony formation, this concentration was selected 
for drug combination analysis. Basically, both EPN-2_E_T1 and EPN-2_I_T1 sublines formed 
smaller colonies in the vehicle and Verapamil treatment when compared to the parental cells 
(EPN-2) and the control subline (EPN-2_C). This difference became more pronounced when 
EPN-2_E_T1 and EPN-2_I_T1 sublines were treated with etoposide or irinotecan, the 
numbers of colonies formed visibly decreased and colony size was smaller when compared 
to those of vehicle and Verapamil treated cells [Figure 7.7 and 7.8, (iii)]. The number of 
colonies formed and colony size were significantly reduced when cells were treated with drug 
combined with Verapamil [Figure 7.7 and 7.8, (iv)]. Representative images are present in 
Figure 7.7 and 7.8 and the size of representative clones is also indicated. For the etoposide 
and irinotecan treatment groups, the range of colony formed size is described in Table 7.1. 
Hence, drug combined with Verapamil effectively reduced the number of surviving colonies 
and in formation of a smaller colony. Figure 7.9 shows the percentage of surviving cells 
treated with single drug compared with surviving cells treated with drug combined with 10 
µM Verapamil. The percentage of surviving colonies after treatment with drug and Verapamil 
was significantly reduced when compared to single drug treatment (unpair student T-test, p 
< 0.01) (Figure 7.9). The survival rate was reduced approximately 4 fold in drug combined 
Verapamil treatment. Therefore, Verapamil enhanced the efficacy of etoposide and 
irinotecan to kill cancer cells.  
 
 
 
 
 
 
 
 
 
 
 248 
 
Table 7.1 The range of colony size for the etoposide and irinotecan treatment 
group 
 
Treatment 
group 
Clone Treatment The range of 
colony size (µM) 
Etoposide 1. EPN-2  Vehicle 760 ± 1,500 
VP 800 ± 1,500 
Eto. 450 ± 1,400 
Eto. + VP 500 ± 1,200 
2. EPN-2_C Vehicle 640 ± 1,600 
VP 650 ± 1,400 
Eto. 300 ± 1,100 
Eto. + VP 240 ± 750 
3. EPN-2_E_T1* Vehicle 840 ± 1,400 
VP 530 ± 1,100 
Eto. 260 ± 970 
Eto. + VP 230 ± 1,300 
Irinotecan 1. EPN-2 Vehicle 540 ± 1,500 
VP 400 ± 1,800 
Eto. 260 ± 1,000 
Irino. + VP 260 ± 600 
2. EPN-2_C Vehicle 420 ± 1,800 
VP 370 ± 1,100 
Eto. 270 ± 700 
Irino. + VP 200 ± 400 
3. EPN-2_E_T1* Vehicle 300 ± 1,000 
VP 300 ± 1,100 
Eto. 270 ± 580 
Irino. + VP 220 - 730 
 
 
VP = Verapamil, Eto. = Etoposide, Irino. Irinotecan 
*the colonies formed were less dense than the other conditions as shown in Figure 7.7 and 
7.8, c. 
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Figure 7.7 Clonogenic assay: Etoposide treatment combined Verapamil reduced colony 
survival and colony size. Colonies formed after the vehicle and Verapamil treatment in both the 
parental cells (EPN-2) and the control subline (EPN-2 C) was not visibly different [A and B, (i) and (ii)] 
VR9HUDSDPLOGLGQRWDIIHFW WKHFHOOV¶DELOLW\ WR IRUPFRORQLHV,Q(31-2, EPN-2_C1 and EPN-2_E_T1 
subline, numbers of colonies formed were decreased and colony size was smaller after etoposide 
treatment [A ± C, (iii)] with particular to after etoposide treatment combined with Verapamil [A ± C, 
(iv)]. EPN-2_E_T1 subline formed a smaller colony in all conditions when compared to the others [C, 
(i) ± (iv)]. Images show the morphologies of colonies formed after different treatments at x1 and x4 
magnification. Colony size is also shown in all representative colonies. (Scale bar = 1,000 µm for x1 
and 250 µm for x4)         
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x1 
x4 
vehicle VP Etoposide Etoposide+VP 
x1 
x4 
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x1 
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A 
B 
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(i) 
(i) 
(i) 
(ii) 
(ii) 
(ii) 
(iii) 
(iii) 
(iii) 
(iv) 
(iv) 
(iv) 
1547.01 µM 1438.60 µM 1072.75 µM 765.03 µM 
1645.90 µM 1324.02 µM  877.20 µM 627.41 µM 
1285.20 µM 1086.10 µM  881.02 µM 731.36 µM 
EPN-2_E_T1 
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Figure 7.8 Clonogenic assay: Irinotecan treatment combined Verapamil reduced 
colony survival and colony size. Similar to previous results, there was no difference 
between the vehicle and Verapamil treatment [A ± C, (i) and (ii)]. When cells were treated 
with irinotecan, colony size was obviously smaller and colony formation numbers declined [A 
± C, (iii)] in particular to when cells were treated with irinotecan combined with Verapami [A 
± C, (iv)]. Additionally, cells appeared to be struggling to survive and form colonies. Similar 
to the EPN-2_E_T1 and the EPN-2_I_T1 sublines consistently formed smaller colonies in all 
conditions when compared to the others [C, (i) ± (iv)]. Colony size is also shown in all 
representative colonies. (Scale bar = 1,000 µm for x1 and 250 µm for x4)         
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Figure 7.9 Verapamil combined drug treatment reduced colony formation in the 
selected EPN-2 sublines. This graph shows the percentage of surviving colonies compared 
between single drug treatment and drug treatment combined with Verapamil. The 
concentration of drug used was that expected to result in survival of 30-40% of colonies (20 
ǋ0HWRSRVLGHDQGǋ0LULQRWHFDQVLQJOHDQGFRPELQHGWUHDWPHQWVZHUHFDUULHGRXWXVLQJ
 ǋ0 9HUDSDPLO 'UXJ WUHDWPHQW FRPELQHG ZLWK 9HUDSDPLO GHPRQVWUDWHG VLJQLILFDQWO\
increased efficacy over the single drug treatment. The percentage of surviving colonies was 
significantly reduced [p < 0.001 (**) and p < 0.05 (*)] when cells were treated with both 
drug and Verapamil. However, a small proportion of colonies still survive after treatment.  
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   7.2.3.2 Neurosphere formation assay 
Five colonies were selected from each condition to perform a neurosphere formation assay 
by growing them in stem cell media for 4 days. Neurosphere formation is illustrated in 
Figure 7.10 and 7.11. The parental cells and the control sublines were able to form nice 
neurospheres after they were treated with vehicle, etoposide, or etoposide with Verapamil 
as shown in Figure 7.10. Whilst single cells and tiny neurospheres comprising 5-10 cells 
were observed in EPN-2_E_T1 subline (Figure 7.10), these would presumably form larger 
neurospheres if they were incubated longer. For irinotecan treatment, effective neurosphere 
formation was observed in EPN-2 and EPN-2_C sublines treated with vehicle and irinotecan 
whilst single cells were observed when they were treated with irinotecan and Verapamil 
(Figure 7.11). In EPN-2_I_T1 subline, they could not form neurospheres after any 
treatments (Figure 7.11). However, a group comprising 5-10 cells was observed and they 
potentially could form neurospheres with longer incubation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 253 
 
 
 
 
Figure 7.10 Neurosphere formation from EPN-2, EPN-2_C and EPN-2_E_T1 sublines 
treated with vehicle, etoposide, or etoposide combined with Verapamil. Five colonies 
from each condition were selected to grow in stem cell media to determine neurosphere 
formation capability. Both EPN-2 and EPN-2_C sublines were able to form neurospheres in 
all conditions whilst the EPN-2_E_T1 subline could not form neurospheres. However, very 
tiny neurospheres, which comprised 5-10 cells, not single cells were visible (boxed region). 
If these cells are incubated longer in stem cell media, they will probably be able to form 
neurospheres. Cells in the small boxed regions have been enlarged (x2) for clarity, which is 
demonstrated by the large boxed region. (Scale bar = 100 µm)   
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Figure 7.11 Neurosphere formation from EPN-2, EPN-2_C and EPN-2_I_T1 sublines 
treated with vehicle, irinotecan, or irinotecan combined with Verapamil. Both EPN-2 
and EPN-2_C subline could form neurospheres when they were treated with vehicle or 
irinotecan whilst they were unable to form neurospheres after irinotecan treatment 
combined with Verapamil. In EPN-2_I_T1 subline, they could only form neurospheres when 
they were treated with vehicle. When they were treated with irinotecan or irinotecan 
combined with Verapamil, they formed very small neurospheres. Cells in the small boxed 
regions have been enlarged (x2) for clarity, which is demonstrated by the large boxed 
region. (Scale bar = 100 µm)    
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   7.2.3.3 Co-staining immunofluorescence in surviving colonies 
after drug treatment combined with Verapamil  
In order to examine marker expression, surviving colonies from clonogenic assay were 
harvested and cytospun onto slides, prior to immunofluorescence assay to determine CD133 
and ABCB1 co-expression. Noticeably, the number of surviving cells after drug treatment or 
drug combined Verapamil treatment was visibly lower than that of vehicle or Verapamil 
alone, again demonstrating the combined effect of drug and Verapamil in cell survival. Co-
staining CD133 and ABCB1 immunofluorescence results are presented in Figure 7.12 ± 7.17 
and show that the majority of surviving cells co-expressed CD133 and ABCB1 at a high level 
after all treatments. However, cells expressing CD133 or ABCB1 alone were detected in the 
control sublines whilst for cells treated with drug alone or drug combined Verapamil cells 
expressing CD133 or ABCB1 alone were rarely detected (Figure 7.12 ± 7.17). The 
immunofluorescence results of the etoposide treatment group are shown in Figure 7.12 ± 
7.14 whereas Figure 7.15 ± 7.17 shows the results from irinotecan treatment group.  
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Figure 7.12 CD133 and ABCB1 expression in the parental EPN-2 cells after vehicle, 
etoposide, or etoposide combined Verapamil treatment. The EPN-2 parental cells were 
treated with vehicle, etoposide, or etoposide combined Verapamil and were harvested then 
cytospun. CD133 and ABCB1 co-expression was detected in all surviving cells. The majority 
of surviving cells co-expressed CD133 and ABCB1 at a high level after any treatment, 
although a small proportion of surviving cells was observed expression of CD133 or ABCB1 
alone. (Scale bar = 25 µm) (green arrows indicates cells expressing CD133 alone, red 
arrows indicates cells expressing ABCB1 alone and white arrows indicates cells not 
expressing CD133 or ABCB1)  
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Figure 7.13 CD133 and ABCB1 expression in the EPN-2 control subline after 
vehicle, etoposide, or etoposide combined Verapamil treatment. A high level of 
CD133 and ABCB1 co-expression was detected in all surviving cells after all treatments. 
However, cells expressing CD133 alone were detected in the vehicle treatment. A higher 
proportion of cells expressing CD133 or ABCB1 was detected in cells treated with the vehicle 
whilst a large proportion of cells observed in etoposide or etoposide combined with 
Verapamil co-expressed CD133 and ABCB1. (Scale bar = 25 µm) (green arrows indicates 
cells expressing CD133 alone, red arrows indicates cells expressing ABCB1 alone and white 
arrows indicates cells no co-expressing CD133 and ABCB1) 
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Figure 7.14 CD133 and ABCB1 expression in the EPN-2_E_T1 subline after vehicle, 
etoposide, or etoposide combined Verapamil treatment. Cells co-expressing a high 
level of CD133 and ABCB1 were observed after all treatments. Even after etoposide 
combined Verapamil treatment, surviving cells still highly co-expressed CD133 and ABCB1. 
Because the increased effect of etoposide, cell number of EPN-2_E_T1 subline after 
treatment was lower than those of the parental cells and the control subline. (Scale bar = 25 
µm) All cells are co-expressing although some faintly after vehicle treatment.  
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Figure 7.15 CD133 and ABCB1 expression in the parental EPN-2 cells after vehicle, 
irinotecan, or irinotecan combined Verapamil treatment. A high level of CD133 and 
ABCB1 co-expression was observed in most of surviving cells after all treatments. All cells 
treated with irinotecan combined Verapamil co-expressed CD133 and ABCB1 whereas some 
of surviving cells after vehicle or irinotecan treatment expressed CD133 or ABCB1 alone. 
(Scale bar = 25 µm) (green arrows indicates cells expressing CD133 alone, red arrows 
indicates cells expressing ABCB1 alone and white arrows indicates cells no co-expressing 
CD133 and ABCB1) 
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Figure 7.16 CD133 and ABCB1 expression in the EPN-2 control subline of after 
vehicle, irinotecan, or irinotecan combined Verapamil treatment. The results were 
similar to etoposide treatment group whereby cells co-expressing CD133 and ABCB1 were 
detected at a high level after all treatments. Some of surviving cells after the vehicle 
treatment expressed CD133 or ABCB1 alone. (Scale bar = 25 µm) (green arrows indicates 
cells expressing CD133 alone, red arrows indicates cells expressing ABCB1 alone and white 
arrows indicates cells no co-expressing CD133 and ABCB1) 
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Figure 7.17 CD133 and ABCB1 expression in the EPN-2_I_T1 subline after vehicle, 
irinotecan, or irinotecan combined Verapamil treatment. A high level of CD133 and 
ABCB1 co-expression was observed in surviving cells after all treatments. However, single 
CD133 expression was observed in vehicle treatment and single ABCB1 expression was 
observed in etoposide alone treatment. (Scale bar = 25 µm) (green arrows indicates cells 
expressing CD133 alone, red arrows indicates cells expressing ABCB1 alone and white 
arrows indicates cells no co-expressing CD133 and ABCB1) 
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7.3 Discussion 
 
Cancer stem cells overexpressing functional ABCB1 were selected after many 
rounds of drug treatment in our cell lines. 
 
In the previous chapter, the expression of ABC transporters and CD133 was assessed after 
drug treatment and the results suggested that ABCB1 was the main transporter that might 
be responsible for drug resistance in our cell lines. Simultaneously, ABCC1 was also 
gradually upregulated during prolonged drug treatment whilst no ABCG2 expression was 
observed in any selected sublines throughout drug treatment. Therefore, ABCB1 was 
focused and further studied for drug resistance. In this chapter, ABCB1 function was 
assessed to prove that ABCB1 expressing cells, which were increased after drug treatment, 
were functionally able to respond to drug treatment.  
 
Flow cytometry was performed to assess ABCB1 function using Rhodamine 123 (Rh123) as a 
substrate and Verapamil as an inhibitor. The results demonstrated that the proportion of 
cells extruding Rh123 in selected sublines was 2-3 fold higher than the parental and the 
control sublines (Figure 7.5). These results correlated with the immunofluorescence results 
from Chapter 6, which showed that cells co-expressing a high level of ABCB1 and CD133 
were observed at a large proportion in all selected sublines after multiple rounds of drug 
treatment whilst the parental cell lines contained a smaller proportion of cells co-expressing 
ABCB1 and CD133 at a low level of expression. Taken together, our parental cell lines 
contained endogenous ABCB1 and ABCC1 at a low level of expression. Therefore, this might 
indicate intrinsic drug resistance in our cell lines. After drug treatment, ABCB1 was the 
major functional drug resistance transporter observed in the selected sublines indicative of 
further acquired drug resistance. This increase in ABCB1 is comparable to previous 
observation made both in other cell lines and in clinical samples. ABC transporters can be 
found in resistant cell lines selected by single drug treatment. For example, cell lines treated 
with Doxorubicin specifically selected for cells overexpressing ABCB1 and ABCC1, yet this 
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cell line also had cross-resistance from ABCC2 and ABCG2 overexpression [Szakács, G. et al 
(2006)]. Increasing ABCB1 after in vitro treatment contributed to failure of 
chemotherapeutic treatment and also correlated with the degree of drug resistance in breast 
cancer cell lines [Mechetner, E. et al (1998)]. Therefore, ABCB1 is an important transporter, 
playing a role in drug resistance in many cancers. In our cell lines, functional ABCB1 
expressing cancer stem cells were selected after many rounds of drug treatment. 
 
Rh123 and Verapamil were used as substrate and inhibitor, respectively, in ABCB1 functional 
analysis. Therefore, the accuracy of this assay depends on the specificity of substrate and 
inhibitor to ABCB1 transporter. If the inhibitor and substrate have less specificity to ABCB1 
transporter, the results might be an under- or overestimate and have less accuracy to 
represent ABCB1 function. However, Rh123 and Verapamil are commonly used to study 
ABCB1 function. Rhodamine 123 is a fluorescent dye and is extensively used as substrate for 
ABCB1 to study ABCB1 efflux function [Lee, J. S. et al (1994), Fontaine, M. et al (1996) and 
Hsing, S. et al (1992)]. However, there is at least one report that ABCC1 transporter is also 
able to efflux Rh123 but less effectively than ABCB1 transporter [Twentyman, P. R. et al 
(1994)]. Therefore, to interpret the result using Rh123 as substrate to examine ABCB1 
function, efflux results might not directly represent ABCB1 function but it possibly results 
from ABCC1 function too. In our cell lines, the major transporter was ABCB1 however, 
ABCC1 was upregulated after more than 10 rounds of treatment. Therefore, Rh123 efflux 
capability in our cell lines might be slightly overestimated from additional efflux function of 
ABCC1 transporter. To avoid the effect from ABCC1 function, we performed all experiments 
on samples at the early passages. Doxorubicin was reported to be a more specific ABCB1 
substrate than Rh123 [van der Sandt, I. C. J. et al (2000)]. Our cell lines were highly 
resistant to Doxorubicin, therefore, Doxorubicin could not be used as substrate in our cell 
lines [Dr. Deema Hussein, personal communication]. One study reported that Rhodamine 
123 was a poor ABCB1 substrate compared to other forms of rhodamine dyes. They revealed 
that tetramethylrosamine had superior quality than other rhodamine dyes as a substrate for 
ABCB1 [Eytan, G. D. et al (1997)]. In 1981, Verapamil was confirmed to able to effectively 
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overcome ABCB1 function in vitro (leukaemic cell line and Vincristine-resistant subline) and 
in vivo (Vincristine-resistant tumour bearing mice) [Tsuruo, T. et al (1981)]. Later, 
Verapamil was generally adapted as an ABCB1 inhibitor to study ABCB1 function [Homolya, 
L. et al (1993), Muller, C. et al (1994), Yu, X. N. et al (2008) and Pauli-Magnus, C. et al 
(2000)]. Additionally, Verapamil combined with chemotherapeutic drugs treatment increased 
survival rate in patients diagnosed with breast cancer or non-small lung cell cancer 
[Belpomme, D. et al (2000) and Millward, M. J. et al (1993)]. Therefore, Verapamil can 
effectively inhibit ABCB1 function, and there is clinical evidence to support the advantage of 
using Verapamil treatment. However, Verapamil is also able to inhibit ABCC1 function but it 
is not a potent ABCC1 inhibitor compared to VX-710 (Biricodar) [Germann, U. A. et al 
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Currently, the third generation of ABCB1 inhibitor had been developed to increased 
specificity to ABCB1 and decrease toxicity e.g. LY335979 (zosuquidar), XR9576 (tariquidar), 
GF120918 (elacridar) and OC144-093 (ontogen). In future studies, the third generation 
might be tested to more specifically inhibit ABCB1 function for drug resistance analysis and 
reduce associated to toxicity. However, to determine ABCB1 function, it is important to 
select a more specific inhibitor for ABCB1 rather than attempting to select specific substrate 
for ABCB1 due to the fact that ABCB1 has broad spectrum substrates and chemotherapeutic 
agents.       
 
From Figure 7.5, the proportion of cells extruding Rh123 in the selected sublines was 
approximately 2-3 fold higher than the corresponding parental cells and control sublines. 
However, the highest proportion of cells extruding Rh123 in the selected sublines and the 
control sublines were observed in EPN-2 cell lines. Noticeably, a homogeneous proportion of 
such cells was observed in the selected EPN-2 sublines. In contrast, a varying proportion 
was observed in both MED-2 and SPNET-1 cell lines. This might be because each tumour 
originates from different cell types resulting in different characteristics of cancer cells in 
maintaining tumour population. Radial glia cells are postulated to be the cells of origin of 
ependymomas [Poppleton, H. and Gilbertson, R. J. (2007)]. Since more than 80% of gene 
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expression observed in ependymoma from supratentorial region were similar to radial glia 
cells from corresponding region and that cancer cells with self-renewal and multipotent 
capacity derived from ependymoma share a similar immunophenotype 
(CD133+/Nestin+/RC2+/BLBP+) with radial glia cells [Taylor, M. D. et al (2005)], it is believed 
that radial glia cells have characteristics very close to stem cells. On the other hand, 
granule-cell progenitors located in the external granular layer (EGL) of the cerebellum are 
currently proposed as the cell of origin of medulloblastoma [Kadin, M. E. et al (1970) and 
Marino, S. et al (2000)].  Therefore, ependymoma originates from cells, which have 
characteristics very close to stem cells in comparison to medulloblastoma, which originates 
from more differentiated progenitor cells. Consequently, a larger proportion of population in 
EPN-2 possibly was cancer stem cells whilst medulloblastoma population might contain a 
large proportion of more differentiating progenitor cells and a small proportion of cancer 
stem cells. For CNS PNET, due the rarity of disease and difficulty in diagnosis because the 
histology is similar to medulloblastoma, the evidence of CNS PNET cell of origin is not 
available. Since cancer stem cells were selected more and more for purity after many rounds 
of drug treatment and they had capacity to maintain themselves and also generate 
progenitors. On the contrary, more differentiating progenitor cells could not survive after 
multiple rounds of drug selection resulting from these cells have a limitation of proliferation 
and self-renewal. Hence, a larger proportion of cancer stem cells expressing functional 
ABCB1 was observed in the selected EPN-2 sublines, which originates from radial glia cells.  
 
In this study, there is no correlation between the proportion of functional ABCB1 cancer 
stem cells and grade or type of tumours or whether they were primary or recurrent. The 
EPN-2 cell line was obtained from a grade II primary ependymoma tumour without 
treatment prior to surgery, and the selected EPN-2 sublines contained the highest number of 
cells extruding Rh123, approximately 80-90%. On the other hand, SPNET-1 cell line is 
derived from grade IV primary CNS PNET tumour and MED-2 cell line is derived from grade 
IV recurrent medulloblastoma. These 2 selected sublines contained a lower number of cells 
extruding Rh123 (~30-60%) than the selected EPN-2 subline. Many significant factors (e.g. 
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the origin of tumour, tumour grading, treatment history and primary or recurrent tumour) 
might have an influence on the characteristics of each cell line and also indicate different 
response to drug treatment in our cell lines. The data of these significant factors are 
summarised in table 7.2. Among these 3 cell lines, although the EPN-2 cell line was derived 
from a low grade tumour (grade II Ependymoma) and had not been treated prior to surgery, 
they contained the highest proportion of cancer stem-like cells expressing functional ABCB1. 
Based on these findings we would predict that the patient from which EPN-2 was derived 
would be likely to relapse however this was the only tumour to be completely resected and 
the patients still alive.  
 
ABCB1 was responsible for drug resistance in our cell lines and Verapamil 
significantly increased drug cytotoxic effect.  
 
The previous results demonstrated that ABCB1 expression increased in the selected sublines 
after multiple rounds of drug treatment was functional. These results suggested that ABCB1 
possibly was responsible for drug resistance in our cell lines. Therefore, to support ABCB1 as 
a significant mechanism protecting cells from drug toxicity, ABCB1 function was inhibited 
and survival rate was observed after drug treatment compared to the control cells. The 
clonogenic assay showed that drug combined with Verapamil treatment significantly 
decreased survival colony numbers (approximately 8-10 fold) compared to drug treatment 
 
Table 7.2 The details of treatment in the original tumours prior to establishment of 
cell lines.  
Cell line The original 
tumour 
WHO 
grade 
Primary or 
Recurrent 
Treatment prior to 
surgery 
Degree of 
surgery 
EPN-2 Ependymoma II Primary  None Macroscopic 
resection 
MED-2 Medulloblastoma IV Recurrent Chemotherapy POG 3021 
regimen (Cisplatin, 
Lomustine, Vincristine) and 
craniospinal radiation 
Partial 
SPNET-1 CNS PNET IV Primary None Partial 
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alone (Figure 7.9). Additionally, the size of colonies treated with drug combined Verapamil 
was far smaller and also the density of colony cells was far less than colonies treated with 
vehicle or Verapamil alone (Figure 7.7 and 7.8). Therefore, these results suggested that 
Verapamil effectively increased cytotoxic effect of drugs and ABCB1 was the main drug 
resistance mechanism to protect cells from drug treatment in the majority of our cell lines. 
Hsiang et al showed that a low concentration (1 µM) irinotecan inhibited mouse 
lymphoblastic leukaemic cells in G2 resulting in a longer cell cycle and hence a slower 
growth rate [Hsiang, Y. H. et al (1989)]. Interestingly, Verapamil was able to completely 
inhibit ABCB1 function in flow cytometry (section 7.2.1) whilst this is not the case for 
clonogenic assay. This might be because of the instability of Verapamil in clonogenic assay. 
For FACS, to determine an efflux function of ABCB1, selected sublines were incubated with 
Rh123 and Verapamil for 2-3 hours. Conversely, after single cells in clonogenic assay were 
incubated with drugs and Verapamil, they were further incubated to allow colony formation 
for at least 7 days. Another possibility is that these surviving cells have other drug 
resistance mechanism rather than ABCB1 drug resistant transporter such as improved DNA 
repair mechanism, increase drug detoxification and metabolism, intracellular change of drug 
target and alteration of cell cycle. As a result they can survive after drug treatment.  
 
Verapamil effectively inhibited ABCB1 function in both FACS and clonogenic assays. 
However, the inhibition seemed less effective in clonogenic assay as discussed above. SiRNA 
of ABCB1 was also attempted to reduce the expression of ABCB1 mRNA in our cell lines 
resulting in silencing ABCB1 function. However, the optimal conditions for ABCB1 SiRNA 
transfection were not achieved. Three different ABCB1 SiRNAs were tested with multiple 
different combinations of SiPORT Amine and SiRNA. There were 2 potential factors 
influencing successfulness of ABCB1 inhibition using SiRNA. Firstly, the selected sublines 
overexpressed an extremely high level of ABCB1 after drug selection compared to the 
parental cell lines or the control sublines. Resistant cell lines selected from drug treatment 
always expressed a very high level of ABC transporters and the level was far higher than the 
level in patients [Yagüe, E. et al (2004)]. This ABCB1 overexpression was far higher than 
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that detected in the parental line (Figure 5.1 ± 5.3). Even if we have tried to use the earliest 
passage of the selected EPN-2 sublines, these sublines still contained a very high proportion 
of cells co-expressing CD133 and ABCB1, as confirmed by immunofluorescence analysis, and 
a high proportion of cells extruding Rhodamine 123 (ABCB1 substrate) detected by flow 
cytometry. The endogenous level of ABCB1 was also high in both the parental cells and the 
control sublines. This may have made it difficult to silence ABCB1 function in the EPN-2 cell 
line. Secondly, SiRNA may have been ineffective due to the short duration of RNAi stability 
from transfected synthetic siRNA as opposed to the long half-life of ABCB1 protein (14-17 
hours) [Muller, C, et al (1995)]. Therefore, SiRNA may not have lasted long enough to result 
in knockout of ABCB1 protein levels. In recent studies, short hairpin RNA (ShRNA) has been 
applied to silence ABCB1 expression because ShRNA is more effective than SiRNA in RNA 
interference [Yu, J. Y. et al (2002)]. Yu et al studied RNA interference using SiRNA and 
ShRNA in mammalian cells and revealed that ShRNA was more effective in inhibition of GFP 
expression than SiRNA. This is because to inhibit a target gene, duplex formation is 
required. ShRNA forms a duplex by folding back itself, which can occur quickly and 
efficiently whilst SiRNA requires another strand of SiRNA to form duplex. Additionally, 
ShRNA can be stably expressed in cells so that it is more effective to target a long half-live 
ABCB1 gene. For long-lived proteins such as ABCB1 it may therefore be important to use 
shRNA since it is faster acting and more stable. It may also be necessary to stable integrate 
the shRNA to achieve knockdown [Yagüe, E. et al (2004)]. In recent studies, shRNA of 
ABCB1 has been attempted to decrease ABCB1 mRNA expression in our cell line with some 
early promise (Dr. Beth Coyle, personal communication). An additional problem was that our 
clones, which have different growth characteristic, required different conditions (the 
proportion of SiPORT Amine and SiRNA) for transfection. Therefore, the optimal condition for 
ABCB1 knockdown in our cell lines should be optimised in every single cell line. To increase 
the effectiveness of SiRNA in silencing of ABCB1 function, using two or more specific SiRNA 
can improve the gene silencing effect compared to a single SiRNA [Ji, J. et al (2003)]. 
Therefore, combined SiRNAs should be attempted to silence ABCB1 expression in the future 
and flow cytometry might be performed to determine the level of ABCB1 expression after 
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knocking down. Flow cytometry might have higher sensitivity than the conventional RT-PCR 
to determine the level of ABCB1 silencing.    
   
Irinotecan affected the ability of cells to form neurospheres after the initial 
treatment.  
 
The neurosphere formation assay showed that capability to form neurospheres of the 
selected EPN-2 sublines was affected after they were treated with multiple rounds of 
etoposide (11 rounds). Whilst, irinotecan combined with Verapamil affected the ability of 
EPN-2, EPN-2_C and EPN-2_I_T1 sublines to form neurospheres, although they were treated 
with the first round of irinotecan. Sublines repeatedly treated with irinotecan obviously could 
not form neurospheres after any treatments.  
 
After the clonogenic assay, resistant colonies were selected from each condition to assess 
the ability of cells to form neurospheres. In Figure 7.10, colonies selected from multiple 
rounds of etoposide treatment (11 rounds) failed to form neurospheres whilst colonies 
selected from the parental cells and the control subline, which had been treated for the first 
round of etoposide, still have ability to form neurospheres. Therefore, this suggested that 
prolonged treatment of etoposide affected the ability of cells to form neurospheres. In 
contrast, the ability of cells to form neurospheres was affected in all colonies selected from 
any conditions of EPN-2 cell lines, even in the cell lines that had been treated with the first 
round of irinotecan (Figure 7.11). Hence, this suggested that the ability of cells to form 
neurospheres was affected even after a single round of irinotecan combined with verapamil 
treatment. Therefore, in our cell lines, prolonged etoposide treatment affected the ability of 
cells to form neurospheres whilst irinotecan inhibited cells to form neurospheres after the 
first round of treatment. In Chapter 6, it was also shown that the first round of methotrexate 
treatment in the parental cell lines affected neurosphere formation ability of cells. Therefore, 
we hypothesised that methotrexate might be able to target cancer stem cells. For irinotecan, 
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it may be that, irinotecan is able to target cancer stem cells even after the first round of 
treatment when it was enhanced to be intracellulary accumulated by Verapamil.  
 
Surviving cells after drug combined Verapamil treatment expressed ABCB1. 
 
After clonogenic assays, surviving cells were examined for CD133 and ABCB1 co-expression. 
This experiment was performed to identify whether surviving cells were positive or negative 
for ABCB1 after ABCB1 function has been inhibited by verapamil and cells were treated with 
cytotoxic drugs. If the majority of surviving cells are negative for ABCB1, this possibly 
suggests that these cells originally have other drug resistance mechanism to survive after 
treatment. However, this is not the case for our cell lines, since the immunofluorescence 
results demonstrated that most of the surviving cells expressed ABCB1 at a high level 
(Figure 7.12 ± 7.17). Therefore, this suggests 2 possibilities. Firstly, surviving ABCB1 cells 
simultaneously developed other drug resistance mechanisms during many rounds of drug 
selection resulting in survival from drug cytotoxicity even though ABCB1 function was 
inhibited. Additional ABC transporters can be upregulated in cells after selection with a single 
drug [Szakács, G. et al (2006)]. Our cell lines possibly upregulate other transporters after 
longer drug exposure; e.g. ABCC1 as found in selected sublines after prolonged drug 
treatment, or maybe ABCG2, and it may be that even if their expression is not detected , 
there is some function of ABCC1 and ABCG2 in these cells. However, the expression of other 
survival mechanisms is also a distinct possibility.  Secondly, the concentration of Verapamil 
may not have been high enough to inhibit ABCB1 function in cells expressing a very high 
level of ABCB1. Consequently, a small proportion of these cells would survive. Since 10 µM 
and 20 µM of Verapamil were tested prior performing clonogenic assay, a concentration 
between 10-20 µM might completely inhibit ABCB1 function in clonogenic assay without 
cytotoxicity. A previous study reported that 2.2 ± 6.6 µM of Verapamil was enough to 
effectively inhibit ABCB1 function in Vincristine-resistant leukaemic cell line [Tsuruo, T. et al 
(1981)]. Hence, our cell lines might have a higher degree of drug resistance resulting in a 
very high level of ABCB1 expression, consequently, Verapamil might be required higher 
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concentration to completely inhibit ABCB1 efflux function in our cell lines. For future study, 
concentrations of Verapamil between 10-20 µM may be tested to inhibit ABCB1 function in 
clonogenic assay. Third generation ABCB1 inhibitors are currently being utilised in the 
laboratory to more selectively inhibit ABCB1. To assess the effectiveness of ABCB1 
inhibition, drug conjugated with immunofluorescence might be used to determine drug 
uptake. There are many interesting points to investigate further for future study to 
understand the behaviour and mechanism of drug resistance in cancer cells. These are 
discussed in the final chapter.  
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Chapter 8: General discussion and conclusion 
 
Hypothesis: Paediatric brain tumour cell lines contain a subpopulation of cancer stem cells 
that use ABC multidrug transporters to efflux chemotherapeutic agents.  
 
This hypothesis was based on the findings that cancer stem cells have been discovered as a 
small proportion of cells in various types of cancers including brain tumours and these cells are 
believed to be chemoresistant based on them sharing characteristics with stem cells. Other 
features in common with normal stem cells are a capacity for self-renewal, proliferation and 
multipotency which together provide a high potential for these cells to re-initiate tumours after 
treatment. ABC transporters, in particular to ABCB1, ABCC1 and ABCG2 have been postulated 
as a major drug resistance mechanism in cancers and these transporters have been 
demonstrated to be expressed by stem cells and CSCs. Therefore, CSCs expressing ABC 
transporters may promote multidrug resistance in cancers. Our cell lines were derived from 5 
different brain tumours including WHO grade II and IV. These selected tumours represent 
tumours that are either highly resistant to chemotherapy or have a high potential to recur. 
Therefore, it is necessary to explore the root of chemoresistance in these tumour types since 
this might lead the way to open a window of hope to cure these malignant diseases in the 
future. 
 
Since all cell lines included in this study are newly established, their basic characteristics were 
first investigated to ensure the quality of cell lines. The results demonstrated that our cell lines 
are stable in prolonged culture conditions and able to preserve significant genetic aberrations 
from the original tumours as shown in Chapter 3 and 4. Hence, our cell lines reliably represent 
the characteristics of the original tumours from which they were derived. Additionally, all of our 
cell lines were able to rapidly form tumours when they were orthotopically transplanted into 
immune-compromised mice. The gross immunohistological characteristics of these orthotopic 
xenografts recapitulated the corresponding original tumours. This indicated that our cell lines 
contained tumourigenic cells (Hussein, D. et al, unpublished data).  
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The key findings in this study are summarised here. The data have shown that neurosphere 
culture conditions enriched for cancer stem-like cells expressing ABCB1 or ABCC1 relative to 
monolayer conditions. Telomere length was maintained and telomerase was active in both 
monolayer and neurosphere conditions at different passages. The results also demonstrated 
that the parental cell lines contained a small proportion of CSCs expressing a low level of 
ABCB1 and ABCC1 but not ABCG2. However, experimental analyses revealed that ABCB1 was 
the major active drug transporter in our cell lines. The results indicated that our parental cell 
lines had intrinsic drug resistance via functional ABCB1 expressed in CSCs (less than 30%). In 
downstream drug resistance analysis, ABCB1 was consistently detected at a high level of 
expression in a large proportion of cells throughout prolonged drug treatment and was 
functional. Whilst ABCC1 was upregulated later, after more than 10 rounds of drug treatment. 
Interestingly, none of our treated cells expressed ABCG2 during drug treatment. Drug 
treatment selected cells overexpressing functional ABCB1 in our cell lines and they were 
enriched approximately 2 fold compared to the controls. The survival rate of colonies was 
significantly reduced when cells were treated with drug combined with a specific ABCB1 
inhibitor (Verapamil) and these surviving colonies still expressed ABCB1 at a very high level. 
Taking all these results together, CSCs expressing functional ABCB1 contribute to multidrug 
resistance in these newly derived paediatric brain tumour cell lines.  
 
Two main techniques were performed to identify subpopulations in our cell lines including co-
staining immunofluorescence and Western blotting analysis. The immunofluorescence assay 
identified cancer stem-like cells by CD133 and SOX2 co-staining and cancer stem-like cells 
expressing ABC transporters by CD133 and ABC transporters (ABCB1, ABCC1 or ABCG2) co-
staining. Western blotting analysis was also performed to confirm the expression of CD133, 
SOX2 and ABC transporters in our cell lines. Whilst functional analysis of ABCB1, based on cells 
extruding Rh123, was determined by flow cytometry. A cartoon depicting the identified 
subpopulations in the EPN-2 cell line is drawn in Figure 8.1. Subpopulations of tumour were 
identified into 3 groups; cells extruding Rh123, cells co-expressing CD133 and SOX2 and cells  
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Figure 8.1 Tumour population in the parental EPN-2 and selected resistant EPN-2 
sublines. The model of tumour population was proposed based on all results from this thesis. 
In the parental EPN-2 cell line, cells extruding Rh123 accounted for approximately one-third of 
the population and roughly only 1 in 4 of these cells co-expressed CD133 and SOX2 (~8%) 
while 1 in 3 of these cells co-expressed CD133 and ABCB1 (~10%). Hence, only about 8% of 
tumour population that were able to extrude Rh123 co-expressed CD133, SOX2 and ABCB1. 
Therefore, the parental cell line comprised approximately 8% cancer stem-like cells expressing 
functional ABCB1. The remaining 22% of cells that were actively extruding Rh123 are predicted 
to be early progenitor cells (a). After many rounds of drug treatment, cells extruding Rh123 
were significantly increased almost 3 fold and cells co-expressing CD133 and ABCB1 were also 
increased nearly 6 fold compared to the parental cells (b). In the total population, however, in 
each case a proportion of cells fails to extrude Rh123 (purple). Drug treatment selected for 
drug resistant cancer stem cells leading to a subsequent increase in drug resistant progenitors 
(red circle alone without yellow).  
            
100% 
~30% 
~10% 
~ 10% 
Tumour cells 
Cells extruding Rh 123 
CD133+SOX2+ cells 
CD133+ABCB1+ cells 
The parental EPN-2 cells 
(monolayers) 
100% 
~80-90% 
~ 50-60% 
Tumour cells 
Cells extruding Rh 123 
The selected resistant EPN-2  
sublines 
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coexpressing CD133 and ABCB1. All CD133 cells were SOX2 positive and the majority of these 
also expressed ABCB1, however a tiny proportion (about 2%) of cells expressed ABCB1 alone. 
Both the CD133/SOX2/ABCB1 and the ABCB1 only population would be expected to extrude 
Rh123. These estimated proportions of subpopulations were used to designate partitioning of 
the whole population pre- and post many rounds of drug selection by comparing the selected 
resistant EPN-2 subline to the parental EPN-2 line. After many rounds of drug treatment, the 
proportion of both cells extruding Rh123 and cells co-expressing CD133 and ABCB1 were 
increased approximately 3 fold and 6 fold, respectively (Figure 8.1, a and b). Cells expressing 
CD133, SOX2 and functional ABCB1 accounted for about 8% and this subpopulation was 
enriched up to 50% after drug treatment. This indicated that drug treatment enriched CSCs 
expressing functional ABCB1 approximately 6 fold in EPN-2 cell line. However, more than half 
of cells extruding Rh123 were negative for CD133 and ABCB1, suggesting that drug treatment 
enriched for drug resistant CSCs resulting in a corresponding increase in drug resistant 
progenitors. The proportion of functional ABCB1 cells extruding Rh123 (Figure 8.1, red) was 
larger than the proportion of cells co-expressing CD133 and ABCB1 (Figure 8.1, yellow). 
Although Rh123 can also be transported by ABCC1 (but less effectively) [Twentyman, P. R. et 
al (1994)] possibly resulting in the increase of the Rh123 extruding population, the specific 
ABCB1 inhibitor, Verapamil, was used to inhibit ABCB1 function hence ABCB1 function is still 
the most likely reason for this extrusion. It might also be possibly that the sensitivity of the 
immunofluorescence analysis, which was optimised based on HEK-B1 cells stably expressing an 
extremely high level of ABCB1, could not detect cells expressing a low level of CD133 and/or 
ABCB1. These low levels ABCB1 cells would still extrude Rh123, consequently, the proportion of 
functional ABCB1 cells detected by flow cytometry could be larger than the proportion of CD133 
and ABCB1 co-expressing cells detected by immunofluorescence analysis. Additionally, multiple 
rounds of drug treatment may have selected drug resistant CSCs resulting in an increase in the 
progenitor population, which has reduced ABCB1 expression. It has previously been reported 
that the expression of CD133 reduces in differentiating cells [Kania, G. et al (2005)] and a 
similar decrease in ABCB1 expression may also occur.   
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Four different drugs (Etoposide, Cisplatin, Irinotecan and Methotrexate) were used to select 
drug resistant sublines for downstream drug resistance analysis. These 4 drugs have different 
targets and mechanisms of action. However, all 4 drugs target proliferating cells. Our cell lines 
are highly proliferative as seen from their doubling times (Chapter 4), therefore, when EPN-2, 
MED-2 and SPNET-1 cell lines were treated with these drugs, the majority of cells were affected 
leading to death. Whilst a small proportion of cells still survived and formed colonies in 
clonogenic assay and neurospheres in neurosphere formation assay after drug removal. Hence, 
this small population was drug resistant and had cancer stem cell characteristics. A previous 
study performed by Dr. Deema Hussein, a postdoctoral researcher in our group, examined 2 
other potential drug resistance mechanisms enriched in CSCs from our cell lines; quiescence of 
CSCs and an elevation of DNA repair (Figure 8.2). Quiescent or non-cycling cells are found in 
the G0 phase of the cell cycle. G0 cells have been directly isolated from chronic myeloid 
leukaemia. These cells had stem cell properties with regard to generating leukaemic 
progenitors and were able to form new tumours after transplantation [Holyoake, T. et al 
(1999)]. Hence, it was proposed that surviving resistant sublines were generated from cancer 
stem cells, which had undergone quiescence resulting in them escaping from drug effects and 
surviving after treatment. Dr. Hussein demonstrated that neurospheres, which were enriched 
with CSCs, contained a higher proportion of G0G1 cells than monolayers (64% and 44%, 
respectively). Cells isolated from these neurospheres from our cell lines (EPN-1, MED-1 and BT-
4 cell lines) were more resistant to Etoposide treatment than monolayers. However, the cell 
cycle profile of nestin positive cancer stem cells showed that nestin positive cells were found in 
all phases of the cell cycle and only 21% of nestin positive cells were found in G0G1. Based on 
these findings, we proposed that although cells grown under neurosphere conditions cycle 
slowly, the majority of nestin positive CSCs are still cycling and hence quiescence does not 
appear to be a major mechanism of drug resistance. Dr. Hussein also used the comet assay to 
demonstrate that DNA damage was reduced faster over time in neurospheres compared to 
monolayers. This result suggested that neurospheres, containing more CSCs, had better DNA 
repair than monolayers. This assay also revealed an increase in DNA damage after initial  
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Figure 8.2 Drug resistance mechanisms in newly established paediatric brain 
tumours. This schematic figure shows possible drug resistance mechanisms in our cell lines. It 
is proposed that the tumour population is heterogeneous and contains different proportions of 
subpopulations at different time points after drug treatment. Two other minor mechanisms of 
drug resistance: DNA repair and quiescence are also shown. If drug uptake is sufficiently 
increased the cell will be unable to repair the damage and we believe the quiescence is a minor 
mechanism in our cells. An alteration of the main drug resistance mechanism in our cell lines 
was observed during drug treatment. The parental cell lines originally contained endogenous 
functional ABCB1, which indicated an intrinsic drug resistance. After prolonged drug treatment, 
drug treatment selected CSCs expressing functional ABCB1 resulting in cells consistently 
enriched for functional ABCB1 expression throughout drug treatment. Whilst ABCC1 was 
upregulated later after many rounds of drug treatment. Hence, using an ABCB1 inhibitor 
combined drug treatment might improve the effectiveness of treatment, however, using ABCB1 
inhibitor in the later stages of treatment might be less effective resulting from further 
increasing functional ABCB1 and other transporters.  
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treatment in monolayers compared to neurospheres (35.3% and 15.8%, respectively). These 
findings support the fact that drug extrusion is the first point of protection in these cells. 
 
My study revealed that functional ABCB1 in CSCs was a major drug resistance mechanism in 
EPN-2, MED-2 and SPNET-1 cell lines resulting in consistent high expression of ABCB1 
throughout drug treatment (Figure 8.2). To confirm functional ABCB1 in our cell lines correlated 
with drug resistance, the clonogenic assay was performed and the results revealed that survival 
rate of colonies was significantly reduced in the EPN-2 line after drug treatment combined with 
an ABCB1 inhibitor as shown in Chapter 7. In the EPN-2, MED-2 and SPNET-1 cell lines, the 
results demonstrated that the level of ABCB1 expression was increased after the initial 
treatment and the level of ABCB1 expression and proportion of ABCB1+ cells were consistently 
high during prolonged drug treatment. Whilst ABCC1 was only upregulated after many rounds 
of drug treatment. These findings were the same for each of the 4 drugs. This is a commonly 
found feature of multidrug resistant cells whereby after treatment with a single drug not only 
the transporter that specifically exported that drug was increased but other transporters were 
also upregulated [Szakács, G. et al (2006)]. The data presented hence suggests that the main 
ABC transporter in our cell lines is ABCB1 and it functions as an active drug transporter, 
pumping drugs out of cells resulting in a decrease in intracellular drug accumulation. From 
figure 8.1 and 8.2, it is suggested that the resistant CSCs will be selected more and more after 
multiple rounds of drug treatment. Consequently, the tumour will be enriched with drug 
resistant CSCs. Hence, it is necessary to develop the means to overcome ABC transporter 
mediated multidrug resistance.  
 
Figure 8.2 demonstrates how the outcome of treatment can be improved by using a highly 
specific ABCB1 inhibitor combined with chemotherapy at the beginning of treatment when the 
proportion of resistant CSCs is low and it is possible to overcome drug resistance compared to 
the late stage of treatment, when multiple drug efflux transporters will be enriched in resistant 
CSCs. Therefore, if the amount of drug accumulated in cells is high enough to cause cytotoxic 
effect in the first round of treatment, it might be sufficient to target all of the CSCs. Hence, a 
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specific ABCB1 inhibitor should be combined with chemotherapy at the beginning of treatment 
based on the findings of this thesis, however, these needs to be tested in animal models. The 
ABCB1 inhibitor used in our study was Verapamil. Verapamil, a calcium channel blocker, is a 
first generation ABCB1 inhibitor and has less specificity compared to later generations. The 
second generation of inhibitor e.g. Valspodar increased the level of chemotherapeutic agents 6-
8 fold in brain, kidney, liver and plasma [Fellner, S. et al (2002)]. Unfortunately, it also 
interacted with cytochrome P450 enzymes resulting in delayed drug elimination and as a result 
increased drug toxicity in normal cells [Wandel, C. et al (1999)]. Current third generation 
ABCB1 inhibitors include elacridar (GF 120918) and tariquidar (XR 9576) which have been 
demonstrated to have reduced side effects and improved effectiveness. Several in vivo studies 
have demonstrated that elacridar co-application with chemotherapeutic agents significantly 
increased level of drugs in brain higher than plasma level [Edwards, J. E. et al (2002) and 
Huisman, M. T. et al (2003)]. Additionally, it was able to selectively reverse ABCB1 transporter 
effects at the blood brain barrier. Paclitaxel co-administered with elacridar or tariquidar was 
highly accumulated in brain compared to plasma level and less systemic cytotoxic effects were 
observed than with valspodar [Hubensack, M. et al (2008)]. Therefore, these third generation 
ABCB1 inhibitors have better efficacy, higher specificity to inhibit ABCB1 in blood brain barrier 
and less systemic cytotoxicity, and are therefore potentially highly useful for clinical 
application.    
 
The clonogenic assay results using drugs combined with Verapamil treatment demonstrated 
that a small proportion of cells survived and were able to form colonies (and therefore were not 
quiescent) and also neurospheres. The results were different from our expectation because our 
cell lines had ABCB1 as a major drug resistance mechanism therefore, when ABCB1 function 
was inhibited, all cells were expected be destroyed and die. Verapamil concentration however 
may also not have been high enough but the higher concentration that was able to inhibit HEK-
B1 (20 µM) was toxic to our cells. Elacridar as described above has a higher potency to inhibit 
ABCB1 function than Verapamil and it may more effectively kill drug resistant cells although our 
preliminary results still show some cells surviving (David Carrier, personal communication). 
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Therefore, several possible protective mechanisms have been postulated in Figure 8.3. After 
multiple rounds of drug selection, the cell population contains a large proportion of CSCs 
overexpressing ABCB1 and a small proportion of CSCs without ABCB1 expression and non-
CSCs. When the line was treated with cytotoxic drug, both CSCs and CSCs overexpressing 
ABCB1 can survive and regenerate (Figure 8.3, a). Three possible explanations for surviving 
cells after drug combined Verapamil treatment have been considered in Figure 8.3. Surviving 
CSCs could have been negative for ABCB1 expression (Figure 8.3, a and b), which was not the 
case for our study. In the first pathway, surviving CSCs may have used other drug resistance 
mechanism(s) to protect themselves from cytotoxic drugs with the exception of ABCB1 and re-
initiated a heterogeneous cell population containing CSCs and progenitor cells (Figure 8.3, b). 
The second pathway proposes that some surviving CSCs acquired mutation(s) resulting in 
regeneration of a cell population containing mutated CSCs, CSCs and progenitor cells (Figure 
8.3, c). Our cell lines, however, fit with the last possibility. We hypothesised that CSCs 
overexpressing ABCB1 were able to survive after treatment, since these cells acquired genetic 
mutation(s) possibly resulting in alteration of drug binding sites or they developed other drug 
resistance mechanisms to protect themselves. Hence, CSCs containing other drug resistance 
mechanism(s) also survived. This second type of CSC reinitiated a cell population consisting of 
mutated CSCs overexpressing ABCB1 and progenitor cells (Figure 8.3, d). The results obtained 
in this study were consistent with pathway d. Due to further genetic mutations occurring after 
multiple rounds of drug treatment in CSCs overepxressing ABCB1, they were not be affected 
with drug treatment. This might indicate that surviving resistant CSCs will acquire more genetic 
aberrations or mutations after multiple rounds of drug treatment resulting in the generation of 
more aggressive and highly drug resistant tumours.  
 
In our cell lines, it is proposed that mutated CSCs overexpressing ABCB1 were able to survive 
after drug treatment co-application with ABCB1 inhibitor as shown in Figure 8.3, c. Normally, 
the DNA-mismatch repair (MMR) process functions to detect DNA damage that has occurred in 
cells and damaged DNA will be repaired if the damage is not too serious. When DNA damage 
reaches a certain threshold, which is over the limitation of MMR to repair, the excess damaged  
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Figure 8.3 Treatment included mutations in surviving cells. Cancer cells treated with 
multiple rounds of drug comprise 3 different subpopulation; CSCs, CSCs overexpressing 
ABCB1 and non-CSCs. Some possible subpopulations resulting after single drug treatment or 
drug combined with Verapamil treatment are demonstrated.  It is proposed that single drug 
treatment at the IC70 only destroyed non-CSCs whilst CSCs and CSCs expressing ABCB1 
survived and regenerated the line (a). At least 3 possibilities are postulated here after drug 
combined Verapamil treatment. In (b), CSCs with other drug resistance mechanism survived 
and regenerated the cell population. In (c), CSCs applied an undefined survival mechanism 
but some CSCs acquired mutations and they initiate mutated CSCs, CSCs and progenitor 
cells (c). The last possibility shows that CSCs expressing ABCB1 acquired further mutation 
allowing them to survive and regenerate a heterogeneous cell population (d). This latter 
mechanism is most consistent with our findings.  
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DNA causes the cell to undergo programmed cell death. However, some resistant cells may 
have impaired MMR resulting in damaged DNA remaining undetected. For example resistant 
cells having impaired MMR are resistant to temozolomide treatment. Temozolomide transfers 
a methyl group to DNA at N7 position of guanine, which is the most common site, followed 
by O3 position of adenine and O6 position of guanine [Denny, B. J. et al (1994)]. However, 
cells with impaired MMR cannot recognise damaged DNA resulting in cells with damaged 
DNA being able resist to methylation and the cytotoxic effects of temozolomide [Liu, L. et al 
(1996)]. A similar phenomenon might occur in CSCs overexpressing ABCB1 surviving after 
etoposide or irinotecan combined verapamil treatment. DNA might have some degree of 
damage in these cells but due to depletion of MMR, CSCs overexpressing ABCB1 having 
damaged DNA could not be recognised and these cells could survive resulting in generating 
more aberrant cells (Figure 8.3, d). Some studies have supported the fact that drug 
resistance to etoposide [Aebi, S. et al (1996)] and cisplatin [Lage, H. et al (1999)] can result 
from depletion of MMR. Therefore, drug resistance in CSCs overexpressing ABCB1 might be 
similar to the mechanism of drug resistance to temozolomide.    
 
In summary, the parental cell lines had intrinsic drug resistance via a low level of 
endogenous functional ABCB1. A basic level of drug resistance may also have been provided 
by elevated DNA repair and quiescence in CSCs. However, functional ABCB1 in CSCs is the 
main drug resistance mechanism in our cell lines. Many rounds of drug treatment selected 
cancer stem-like cells overexpressing functional ABCB1 and cancer stem-like cells 
expressing ABCC1 were also ultimately upregulated after serial drug treatment. There is also 
evidence for selection of another protective mechanism after prolonged treatment. Based on 
the data presented here it is therefore important to include ABCB1 inhibitors at the start of 
chemotherapy and to investigate other potential survival mechanisms. Other mechanisms 
correlating to drug resistance in cancer cells include intracellular alteration or mutation 
changing drug targets, binding sites and increase detoxification mechanism such as increase 
OHYHO RI JOXWDWKLRQH Ǆ-glutamylcysteinylglycine, GSH) and depletion of DNA-mismatch 
repair. 
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Future studies 
 
x Animal models: Drug combined with Verapamil treatment can be attempted to 
treat brain tumour xenografts in animal models. For future study, an immunodeficient 
mouse might be orthotopically transplanted with our cell lines into mouse brain leading to 
brain tumour development. Immunofluorescence analysis on xenografted tumours can be 
used to investigate the expression of stem cell markers and ABC transporters. Mice can then 
be intravenously treated with Verapamil to inhibit ABCB1 function following by 
chemotherapeutic agents or drug/Verapamil alone. The appropriate dose of Verapamil and 
drugs might be derived from the concentrations used in vitro treatment from this thesis or 
from other in vivo studies. To determine the efficacy of treatment, size of tumour can be 
measured, as will the level of drug in brain, liver, kidney and plasma to evaluate the 
distribution of drug. There is a study using novel compound of ABCB1 inhibitor (FG020318) 
combined with chemotherapeutic drugs to reverse ABCB1 function in vitro and in vivo. The 
ability of FG020318 in ABCB1 reversal was determined by MTT assay and flow cytometry. 
They found that FG020318 significantly increased chemosensitivity of MCF-7/adr cells and 
KBv200 cells [Chen, L. M. et al (2004)]. 
   
x Using the third generation ABCB1 inhibitor: Elacridar and tariquidar are the 
third generation ABCB1 inhibitor. These two drugs should be used to inhibit ABCB1 in 
treatment combining with chemotherapeutic agents. Elacridar and tariquidar can be tested 
both in vitro similar to our studies when using Verapamil as ABCB1 inhibitor and in vivo as 
mentioned earlier. For in vitro studies, clonogenic assay might be performed to investigate 
colony survival after treatment, flow cytometry can determine function of the inhibitor and 
immunofluorescence/Western blotting analysis or flow cytometry can examine any alteration 
of stem cell markers and ABC transporters. In preliminary experiments of our study 
performed using elacridar combined with etoposide or irinotecan treatment in our cell lines, 
cancer cells were effectively killed, however, a small proportion of cells still survived after 
combine treatment.  
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x Investigation of other drug resistance mechanisms: There are many drug 
resistance mechanisms in cancer cells. Other ABC transporters (ABCC1 and ACBG2) might 
be investigated functionally by flow cytometry in our cell lines, although the expression is 
low or absent as detected by immunofluorescence analysis due to the sensitivity of this 
technique. For future study, fow cytometry might be performed to investigate function of 
ABCC1 (Calcein as substrate and biricodar or cyclosporine A as inhibitor) and ABCG2 
(BODIPY-prazosin or Hoechst 33342 as substrate and fumitremorgin as inhibitor). The level 
of gluthatione (GSH) should be determined in our cells since increasing GSH can lead to 
increase drug detoxification. DNA mismatch repair (MMR) system might also be the 
resistance mechanism in our cell lines therefore mapping gene associating to human MMR 
system might be investigated in our cell lines such as hMSH2 [Reenan, R. A. G. and 
Kolodner, R. D. (1992), hMLH1 [Bronner, C. E. et al (1994), hPMS2 [Nicolaides, N. C. et al 
(1994)], hMSH3 [Fujii, H. and Shimada, T. (1989)] and hMSH6 [Papadopoulos, N. et al 
(1995)]. Other DNA repair mechanisms should also be investigated.       
  
x Using shRNA to knockdown ABCB1:  shRNA has also been found to reduce 
ABCB1 mRNA expression resulting in inhibition of ABCB1 function [Yagüe, E. et al (2004)]. 
SiRNA knockdown of ABCB1 was unsuccessful. Therefore, shRNA, which is more stable than 
SiRNA, should be optimised in our cell lines for future study. Real time PCR should be used 
to determine the degree of ABCB1 knockdown, since only a proportion of cells will be 
affected so a more sensitive assay is required.  
 
x More samples should be included: To make a stronger conclusion, more brain 
tumour cell lines should be included.  
 
x Different time points of treatment: In vitro and in vivo treatment might be 
attempted in our cell lines for future study to prove that using specific ABCB1 inhibitor 
combined with drug treatment at an early stage provides an advantage over inhibition after 
many rounds of treatment. In vitro study, cell viability analysis might be compared at 
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different time points after cells are serially treated with drug combined specific ABCB1 
inhibitor. In vivo study, cell lines might be transplanted into brain of immunodeficient mouse 
to generate tumours. Mouse can be intravenously treated with drug combined specific 
ABCB1 inhibitor then biomarker will be determines by magnetic resonance spectroscopy 
(MRS) to examine treatment response [Mirbahai, L. et al (2010)].    
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Appendix A: Results 
A1: Co-staining immunofluorescence in the parental cell lines after 
the first round of drug treatment 
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Figure A1.1 Co-staining CD133 and ABCB1, ABCC1 or ABCG2 
immunofluorescence in EPN-2 monolayers after the first round of cisplatin and 
methotrexate treatment. After the first treatment of cisplatin and methotrexate, a low 
proportion of cells co-expressing CD133 and ABCB1 or ABCC1 at a low level was 
observed [a ± d, (i) ± (iii)] whereas treated EPN-2 cells were negative for CD133 and 
ABCG2 co-staining [e and f, (i) ± (iii)]. When compared to etoposide and irinotecan 
treatment, which showed distinctive results of CD133 and ABCB1 co-expression, cisplatin 
and methotrexate were not selected to treat EPN-2 cells for further analysis, cisplatin and 
methotrexate EPN-2 cells were hence frozen down in liquid nitrogen. For each treatment 
a co-staining cell has been enlarged (x2) for clarity. 
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Figure A1.2 Co-staining CD133 and ABCB1, ABCC1 or ABCG2 
immunofluorescence in MED-2 monolayers after the first round of etoposide and 
methotrexate treatment. Cells co-expressing CD133 and ABCB1 at a high level were 
detected in MED-2 treated with etoposide and methotrexate [a and b, (i) ± (iii)]. 
etoposide treated MED-2 displayed a giant co-expressing cell [a, (i) ± (iii)]. No CD133 
and ABCC1 or ABCG2 co-expressing cells were observed after these 2 treatments [c ± f, 
(i) ± (iii)]. MED-2 cells after etoposide and methotrexate treatment were not selected for 
further analysis and they were frozen down in liquid nitrogen for future study. For each 
treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A1.3 Co-staining CD133 and ABCB1, ABCC1 or ABCG2 
immunofluorescence in SPNET-1 monolayers after the first round of etoposide 
and methotrexate treatment. SPNET-1 cells after etoposide treatment displayed cells 
co-expressing CD133 and ABCB1 at a low level [a, (i) ± (iii)] whereas a low proportion of 
cells expressing ABCB1 at a high level were observed in cells treated with methotrexate 
[b, (i) ± (iii)]. No cells co-expressing CD133 and ABCC1 or ABCG2 were present after 
these 2 treatments [d ± f, (i) ± (iii)]. Therefore, SPNET-1 cells after etoposide and 
methotrexate treatment were not carried on for further analysis and they were frozen 
down in liquid nitrogen as a stock for future study. For each treatment a co-staining cell 
has been enlarged (x2) for clarity. 
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A2: Cellular morphologies of the selected sublines after multiple 
rounds of drug treatment 
 
 
Figure A2.1 The cellular morphology of a control subline and the selected EPN-2 
sublines after multiple rounds of drug treatment.  The control subline comprised a 
homogeneous population of cells with similar shape and size. The majority of cells in the 
selected EPN-2 sublines were similar to the control subline, whilst the remainder were 
large multinucleated cells indicated by white arrows. The selected etoposide EPN-2 
sublines were struggling to survive after repeated treatments, consequently, EPN-2_E_T1 
and T2 failed to grow. Both etoposide and irinotecan EPN-2 sublines grew slower than the 
control sublines in particular to the etoposide EPN-2 sublines. 
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Figure A2.2 The cellular morphology of a control subline and the selected SPNET-
1 sublines after multiple rounds of drug treatment.  Similar to the selected EPN-2 
and MED-2 sublines, a homogeneous population was observed in the control sublines. 
Two different cell morphologies were observed in all selected SPNET-1 sublines: a small 
proportion of cells, which was large irregular cells (indicated by white arrows) and the 
majority of cells, which were homogeneous.   
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A3: Co-staining immunofluorescence in the selected sublines after 
repeat treatment at early passage (less than 10 passages) 
 
 
 
Figure A3.1 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
EPN-2 sublines treated for less than 10 passages. Co-staining immunofluorescence 
results after first round of treatment showed that a high level of CD133 and ABCB1 co-
expression was observed in EPN-2 after all drug treatments. Cells co-expressing CD133 
and ABCB1 were consistently observed in all selected EPN-2 sublines. Thereby, all 
selected EPN-2 sublines expressed a high level of CD133 and ABCB1 co-expression and 
contained a large proportion of cells co-expressing CD133 and ABCB1 after treatment 
especially in the EPN-2_E_T1 and EPN-2_I_T1 sublines. For each treatment a co-staining 
cell has been enlarged (x2) for clarity. 
CD133 ABCB1 Merged 
EPN-2_I_T2 
EPN-2_I_T3 
EPN-2_E_T1 
EPN-2_I_T1 
 317 
 
 
 
 
 
Figure A3.2 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
EPN-2 sublines treated for less than 10 passages. None of the selected EPN-2 
sublines co-expressed CD133 and ABCC1. CD133 expression was observed in all selected 
EPN-2 sublines but these cells were not co-stained with ABCC1. Some cells expressing 
ABCC1 were detected in the EPN-2_E_T1 subline but there was no CD133 co-staining.  
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Figure A3.3 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
EPN-2 sublines treated for less than 10 passages. After the first round of etoposide 
and irinotecan treatment, EPN-2 monolayers co-expressed a low level of CD133 and 
ABCG2. After many rounds of treatment, a low CD133 and ABCG2 co-expression level 
and a low proportion of cells co-expressing CD133 and ABCG2 were observed in all 
selected EPN-2 sublines. For each treatment a co-staining cell has been enlarged (x2) for 
clarity. 
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Figure A3.4 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
MED-2 sublines treated for less than 10 passages. All selected MED-2 sublines 
expressed high levels of CD133 and ABCB1 and contained a high proportion of CD133 
and ABCB1 co-expressing cells. Similar to previous co-staining immunofluorescence 
results, after the first round of treatment, cells co-expressing CD133 and ABCB1 were 
detected in MED-2 monolayers after cisplatin and irinotecan treatment. For each 
treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A3.5 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
MED-2 sublines treated for less than 10 passages. Co-staining immunofluorescence 
results previously showed no cells co-expressing CD133 and ACBC1 in MED-2 monolayers 
after the first round of cisplatin and irinotecan treatment. After multiple rounds of 
treatment, all selected MED-2 sublines were still negative for CD133 and ABCC1 co-
staining with the exception of MED-2_C_T1 subline, which contained some cells 
expressing CD133 and ABCC1. For each treatment a co-staining cell has been enlarged 
(x2) for clarity. 
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Figure A3.6 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
MED-2 sublines treated for less than 10 passages. Similar to the previous 
immunofluorescence after the first round of treatment, the selected cisplatin MED-2 
sublines were negative for CD133 and ABCG2 co-staining. However, cells expressing 
CD133 were still observed in all selected MED-2 sublines. Interestingly, CD133 and 
ABCG2 co-expressed cells were detected in all selected irinotecan MED-2 sublines while 
they were previously negative for CD133 and ABCG2 co-staining after the first round of 
treatment. For each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A3.7 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
SPNET-1 sublines treated for less than 10 passages. CD133 and ABCB1 co-
expressed cells were obviously observed in all selected SPNET-1 sublines and they were 
consistently detected at a high level of expression after the first round of treatment. For 
each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A3.8 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
SPNET-1 sublines treated for less than 10 passages. All selected SPNET-1 sublines 
were negative for CD133 and ABCC1 co-staining whilst SPNET-1 monolayers treated with 
irinotecan previously expressed a low level of CD133 and ABCC1 expression after the first 
round of treatment. CD133 expression was still observed in all sublines. 
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Figure A3.9 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
SPNET-1 sublines treated for less than 10 passages. After the first round of 
treatment, the immunofluorescence results showed that cisplatin and irinotecan treated 
SPNET-1 monolayers were definitely negative for CD133 and ABCG2 co-staining. After 
multiple rounds of treatment, cells co-expressing CD133 and ABCG2 were however 
detected in all selected SPNET-1 sublines with the exception of SPNET-1_C_T2 subline, 
which was just CD133 positive. For each treatment a co-staining cell has been enlarged 
(x2) for clarity. 
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 A4: Co-staining immunofluorescence in the selected sublines after 
repeat treatment at later passage (more than 10 passages) 
 
 
 
 
Figure A4.1 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
EPN-2 sublines treated for more than 10 passages. After repeat treatment for more 
than 10 passages, a high level of CD133 and ABCB1 expression and a high proportion of 
cells expressing CD133 and ABCB1 were consistently observed in all selected EPN-2 
sublines. For each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A4.2 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
EPN-2 sublines treated for more than 10 passages. Previous co-staining 
immunofluorescence results showed that all selected EPN-2 sublines were negative for 
CD133 and ABCC1 co-staining. However, all those sublines now obviously expressed a 
high level of CD133 and ABCC1 and comprised a high proportion of cells co-expressing 
CD133 and ABCC1 after prolonged treatment. For each treatment a co-staining cell has 
been enlarged (x2) for clarity. 
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Figure A4.3 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
EPN-2 sublines treated for more than 10 passages. Similar to the previous 
immunofluorescence results, cells co-expressing CD133 and ABCG2 were detected in all 
selected EPN-2 sublines. For each treatment a co-staining cell has been enlarged (x2) for 
clarity. 
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Figure A4.4 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
MED-2 sublines treated for more than 10 passages. After multiple rounds of 
treatment for more than 10 passages, cells co-expressing CD133 and ABCB1 at a high 
level were consistently observed in all selected MED-2 sublines. Additionally, a high 
proportion of cells co-expressing CD133 and ABCB1 was also observed. For each 
treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A4.5 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
MED-2 sublines treated for more than 10 passages. CD133 and ABCC1 co-
expressing cells were observed in all selected irinotecan MED-2 sublines whereas all 
selected cisplatin MED-2 sublines expressed ABCC1, which was not co-stained with 
CD133. For each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A4.6 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
MED-2 sublines treated for more than 10 passages. A high level of CD133 and 
ABCG2 co-expression was detected in all selected MED-2 sublines with the exception of 
MED-2_C_T3 subline. A high proportion of cells expressing CD133 and ABCG2 was 
observed in the selected irinotecan MED-2 sublines. For each treatment a co-staining cell 
has been enlarged (x2) for clarity. 
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Figure A4.7 Co-staining CD133 and ABCB1 immunofluorescence in the selected 
SPNET-1 sublines treated for more than 10 passages. Cells co-expressing CD133 
and ABCB1 were consistently detected at high level of co-expression in all selected 
SPNET-1 sublines and those sublines also comprised a high proportion of cells co-
expressing CD133 and ABCB1. For each treatment a co-staining cell has been enlarged 
(x2) for clarity. 
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Figure A4.8 Co-staining CD133 and ABCC1 immunofluorescence in the selected 
SPNET-1 sublines treated for more than 10 passages. Most of selected SPNET-1 
sublines were negative for CD133 and ABCC1 co-staining whilst SPNET-1_I_T1 and 
SPNET-1_I_T2 sublines co-expressed CD133 and ABCC1 at a high level. For each 
treatment a co-staining cell has been enlarged (x2) for clarity. 
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Figure A4.9 Co-staining CD133 and ABCG2 immunofluorescence in the selected 
SPNET-1 sublines treated for more than 10 passages. Similar to previous 
immunofluorescence results, which were performed on cells, treated for less than 10 
passages, a high level of CD133 and ABCG2 co-expression and a high proportion of 
CD133 and ABCG2 co-expressing cells were observed in all selected SPNET-1 sublines. 
For each treatment a co-staining cell has been enlarged (x2) for clarity. 
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Appendix B: Materials and Methods 
B1: Cell culture 
Table B1.1 Cell culture media 
Media Composition 
1. Stem cell media - 5% of 1× Heparin (Sigma, T1027) + 2% of B27 (Fisher, 17504-044) 
  RI ) *LEFR  LQ+LJK JOXFRVH 'XOEHFFR¶V 0RGLILHG
(DJOH¶V0HGLXP'0(06LJPD' 
- Before use: 20 ng/ml of both Fibroblast Growth Factor (FGF) 
(Invitrogen, PHG0026) and Epidermal Growth Factor (EGF) (Fisher, 
13247-051) were added to stem cell media  
2. Tumour media - 15% of Fetal Bovine Serum (FBS) (Fisher, VX10108-165) +  1% of L-
glutamine (Fisher, VX25030-LQPORI/RZJOXFRVH'XOEHFFR¶V
ModifiHG(DJOH¶V0HGLXP'0(06LJPD' 
3. PFSK media - 10-15% of Fetal Bovine Serum (FBS) (Fisher, VX10108-165) in 500 
ml of  RPMI 1640 medium with L-glutamine (Sigma, R8758) 
4. NTERA media - 10% of FBS in 500 ml of High glucose DMEM 
- Before use: 1:100 Gentamicin was added to NTERA media 
 
 B2: Immunofluorescence analysis 
Table B2.1 Solution for fixation 
Solutions Composition 
1. Fixative reagent - 0.4% Paraformaldehyde (PFA) in HBSS 
2. Resuspended solution for NS - 30% Sucrose in HBSS 
 
Table B2.2 Solution for immunofluorescent staining  
Solutions Composition 
1. Blocking reagent for membranous 
antigen (single staining) 
- 5% Normal Goat Serum (NGS) (Vector, S-
1000) in Phosphate Buffer Saline (PBS) 
2. Blocking reagent for internal antigen 
(single staining) 
- 5% NGS + 0.25% Triton X-100 (Sigma, 
T9284) in PBS 
3. Blocking reagent for double staining - 10% NGS + 1% Bovine serum albumin 
(BSA) (Sigma, B4287) + 0.1% Triton X-100 
in PBS 
4. Antibody solution for membranous 
antigen 
- 2% NGS in PBS 
5. Antibody solution for internal antigen - 2% NGS + 0.1% Triton X-100 in PBS 
6. Antibody solution for double staining - 2% NGS + 0.1% Triton X-100 + 1% BSA 
in PBS 
7. Washing solution for single staining - PBS 
8. Washing solution for double staining - 1% BSA in PBS or PBS 
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B3: Western blot analysis 
Table B3.1 General solution for Western blotting analysis 
Solutions Compositions 
1. Protease cocktail inhibitor  
(50X concentration) 
- 1 tablet of Complete mini protease inhibitor (Roche, 
10946900) dissolved in 200µl of distilled water 
2. Lysis buffer for standard 
protein extraction 
- 150 mM of NaCl + 50 mM of Tris +  0.1% SDS (W/V) + 
1% Triton X-100  
3. Lysis buffer for microsomal 
membrane extraction 
- 250mM of sucrose + 10mM of Tris pH7.4 + 0.2mM of 
CaCl2 
4. Lower gel buffer  - 1.5M of Tris + 0.4% of SDS then filtered though 0.45µm 
filter, pH8.8 
5. Upper gel buffer - 0.5M of Tris + 0.4% of SDS then filtered through 
0.45µm filter, pH6.7 
6. Electrode buffer - 25mM of Tris + 193mM of Glycine + 1% of SDS 
7. Transfer buffer - 25mM of Tris + 193mM of Glycine + 20% Methanol 
8. 10X Tris buffered saline 
(TBS) 
- 20mM of Tris + 135Mm of NaCl 
** pH 7.6 
9. TBS-T - 1X TBS + 0.1% Tween (MERCK, 437082Q)  
10. Blocking solution  - 5% of Dried semi skimmed milk power (Marvel) in TBS-
T solution   
11. Sample buffer - 0.76% of Tris + 15% of Glycerol + 2% of SDS + 5% of 
ǃ-mercaptoethanol + 0.05% of Bromophenol blue pH 6.8 
 
Table B3.2 Lower gel (Resolving gel) 
Chemicals Percentage of lower gel 
5% 7% 10% 13% 15% 
Lower gel buffer 1ml 1ml 1ml 1ml 1ml 
Acrylamide (Severn 
Biotech, 20-2100-05) 
0.67ml 0.93ml 1.33ml 1.73ml 2ml 
dH2O 2.33ml 2.07ml 1.67ml 1.27ml 1ml 
10%APS (Sigma, A3678) 25µl 25µl 25µl 25µl 25µl 
Temed 3.3µl 3.3µl 3.3µl 3.3µl 3.3µl 
 
Table B3.3 Upper gel (Stacking gel) 
Chemicals Amount of gel 
X1 X2 X3 X4 
Upper gel buffer 625 µl 1,250 µl 1,875 µl 2,500 µl 
Acrylamide 312 µl 624 µl 936 µl 1,248 µl 
dH2O 1,500 µl 3,000 µl  4500 µl 6,000 µl 
10% APS 12.5 µl 25 µl 37.5 µl 50 µl 
Temed 2.5 µl 5 µl 7.5 µl 10 µl 
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B4: DNA extraction 
Table B4.1 Lysis buffer 
Solutions  Compositions 
1. DNA lysis buffer (500 ml) - 50mM Tris, pH 8.0 + 100mM EDTA, pH 8.0 + 1% 
SDS + 100mM NaCl in 500 ml distilled water 
 
   
B5: TRF assay 
Table B5.1 Solution for TRF assay 
 
Solutions  Compositions 
1. Denaturing solution  
(1 litre) 
- 1.5M NaCl + 0.5M NaOH in 1 litre distilled 
water 
2. Neutralising solution  
(2 litres) 
- 0.5M Tris + 1.5M NaCl in 2 litres distilled 
water 
3. 20x SSC  
(1 litre) 
- 3M NaCl + 0.3M Tri-Sodium Citrate in 1 litre 
distilled water 
4. 1x TAE - 40 mM Tris-acetate + 1mM EDTA 
50x TAE: 242 g of Tris base + 57.1 ml of 
glacial acetic acid in 100 ml of 0.5 M EDTA (pH 
8.0) 
5. Washing buffer  
(100 ml) 
- 10 ml TRF solution (#1) (DIG wash & block 
buffer set 1, 10 conc.) + 90 ml distil water 
6. Blocking solution  
(200 ml) 
- 20 ml TRF solution (#2)* (DIG wash & block 
buffer set 2, 10 conc.) + 20 ml blocking serum 
+ 160 ml distil water 
7. Anti-DIG-AP solution  
(100 ml) 
- 100 ml blocking solution* + 10 µl of anti-DIG-
AP* 
8. Detection solution  
(100 ml) 
- 10 ml TRF solution (#4)* + 90 ml distil water 
 
 
(* Supplied with Telo TAGGG Telomere Length assay kit (Roche, 12209136001) 
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 B6: TRAP assay 
Table B6.1 Solution for TRAP assay 
 
Solutions  Compositions 
1. Coomassie reagent - 0.05% Coomassie G-250 powder + 25% 
ethanol + 50% Perchloric acid 
2. 5xTBE (Tris-borate) buffer - 5.4% Tris + 2.75% Boric acid + 10mM Na2EDTA 
(pH 8.0) in distilled water 
*Filter through 0.45 µm filter* 
3. 1xTE buffer - 10 mM Tris (pH 8.0, 7.6 or 7.4) + 1 mM 
Na2EDTA (pH 8.0) in distilled water 
*Store at room temperature* 
4. 10% Polyacrylamide gel - 40% Acrylamide mix (Fisher Scientific, BP1406-
1) + 10% 0.5xTBE buffer + 0.1% TEMED + 0.1% 
APS in nuclease free water  
5. Gel running buffer - 0.5xTBE buffer 
6. DNA molecular marker - 1.25% DNA marker VIII (Roche, 11336045001) 
+ 18.75% loading buffer in nuclease free water 
7. Staining solution - 0.01% SyBR Green1 in 1x TE buffer 
   
 
B7: FACS functional analysis 
 
Table B7.1 Buffer for FACS 
 
Solutions  Compositions 
1. FACS buffer - 0.5% BSA (albumin bovine serum) in 
'HOEXFFR¶VPRGLILHG(DJOH¶VPHGLXP'0(0
with 1000mg glucose without phenol red 
(Sigma, D5921) 
2. 10 mM EDTA - 372 g of EDTA in 100 ml of DPBS 
                                                                                
